



**World Health  
Organization**

REGIONAL OFFICE FOR **Europe**

## **SURVEILLANCE** REPORT



# Tuberculosis surveillance and monitoring in Europe

# 2013

[www.ecdc.europa.eu](http://www.ecdc.europa.eu)  
[www.euro.who.int](http://www.euro.who.int)



**Tuberculosis surveillance  
and monitoring in Europe**

**2013**

This report has been published jointly by the WHO Regional Office for Europe (WHO/Europe) and ECDC. WHO/Europe developed the description of the European Region and validated the figures of the non-EU countries and ECDC developed the text for the EU/EEA countries and validated the EU/EEA figures.

The report was coordinated by Vahur Hollo (ECDC) and Andrei Dadu (WHO/Europe).

Contributing authors: Masoud Dara and Kristin Kremer (WHO/Europe), Marieke J. van der Werf, Csaba Ködmön and Phillip Zucs (ECDC).

This report was sent for consultation and review to the TB disease-specific experts and focal points in the Member States.

We would like to acknowledge the contribution and dedication of the experts in the Member States in reporting the data used for the production of this report.

Suggested citation for full report:

European Centre for Disease Prevention and Control/WHO Regional Office for Europe. Tuberculosis surveillance and monitoring in Europe 2013. Stockholm: European Centre for Disease Prevention and Control, 2013.

Tables and figures should be referenced:

European Centre for Disease Prevention and Control/WHO Regional Office for Europe. Tuberculosis surveillance and monitoring in Europe 2013.

This report follows the European Union Interinstitutional Style Guide with regard to country names.

The maps are reproduced with the permission of the WHO Regional Office for Europe. The designations employed and the presentation of this material do not imply the expression of any opinion whatsoever on the part of the Secretariat of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers and boundaries.

The WHO Regional Office for Europe is responsible for the accuracy of the translation of the Russian summary.

© World Health Organization

Cover picture © CDC/ Dr Ray Butler; Janice Carr

ISBN 978-92-9193-447-8

ISSN 1977-3986

DOI 10.2900/77696

© European Centre for Disease Prevention and Control, 2013

Reproduction is authorised, provided the source is acknowledged.

# Contents

<b>Abbreviations</b> .....	v
<b>Summary</b> .....	1
<b>1. Background and technical note</b> .....	7
1.1 Data reporting and analysis .....	9
1.2 Definitions.....	10
<b>2. Commentary</b> .....	13
2.1 The WHO European Region .....	15
2.2 European Union and European Economic Area countries .....	22
<b>3. Commentary – Monitoring</b> .....	27
<b>4. Tables</b>	
<b>Summary table:</b> Tuberculosis surveillance data by region, European Region, 2011 .....	33
<b>Table 1:</b> Estimates of the TB disease burden 2011, European Region .....	34
<b>Table 2:</b> Estimates of TB/HIV and MDR-TB 2011, European Region .....	36
<b>Table 3:</b> Tuberculosis cases, notification rates per 100 000 population and mean annual change in rates, European Region, 2007–2011.....	38
<b>Table 4:</b> Tuberculosis cases and age-standardised rates per 100 000 population, European Region, 2007–2011.....	40
<b>Table 5:</b> New TB cases and relapses, notification rates per 100 000 population, European Region, 2002–2011.....	42
<b>Table 6:</b> Tuberculosis cases by history of previous TB treatment, European Region, 2011 .....	46
<b>Table 7:</b> Tuberculosis cases by site of disease, European Region, 2011 .....	47
<b>Table 8:</b> New pulmonary tuberculosis cases by laboratory confirmation, European Region, 2011 .....	48
<b>Table 9:</b> Laboratory-confirmed tuberculosis cases by confirmation method, EU/EEA, 2011 .....	50
<b>Table 10:</b> Classification of tuberculosis cases according to EU case definition, EU/EEA, 2011.....	51
<b>Table 11:</b> New TB cases by age group, European Region, 2011.....	52
<b>Table 12:</b> Tuberculosis cases in children and adults, European Region, 2011.....	55
<b>Table 13:</b> Tuberculosis cases by origin and sex ratio, European Region, 2011.....	56
<b>Table 14:</b> Tuberculosis cases in children (<15 years old), by age group and origin, EU/EEA, 2011 .....	58
<b>Table 15:</b> Laboratory practices and quality assurance for anti-TB drug susceptibility testing, European Region, 2011.....	59
<b>Table 16:</b> Characteristics of anti-TB drug resistance surveillance of laboratory-confirmed cases, European Region, 2011 .....	60
<b>Table 17:</b> Multidrug-resistant TB among laboratory-confirmed TB cases by previous history of TB treatment, European Region, 2011.....	61
<b>Table 18:</b> Anti-TB drug resistance among new laboratory-confirmed pulmonary TB cases, European Region, 2011.....	62
<b>Table 19:</b> Anti-TB drug resistance among previously treated laboratory-confirmed pulmonary TB cases, European Region, 2011 .....	63
<b>Table 20:</b> Number and proportion of notified XDR-TB cases among MDR-TB cases with second-line drug susceptibility testing, European Region, 2009–2011.....	64
<b>Table 21:</b> Anti-TB drug resistance among all TB cases by origin, EU/EEA, 2011 .....	66
<b>Table 22:</b> Tuberculosis cases with HIV infection, European Region, 2011 .....	68
<b>Table 23:</b> Treatment outcome of new laboratory-confirmed pulmonary TB cases after 12 months, European Region, 2010 .....	69
<b>Table 24:</b> Treatment outcome of previously treated laboratory-confirmed pulmonary TB cases, European Region, 2010.....	70
<b>Table 25:</b> Treatment outcome of all TB cases, European region, 2010 .....	71
<b>Table 26:</b> Treatment outcome of all MDR-TB cases after 24 months, European region, 2009.....	72
<b>Tables on specific topics in the 2013 report: TB in prisons and site of the disease</b>	
<b>Table A:</b> TB in Prisons, European Region, 2010.....	75
<b>Table B:</b> Extrapulmonary TB cases, notification rates per 100 000 population and % of all TB, EU/EEA 2002–2011 .....	76
<b>Table C:</b> All tuberculosis cases by site of disease, EU/EEA, 2011.....	78
<b>Table D1:</b> All tuberculosis cases by site of disease in children, EU/EEA, 2011.....	80
<b>Table D2:</b> All tuberculosis cases by site of disease in adults, EU/EEA, 2011.....	82
<b>Table E:</b> Extrapulmonary TB cases by laboratory confirmation and multidrug resistance, EU/EEA, 2011 .....	85
<b>Table F1:</b> All TB cases by site and origin, EU/EEA, 2011 .....	86
<b>Table F2:</b> All TB cases by site and origin, EU/EEA, 2011.....	88

Table F3: All TB cases by site and origin, EU/EEA, 2011 .....	90
Table G: Treatment success for all TB cases by site of disease, EU/EEA, 2010 .....	92
Table H: Tuberculosis cases with HIV infection by site of disease, EU/EEA, 2011 .....	94

### Trend tables

Table I: All notified TB cases, rates per 100 000 population and mean annual change in rates, European Region, 1995–2011 .....	96
Table II: All laboratory confirmed tuberculosis cases, European Region, 1995–2011 .....	100
Table III: Tuberculosis cases in children (<15 years old), European Region, 1995–2011 .....	104
Table IV: Tuberculosis cases of foreign origin, EU/EEA, 1995–2011 .....	110
Table V: MDR-TB notification among all laboratory confirmed TB cases, European Region, 2000–2011 .....	112
Table VI: MDR-TB notification among all culture positive TB cases with available DST results, European Region, 2007–2011 .....	116
Table VII: XDR-TB notification among all MDR-TB cases with second line drug sensitivity test results, European Region, 2006–2011 .....	118
Table VIII: Tuberculosis cases with HIV infection, European Region, 2001–2011 .....	121
Table IX: Treatment success of new laboratory-confirmed pulmonary TB cases, European Region, 2001–2010 .....	124
Table X: Treatment success of previously treated laboratory confirmed pulmonary TB cases, European Region, 2001–2010 .....	128
Table XI: Treatment success of all MDR-TB cases, European Region, 2005–2009 .....	132

## 5. Maps & figures

Figure A: Estimated TB incidence (per 100 000 population) and case detection rates (as a percentage), WHO European Region, 1990–2011 .....	16
Figure B: Estimated TB incidence per 100 000 population, European Region, 2011 .....	17
Map 1a: Estimated TB mortality per 100 000 population, European Region, 2011 .....	136
Map 1b: Estimated TB prevalence per 100 000 population, European Region, 2011 .....	137
Map 1c: Estimated TB incidence per 100 000 population, European Region, 2011 .....	137
Map 2: TB notification rates per 100 000 population, European Region, 2011 .....	138
Map 3: TB notification rates, new and relapse cases per 100 000 population, European Region, 2011 .....	138
Map 4: Percentages of notified TB cases of foreign origin among all TB cases, European Region, 2011 .....	139
Map 5: Percentages of notified extrapulmonary TB cases among all TB cases, European Region, 2011 .....	139
Map 6: Percentages of smear positive pulmonary TB cases among new pulmonary TB, European Region, 2011 .....	140
Map 7: Percentage of TB cases confirmed by culture and smear among new pulmonary TB cases, European Region, 2011 .....	140
Map 8: Percentage of notified TB cases with multidrug resistance among new laboratory-confirmed pulmonary TB cases, European Region, 2011 .....	141
Map 9: Percentage of notified TB cases with multidrug resistance among previously treated laboratory-confirmed pulmonary TB cases, European Region, 2011 .....	141
Map 10: Percentage of notified TB cases with multidrug resistance among all TB cases with DST results, European Region, 2011 .....	142
Map 11: Percentage of notified TB cases with extensive drug resistance among MDR-TB cases with second-line DST results, European Region, 2011 .....	142
Map 12: Percentage of HIV positive TB cases among all TB cases with known HIV status, European Region, 2011 .....	143
Map 13: Success rate of new laboratory-confirmed pulmonary TB cases, European Region, 2010 .....	143
Map 14: Success rate of previously treated laboratory-confirmed pulmonary TB cases, European Region, 2010 .....	144
Map 15: Success rate of all MDR-TB cases after 24 months, European Region, 2009 .....	144
Figure 1: TB estimated incidence and notification per 100 000 population, European Region, 2002–2011 .....	145
Figure 2: Estimated TB prevalence per 100 000 population, European Region, 2002–2011 .....	146
Figure 3: Estimated TB mortality per 100 000 population, European Region, 2002–2011 .....	147
Figure 4: Total TB notifications by previous treatment history and total TB case rates, Europe, 2002–2011 .....	148
Figure 5: Percentages of MDR among laboratory-confirmed TB cases, European Region, 2002–2011 .....	149
Figure 6: Percentage of TB cases with HIV infection among TB cases with known HIV status, Europe, 2008–2011 .....	150
Figure 7: Treatment outcome, new laboratory-confirmed pulmonary TB cases, Europe, 2001–2010 .....	151
Figure 8: Treatment outcome, previously treated laboratory-confirmed pulmonary TB cases, Europe, 2001–2010 .....	152
Figure 9: Treatment outcome after 24 months of MDR-TB cases, Europe, 2007–2009 .....	153

6. Country profiles .....	155
---------------------------	-----

7. Annexes .....	211
------------------	-----

# Abbreviations

<b>AFB</b>	Acid-fast bacilli
<b>AIDS</b>	Acquired immunodeficiency syndrome
<b>CI</b>	Confidence interval
<b>CISID</b>	Centralized Information System for Infectious Diseases
<b>DOTS</b>	Directly Observed Treatment Short-Course (internationally recommended strategy for the control of tuberculosis)
<b>DRS</b>	Drug resistance surveillance
<b>DST</b>	Drug susceptibility testing
<b>ECDC</b>	European Centre for Disease Prevention and Control
<b>EEA</b>	European Economic Area
<b>EITUD</b>	European individual tuberculosis dataset
<b>EQA</b>	External quality assessment
<b>ERLN-TB</b>	European Reference Laboratory Network for TB
<b>EU</b>	European Union
<b>HIV</b>	Human immunodeficiency virus
<b>HPC</b>	High-priority countries
<b>ICD</b>	International Classification of Diseases
<b>ISO</b>	International Organization for Standardization
<b>MDB</b>	Mortality Database
<b>MDR</b>	Multidrug resistance
<b>MDR-TB</b>	Multidrug-resistant tuberculosis
<b>M/XDR-TB</b>	Multidrug and extensively drug-resistant tuberculosis
<b>MSM</b>	Men who have sex with men
<b>PR</b>	Prevalence ratio
<b>PWID</b>	People who inject drugs
<b>STAG-TB</b>	Strategic and Technical Advisory Group for Tuberculosis (STAG-TB), WHO
<b>TB</b>	Tuberculosis
<b>TESSy</b>	The European Surveillance System
<b>TME</b>	WHO Tuberculosis Monitoring and Evaluation platform
<b>TOM</b>	Treatment outcome monitoring
<b>UN</b>	United Nations
<b>WHO</b>	World Health Organization
<b>XDR</b>	Extensive drug resistance
<b>XDR-TB</b>	Extensively drug-resistant tuberculosis






# Summary



**Map: Tuberculosis surveillance in Europe 2011<sup>a</sup>**



<sup>a</sup> Data from UN Administrated Province of Kosovo (in accordance with Security Council Resolution 1244 (1999)) is not included in the figures reported for Serbia.

# Executive Summary

This is fifth report launched jointly by the European Centre for Disease Prevention and Control (ECDC) and the WHO Regional Office for Europe (WHO/Europe) following on from reports under the EuroTB project, established in 1996.

## The WHO European Region

The 2015 Millennium Development Goal (MDG) target of halting the prevalence and death associated with tuberculosis (TB) and reversing its incidence has been partially achieved in 2011, with TB incidence falling in the Region at a rate of about 5% per year between 2000 and 2011. Nevertheless, the prevalence of TB was estimated at 56 cases per 100 000 population (about 500 000 prevalent cases) in the Region and TB mortality was 4.9 deaths per 100 000 population (around 44 000 in total). It will therefore not be possible to reach the target of 50% reduction by 2015.

The incidence of TB in the European Region varies among and within the countries, from a range of less than one TB case per 100 000 population to above 200 TB cases per 100 000 in others. The 53 countries of the WHO European Region account for around 4.4% of the world's cases, representing an estimated 380 000 individuals with a new episode of TB (or relapse), or 42 cases per 100 000 population.

Since 2005, TB notifications have decreased by almost one quarter, from 41 to 33 cases per 100 000 population. In 2011, the countries of the WHO European Region detected 295 968 new TB cases and relapses. When compared to the incidence for the Region, this indicates that 78% of the estimated cases were detected, making the Region's surveillance system one of the most sensitive in the world.

Among the 380 366 cases of all types and forms of TB, 71% (271 288) were identified as new cases in 2011. Of those 55% (123 525) were confirmed by sputum smear microscopy and/or culture. The number of laboratory confirmations was higher in the western part of the Region than in the eastern countries (74% and 50.3% respectively).

Overall, there were twice as many male cases reported as female cases, however a large variation was observed for male predominance in the gender distribution of TB cases, ranging from almost even distribution in some western countries (1.2:1) to around three times greater in others (2.9:1).

In 2011, most of the new TB cases registered in the European Region were in the 25–44 years age group (41%). Over the last five years, region-wide trends in overall TB notification among children (age group 0–14 years) have decreased by 23%, from 8.7 to 6.7 cases per 100 000 population, accounting for 11 054 cases in 2011. However, the average percentage of patients within this age group in the Region has remained stable at around 6% over the same period.

There were ten countries where under-fives accounted for more than half of the cases detected among children.

In 2011, 12 751 TB cases with HIV co-infection (56.5%) were detected from the 22 500 estimated cases in the European Region. The estimated prevalence of HIV infection among TB patients was 6%. The fact that prevalence among all tested TB cases was very similar (6.2%) gives an indication of the accuracy of TB-HIV surveillance in the Region. However, since HIV testing coverage is at 60%, the status was only known for 205 578 new and previous TB cases, 12 751 of which had an HIV co-infection.

Given that so few countries report TB from correctional institutions it was difficult to calculate the extent to which prisons contribute to the regional TB burden. However, there were some countries in eastern Europe where TB cases in prisons exceeded 10% of the countrywide total of new TB cases, and in others the notification rate was close to or exceeded 1 000 cases per 100 000 prison population. In some low-incidence countries however, there was a higher risk of TB in prisons than in the general population. This was related to the higher rate of TB transmission there due to poor control measures and/or the concentration of vulnerable population sub-groups (such as immigrants from countries with a high TB incidence).

In 2011, of an estimated 78 000 multidrug-resistant tuberculosis (MDR-TB) cases in the European Region, 29 473 (38%) were detected. The prevalence of MDR among new TB cases in the Region amounted to 14% and 47.7% among previously treated cases. Testing coverage for resistance to second line drugs almost doubled compared to last year, however it is still at a very low level (9% of MDR-TB cases). Nevertheless, this allowed detection of 381 cases of extensively drug-resistant tuberculosis (XDR-TB), representing 11% of the MDR-TB cases tested for second line drug susceptibility in the Region. New rapid methods to support TB diagnosis have recently been introduced in some countries within the Region.

During the last five years, a gradual decrease in treatment success has been observed. Success rates are now down to 67.2%, 49.2% and 48.5% among new, previously treated and MDR-TB cases respectively. A decrease in the first two of the three cohorts is mostly related to an increase in the proportion of MDR-TB among them. In the third cohort it might be due to a rapid increase in the reporting coverage to nearly double that of last year (from almost 7 000 to over 12 000) and the lack of quality-assured administration of second-line drugs according to the most efficient regimens recommended by WHO.

Given the above and the fact that the vast majority of the TB burden occurs in the 18 high-priority countries of the

European Region<sup>1</sup> (87% of the TB incidence, 87% of the prevalence, 92% of the mortality caused by TB, 91% of TB/HIV co-infections, and 99% of the MDR-TB), the main efforts to combat and prevent TB in the Region need to be focused there. However, in western Europe and particularly in the large cities, the TB situation still needs continuous attention.

In cooperation with national and international partners and civil society organisations, WHO Regional Office for Europe has been implementing a Consolidated Action Plan to Prevent and Combat Multidrug- and Extensively Drug-Resistant Tuberculosis and helping Member States to adopt evidence-based interventions in order to improve TB and multidrug- and extensively drug-resistant TB (M/XDR-TB) prevention and control. All countries with a high burden of MDR-TB, except the Russian Federation, have prepared and finalised their national MDR-TB action plans in line with the regional plan. In some countries the national plans are yet to be endorsed officially by the Ministries of Health.

The WHO Regional Office for Europe has established the European Green Light Committee and the European Laboratory Initiative to help countries develop and/or adjust their national plans in response to the M/XDR-TB threat. This will help countries to reduce the proportion of MDR-TB cases among those previously treated by 20% detect 85% of estimated MDR-TB patients and successfully treat at least 75% of them.

## European Union and European Economic Area countries

In 2011, 72 334 cases of TB were reported in 29 EU/EEA countries, which was 4% less than in 2010. The EU/EEA notification rate was 14.2 per 100 000 population, continuing the long-term decreasing trend.

In total, 80% of all notified TB cases were newly diagnosed and 69% of all new pulmonary TB cases were culture-confirmed.

Adult age groups were equally affected by TB while the notification rate in children under the age of 15 years was 4 per 100 000, consistent with a slightly decreasing long-term trend. Overall, males were overrepresented by 80%.

In total, 26% of all TB cases were of foreign origin, mostly residing in low-incidence countries.

MDR-TB was reported for 5% of cases with drug susceptibility testing results (2% of new TB cases and 17% of previously treated cases) and continues to be most prevalent in the three Baltic countries. The overall trend is slightly decreasing.

Extensively drug-resistant TB (XDR-TB) was reported for 13% of 1 017 MDR-TB cases tested for second-line drug susceptibility.

In all, 5% of TB cases with known HIV status were co-infected with the virus.

Seventy-four percent of TB cases notified in 2010 and 32% of MDR-TB cases notified in 2009 had successfully completed their treatment.

In total, 22% of all cases were notified with exclusively extrapulmonary TB (mostly lymphatic and pleural TB); 35% of them were confirmed by culture, 1% was multidrug-resistant and 82% were labelled treatment successes. Children and cases of foreign origin were at least twice as likely to be reported with extrapulmonary TB as adults and native cases, respectively. The distribution of clinical presentations in each of these two risk groups was distinctly different from the remaining cases.

<sup>1</sup> The 18 high-priority countries (HPC) are: Armenia, Azerbaijan, Belarus, Bulgaria, Estonia, Georgia, Kazakhstan, Kyrgyzstan, Latvia, Lithuania, Moldova, Romania, Russia, Tajikistan, Turkey, Turkmenistan, Ukraine and Uzbekistan.

# Исполнительное резюме

Представленный документ, является пятым докладом, изданный совместными усилиями Европейского центра по контролю и профилактике заболеваний (ЕЦКЗ) и Европейского регионального бюро ВОЗ (ЕРБ ВОЗ) вслед за ежегодными отчетами проекта EuroTB, учрежденным в 1996 г. в Европейском регионе ВОЗ.

## Европейский регион ВОЗ

Цели развития тысячелетия (ЦРТ) - к 2015 г. вдвое сократить показатели распространенности и смертности, ассоциированные с туберкулезом, и обратить вспять заболеваемость - были частично достигнуты. Темп заболеваемости ТБ в Регионе в период между 2000 и 2011 годами достиг 5% снижения в год. По расчетным данным, в 2011 г. показатель распространенности ТБ составил 56 случаев на 100 000 населения (всего около 500 000), а смертности 4,9 случаев на 100 000 населения (всего около 44 000), однако по прогнозам, пятидесятипроцентного сокращения смертности к 2015 г. достигнуть не удастся.

Заболеваемость ТБ в Европейском регионе варьируется по странам и внутри стран в диапазоне от менее одного случая ТБ на 100 000 населения до свыше 200 случаев ТБ на 100 000 населения. На 53 страны Европейского региона ВОЗ приходится почти 4,4% всех случаев ТБ в мире, что по оценочным данным составляет около 380 тысяч больных с новыми эпизодами ТБ (или рецидивами) или 42 случая на 100 000 населения.

С 2005 г. показатель регистрации ТБ сократился примерно на четверть – с 41 до 33 случаев на 100 000 населения. В 2011 г. в странах Европейского региона ВОЗ было выявлено 295 968 новых случаев и рецидивов ТБ. При сопоставлении с расчетной заболеваемостью в Регионе, эта цифра указывает на то, что выявляется в среднем 78% случаев, что делает систему эпиднадзора Европейского региона одной из наиболее эффективных в мире.

В 2011 г среди 380 366 случаев всех типов и форм туберкулеза, 71% (271 288) был выявлен как новые случаи. Из них 55% (123 525) были подтверждены мазком мокроты и/или посевом. Лабораторная диагностика была более эффективной в западной, чем в восточной части Европейского региона, 74% и 50,3%, соответственно.

В целом, было зарегистрировано в два раза больше случаев среди мужчин, чем среди женщин, однако в гендерном распределении случаев ТБ наблюдалось значительное варьирование в преобладании случаев заболевания среди мужчин – от почти равного распределения в некоторых западных странах (1,2:1) до примерно трехкратного превышения в других (2,9:1).

В 2011 г. чаще всего впервые выявленный туберкулез регистрировался у больных в возрастной группе 25–44 лет (41%). За последние пять лет наблюдаемое по всему Региону тенденция общей регистрации ТБ среди детей (возрастная группа 0–14 лет) характеризовалась сокращением на 23% - с 8,7 до 6,7 случаев на 100 000 населения, что в 2011 г. составило 11 054 случаев. Однако средний процент больных этой возрастной группы в регионе оставался стабильным на уровне примерно 6% за тот же период времени. В десяти странах на возрастную группу младше 5 лет приходилось более половины случаев всего детского туберкулеза.

В 2011 году из 22,5 тысяч расчетных случаев ТБ-ВИЧ в Европейском регионе выявили 12 751 случай ТБ с сочетанной инфекцией ВИЧ (56.5%). Расчетная распространенность ВИЧ-инфекции среди больных ТБ составила 6%. Тот факт, что распространенность среди всех протестированных случаев ТБ (6,2%) была весьма сходной с расчетной, указывает на высокую специфичность системы эпиднадзора за ТБ-ВИЧ в Регионе. Однако в связи с тем, что охват тестированием на ВИЧ составляет лишь 60%, статус был известен лишь у 205 578 новых и ранее леченых случаев ТБ, из них 12 751 имели сочетанную ВИЧ-инфекцию.

Поскольку лишь небольшое число стран сообщают о случаях ТБ в исправительных учреждениях, сложно рассчитать, до какой степени ситуация в пенитенциарных учреждениях влияет на региональное бремя ТБ. Однако в некоторых странах Восточной Европы случаи ТБ в пенитенциарных учреждениях превышали 10% от всех новых случаев ТБ в целом по стране, а в других показатель регистрации был близок к 1000 случаев на 100 000 населения в местах лишения свободы или даже превышал это значение. Тем не менее, в некоторых странах с низкой заболеваемостью риск ТБ в местах лишения свободы был выше, чем среди населения в целом. Это было связано с более высоким показателем распространения ТБ в этих учреждениях вследствие неудовлетворительных мер контроля и/или концентрации уязвимых подгрупп населения (таких как мигранты из стран с высокой заболеваемостью ТБ).

В 2011 г. из расчетных 78 тысяч случаев туберкулеза с множественной лекарственной устойчивостью (МЛУ-ТБ) в Европейском регионе было выявлено 29 473 (38%). Распространенность МЛУ-ТБ среди новых зарегистрированных случаев ТБ в Регионе составила 14% и среди ранее леченых случаев - 47,7%. Охват тестированием чувствительности к препаратам второго ряда вырос почти в два раза по сравнению с прошлым годом, однако он все еще находится на очень низком уровне (9% случаев МЛУ-ТБ). Тем не менее, это позволило выявить 381 случай туберкулеза с широкой лекарственной устойчивостью (ШЛУ-ТБ), т.е. 11% случаев МЛУ-ТБ в Регионе, протестированных на чувствительность к препаратам

второго ряда. Недавно в помощь диагностике ТБ в некоторых странах Региона были внедрены быстрые методы.

За последние пять лет наблюдалось постепенное снижение показателей успешного лечения, которые теперь сократились до 67,2%, 49,2% и 48,5% среди новых, ранее леченых и МЛУ-ТБ случаев, соответственно. Снижение показателя в первых двух из трех когорт связано, главным образом, с увеличением доли МЛУ-ТБ в этих когортах. В третьей когорте это может быть следствием быстрого увеличения охвата отчетностью – почти в два раза по сравнению с прошлым годом (почти с 7 до свыше 12 тысяч больных) и с недостатком препаратов второго ряда гарантированного качества для лечения в соответствии с наиболее эффективными схемами, рекомендованными ВОЗ.

Принимая во внимание вышесказанное, а также тот факт, что большая часть бремени ТБ приходится на 18 стран высокого приоритета Европейского региона<sup>2</sup> (87% заболеваемости ТБ, 87% распространенности, 92% смертности вследствие ТБ, 91% сочетанных инфекций ТБ/ВИЧ и 99% МЛУ-ТБ), основные усилия в борьбе с ТБ и профилактике этого заболевания в Регионе должны быть сосредоточены именно там. Однако в Западной Европе и, в особенности, в больших городах ситуация с ТБ требует постоянного внимания.

В сотрудничестве с национальными и международными партнерами и организациями гражданского общества Европейское региональное бюро ВОЗ реализует Комплексный план действий по профилактике и борьбе с туберкулезом с множественной и широкой лекарственной устойчивостью и помогает государствам-членам адаптировать доказательные меры вмешательства для совершенствования профилактики и контроля туберкулеза и туберкулеза с множественной и широкой лекарственной устойчивостью (М/ШЛУ-ТБ). Все страны с высоким бременем МЛУ-ТБ, за исключением Российской Федерации, подготовили и приняли окончательную редакцию своих национальных планов действий в отношении МЛУ-ТБ в соответствии с Региональным планом. В некоторых странах национальные планы еще должны быть официально одобрены Министерствами здравоохранения.

Европейское региональное бюро ВОЗ учредило Европейский комитет зеленого света и Европейскую лабораторную инициативу для оказания помощи странам в разработке и/или корректировке их национальных планов в ответ на угрозу М/ШЛУ-ТБ. Это поможет странам снизить долю случаев МЛУ-ТБ среди ранее леченых больных на 20%, выявлять 85% расчетного числа больных МЛУ-ТБ и успешно лечить, как минимум, 75% из них.

## Страны Европейского союза и Европейской экономической зоны

В 2011 году 29 стран ЕС/ЕЭЗ сообщили о 72 334 случаях ТБ, что на 4% меньше, чем в 2010 г. Показатель регистрации в ЕС/ЕЭЗ, продолжая многолетнюю тенденцию к снижению, составил 14,2 на 100 000 населения.

В общей сложности, 80% всех зарегистрированных случаев ТБ были диагностированы впервые и 69% всех новых случаев легочного туберкулеза имели культуральное подтверждение.

Туберкулез в равной степени затронул возрастные группы взрослых людей, а показатель регистрации у детей младше 15 лет составил 4 на 100 000, с тенденцией сопоставимой многолетней динамики у населения в целом. Мужчины составили 80% от всех случаев ТБ в странах ЕС.

В целом 26% всех случаев ТБ имели иностранное происхождение и большинство из них проживали в странах с низкой заболеваемостью.

МЛУ-ТБ был зарегистрирован у 5% случаев с результатами теста лекарственной чувствительности (2% новых случаев ТБ и 17% ранее леченых случаев), эта форма заболевания продолжает быть особенно распространенной в трех странах Балтии. В целом отмечается тенденция к некоторому снижению. ШЛУ-ТБ был зарегистрирован у 13% из 1 017 случаев МЛУ-ТБ, прошедших тестирование лекарственной чувствительности.

Всего 5% случаев ТБ с известным статусом ВИЧ имели сочетанную инфекцию вирусом.

Успешно закончили свое лечение 74% случаев ТБ, зарегистрированных в 2010 г., и 32% случаев МЛУ-ТБ, зарегистрированных в 2009 г.

В общей сложности 22% всех случаев ТБ было зарегистрировано исключительно с внелегочным ТБ (в основном ТБ лимфатических узлов и плевры); 35% из них имели культуральное подтверждение, 1% - множественную лекарственную устойчивость и 82% были учтены как успех лечения. Вероятность регистрации внелегочного ТБ у детей и случаев иностранного происхождения была как минимум в два раза выше, чем у взрослых и случаев среди коренного населения, соответственно. Распределение клинических проявлений в каждой из этих двух групп риска заметно отличалось от остальных случаев.

<sup>2</sup> 18 стран высокого приоритета (СВП): Азербайджан, Армения, Беларусь, Болгария, Грузия, Казахстан, Кыргызстан, Латвия, Литва, Республика Молдова, Румыния, Российская Федерация, Таджикистан, Туркменистан, Турция, Украина, Узбекистан и Эстония.

# 1. Background and technical note







# 1. Background and technical note

Between 1996 and 2007, TB surveillance data from the European Region were collected and analysed annually under the 'EuroTB' project.

Since 1 January 2008, ECDC and the WHO Regional Office for Europe (WHO/Europe) have jointly coordinated the collection and analysis of TB surveillance data in Europe, aiming to ensure data standardisation and high quality across the countries of the WHO European Region (except Liechtenstein, Monaco and San Marino). The underlying standards and definitions have been agreed by leading European experts [1].

This year's report highlights two subsets of TB cases that tend to be neglected by routine surveillance: extrapulmonary TB cases (based on data from The European Surveillance System (TESSy)) and prisoners with TB (based on Tuberculosis Monitoring and Evaluation (TME) data).

The data published in this report may vary from figures in national reports due to different reporting periods. The deadline for correcting and updating the data in the joint database used in this report was 31 October 2012.

## 1.1 Data reporting and analysis

Designated experts within the national surveillance institutes submitted their TB surveillance and control programme management data for 2011 electronically to the ECDC–WHO/Europe Joint TB Information System via a common portal<sup>3</sup>. The TB surveillance data from the European Union and European Economic Area (EU/EEA) countries were redirected to The European Surveillance System (TESSy) platform hosted by ECDC (Annex 1). The surveillance data from the non-EU/EEA countries and the programme management data from the entire European Region were processed through WHO's Tuberculosis Monitoring and Evaluation (TME) platform. A total of 29 EU/EEA Member States reported case-based data<sup>4</sup>. They were also asked to provide updates for 2008, 2009 and 2010 to allow for the exclusion of duplicate cases or those later found not to have TB, as well as for updates of treatment outcome variables. The remaining countries of the European Region reported aggregate data.

The TESSy variable list for the 2012 data collection (Annex 2) has undergone some minor changes to facilitate the reporting of molecular surveillance data: 'IsolateID' has replaced 'StrainNumber', and a new variable ('ECDCIsolateID') has been added.

Reporting completeness (Annex 3) varied among countries due to differences in national surveillance systems,

legislation and TB case ascertainment. Although the quality and comparability of reported data have improved considerably in recent years, the reader is still cautioned against making direct comparisons across countries.

For the calculation of notification rates, country population denominators by age group and gender were obtained from Eurostat<sup>5</sup> for the EU and EEA countries and from United Nations statistics<sup>6</sup> for all others. Overall notification rates were directly age-standardised using a 2000–2010 EU/EEA average as the standard population.

Notification data were analysed by the main epidemiological (location, gender and age) and case management determinants (history of previous anti-TB treatment, localisation of disease, laboratory results and HIV serostatus). Where relevant, particularly for countries in the EU/EEA, analyses were stratified by origin of the case (native/foreign origin).

Correlations were expressed as Spearman's rank correlation coefficients and considered significant if  $p < 0.05$ . Associations between variables were quantified as prevalence ratios and their 95% confidence intervals, assuming an association if the confidence interval did not include 1.

### TB/HIV co-infection

Belgium, Bulgaria, Czech Republic, Estonia, Iceland, Ireland, Luxembourg, Malta, Romania, Slovenia, Slovakia and Spain reported case-based HIV serostatus, while France, Latvia, the Netherlands and all non-EU/EEA countries submitted this information in aggregate format via TME. Denmark, Finland, Hungary and Poland reported the number of HIV-infected TB cases, but not the denominator of known HIV test results, and were therefore excluded from the analysis. The number of cases with known HIV status was expressed as a percentage of all reported TB cases. To be considered complete HIV data must be available for >50% of all TB cases. Only EU/EEA countries reported TB/HIV cases by site of disease (Table H).

### Drug resistance

Since the reporting year 1998, the results of drug susceptibility testing (DST) from initial isolates of *Mycobacterium tuberculosis* have been collected for isoniazid, rifampicin, ethambutol and streptomycin. Data on second-line drug resistance for amikacin, kanamycin, capreomycin, ciprofloxacin and ofloxacin have been reported via TESSy since 2008 and via CISID/TME since 2009. In countries where DST results are linked to TB case notifications, case-based information on DST is collected (26 countries in 2011). When individual DST data are not available, data are collected in aggregate format in CISID/TME on the basis of previous

<sup>3</sup> ECDC/WHO/Europe Joint Surveillance <http://www.ecdcwhosurveillance.org/>

<sup>4</sup> As Liechtenstein only provided TB data for five cases in 2007, it is not included in the commentary.

<sup>5</sup> Available from: <http://epp.eurostat.ec.europa.eu/portal/page/portal/eurostat/home/>

<sup>6</sup> Population by UN Population Division, World Population Prospects: The 2010 Revision, medium variant (2012).

anti-TB treatment history. Information on the organisation and laboratory practices of anti-TB DST in the country is also collected using the TME module of the joint TB surveillance system. Drug resistance surveillance (DRS) methods vary across countries. Initial DST results may be collected routinely for all culture-positive TB cases notified, or only for cases included in specific surveys or diagnosed in/referred to selected laboratories. Geographic coverage of DRS is partial in Azerbaijan, Italy, Kyrgyzstan, Spain, Tajikistan, Turkey, Turkmenistan and Uzbekistan.

DRS data are considered as complete if:

- they are collected nationwide and linked to TB case notification in countries using culture routinely (>50% culture confirmation);
- DST results for isoniazid and rifampicin are available for >80% of culture-positive cases and;
- External Quality Assessment (EQA) results show 95% or more confirmation by a supranational reference laboratory.

Data were reported on DST for isoniazid, rifampicin, ethambutol and streptomycin at the start of treatment. Percentages of laboratory-confirmed drug-resistant cases were calculated using as a denominator those cases for which DST results were available for at least isoniazid and rifampicin. If the cases had DST results for ethambutol and streptomycin these were also shown. The results of DST for second-line drugs were analysed for MDR cases only.

### Treatment outcome monitoring (TOM)

Since the reporting year 2002, treatment outcome data have been provided by EU/EEA countries through the submission of an updated dataset for cases notified one year prior to the year of reporting. The same applies to MDR treatment outcome for cases reported two years earlier. Thus, as part of the 2012 data call, outcome data were collected for TB cases notified in 2010, and MDR-TB cases reported in 2009. Non-EU/EEA countries have reported similar aggregated treatment outcome data for the past three years. This report includes a data analysis for outcome at 12 months and first-time outcome at 24 months after starting treatment.

Case cohorts eligible for outcome analysis are expected to include all laboratory-confirmed pulmonary TB cases notified in the calendar year of interest, although the confirmation level varies, especially among the non-EU/EEA countries. For countries reporting case-based data, the most recently updated information has been used for the purposes of this report. Hence, for these countries, the cohort is defined on the basis of the new dataset, updated following initial notification. This could result in denominators differing from the number of notified cases reported in the previous year's report. For countries reporting aggregate outcome data, completeness of cohorts is assessed by comparing the total number of cases included in TOM cohorts with those initially notified as pulmonary and culture or smear-positive, depending on the type of cohort.

### Geographical areas

The 27 EU Member States and three EEA countries are presented separately in tables and in Chapter 2.2. These are: Austria, Belgium, Bulgaria, Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Iceland, Ireland, Italy, Latvia, Liechtenstein, Lithuania, Luxembourg, Malta, the Netherlands, Norway, Poland, Portugal, Romania, Slovakia, Slovenia, Spain, Sweden and the United Kingdom.

The 24 remaining countries in the WHO European Region (non-EU/EEA) are: Albania, Andorra, Armenia, Azerbaijan, Belarus, Bosnia and Herzegovina, Croatia, Georgia, Israel, Kazakhstan, Kyrgyzstan, the former Yugoslav Republic of Macedonia, Moldova, Monaco, Montenegro, Russia, San Marino, Serbia, Switzerland, Tajikistan, Turkey, Turkmenistan, Ukraine and Uzbekistan.

In order to highlight the 18 high-priority countries (HPC) [3] identified by WHO, their data are presented in italics and as subtotals alongside the subtotals for the EU/EEA and non-EU/EEA Member States. The 18 HPC are: Armenia, Azerbaijan, Belarus, Bulgaria, Estonia, Georgia, Kazakhstan, Kyrgyzstan, Latvia, Lithuania, Moldova, Romania, Russia, Tajikistan, Turkey, Turkmenistan, Ukraine and Uzbekistan.

TB notifications from Greenland are footnoted in tables but are not included in the totals for the European Region.

## 1.2 Definitions

### TB case definition for surveillance

Information from EU/EEA countries was collected to enable the classification of cases according to the case definition approved by the EU Member States and published by the European Commission [4]. It classifies cases as 'possible', 'probable' or 'confirmed'. Possible cases meet clinical criteria only. Probable cases are defined by the additional detection of acid-fast bacilli (AFB) or *M. tuberculosis* nucleic acid or granulomata. Confirmed cases require a positive culture or detection of both AFB with microscopy and *M. tuberculosis* in nucleic acid amplification test.

Data from the remaining countries of the European Region follow the WHO-recommended definition. This defines a 'case of tuberculosis' as a patient in whom TB has been confirmed by bacteriology or diagnosed by a clinician. A 'definite case' is defined as a patient with culture confirmation of *Mycobacterium tuberculosis* complex. In countries where culture is not routinely available, a patient with one sputum smear-positive for AFB (AFB+) is also considered a definite case.

Cases discovered post-mortem, with gross pathological findings consistent with active TB that would have indicated anti-TB treatment had the patient been diagnosed before dying, also fit the clinical criteria and are included.

### Previous anti-TB treatment status

**Never treated (new case):** a case never having previously received drug treatment for active TB, or having received anti-TB drugs for less than one month.

**Previously treated case (retreatment case):** a case previously diagnosed with TB having received treatment with anti-TB drugs (excluding preventive therapy) for at least one month. Previously treated cases were reported from 24 EU/EEA Member States. In the remaining five (Belgium, Denmark, Ireland, Norway and United Kingdom), information about previous treatment was not collected or incomplete and previous diagnosis was reported instead and used as a proxy for previous history.

**Relapse (Table 5):** a case previously diagnosed with TB and then re-diagnosed as a definite (laboratory-confirmed) tuberculosis case after having been declared cured or having completed treatment (smear-negative pulmonary and extrapulmonary cases may also be relapses if supported by pathological or bacteriological evidence).

### Site of disease

**Pulmonary case:** a case with TB affecting the lung parenchyma, the tracheo-bronchial tree or the larynx are also included in pulmonary TB for cases reported to TESSy.

**Extrapulmonary case:** a case with TB affecting any site other than pulmonary (see above). Pleural TB and intrathoracic lymphatic TB by themselves are considered as extrapulmonary. Detailed information on further distribution of extrapulmonary cases was provided by 25 EU/EEA countries.

### Notes on the definition

- The above definitions are in accordance with the European Commission's approved definitions for TB surveillance.
- All possible, probable and confirmed cases are reported to the joint European surveillance database. For countries with laboratory-based reporting where no clinical information is available, laboratory-confirmed cases should be reported.
- Cases should be notified only once in a given 12-month period. However, a case should be reported again if the diagnosis of confirmed tuberculosis is made following completion of anti-TB treatment (relapse case), even if this occurs within 12 months of reporting the initial episode of disease.
- Cases which have never been treated are commonly referred to as new cases, although this term should not be considered to indicate incidence in the strict epidemiological sense.
- Among re-treated cases, relapses are included in notifications from all countries, whereas cases re-treated after failure or default and chronic cases are not included. DST data have been analysed for laboratory-confirmed cases.

### Origin

The geographic origin of a TB case is classified according to place of birth (born in the country/foreign origin) for Bulgaria, Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Germany, Iceland, Ireland, Italy, Latvia, Liechtenstein, Lithuania, Luxembourg, Malta, Netherlands, Norway, Portugal, Romania, Slovakia, Slovenia, Spain, Sweden and United Kingdom. The countries of Austria, Belgium, Poland, Greece, Hungary, Armenia, Belarus, Bosnia and Herzegovina, Georgia, Kazakhstan, Kyrgyzstan, Moldova, Montenegro, Russia, Serbia, Tajikistan, Ukraine and Uzbekistan use the classification of citizenship (citizen/non-citizen). In Denmark, the birthplace of the parents is also used to classify origin (similarly, in the Netherlands the birthplace of parents is notified for case management purposes). The country of origin is included in case-based data. The term 'native' as used in this report refers to cases born in, or having citizenship (nationality) of the country of report. 'Foreign origin' refers to cases born in (or citizens of) a country different from the reporting country.

### Drug resistance

**Resistance among cases never treated:** indicates primary drug resistance due to infection with resistant bacilli.

**Resistance among cases previously treated:** usually indicates acquired drug resistance emerging during treatment as a consequence of selection of drug-resistant mutant bacilli. It can also result from exogenous re-infection with resistant bacilli.

**Multidrug resistance (MDR):** resistance to at least isoniazid and rifampicin.

**Extensive drug resistance (XDR):** resistance to (i) isoniazid and rifampicin (i.e. MDR), and (ii) resistance to a fluoroquinolone, and (iii) resistance to one or more of the following injectable drugs: amikacin, capreomycin, or kanamycin [5].

### Treatment outcome

#### Cohort

All TB cases notified in the calendar year of interest, after exclusion of cases with final diagnosis other than TB or cases found to have been reported more than once.

Note: MDR-TB cohort (2009): 24 month outcome was collected for MDR-TB cases notified in 2009.

#### Period of observation

Cases are observed until the first outcome up to a maximum of 12 months after the start of treatment. For multidrug-resistant cases in EU/EEA countries, treatment outcome after 24 months should be reported if treatment lasts longer than 12 months and the reported 12-month outcome is coded as 'still on treatment'<sup>7</sup>. Non-EU/EEA countries evaluate treatment outcomes according to the WHO definition.

<sup>7</sup> The degree of adherence to the 12-month limit is unknown, and a number of countries are known to exceed it. Outcome at 36 months is not included in the report.

### Treatment outcome categories

In general, the outcome categories used are those recommended, with two additional categories: 'still on treatment at 12 months', and 'unknown' [6]. The categories are as follows:

**Cured:** treatment completion and:

- culture-negative samples taken at the end of treatment and on at least one previous occasion;

or

- in countries where sputum smear-positive cases are classified as definite (laboratory-confirmed), sputum microscopy negative for AFB at the end of treatment and on at least one previous occasion.

**Cured for MDR-TB:** MDR-TB patient who has completed treatment according to programme protocol and has at least five consecutive negative cultures from samples collected at least 30 days apart during the final 12 months of treatment.

**Completed:** treatment completed, but does not meet the criteria to be classified as cured or treatment failure.

**Failed:** culture or sputum smear remaining positive or becoming positive again five months or later into the course of treatment. Patients found to be infected with an MDR strain at any point during that episode of treatment are also included in this definition, whether they were initially smear-negative or -positive.

**Failure for MDR-TB case:**

- Two or more of the five cultures recorded in the final 12 months of therapy are positive, or any one of the final three cultures is positive;

or

- a clinical decision has been made to terminate treatment early because of poor clinical or radiological response or adverse events. The latter failures can be indicated separately in order to perform a sub-analysis [6].

**Died:** death before cure or treatment completion, irrespective of cause.

**Defaulted:**

- Treatment interrupted for two months or more, not resulting from a decision of the care provider;

or

- patient lost to follow-up for two months or more before the end of treatment, except if transferred.

**Transferred:** patient referred to another clinical unit for treatment and information on outcome not available.

**Still on treatment<sup>8</sup>:**

- Patient still on treatment at 12 months without any other outcome during treatment;

or

- patient reported as still on treatment at 12 months and still on treatment at 24 months without any other outcome.

**Unknown:** information on outcome not available, for cases not known to have been transferred.

**In this report:**

- 'Success' refers to the combined treatment outcome categories cured and completed.
- 'Lost to follow-up' is the combination of transferred and unknown for country profiles.

<sup>8</sup> Definition applicable to the EU/EEA countries only.

## 2. Commentary





## 2. Commentary

### 2.1 The WHO European Region

#### Key conclusions for the European Region

- In 2011, the countries of the WHO European Region reported 295 968 new episodes (new and relapses) of TB (33 per 100 000 population) out of an estimated 380 000 (range 321–437 000), which would correspond to 42 cases per 100 000 population (range 36–49). More than 85% of them were in the 18 high priority countries (HPC) of the WHO European Region.
- The Region maintained a relatively high case detection rate for all cases: 78% (range 67–92%).
- More than 44 000 (44–46 000) deaths were estimated to have been caused by TB in the Region (4.9 per 100 000 population) (range 4.7–5.3). Overall, 92% of deaths occurred in the 18 HPC.
- The notification shows a 24% decrease compared to 2005, however there is a significant difference in TB notification rates among the countries, from 2 to 119 per 100 000 population.
- In ten countries of the Region (all in EU/EEA), the under-fives accounted for more than half of the cases detected among children.
- In 2011, there were 12 751 (56.5%) TB cases with HIV co-infection detected from the 22 500 (range 18–27 000) estimated in the WHO European Region. Estimated prevalence of HIV infection among incident TB patients was 6% (range 5.6–6.2%), with 3.6% of these cases occurring in the EU/EEA countries and 6.5% in the non-EU/EEA countries. Due to the low reporting coverage of HIV testing (60%), only 12 751 (6.2%) of the 205 578 new TB and previously treated cases were found to have HIV co-infections. Three countries reported higher rates of HIV positivity among TB patients: Ukraine (18.5%), Malta (16.7%) and Estonia (15%).
- Of the 78 000 estimated MDR-TB cases in the Region, around 30 000 (38%) were detected in 2011. In all, 98% of them were reported by 18 HPC. The prevalence of MDR among new TB cases in the Region amounted to 14% and 47.7% among previously treated cases. Although testing coverage for XDR has almost doubled in the Region, it is still only at 9%, documenting that 11% of MDR-TB patients are XDR-TB.
- Treatment success of new TB patients and previously treated patients is still very low (67.2% and 49.2% respectively). Over the last five years, a gradual decrease in treatment success has been noted in the Region.

- The number of MDR-TB patients with reported treatment outcome almost doubled compared to last year (from nearly 7 000 to over 12 000), however the treatment success rate was lower among MDR-TB patients (56.3–48.5%) respectively and some Member States in western Europe still do not provide information on treatment outcome.
- In response to the alarming problem of MDR-TB, all 53 Member States have fully endorsed the Consolidated Action Plan to Prevent and Combat Multidrug- and Extensively Drug-Resistant Tuberculosis in the WHO European Region 2011–2015 and its accompanying Resolution EUR/RC61/R7 from the sixty-first session of the WHO Regional Committee for Europe in 2011. The Action Plan includes a set of activities for countries, WHO and partners in order to achieve universal access to prevention and treatment of M/XDR-TB. WHO is currently preparing a detailed report on progress with the implementation of the Consolidated Action Plan to Prevent and Combat Multidrug- and Extensively Drug-Resistant Tuberculosis in 2013.

#### Tuberculosis burden estimates

The 2015 Millennium Development Goal target of halting the prevalence and death associated with TB and reversing its incidence has been partially achieved, with TB incidence having fallen in the Region at a rate of around 5% per year between 2000 and 2011. TB prevalence was estimated at 56 (range 34–101) cases per 100 000 population in 2011 and the target for TB prevalence is on track to drop to 34 cases per 100 000 population in 2015. However, in 2011, TB mortality was 4.9 (range 4.7–5.3) deaths per 100 000 population and the Region will therefore not achieve the target of 50% reduction by 2015 compared to 1990 (4.4 per 100 000 population in 1990 and 8 per 100 000 population in 2000).

The burden of TB in the European Region varies among and within the countries, from a range of less than one TB case per 100 000 population in some to over 200 TB cases per 100 000 in others. Even within each of the countries in western Europe, there are significant differences from one region to another, with TB rates above 100 per 100 000 population in some areas.

The WHO European Region accounts for around 4.4% of the newly detected tuberculosis and relapse cases in the world [2]. This represents the emergence in the Region of an estimated 380 000 (range 321–437 000) individuals with a new episode of TB (new or relapse) during 2011. The incidence in the Region amounts to an estimated 42 (range 36–49) per 100 000 population (Table 1, Figure 1).

In 2011, case detection rates increased to 78%.

Over 44 000 (44–46 000) deaths were attributed to TB, equivalent to 4.9 (range 4.7–5.3) per 100 000 population.

The vast majority of TB cases occur in the 18 HPC<sup>9</sup>. These countries represent 87% of the TB incidence and 92% of the mortality caused by TB in the Region (Figure 2).

Out of an estimated 78 000 MDR-TB cases in the European Region in 2011, around 30 000 (38%) were detected. A total of 98% of these were reported by the 18 HPC.

In 2011, HIV infection was a contributory factor in 6% (5.6–6.2%) of the total incident (new and relapse) TB cases in the Region, representing 3.6% (3.2–4%) in the EU/EEA group of countries and 6.5% (6.2–6.7%) in the non-EU/EEA group of countries (Table 2). The countries with significantly high proportions of HIV are Ukraine (20%), Malta (17%), Estonia (15%) and Portugal (14%).

### Trends in notification

In 2011, a total of over 380 000 TB cases were reported from 51 countries<sup>10</sup> in the WHO European Region (42 per 100 000 population) (Table 3). This represents a 27% decrease on the 2007 rate (53.6 per 100 000), a 5.6% decrease on 2010 (43.6) and a 5.7% mean annual decrease for the period 2007–2011. However, during 2007–2008, there was an increase in notification of all types of TB in the Region, largely due to changes in the notification policy for TB patients in Kazakhstan and Russia. This policy meant that previously notified cases were included in the category of previously treated, thus artificially inflating the number of cases in Kazakhstan and Russia by counting them twice. Since 2009, none of the countries in the Region report prevalent TB cases in the overall notification.

During the period 2005–2011, a 24% decline in notification rates was observed (around 295 968 new TB cases

and relapses), decreasing from 41 to 33 cases per 100 000 population (Table 5). This trend reflects a true reduction in the spread of the disease, strongly influenced by the 24% decrease in notification rates in the Region's 18 HPC (from 80 to 64 per 100 000 population) (Figure 4). Before 2004 there was a sustained plateau in the notification rate for new TB and relapses. Nevertheless, despite encouraging trends, the notification rate of new and relapse cases in the HPC remained twice as high as for the Region overall (64 compared with 33 cases per 100 000), and more than 5.3 times higher than the rate in the EU/EEA (12 cases per 100 000 population).

The notification rate of new and relapse cases varies widely among countries, from two (Luxemburg) to 119 (Moldova) per 100 000 population (Table 5). It is noteworthy that some countries, including Luxemburg, have a considerably high (more than 25%) proportion of patients with unknown treatment history and, as a result, have reported less new and relapse cases. In addition to Moldova, there were three countries with notification rates above 100 per 100 000 population for new and relapse cases: Kyrgyzstan (103), Georgia (105) and Kazakhstan (113).

After accounting for effect of age, when applying the standardised notification rate only for new cases Tajikistan reaches the level of 111 per 100 000 population, versus the crude rate of 85, indicating that the relatively low notification rate in Tajikistan is due to the large child population, which shifts the crude rates towards lower values.


In 2011, the number of countries with low notification of new and relapse cases (less than 20 cases per 100 000) [1] was 32. All of these 32 countries are in the western and central part of the Region and the majority of them are high-income countries<sup>11</sup> which account for 16% of the notified burden in the Region. Nine countries reported new or relapse case rates of between 20 and 50 per 100 000 population: Turkey (20.4), Poland (20.8), Estonia (22.2), Portugal (22.7), Bulgaria (29.0), Bosnia and Herzegovina

9 The 18 countries are: Armenia, Azerbaijan, Belarus, Bulgaria, Estonia, Georgia, Kazakhstan, Kyrgyzstan, Latvia, Lithuania, Moldova, Romania, Russia, Tajikistan, Turkey, Turkmenistan, Ukraine and Uzbekistan.

10 There are 53 countries in WHO European Region. San Marino and Turkmenistan did not report data in 2011.

11 High-income countries are those with a per capita gross national income of USD 12 476 or more in 2011, as defined by the World Bank (<http://data.worldbank.org/about/country-classifications>).

**Figure A: Estimated TB incidence (per 100 000 population) and case detection rates (as a percentage), WHO European Region, 1990–2011**



Global TB database, WHO (<http://www.who.int/tb/country/data/download/en/index.html>), accessed on 3 January 2013.



(36.2), Latvia (38.8), Armenia (40.7) and Belarus (49). Seven reported between 50 and 100 cases per 100 000 population: Uzbekistan (52), Lithuania (54), Azerbaijan (70), Ukraine (76), Russia (79), Romania (80) and Tajikistan (90). The 11 countries with new and relapse case notifications above 50 per 100 000 account for around 76% of the regional burden, with the largest contribution coming from Russia: 112 910 cases and 15% of the Region's population (143 million).

Due mainly to the revised case notification in Russia and Kazakhstan, the percentage of reported cases that had been previously treated decreased slightly, from 32% in 2007 to 29.8%<sup>12</sup> in 2008, and to 26.7% in 2011 (Table 3). The percentage of previously treated cases in 2011 was 12.3% and 30.1% for the EU/EEA and non-EU/EEA respectively.

There were 15 countries in which previously treated cases accounted for 15% or more of all TB cases: Azerbaijan (47.6%), Kazakhstan (45.1%), Russia (34.6%), Moldova (27.7%), Ukraine (26.9%), Andorra (25%), Romania (24.3%), Armenia (24.1%), Georgia (23.7%), Kyrgyzstan (22.3%), Estonia (22.3%), Belarus (21.0%), Lithuania (19.4%), Hungary (15.3%) and Macedonia (15.2%). Reasons for the high percentage of previous treatment among all cases include clinical failures and lack of programme management, possible re-infection and/or misclassification. TB cases with unknown treatment history were more often notified by countries in the western part of the Region.

<sup>12</sup> European Centre for Disease Prevention and Control/WHO Regional Office for Europe: Tuberculosis Surveillance Report in Europe, 2008. Stockholm: ECDC, 2010.

These included eight countries where more than 25% of TB cases identified had no previous treatment history: Luxemburg (53.8%), France (41.3%), Italy (39.8%), Austria (39.4%), Cyprus (37.0%), Belgium (26.8%), Ireland (27.8) and Switzerland (25.1%).


### Notification by site of disease

In 2011, pulmonary localisation was notified in about 81% of the overall TB cases in the Region, a proportion similar to that observed over the last five years. In EU/EEA countries a somewhat lower proportion of pulmonary localisation was seen (77%) than in non-EU/EEA countries (82%). Data completeness on disease localisation in the Region increased significantly in 2011, with only 5% of unknown disease sites remaining. However, four non-EU/EEA and one EU/EEA country still need to improve their notification by disease localisation: Armenia (15.0% unknown disease sites), Georgia (14.3%), Ukraine (13.5%), Switzerland (9.3%) and Denmark (24.7%). Extrapulmonary TB was notified on average for 13% of all TB cases in the Region. However, seven countries reported more than 30% of their tuberculosis cases to have extrapulmonary localisation, and four countries had rates exceeding 40%: Iceland (66.7%), United Kingdom (48.1%), Netherlands (43.8%) and Norway (43.8%).

### Notification by laboratory confirmation

Laboratory confirmation of TB diagnosis was reported for 123 525 (55.0%) of all 224 549 new pulmonary cases in the Region; 103 174 (45.9%) cases were confirmed by

**Figure B: Estimated TB incidence per 100 000 population, European Region, 2011<sup>a</sup>**



<sup>a</sup> Data from UN Administrated Province of Kosovo (in accordance with Security Council Resolution 1244 (1999)) is not included in the figures reported for Serbia

culture and 20 351 (9.1%) by microscopy (Table 8). New rapid methods to support TB diagnosis have recently been introduced in some countries of the Region, and this year for the first time limited data was reported on cases in EU/EEA countries that were confirmed by microscopy and nucleic acid tests. Confirmation of TB diagnosis by culture among newly detected pulmonary TB cases was lower in non-EU/EEA countries (40.3%) than in EU/EEA countries (69.2%) (Table 8). Nine countries had more than 30% of new pulmonary cases that were sputum smear negative and culture-positive, underlining the need for the culture of smear negative isolates: Sweden (42.7%), Finland (38.7%), Latvia (38.4%), Czech Republic (38.4%), Slovenia (36.8%), Belgium (33.3%), Estonia (32.4%), Cyprus (32.0%) and Israel (31.0%).

### Notification by gender and age

Although there were twice as many males reported as females among all TB cases (Table 3), a large variation was observed for male predominance in the gender distribution of TB cases. This ranged from an almost even distribution in Norway (1.2:1) to around three times greater in Armenia and Georgia (2.9:1 each). There were twelve other countries where the female to male ratio among TB cases was greater than two: Albania, Belarus, Czech Republic, Estonia, Greece, Israel, Lithuania, Malta, Poland, Russia, Romania and Ukraine. This gender difference in TB case notification most likely reflects the over-representation of males in the various risk groups for TB, notably the homeless, prisoners, seasonal migrant workers and HIV-infected individuals among men who have sex with men (MSM) and people who inject drugs (PWID).

In 2011, most (41%) of the newly detected TB cases in the European Region were in the 25–44 year age group (Table 11). This was also the most affected age group in both EU/EEA and non-EU/EEA countries, accounting for 35.4% and 39.9% of new TB notifications respectively. In eleven countries the oldest age group (65+ years) contained more than 25% of the new TB cases: Finland (49%), Bosnia and Herzegovina (35.4%), Serbia (31%), Croatia (30.9%), Slovenia (30.9%), Czech Republic (29.7%), Slovakia (29.1%), Germany (28.5%), Poland (26.1%), Greece (25.7%) and Hungary (25.5%).

During 2007–2011, region-wide trends of overall TB notification in children (age group 0–14 years) decreased by 23% in the Region from 8.7 to 6.7 cases per 100 000 population (Trends Table III). These trends were strongly influenced by the 23% decrease in TB notification among children observed in the 18 HPC (from 15.1 to 11.6 cases per 100 000 population). However, the average percentage of patients within this age group in the Region remained stable at around 6% over the same period (Table 11). In 14 of the Region's countries children represented more than 5% of all TB cases. In ten countries youngsters under the age of five years accounted for more than half of the cases detected among children: Czech Republic (83%), Hungary (67%), Austria (63%), Slovakia (59%), Switzerland (58%), Belgium (57%), Spain (56%), France (54%), Germany (51%) and Slovenia (50%) (Table 11).

### Tuberculosis and HIV co-infection.

Due to the limited information and HIV testing coverage still being reported by many countries, it is not possible to make comparisons between groups of countries, or to comment on temporal trends other than for single countries. In 2011, many countries increased their HIV testing coverage compared to 2010, while a significant reduction was reported by Kyrgyzstan (from 100% to 2.4%) and Russia (from 100% to 49.8%), most probably due to the gaps in their recording/reporting system. Among those countries reporting representative HIV testing, three could document a significant overlap of the HIV and TB epidemics by exceeding 15% HIV prevalence among new and re-treatment TB cases (Table 22): Ukraine (18.5%), Malta (16.7%) and Estonia (15%). A number of other countries follow with more than 5% HIV prevalence: Latvia (9.4%), Spain (9.1%), France (7%), Netherlands (6.7%), Israel (6.3%), Moldova (5.7%), Belgium (5.2%) and Russia (5.2%).

Of the EU/EEA countries that reported TB/HIV cases by site of TB disease, only 18% were extrapulmonary TB cases and the proportion of HIV testing was similar to that for pulmonary TB cases (51.1% vs. 58.2%). The rate of HIV infection was higher among the extrapulmonary TB cases tested than the pulmonary TB cases (6.1% vs. 3.9%).

### Notification by history of imprisonment

There are still too few countries reporting complete quality data on TB detection in prisons (Table A). The most important information is missing from those countries that have high prison population rates<sup>13</sup> such as Kazakhstan and Russia. Among those countries reporting complete data, three had TB cases in prisons exceeding 10% of the countrywide total of new TB cases: Georgia (20.8%), Slovakia (18.9%) and Israel (11%). The highest TB notification rates in prisons were in Azerbaijan (1984 per 100 000 detainees), Lithuania (948 per 100 000 detainees), Tajikistan (886 per 100 000 detainees) and Slovakia (856 per 100 000 detainees). The highest relative risk of TB in prison is calculated for Slovakia (1445 RR) and Israel (57 RR). Given that so few countries report, it is difficult to calculate how much prisons contribute to the regional TB burden. Countries with high TB incidence and large prison populations are thought to contribute significantly. The high TB relative risk in prisons is not related to the level of TB incidence in the country but to the higher TB transmission there due to poor control measures and/or the concentration of vulnerable sub-groups of populations (such as immigrants from high TB incidence countries).

### Notification by patient origin

TB cases of foreign origin represent 25.8% of the total TB cases (new and relapse) reported from EU/EEA countries and only 2.1% from non-EU/EEA countries (Table 13). TB cases of foreign origin represent a large majority in many countries: Israel (89.5%), Sweden (89.4%), Norway (87.8%), Malta (84.8%), Cyprus (83.3%), Luxembourg (80.8%), Iceland (77.8%), Switzerland (74%), the Netherlands (70.5%) and

13 Walmsley R. World prison population list (Ninth Edition). London: International Centre for Prison Studies, 2012.

United Kingdom (70.1%). This is also an indication that access to TB diagnosis in these countries is good and that they are committed to global efforts towards TB control. The smaller number of TB cases reported by origin (comparing Table 13 with Table 4) may diminish the TB epidemiological relevance of recent and past immigration, especially in some of the non-EU/EEA countries. Extrapulmonary TB was reported as higher among foreign-origin cases than among pulmonary TB cases in EU/EEA countries (37.8% vs. 16.5%) (Table F). EU/EEA countries also reported MDR-TB by origin (Table 21), showing higher rates of DST but lower rates of MDR-TB in foreign-origin than in native cases (67.7% vs. 45.7% and 3.4% vs. 5.4% respectively). This is probably the result of a more selective DST among native TB cases.

### Laboratory network performance

Forty-five countries in the WHO European Region reported on their laboratory capacity. In total, these countries have 7 879 laboratories performing sputum smear microscopy, 1 735 laboratories performing mycobacteriology cultures and 578 performing drug susceptibility testing (DST) (Table 15). The methods for rapid detection of TB and MDR-TB were the WHO recommended line probe assay (LPA) and, for the first time, the Xpert MTB/RIF assay. In all, 157 laboratories used the LPA and 104 used the Xpert MTB/RIF assay. Although the number of smear microscopy laboratories in non-EU/EEA countries is much higher than in the EU/EEA countries (6 547 vs. 1 332), the number of laboratories able to perform culture, DST and rapid diagnosis is much lower in non-EU/EEA countries (639 in non-EU/EEA vs. 1 096 in EU/EEA countries for culture, 208 vs. 370 for DST, 39 vs. 118 for LPA, and 40 vs. 64 for Xpert MTB/RIF, respectively). If we look at the number of laboratories in relation to the number of TB cases, the availability of microscopy is nearly equal in the EU/EEA and non-EU/EEA. However, the limited availability of culture, DST and rapid diagnosis in non-EU/EEA countries becomes even more pronounced.

Forty-three of the 45 countries reporting on their laboratory network had established in-country external quality assurance (EQA) systems for smear microscopy and DST, and 42 participated in international EQA programmes for DST. Reporting on the results of the quality assurance was incomplete and also suggests that the performance of the laboratory network in some countries is poor and requires better coordination and monitoring at national level. International EQA shows good quality of DST at national reference laboratory level. All except three countries scored over 95% of DST results correctly for isoniazid and rifampicin.

Laboratory data from 19 countries in the EU/EEA and seven non-EU/EEA countries are based on defined criteria (national coverage of 100% or culture results available for 90% of all cases; 50% of all cases culture-positive, with DST results for 80% of culture-positive cases and EQA results matching for 95% or higher) (Table 16). Of the 380 474 cases registered in the countries of the Region, 40.8% (155 145) were confirmed by culture. This confirmation rate was slightly higher than in 2010 when it was 39.3%. The culture confirmation rate was much higher in EU/

EEA than in non-EU/EEA sub-regions (63.5% vs. 35.4%). The percentage of positive cultures subjected to DST for first-line drugs decreased from 85.7% (131 007) in 2010 to 82.5% (127 936) in 2011 (Table 16).

### Multidrug-resistant tuberculosis notification

In 2011, 49 countries in the Region reported on first-line anti-TB drug susceptibility test results, representing a slight decrease on 2010 when all countries reported data. In 2011, the prevalence of MDR-TB among 89 877 new TB cases tested for first-line DST in the Region was 13.2%, which is similar to the 2010 data (12.9%). While 14 countries reported 0 or less than 1% MDR among new TB cases, for six countries this rate was over 20% (Table 17). Except for the Baltic States, where MDR-TB among new cases varied from 11.1% in Lithuania to 22.9% in Estonia, the prevalence was 4% or lower in all EU/EEA countries. In the non-EU/EEA area, four countries had an MDR-TB prevalence ranging from 10–20% among new cases tested for first-line DST. Five countries had an even higher prevalence: Belarus (26%), Moldova (26.0%), Kazakhstan (30.3%), Uzbekistan (35.1%) and Tajikistan (44.7%). The data from Tajikistan and Uzbekistan are not representative for the whole country and therefore should be interpreted with care.

The proportion of MDR-TB among 31 929 previously treated TB cases whose isolates were tested for first-line DST was 46.4%, comparable to the rate measured in 2010 (49.9%). Twelve countries had between 15% and 50% MDR-TB among previously treated cases tested for first line DST. In eight countries this rate was even higher: Kazakhstan (51.3%), Ukraine (51.7%), Russia (52.8%), Estonia (57.7%), Moldova (63.8%), Belarus (65.6%), Uzbekistan (72.4%) and Tajikistan (74.2%) (Table 17). However, due to the fact that data from some countries is not nationally representative, these data should be interpreted with care (Table 16).

Over the past five years the MDR-TB notification rate among culture-positive cases with available DST results has been collected and trends have differed significantly by country (Trends Table VI). Overall, in the past five years the rate of MDR among tested cases was stable in the EU/EEA Region (4.5% in 2011). In the non-EU/EEA countries it increased from 20.3% in 2007 to 30.2% in 2011.

When scaling up the rapid tests for MDR-TB detection, it should be noted that the percentage of isolates resistant to at least rifampicin but not to isoniazid is only 0.5% among new cases and 0.9% among previously treated cases (Tables 18 and 19). This underlines the strong correlation between rifampicin and MDR-TB in the Region and justifies the use of rifampicin as a marker for MDR-TB.

### XDR-TB notification

In 2011, only 34 countries reported on second-line DST (21 EU/EEA and 13 non-EU/EEA countries, Table 20). Of the 3 448 MDR-TB cases subjected to second-line DST, 381 (11.0%) were extensively drug-resistant (XDR-TB). Compared to 2010, twice as many MDR-TB isolates were subjected to second-line DST in 2011. However, the prevalence of MDR in the Region was comparable to that for 2010. In EU/EEA countries, where SLD testing was reasonably high (70.7%

of MDR-TB cases were tested for SLD), prevalence of XDR among MDR cases was 13.4%, which is slightly higher than the prevalence recorded in 2010 (12.6%). These percentages represent 136 and 114 cases, respectively. In contrast, the number of XDR-TB cases among MDR cases tested for second-line drugs reported from non-EU/EEA countries (where only 9.6% of notified MDR cases had an SLD DST result) decreased from 11.9% in 2010 to 10.0% in 2011. The XDR-TB prevalence varies widely from country to country (from 0 to 40%), however the small number of cases tested and probable selection bias dictates caution in interpreting these results. In Belarus, within the framework of a nationwide anti-TB drug resistance survey in Minsk, SLD DST conducted among 107 MDR patients yielded 14.0% (15/107).

### Treatment outcome

In 2010, the treatment success rate among 98 433 newly detected TB cases with laboratory-confirmed pulmonary disease was 67.2% (Table 23). This represents a further slight decrease on the treatment success rates recorded in previous years (68.7% for 2009, 69.7% for 2008, 70.7% for 2007 and 73.1% for the 2006 yearly cohorts) and may be explained by an increase in failures due to the growing MDR-TB burden and other unfavourable outcomes. The treatment success rate was higher in the EU/EEA countries than in non-EU/EEA countries (76.8% vs. 63.4%). Only eleven countries reached the target of 85% treatment success among newly detected cases with laboratory-confirmed TB. Another six were close to the target, with success rates between 80 and 85%. Four countries had treatment success rates below 60%. The lower overall success rate for the non-EU/EEA area was impacted mainly by Russia and Ukraine, which together represented 61% of cases in this sub-Region and reported treatment successes of 53.1% and 59.8% respectively.

In the 2010 yearly cohort, a total of 8 321 (8.5%) new pulmonary laboratory-confirmed cases were reported to have died, 5.8% to have defaulted and 11.7% to have had treatment that failed. These unfavourable outcomes were lower in the EU/EEA countries than in the rest of the Region, exemplified by the proportion of patients with failed treatment – 1.6% in EU/EEA versus 15.7% in non-EU/EEA countries (Table 23). Seven of the 12 countries with lethal outcomes in excess of 10% were in the EU/EEA countries. Six countries reported a treatment failure rate greater than 10%; Armenia (15.0%), Belarus (22.5%), Russia (23.1%), Ukraine (16.7%), Georgia (11.6%) and Tajikistan (10.7%). The high failure rates can largely be explained by the high MDR-TB prevalence in these countries. Kazakhstan reported a 26.9% treatment outcome for the category transferred or unknown. Because of the current definition of treatment outcomes, countries applying rapid diagnostic sensitivity tests are likely to report better outcomes, by placing new MDR cases directly into second-line treatment programmes, bypassing the new cases cohort. A revision of the case definition was recommended by the WHO's Strategic and Technical Advisory Group for Tuberculosis (STAG-TB) and is expected to be rolled out for implementation in the second quarter of 2013.

Other reasons for poor treatment outcomes are the high rate of HIV co-infection, shortage of drug supplies and high rates of drug use and alcoholism in some countries [7–9].

Six non EU/EEA and nine EU/EEA countries have reported treatment default rates above five percent among new sputum smear positive pulmonary TB patients. High default rates in some Member States require further investigation to determine the reasons for treatment interruption and there should be appropriate intervention for patients in programmes.

As expected, the treatment outcome among previously treated TB cases was lower than among newly detected cases. The treatment success rate among 56 234 laboratory-confirmed cases notified in 2010 with previously treated pulmonary disease was 49.2% (Table 24), a slight increase on the 48.0% recorded in 2009. As with the new TB cases, the success rate was higher in the EU/EEA countries than in non-EU/EEA countries (53.7% vs. 48.6%). Nine countries had a treatment success rate of 50% or lower among previously treated TB cases. Eleven had a success rate above 70%, and six of these had a success rate of 80% or higher: Finland (85.7%), Slovakia (82.8%), Albania (90.0%), Bosnia and Herzegovina (95.0%), Israel (80.0%) and Montenegro (85.7%). These countries reported very few cases, except for Bosnia and Herzegovina which reported on the outcome of 101 cases. Out of all the previously treated cases in the Region with unsuccessful outcomes 10.4% died, 16.7% failed and another 10.3% defaulted.

The treatment outcome of 12 110 MDR-TB cases, all representing culture-confirmed MDR-TB cases notified in 2009, was reported by 34 countries (Table 26). For the whole Region the treatment success among MDR-TB cases was 48.5% and, in contrast to the other cohorts, the proportion of successfully treated MDR-TB cases was higher in the non-EU/EEA countries than in the EU/EEA countries (50.8% vs. 31.6%). The countries that performed best were: Kazakhstan (73.2%), Azerbaijan (74.0%), Israel (83.3%), United Kingdom (75.0) and Sweden (84.6%). In EU/EEA countries, 19.8% of MDR-TB cases died, 19.8% failed and 19.9% defaulted, while in non-EU/EEA countries 15.8% died, 8.6% failed and 12.4% defaulted.

### Conclusions and recommendations

The 2015 Millennium Development Goal target of halting the prevalence and death associated with TB and reversing the incidence has been partially achieved, with TB incidence having fallen in the Region at a rate of about 5% per year between 2000 and 2011. The prevalence of TB was estimated at 56 (range 34–101) cases per 100 000 population in 2011 and the target for TB prevalence is on track to reach 34 cases per 100 000 population in 2015. However, in 2011, TB mortality was 4.9 (range 4.7–5.3) deaths per 100 000 population, meaning that the Region will not reach the target of 50% reduction by 2015 compared to 1990 (4.4 per 100 000 population in 1990 and 8.0 per 100 000 population in 2000).

As in the previous year, tuberculosis surveillance reveals a mixed epidemiological picture among the Member States

of the WHO European Region. Member States in the east have much higher notification rates than the west. Although the Region accounts for only 4.4% of the world's newly detected and relapsed TB cases, it reported about 300 000 new episodes of TB (33 per 100 000 population) out of an estimated 380 000 (range 321–437 000), which was 42 cases per 100 000 population (range 36–49). It also maintained a high case detection rate of 78% (range 67–92%). This demonstrates that, on average, the countries of the Region have one of the most sensitive surveillance systems in the world. More than 44 000 (44–46 000) deaths were estimated to have been caused by TB in the Region (4.9 per 100 000 population) (range 4.7–5.3).

TB notifications have been decreasing since 2005 from 41 to 33 cases per 100 000 population (295 968 new cases and relapses). Trends are confirmed by the fall in the registration of patients coming under the categories 'previous treatment history' and 'laboratory-confirmed' by smear or culture.

Despite this encouraging trend, notification rates for newly detected and relapsed TB cases in the 18 HPC remained almost eight times higher (64 per 100 000 population) than in the rest of the Region (8.8 per 100 000) and twice as high as the regional average (33 per 100 000 population).

Unknown treatment history and undocumented localisation of disease was more often reported by countries in the west of the Region. Similarly, the use of the standard definition also needs to be improved in some countries.

Culture confirmation of newly detected pulmonary TB cases was extremely low among non-EU/EEA countries (40.3%) compared with EU/EEA countries (69.2%). Several countries had a significant proportion of sputum smear negative culture-positive patients, indicating challenges in assuring the quality of smear microscopy diagnosis and/or adhering to the recommended diagnostic algorithm. New rapid methods for diagnosis of TB have recently been introduced in some countries within the Region, but data from these new tests have not been collected for 2011.

During 2007–2011, region-wide trends of overall TB notification in children decreased by 23%, from 8.7 to 6.7 cases per 100 000 population, mainly driven by a 23% decrease in the 18 HPC (from 15.1 to 11.6 cases per 100 000 population). However, in the EU/EEA countries, this trend levelled off at around 4% during the same period. It is also alarming that over half of the children reported by 10 countries in the west of the Region were under five years of age. There is a need to ensure adequate and timely diagnosis and accurate recording and reporting of TB among children across the Region.

The low proportion of TB in citizens of foreign origin in non-EU/EEA countries may be due to a lack of notification for this indicator in several countries. For a more accurate interpretation of the role of migration in spreading the disease based on routinely reported data, countries should initiate notification of patients using this criterion. When linked with the genotyping of mycobacterium strains this data will allow us to better understand molecular epidemiology and geographical spread across the Region and beyond.

The majority of TB-HIV co-infected individuals (92%) were notified in the non-EU/EEA countries. The prevalence of HIV among TB cases in the Region increased from 3.6% in 2008 to 6.2% in 2011. Among countries reporting representative HIV testing, three could document a significant overlap of the HIV and TB epidemics by exceeding 15% HIV prevalence among new and re-treatment TB cases: Ukraine (18.5%), Malta (16.7%) and Estonia (15%). The increase in TB-HIV co-infection warrants a strengthening of collaborative TB/HIV activities.

In 2011, the prevalence of MDR among new TB cases in the Region amounted to 14%, which is almost identical to the result for 2010 (13.7%). Except for the Baltic States, where MDR among new cases varied from 11.1% in Lithuania to 23.3% in Estonia, the percentage was under 3% in all EU/EEA countries. In the non-EU/EEA sub-region, four countries had a prevalence of MDR among new cases ranging from 10–20%, and five countries had an even higher prevalence: Moldova (26%), Belarus (26%), Kazakhstan (30.3%) Tajikistan (44.7%) and Uzbekistan (35.1%).

The prevalence of MDR-TB among previously treated cases was 47.4% in 2011, comparable to the rate measured in 2010 (48.7%). Countries with more than 50% of previously treated cases that were tested for drug susceptibility and found to be infected with MDR-TB include: Armenia (53.6%), Belarus (65.6%), Estonia (58.8%), Kazakhstan (51.3%), Moldova (63.8%), Russia (52.8%), Tajikistan (74.2%), Ukraine (51.7%) and Uzbekistan (72.4%).

The XDR-TB rate reported among MDR-TB cases was 11%, which is lower than 2010 (13%). Due to low testing coverage (only 3% and 9% of MDR cases respectively were subjected to second-line DST in 2010 and 2011 in the non EU/EEA region) or because data may be biased towards testing for more severe cases, it should not be considered representative.

Over the last five years treatment success rates have continued to decrease, dropping to 67.2% for new cases and 49.2% for previously treated cases in 2011. Treatment success rates among newly detected pulmonary laboratory-confirmed TB and previously treated cases were higher in EU/EEA countries than in the rest of the Region – 76.8% vs. 63.4% and 51.1% vs. 48.6% respectively.

In 2011, a total of 8 321 (8.5%) of new pulmonary laboratory-confirmed cases were reported to have died, 5.8% to have defaulted and 11.7% to have failed treatment. These rates were lower in the EU/EEA countries than outside the EU/EEA area, exemplified by the proportion of patients that failed treatment: 1.6% in EU/EEA against 15.7% in non-EU/EEA countries. These high failures rates can be explained by the high MDR-TB prevalence in countries that account for the majority of the burden in the Region. The high default rates of patients in some Member States require investigation to determine the underlying factors and measures to address them.

A lower treatment success rate was seen among MDR-TB patients from the 2009 cohort (48.5%) compared to 2008 (56.3%), however this may be due to the fact that the number

of MDR-TB cases with treatment outcomes reported almost doubled, from 6 920 to 12 110.

Despite the decrease in TB notification, drug-resistant TB is becoming a major concern and there is an urgent need to address the root causes of its emergence and transmission. Shortcomings in health systems and social determinants of health in relation to TB should be addressed in every country. Early detection of TB, particularly drug resistant TB, and adequate treatment with patient-friendly services need to be ensured across the Region. Even in the EU/EEA countries the current treatment success of MDR-TB cohorts is very low (31.6%). In close consultation with the Member States, experts, patients and communities suffering from the disease, WHO Regional Office for Europe has developed a Consolidated Action Plan to Prevent and Combat Multidrug and Extensively Drug-Resistant Tuberculosis 2011–2015<sup>14</sup>. The Plan takes into account new diagnostic techniques, patient-centred models of care and tailored services for specific populations. All 53 Member States have fully endorsed the Consolidated Action Plan and the accompanying Resolution EUR/RC61/R7 from the sixty-first session of the WHO Regional Committee for Europe. It is important to join forces and ensure the Plan is being implemented. From 2013 onwards, the Joint ECDC-WHO/Europe report and/or similar mechanism will be used to monitor progress on the implementation of the Action Plan and the Berlin Declaration<sup>15</sup>. To this end, specific monitoring frameworks have been developed for each of these two important regional commitments, as presented below. These frameworks complement one another and the ECDC Framework Action Plan to Fight Tuberculosis in the European Union<sup>16</sup>.

## 2.2 European Union and European Economic Area countries

### Data completeness

As for TB cases notified in 2010, reporting of non-mandatory variables in 2011 was complete or near-complete for classification, age, gender and most variables defining the origin of a case (Annex 3). Previous diagnosis and treatment were available for just over 90% of cases and previous treatment completion for 82%, with the latter being reported from four more countries than in 2010.

The results of culture (78%) and microscopy (73%) were reported a little less frequently than in the previous year while the completeness of reporting for the causative pathogen decreased by ten percentage points to 42% in 2011. Drug susceptibility reporting improved throughout, involving an increased number of countries for several of the drugs under surveillance, reaching 13% for ciprofloxacin and 66% for kanamycin. Similar improvements were seen with the reporting of HIV status, which was provided by 16 countries for 26% of cases. Reporting of typing results remained limited to a maximum of 1% of cases from up to five countries.

Compared with 2010, twelve-month and 24-month treatment outcomes were reported by one and three more countries, respectively. Twelve-month treatment outcome reporting completeness increased from 75% to 78% of TB cases, while 24-month treatment outcome decreased from 41% to 39% of MDR-TB cases.

### Time and place

In 2011, 72 334 cases of TB were reported in 29 EU/EEA countries, 4% less than in 2010 (Table 3). Romania accounted for 19 212 (27%) of all cases (rate: 89.7 per 100 000) and for 56% of the overall decrease from 2010. The EU/EEA notification rate in 2011 was 14.2 per 100 000 population, continuing the decreasing trend observed since the launch of European enhanced TB surveillance in 1996. Country-specific notification rates in 2011 differed more than 30-fold, ranging from 2.8 in Iceland to 89.7 in Romania. Rates were below 10 per 100 000 in 19 countries and below 20 in 22 countries. In most Member States, long-standing decreasing trends in TB notification rates continued in 2011 (Table 3) whereas in very few countries, such as Norway and the United Kingdom, long-term trends seemed to be slightly increasing.

### Classification and laboratory confirmation

The distribution of cases was very similar to that for 2010: 57 659 (80%) of 72 334 TB cases reported in 2011 were newly diagnosed, 8 916 (12%) had been previously treated for TB and 5 759 (8%) had an unknown previous treatment status (Table 6). Country-specific proportions of new cases ranged from 42% in Luxembourg to 96% in Finland. The Member States with the lowest proportions of new cases had the

<sup>14</sup> Consolidated Action Plan to Prevent and Combat Multidrug and Extensively Drug-Resistant Tuberculosis in the WHO European Region [http://www.euro.who.int/\\_\\_data/assets/pdf\\_file/0014/152015/e95786.pdf](http://www.euro.who.int/__data/assets/pdf_file/0014/152015/e95786.pdf)

<sup>15</sup> The Berlin Declaration on Tuberculosis, WHO European Ministerial Forum, 22 October 2007 [http://www.euro.who.int/\\_\\_data/assets/pdf\\_file/0008/68183/E90833.pdf](http://www.euro.who.int/__data/assets/pdf_file/0008/68183/E90833.pdf)

<sup>16</sup> ECDC Framework Action Plan to Fight Tuberculosis in the European Union, Stockholm, February 2008 [http://ecdc.europa.eu/en/publications/publications/0803\\_spr\\_tb\\_action\\_plan.pdf](http://ecdc.europa.eu/en/publications/publications/0803_spr_tb_action_plan.pdf)

highest proportions of cases with unknown previous treatment status. Member States with higher TB notification rates had higher proportions of previously treated cases (Spearman's  $\rho=0.6$ ;  $p=0.002$ ).

Laboratory confirmation was reported for 44 361 (61%) of 72 334 cases overall (Table 9) and culture confirmation for 30 265 (69%) of 43 731 new pulmonary cases (Table 8). All but 51 (0.1%) of the laboratory-confirmed cases were confirmed by culture or nucleic acid amplification test. Country-specific proportions of laboratory-confirmed cases ranged from 28% in Italy (provisional data) to 95% in Slovenia. Overall, the trend in case confirmation by culture, nucleic acid detection and sputum smear has been steadily increasing since 1995 (Table II). In most Member States this trend has also increased or remained stable, but in Denmark it decreased by 20 percentage points.

According to the EU case definition, 44 361 (61%) of 72 334 TB cases reported in 2011 would be classified as confirmed, 5 246 (7%) as probable and 22 727 (31%) as possible (Table 10).

### Age and gender

The male-to-female ratio notified in TB cases for 2011 was 1.8. Males were over-represented in all EU/EEA Member States but Iceland (Table 3).

Among new TB cases, the age group most affected was that of adults aged 25–44 years (Table 11). However, although this age group and the next (45–64 years) accounted for 64% of all new cases, notification rates in the age groups of 15 years and above did not differ substantially from one other.

Of all 72 274 TB cases notified in 2011 with known age, 3 190 (4%) were younger than 15 years, resulting in a notification rate of 4 per 100 000 children, the same as in 2010 (Table 12). Romania, Spain and the United Kingdom accounted for 54% of this subset, while four of the five high-incidence countries had the highest age-specific notification rates. Overall, the trend in the paediatric TB notification rate has declined slightly during the past ten years from a peak of 5.7 in 2001 (Table III). However, some countries, such as Bulgaria, Finland and Italy, have seen increasing trends in recent years.

### Origin of cases

Of the 72 334 TB cases notified in 2011, 51 191 (72%) were EU/EEA inhabitants (referred to as 'native'), 18 646 (26%) were of foreign origin and 1 497 (2%) were of unknown origin (Table 13). Country-specific proportions of foreign-origin TB cases ranged from 0.3% in Romania to 89% in Sweden and were inversely correlated with countries' TB notification rates (Spearman's  $\rho=-0.6$ ;  $p=0.005$ ). Overall, the proportion of foreign-origin cases has been on the rise since 2001 (Table IV) which, in some countries has been due to a real increase, whereas in others, it is attributable to the sizeable drop in native cases (country profiles).

### Drug resistance

Table 15 displays laboratory EQA participation and results by Member State.

Of 45 955 laboratory-confirmed TB cases notified in 2011, 33 559 (73%) underwent isoniazid and rifampicin susceptibility testing. Twenty-one Member States tested at least 90% of their cases. Resistance to at least one anti-TB drug was reported for 4 289 (13%) of the cases tested overall (Table 16) and for 34–41% in Estonia, Latvia and Lithuania.

MDR-TB was reported for 1 522 (5%) of 33 559 cases with drug susceptibility testing (DST) results: 629 (2%) of 25 810 new TB cases and 809 (17%) of 4 816 cases that had previously received TB treatment (Table 17; for DST results among new and previously treated pulmonary cases, see Tables 18 and 19). As in previous years, MDR-TB was most frequently observed in the three Baltic countries, with 11–23% of all new cases affected. Among previously treated cases, MDR-TB was more widespread, reaching 29–58% in the Baltic States, but also affecting some low-incidence countries. Among culture-positive cases, the overall five-year-trend in MDR-TB proportion has decreased slightly, whereas country-specific trends have been increasing in some Member States such as Austria, Estonia, Finland and France (Table VI). In 2011, among cases with test results for drug resistance, MDR-TB was reported for 1 119 (5%) of 20 817 natives and 320 (3%) of 9 517 citizens of foreign-origin (Table 21). The MDR-TB risk in natives was 1.6 times the risk in foreigners (prevalence ratio [PR]=1.6; 95% confidence interval [CI]=1.4–1.8).

Extensively drug-resistant TB was reported for 136 (13%) of 1 017 MDR-TB cases that had undergone second-line drug susceptibility testing (Table 20). Since 2006, no clear trend in XDR-TB notifications has been visible (Table VII).

### HIV co-infection

With the exception of five countries only reporting HIV-positive cases, HIV status was reported for 21 530 (54%) of 40 188 TB cases from 16 countries (Table 22). Of 21 530 cases with known HIV status, 1 003 (5%) were reported as HIV-positive. In Member States with at least five HIV-co-infected TB cases, the proportion of such cases among TB cases with known HIV status was highest in Ireland, Malta and Estonia at 20%, 17% and 15% respectively. The trend in reporting HIV status increased from 2007 to 2010, levelling off in 2011, while no clear trend has been observed in the proportion of HIV-co-infected TB cases (Table VIII). Country-specific five-year trends in reported TB/HIV co-infection have been decreasing in the Czech Republic, the Netherlands and Spain, increasing in Latvia, and inconclusive in the remaining countries.

### Treatment outcome

Of 8 916 previously treated TB cases notified in 2011, 4 979 (56%) had completed treatment; in 905 cases (10%), treatment had failed; 1 051 (12%) had defaulted and for 1 981 (22%), the outcome of previous incomplete treatment was unknown.

Of 62 655 TB cases notified in 2010 with known treatment outcome, 46 545 (74%) had been treated successfully, 4 560 (7%) had died, 1 122 (2%) had experienced treatment failure, 3 877 (6%) had defaulted, 1 835 (3%) were still on treatment and 4 716 (8%) had been transferred or had an unknown outcome (Table 25). France, Greece, Italy and Portugal did not report treatment outcome. Country-specific TB notification rates were not correlated with treatment success or death during TB treatment. However, Member States with higher notification rates had higher proportions of failed (Spearman's  $\rho=0.4$ ;  $p=0.03$ ) and defaulted treatments (Spearman's  $\rho=0.6$ ;  $p=0.0009$ ).

Of 27 777 new laboratory-confirmed pulmonary TB cases notified in 2010, 21 327 (77%) had been treated successfully, 1 841 (7%) had died, 438 (2%) had experienced treatment failure, 1 458 (5%) had defaulted, 714 (3%) were still on treatment and 1 999 (7%) had been transferred or had an unknown outcome (Table 23). In 23 Member States with no more than 25% unknown treatment outcome, treatment success ratios ranged from 65% (Austria and Denmark) to 91% (Norway). The overall treatment success ratio in new laboratory-confirmed pulmonary TB cases has been stable since 2002 (Table IX).

Of the 6 481 previously treated TB cases notified in 2010, 3 495 (54%) had been treated successfully, 652 (10%) had died, 633 (10%) had experienced treatment failure, 991 (15%) had defaulted, 490 (8%) were still on treatment and 233 (4%) had been transferred or had an unknown outcome (Table 24). In 20 Member States with no more than 25% unknown treatment outcome, treatment success ratios ranged from 31% in Lithuania to 86% in Finland. Following an increase between 2004 and 2010, the overall treatment success ratio in previously treated TB cases dropped again in 2011 (Table X).

Of 1 456 MDR-TB cases notified in 2009, 460 (32%) had been treated successfully, 288 (20%) had died, 289 (20%) had experienced treatment failure, 290 (20%) had defaulted, 94 (7%) were still on treatment and 30 (2%) had been transferred or had an unknown outcome (Table 26). In Member States with no more than 25% unknown treatment outcome, treatment success ratios ranged from 0 in the Czech Republic to 85% in Sweden. Member States with higher TB notification rates had higher MDR-TB failed treatment (Spearman's  $\rho=0.5$ ;  $p=0.02$ ) and case-fatality ratios (Spearman's  $\rho=0.5$ ;  $p=0.04$ ). Despite positive signals in some Member States, overall the 24-month MDR-TB treatment success ratio decreased steadily from 2005 to 2009 (Table XI).

### Special focus: extrapulmonary tuberculosis

Of the 72 334 cases reported in 2011, 55 939 (77%) suffered from pulmonary TB, including 4 586 (6%) with additional extrapulmonary manifestations (Table 7). Purely extrapulmonary TB affected 16 116 (22%) of all notified cases. Country-specific proportions of extrapulmonary TB ranged from 4% in Hungary to 67% in Iceland while rates varied 1000-fold. The overall proportion increased from 2002 to 2009, remaining at 22% in 2010 and 2011 (Table B).

The notification rate was stable at 3.2 to 3.5 per 100 000 over time.

In 2011, of 16 116 purely extrapulmonary TB cases notified, 3 521 (22%) had lymphatic TB, 3 084 (19%) had pleural TB, and 3 320 (21%) suffered from TB at other extrapulmonary sites (Table C). No site was specified for all 6 191 (38%) extrapulmonary TB cases reported from Finland, Spain and the United Kingdom.

In children under 15 years, extrapulmonary TB accounted for 1 347 (43%) of 3 145 cases with site information, and in adults aged 15 years and above it accounted for 14 761 (21%) of 68 851 cases. Children were twice as likely as adults to be reported with extrapulmonary TB (PR=2.0; 95%CI=1.9-2.1) (Table D). Compared with adults, children with extrapulmonary site-specified TB were twice as likely to be reported with lymphatic TB (PR=2.1; 95%CI=2.0-2.3) and had a 40% higher risk of meningitis (PR=1.4; 95%CI=1.04-2.0). However, they were 50% less likely to present with bone manifestations of TB (PR=0.5; 95%CI=0.4-0.8); 60% less likely to be reported with pleural TB (PR=0.4; 95%CI=0.3-0.5); 70% less likely to be reported with gastrointestinal TB (PR=0.3; 95%CI=0.1-0.5); 80% less likely to be reported with disseminated TB (PR=0.2; 95%CI=0.1-0.6), had a 90% lower risk of spinal TB (PR=0.1; 95%CI=0.06-0.3) and a more than 90% lower risk of urogenital TB (PR=0.04; 95%CI=0.01-0.1). No significant difference between children and adults was found for other central nervous system manifestations of TB.

Of 16 116 notified cases of extrapulmonary TB, 5 571 (35%) were confirmed by culture (Table E). In Member States with no more than 25% unknown culture results, 16–82% of extrapulmonary TB cases were culture-confirmed. Representing only 1% of cases, culture-confirmed MDR-TB was rare.

In native cases, extrapulmonary TB accounted for 8 604 (17%) of 52 067 cases with site information, in cases of foreign origin 7 039 (38%) of 18 531 (Table F). The latter were over twice as likely to be notified with extrapulmonary TB (PR=2.3; 95%CI=2.2-2.4). Compared to native cases, cases of foreign origin with extrapulmonary site-specified were twice as likely to be reported with disseminated TB (PR=2.0; 95%CI=1.4-2.9); 80% more likely to be reported with lymphatic TB (PR=1.8; 95%CI=1.7-1.9); 60% more likely to be reported with gastrointestinal TB (PR=1.6; 95%CI=1.3-2.0) and had a 30% higher risk of bone TB (PR=1.3; 95%CI=1.1-1.5). However, they were 30% less likely to be notified with meningitis (PR=0.7; 95%CI=0.6-0.96); 50% less likely to present with urogenital TB (PR=0.5; 95%CI=0.4-0.7) and 60% less likely to be reported with pleural TB (PR=0.36; 95%CI=0.3-0.4). No significant differences were found between the two strata for any of the remaining extrapulmonary sites.

Of 13 366 extrapulmonary TB cases with treatment outcome information, 10 988 (82%) were treated successfully, compared to 35 317 (72%) of 48 789 of pulmonary TB cases (PR=1.13; 95%CI=1.12-1.14) (Table G). Among cases with extrapulmonary TB, the lowest treatment success ratios were found in those with disseminated TB, TB meningitis



and other CNS manifestations (53%, 63% and 68% respectively).

Positive and negative HIV test results were reported for 3 097 (19%) of the 16 116 extrapulmonary TB cases, compared to 15 858 (28%) of 55 939 pulmonary TB cases (Table 6). Among extrapulmonary TB cases with known HIV status, 190 (6%) were reported as HIV-positive, whereas 614 (4%) were reported as HIV-positive among pulmonary TB cases (PR=1.4; 95% CI=1.2-1.7) (Table H).

### Conclusions for the EU/EEA

This report highlights a number of positive developments in European TB epidemiology. Reporting completeness remains high for many variables and has improved for DST and HIV status compared to 2010. More countries have reported treatment outcome. Overall and in the vast majority of EU/EEA Member States, the TB notification rate continues to decrease, confirming the sustained effectiveness of national TB prevention and control programmes despite the economic crisis. At the same time, the proportion of culture-confirmed cases continues to increase, both overall and at Member State level, illustrating the success of the efforts invested in proper laboratory diagnosis of TB. Although displaying a wide range across countries, the rather even age distribution of TB notification rates at EU/EEA level indicates that none of the adult age groups is at a markedly higher risk of developing symptomatic disease. At the same time, the low and continuously declining prevalence of paediatric TB suggests that recent transmission does not contribute strongly to current TB dynamics.

Although extrapulmonary TB never received much attention in the past, in 2011 it accounted for over 20 000 European cases of TB notified. Consequently, in this report it has been analysed in more depth. The huge differences between country-specific notification rates are probably partly explained by differing degrees of under-diagnosis and under-reporting of extrapulmonary TB. Real differences in disease prevalence could be partly due to differing distributions of children and citizens of foreign origin who were both found to be at least twice as likely to contract extrapulmonary TB as adults and persons of native origin. Clinical presentation of extrapulmonary TB also differed distinctly between children and adults and between natives and citizens of foreign origin. Children were reported to be more prone than adults to lymphatic TB and TB meningitis, but less likely to suffer from most of the other extrapulmonary manifestations. Cases of foreign origin were more likely than native cases to be reported with disseminated, lymphatic, gastrointestinal and bone TB, but less likely to present with TB meningitis, urogenital or pleural TB. Despite extrapulmonary TB being associated with HIV co-infection, the proportion of successful treatment was 10% higher for extrapulmonary than for pulmonary TB, perhaps partly due to the much lower prevalence of MDR in extrapulmonary cases.

This report also reminds us of the persistent challenges associated with TB surveillance, prevention and control in Europe. For some Member States, collecting and reporting surveillance data to ECDC remains a formidable task: eight

countries did not report any second-line DST results; 13 countries did not report complete HIV co-infection data; four countries provided no 12-month treatment outcome and 11 countries no 24-month outcomes. Lack of surveillance data hampers in-depth understanding of TB epidemiology, monitoring of TB programmes at national and European level, appropriate allocation of resources, and ultimately TB prevention and control itself.

For high-incidence countries, reducing the TB burden is still an uphill struggle. In 2011, they were not only faced with notification rates up to 30 times higher than those in low-incidence countries, but also with higher proportions of previously treated cases, more drug and multidrug resistance and, to some extent, worse treatment outcomes. Although gradual progress in effective TB prevention and control is evident in the hardest-hit countries through consistently decreasing trends over time, there is still a considerable gap to close before all of Europe can truly envisage TB elimination.

For many low-incidence countries, TB in citizens of foreign origin poses a growing problem. Migrants may import the disease after visiting their home countries where TB is endemic and refugees are more likely to contract TB in overcrowded detention camps. Cases of foreign origin are less prone to MDR, but at higher risk of extrapulmonary TB, possibly related to HIV co-infection. They may not necessarily fuel widespread community transmission of TB, but they tend to be harder to reach from a healthcare point of view and could eventually prove to be one of the major obstacles to TB elimination in low-incidence countries.

Neither MDR nor XDR-TB trends seem to be increasing overall, but European XDR-TB surveillance in particular is still so patchy that no solid conclusions can be drawn. In the Baltic countries, but also among previously treated cases elsewhere, MDR-TB is still highly prevalent, and in some countries even on the rise, justifying the continued need for the utmost vigilance and antimicrobial stewardship.

European surveillance of TB/HIV co-infection is still in its infancy and is severely hampered by the initial stigmatisation of HIV and AIDS that has led to exceptionally rigid HIV data protection in many Member States, precluding any record linkage between TB and HIV surveillance databases. Given that Western society has grown much more tolerant over the past 30 years and that TB and HIV epidemiology influence one another and should therefore be analysed and interpreted in conjunction, the persistent over-cautiousness in this matter is anachronistic and detrimental to public health.

A final challenge has only just begun to appear: the molecular surveillance of MDR-TB currently piloted in TESSy, which is expected to improve the very poor reporting of molecular typing data. In order to be useful, molecular TB surveillance requires improved population coverage, linkage between epidemiological and laboratory data at Member State level and thus close cooperation between experts from both fields. If successful, the collection, storage, analysis, interpretation and public health use of typing and epidemiological data will add an important new

response support dimension to European TB surveillance, enabling early detection and the monitoring and containment of international outbreaks that might otherwise go unnoticed.

ECDC and the EU/EEA Member States should vigorously tackle these challenges, even more so in the light of the austerity measures jeopardising national public health programmes all over Europe. The higher the quality of TB surveillance data, the clearer and more convincing the public health messages will be, making it more difficult to ignore the risks of down-prioritising TB elimination, both politically and economically.

## References

1. Broekmans JF, Migliori GB, Rieder HL et al. European framework for tuberculosis control and elimination in countries with a low incidence. Recommendations of the World Health Organization (WHO), International Union Against Tuberculosis and Lung Disease (IUATLD) and Royal Netherlands Tuberculosis Association (KNCV) Working Group. *Eur Respir J* 2002;19:765–75.
2. World Health Organization. Global Tuberculosis Report 2012. Geneva: WHO, 2012. WHO/THM/TB/2012.6. Available from: [http://www.who.int/tb/publications/global\\_report/en/index.html](http://www.who.int/tb/publications/global_report/en/index.html)
3. WHO Regional Office for Europe. Plan to Stop TB in 18 High-priority Countries in the WHO European Region, 2007–2015. Copenhagen: WHO, 2007
4. European Union Commission. 2008/426/EC: Commission Decision of 28 April 2008 amending Decision 2002/253/EC laying down case definitions for reporting communicable diseases to the Community network under Decision No 2119/98/EC of the European Parliament and of the Council (notified under document number C(2008) 1589). OJ L 159, 18.06.2008, p. 46
5. World Health Organization. Guidelines for surveillance of drug resistance in tuberculosis (4th ed.). Geneva: WHO, 2009. WHO/CDS/TB/2009.422
6. Falzon D, Scholten J, Infuso A. Tuberculosis outcome monitoring – Is it time to update European recommendations? *Euro Surveill* 2006;11(3):20–5
7. Compendium of Indicators for Monitoring and Evaluating National Tuberculosis Programs, World Health Organization 2004, WHO/HTM/TB/2004.344.
8. Gelmanova IY, Keshavjee S, Golubchikova VT, Berezina VI, Strelis AK, Yanova GV et al. Barriers to successful tuberculosis treatment in Tomsk, Russian Federation: non-adherence, default and the acquisition of multidrug resistance, *Bulletin of the World Health Organization*, Volume 85, Number 9, September 2007, 649-732
9. Shin SS, Pasechnikov AK, Gelmanova IY, Peremitin GG, Strelis AK, Mishustin S et al. Treatment outcomes in an integrated civilian and prison MDR-TB treatment program in Russia, *Int J Tuberc Lung Dis*. 2006 Apr;10(4):402-8.
10. Skrahina A, Hurevich H, Zalutskaya A, Sahalchik E, Astrauko A, van Gemert W, et al. Alarming levels of drug-resistant tuberculosis in Belarus: results of a survey in Minsk. *Eur Respir J*. 2012 June; 39(6): 1425–1431. Published online 2011 October 17. doi: 10.1183/09031936.00145411

## **3. Commentary – Monitoring**





### 3. Commentary – Monitoring

Last year marked the production of the first TB monitoring report, providing an overview of progress on TB control in the WHO European Region and the EU/EEA. For the WHO European Region, two monitoring frameworks were developed by WHO's Regional Office for Europe, aimed at monitoring the Consolidated Action Plan to Prevent and Combat Multidrug- and Extensively Drug-Resistant Tuberculosis in the WHO European Region 2011–2015 [1], and the implementation of the 2007 Berlin Declaration on Tuberculosis [2]; confronting the overall TB health threat to the Region. In 2010, ECDC launched the epidemiological and strategic monitoring framework 'Progressing towards TB elimination' [3]. The feasibility of applying this monitoring framework in the EU/EEA was first presented in 2011 [4]. The 2012 report [5] presented the first measurement of the indicators described in the monitoring framework 'Progressing towards TB elimination'. This report also presented the monitoring framework for follow-up of the Consolidated Action Plan to Prevent and Combat Multidrug- and Extensively Drug-Resistant Tuberculosis in the WHO European Region 2011–2015 and the Berlin Declaration Monitoring and Evaluation Framework.

It was agreed to report on progress every other year, so the next monitoring results will be presented in 2014. More in-depth discussion and lists of indicators can be found in the 2012 report [5]. According to the Resolution of the WHO Regional Committee for Europe EUR/R61/R7 [6], the WHO Regional Director will report on progress in implementing the Consolidated Action Plan to Prevent and Combat Multidrug- and Extensively Drug-Resistant Tuberculosis in the WHO European Region 2011–2015. The progress report will be presented at the 63rd session of the WHO Regional Committee for Europe in September 2013. For this WHO/Europe and its partners will prepare an overview of implementation progress in the 15 high-burden MDR-TB countries within the WHO European Region using quantitative data collected and presented in this report. The latest qualitative data on progress in implementing the Action Plan will be analysed at WHO's Regional Office for Europe in collaboration with partners.

#### References

1. The World Health Organization Regional Office for Europe. Consolidated Action Plan to Prevent and Combat Multidrug- and Extensively Drug-Resistant Tuberculosis (M/XDR-TB) in the WHO European Region 2011–2015. Copenhagen: WHO/Europe, 12-15 Sep 2011.
2. The WHO European Ministerial Forum. The Berlin Declaration on Tuberculosis. Copenhagen: WHO/Europe, 22 October 2007.
3. European Centre for Disease Prevention and Control. Progressing towards TB elimination. A follow-up to the Framework Action Plan to Fight Tuberculosis in the European Union, 2010.
4. European Centre for Disease Prevention and Control/WHO Regional Office for Europe. Tuberculosis surveillance in Europe 2009. Stockholm: ECDC, 2011.
5. European Centre for Disease Prevention and Control/WHO Regional Office for Europe. Tuberculosis surveillance and monitoring in Europe 2012. Stockholm: ECDC, 2012.
6. The World Health Organization Regional Committee for Europe. Resolution EUR/RC61/R7. Multidrug- and extensively drug-resistant tuberculosis in the WHO European Region. Baku, Azerbaijan, 12–15 September 2011



## 4. Tables







**Summary table: Tuberculosis surveillance data by region, European Region, 2011**

	Table showing data by country	Region <sup>a</sup>							
		EU/EEA		Non-EU/EEA		Total		18 High-Priority Countries (HPC)	
		Number of reporting countries <sup>b</sup>		Number of reporting countries <sup>b</sup>		Number of reporting countries <sup>b</sup>		Number of reporting countries <sup>b</sup>	
<b>Total population (millions)</b>	-	<b>29</b>	<b>507.8</b>	<b>24</b>	<b>392.3</b>	<b>53</b>	<b>899.4</b>	<b>18</b>	<b>388.7</b>
<b>Estimates of TB disease burden 2011<sup>b</sup></b>									
Estimated TB prevalence rate per 100 000 population	1	29	18.4	24	104.4	53	55.9	18	113.1
Estimated TB mortality rate per 100 000 population	1	29	0.9	23	10.1	52	4.9	18	10.5
Estimated TB incidence rate per 100 000 population	1	29	14.0	24	78.3	53	42.0	18	84.6
Estimated proportion of HIV-infection among incident TB cases (new and relapses)	2	29	3.6%	24	6.5%	53	6.0%	18	6.2%
Estimated number of HIV-infection among TB incidence (new and relapses)	2	27	2541	24	20 014	53	22 554	18	20 460
Estimated proportion of MDR-TB among notified TB cases (new and previously treated)	2	29	3.1%	24	24.1%	53	20.2%	18	22.8%
Estimated number of MDR-TB cases 2011	2	29	2913	24	98 128	53	101 040	18	100 355
<b>Notifications of TB cases, 2011</b>									
Total number of TB cases	3	29	72 334	21	308 032	50	380 366	17	326 656
All TB cases per 100 000 population	3	29	14.2	21	78.1	50	42.2	17	84.0
Mean annual % change in overall notification rate (2007–2011)	3	29	-4.0%	21	-7.6%	50	-5.7%	17	-5.9%
New TB cases and relapses per 100 000 population	5	29	12.1	21	58.3	50	32.8	17	64.3
Percentage of new cases among all TB cases	6	29	79.7%	80	70.2%	51	72.1%	17	70.4%
Percentage of pulmonary TB among all TB cases	7	29	77.3%	21	82.4%	51	81.4%	17	82.8%
Percentage of extrapulmonary TB among all TB cases	7	29	22.3%	21	11.1%	51	13.2%	17	11.3%
Percentage of laboratory-confirmed cases among all TB cases	10	29	61.3%	-	-	-	-	-	-
Percentage of laboratory-confirmed cases among new TB cases	8	29	74.6%	80	50.3%	51	55.0%	17	52.0%
Sex ratio of all TB cases (male to female)	3	29	1.8	80	1.9	51	1.9	17	2.0
<b>Multidrug resistance (MDR) and extensive drug resistance (XDR), 2011</b>									
Percentage of MDR-TB among all TB cases	16	29	4.5%	20	25.6%	49	19.0%	16	23.8%
Mean annual % change in MDR-TB notification rate (2007–2011)	VI	22	0.0%	-	21.4%	-	20.0%	-	21.6%
Percentage of XDR-TB among all MDR-TB cases with DST against SLD <sup>c</sup>	20	19	13.4%	12	10.1%	31	11.0%	12	11.2%
<b>TB-HIV coinfection, 2011</b>									
Percentage of all TB cases with known HIV status	22	16	53.6%	18	61.2%	34	60.3%	17	61.0%
Percentage of HIV-positive cases among all TB cases with known HIV status	22	16	4.7%	18	6.4%	34	6.2%	17	6.2%
<b>Treatment outcome</b>									
Treatment outcome of new laboratory-confirmed pulmonary cases reported in 2010 <sup>d</sup>	23	24	89.6%						
Success (cure or treatment completion)	23	24	76.8%	18	63.4%	41	67.2%	16	65.7%
Death	23	24	6.6%	18	9.2%	41	8.5%	16	8.7%
Failure	23	24	1.6%	18	15.7%	41	11.7%	16	14.2%
Default	23	24	5.3%	18	6.1%	41	5.8%	16	6.1%
Still on treatment	23	24	2.6%			24	0.7%	5	0.4%
Lost to follow-up (transferred, unknown)	23	24	7.2%	18	5.7%	41	6.1%	16	4.9%
Treatment outcome of all laboratory-confirmed pulmonary MDR-TB cases reported in 2009 <sup>d</sup>	26	22	87.3%						
Success (cure or treatment completion)	26	22	31.6%	16	50.8%	38	48.5%	15	48.3%
Death	26	22	19.8%	16	15.8%	38	16.2%	15	16.4%
Failure	26	22	19.8%	16	8.6%	38	9.9%	15	10.0%
Default	26	22	19.9%	16	0.0%	38	0.8%	15	0.6%
Still on treatment	26	22	6.5%			22	0.8%	5	0.6%
Lost to follow-up (transfer, unknown)	26	22	2.4%	16	12.5%	38	11.3%	15	11.3%

<sup>a</sup> 'European Region' comprises the 53 countries of the WHO European Region and Liechtenstein

HPC: 18 high priority countries to STOP TB in the WHO European Region: Armenia, Azerbaijan, Belarus, Bulgaria, Estonia, Georgia, Kazakhstan, Kyrgyzstan, Latvia, Lithuania, Moldova, Romania, Russia, Tajikistan, Turkey, Turkmenistan, Ukraine, Uzbekistan.

<sup>b</sup> Number of countries with available data and included in the statistics.

<sup>c</sup> WHO estimates, as published in report: Global tuberculosis control 2012

<sup>d</sup> SLD - Anti-TB second line drugs

<sup>e</sup> Laboratory-confirmed means confirmed case by EU case definition for EU/EEA countries and smear and/or culture confirmation for non-EU/EEA countries

<sup>f</sup> For non-EU/EEA countries this included MDR/TB cases enrolled for treatment

Table 1: Estimates of the TB disease burden 2011, European Region

Country	Population <sup>a</sup>	Estimated number of deaths from TB (all forms, excluding HIV)						Estimated prevalence of TB (all forms)					
		Number			per 100 000			Number			per 100 000		
		Best	Low	High	Best	Low	High	Best	Low	High	Best	Low	High
<b>EU/EEA</b>													
Austria	8 413 429	33	33	33	0.4	0.4	0.4	390	160	720	4.6	1.9	8.6
Belgium	10 754 056	23	23	24	0.2	0.2	0.2	1100	430	2000	10.2	4.0	18.6
Bulgaria	7 446 135	190	190	190	2.5	2.5	2.6	3300	1300	6300	44.3	17.5	84.6
Cyprus	1 116 564	1	1	2	0.1	0.1	0.1	57	22	110	5.1	2.0	9.9
Czech Republic	10 534 293	36	36	36	0.3	0.3	0.4	810	320	1500	7.7	3.0	14.2
Denmark	5 572 594	14	13	14	0.3	0.2	0.3	450	180	850	8.1	3.2	15.3
Estonia	1 340 537	36	35	37	2.7	2.6	2.7	380	160	710	28.3	11.9	53.0
Finland	5 384 770	17	17	17	0.3	0.3	0.3	480	170	950	8.9	3.2	17.6
France	63 125 894	290	280	300	0.5	0.4	0.5	3500	1700	6100	5.5	2.7	9.7
Germany	82 162 512	280	280	280	0.3	0.3	0.4	4700	1800	8800	5.7	2.2	10.7
Greece	11 390 031	91	86	96	0.8	0.8	0.8	550	220	1000	4.8	1.9	8.8
Hungary	9 966 116	81	81	81	0.8	0.8	0.8	2300	890	4300	23.1	8.9	43.1
Iceland	324 366	1	1	1	0.3	0.3	0.3	20	8	37	6.2	2.4	11.4
Ireland	4 525 802	20	20	20	0.5	0.5	0.5	420	170	790	9.3	3.8	17.5
Italy	60 788 694	350	340	360	0.6	0.6	0.6	2100	860	4000	3.5	1.4	6.6
Latvia	2 243 142	93	90	95	4.1	4.0	4.2	1100	460	2100	49.0	20.5	93.6
Lithuania	3 307 481	280	270	280	8.3	8.3	8.4	2500	950	4700	75.6	28.7	142.1
Luxembourg	515 941	0	0	0	0.0	0.0	0.0	3	1	6	0.7	0.3	1.2
Malta	417 855	1	1	1	0.3	0.3	0.3	44	16	85	10.5	3.8	20.3
Netherlands	16 664 746	35	34	36	0.2	0.2	0.2	1400	560	2700	8.4	3.4	16.2
Norway	4 924 848	7	7	7	0.2	0.1	0.2	380	150	710	7.7	3.0	14.4
Poland	38 298 949	790	750	820	2.1	2.0	2.1	11000	4400	21000	28.7	11.5	54.8
Portugal	10 689 663	130	120	140	1.2	1.1	1.3	3000	1300	5600	28.1	12.2	52.4
Romania	21 436 495	1300	1300	1300	6.0	6.0	6.0	31000	13000	56000	144.6	60.6	261.2
Slovakia	5 471 502	42	42	43	0.8	0.8	0.8	510	200	960	9.3	3.7	17.5
Slovenia	2 035 012	22	22	22	1.1	1.1	1.1	240	95	460	11.8	4.7	22.6
Spain	46 454 895	250	250	260	0.6	0.5	0.6	8700	3500	16000	18.7	7.5	34.4
Sweden	9 440 747	17	17	17	0.2	0.2	0.2	810	320	1500	8.6	3.4	15.9
United Kingdom	62 417 431	350	340	350	0.6	0.5	0.6	12000	5200	20000	19.2	8.3	32.0
<b>Subtotal EU/EEA</b>	<b>507 164 500</b>	<b>4781</b>	<b>4679</b>	<b>4862</b>	<b>0.9</b>	<b>0.9</b>	<b>1.0</b>	<b>93244</b>	<b>38542</b>	<b>169988</b>	<b>18.4</b>	<b>7.6</b>	<b>33.5</b>
<b>Non-EU/EEA</b>													
Albania	3 215 988	7	5	9	0.2	0.2	0.3	460	130	1000	14.3	4.0	31.1
Andorra	86 165	0	0	1	0.3	-	1.1	7	3	12	7.5	2.9	13.9
Armenia	3 100 236	270	220	330	8.8	7.2	11.0	2400	1100	4300	77.4	35.5	138.7
Azerbaijan	9 306 023	340	240	440	3.6	2.6	4.8	16000	7700	28000	171.9	82.7	300.9
Belarus	9 559 441	790	740	840	8.3	7.8	8.8	9600	4200	17000	100.4	43.9	177.8
Bosnia and Herzegovina	3 752 228	250	240	270	6.8	6.4	7.2	2500	1000	4500	66.6	26.7	119.9
Croatia	4 395 560	88	85	91	2.0	1.9	2.1	970	380	1800	22.1	8.6	41.0
Georgia	4 329 026	160	140	190	3.7	3.2	4.3	6900	2800	13000	159.4	64.7	300.3
Israel	7 562 194	15	14	15	0.2	0.2	0.2	530	210	1000	7.0	2.8	13.2
Kazakhstan	16 206 750	2200	2000	2500	14.0	12.0	15.0	27000	11000	51000	166.6	67.9	314.7
Kyrgyzstan	5 392 580	670	590	760	12.0	11.0	14.0	9400	3900	17000	174.3	72.3	315.2
Macedonia, the former Yugoslav Republic of	2 063 893	25	24	27	1.2	1.1	1.3	570	250	1000	27.6	12.1	48.5
Moldova	3 544 864	600	550	640	17.0	16.0	18.0	8300	3800	15000	234.1	107.2	423.1
Monaco	35 427	0	0	0	0.2	-	0.6	1	1	3	4.0	1.6	7.6
Montenegro	632 261	1	1	2	0.2	0.2	0.2	120	37	260	19.0	5.9	41.1
Russia	142 835 555	22000	22000	23000	16.0	15.0	16.0	180000	72000	330000	126.0	50.4	231.0
San Marino	31 735	0	0	0	-	-	-	1	0	1	1.8	0.7	3.5
Serbia	9 853 969	160	140	180	1.6	1.4	1.9	2400	740	5100	24.4	7.5	51.8
Switzerland	7 701 690	17	16	17	0.2	0.2	0.2	460	180	860	6.0	2.3	11.2
Tajikistan	6 976 958	1100	760	1500	16.0	11.0	22.0	24000	12000	41000	344.0	172.0	587.6
Turkey	73 639 596	530	170	1100	0.7	0.2	1.5	17000	8100	30000	23.1	11.0	40.7
Turkmenistan	5 105 301	500	330	720	9.9	6.4	14.0	4900	1800	9600	96.0	35.3	188.0
Ukraine	45 190 180	8100	7800	8300	18.0	17.0	18.0	47000	21000	84000	104.0	46.5	185.9
Uzbekistan	27 760 267	1700	1400	2000	6.1	5.2	7.1	49000	24000	84000	176.5	86.5	302.6
<b>Subtotal non-EU/EEA</b>	<b>392 277 887</b>	<b>39523</b>	<b>37465</b>	<b>42932</b>	<b>10.1</b>	<b>9.6</b>	<b>10.9</b>	<b>409518</b>	<b>176330</b>	<b>739436</b>	<b>104.4</b>	<b>45.0</b>	<b>188.5</b>
<b>Total European Region</b>	<b>899 442 387</b>	<b>44304</b>	<b>42144</b>	<b>47794</b>	<b>4.9</b>	<b>4.7</b>	<b>5.3</b>	<b>502763</b>	<b>214872</b>	<b>909424</b>	<b>55.9</b>	<b>23.9</b>	<b>101.1</b>
<b>Subtotal 18 HPC</b>	<b>388 720 567</b>	<b>40859</b>	<b>38825</b>	<b>44222</b>	<b>10.5</b>	<b>10.0</b>	<b>11.4</b>	<b>439780</b>	<b>189270</b>	<b>793710</b>	<b>113.1</b>	<b>48.7</b>	<b>204.2</b>

WHO European Region 18 TB High Priority Countries presented in italics.

<sup>a</sup> Population estimate 2011 by UN Statistical database for all countries

	Estimated number of incident cases (all forms)					
	Number			per 100 000		
	Best	Low	High	Best	Low	High
	310	270	350	3.7	3.2	4.2
	870	760	990	8.1	7.1	9.2
	2600	2300	3000	34.9	30.9	40.3
	44	39	50	3.9	3.5	4.5
	640	560	720	6.1	5.3	6.8
	360	320	410	6.5	5.7	7.4
	330	290	380	24.6	21.6	28.3
	400	350	450	7.4	6.5	8.4
	2700	2500	2900	4.3	4.0	4.6
	3700	3200	4200	4.5	3.9	5.1
	430	380	490	3.8	3.3	4.3
	1800	1600	2000	18.1	16.1	20.1
	16	14	18	4.9	4.3	5.5
	340	300	380	7.5	6.6	8.4
	1700	1500	2000	2.8	2.5	3.3
	930	820	1100	41.5	36.6	49.0
	1900	1700	2200	57.4	51.4	66.5
	3	2	3	0.5	0.5	0.6
	38	33	43	9.1	7.9	10.3
	1100	990	1300	6.6	5.9	7.8
	300	260	340	6.1	5.3	6.9
	8700	7600	9900	22.7	19.8	25.8
	2600	2300	3000	24.3	21.5	28.1
	22000	18000	26000	102.6	84.0	121.3
	390	350	450	7.1	6.4	8.2
	190	170	210	9.3	8.4	10.3
	7200	6300	8100	15.5	13.6	17.4
	640	560	720	6.8	5.9	7.6
	8800	8200	9400	14.1	13.1	15.1
	<b>71031</b>	<b>61668</b>	<b>81104</b>	<b>14.0</b>	<b>12.2</b>	<b>16.0</b>
	420	360	490	13.1	11.2	15.2
	5	4	6	5.9	5.1	6.6
	1700	1400	2000	54.8	45.2	64.5
	11000	8700	13000	118.2	93.5	139.7
	6700	5500	8100	70.1	57.5	84.7
	1800	1600	2100	48.0	42.6	56.0
	760	660	860	17.3	15.0	19.6
	5400	4800	6100	124.7	110.9	140.9
	440	380	490	5.8	5.0	6.5
	21000	18000	24000	129.6	111.1	148.1
	6900	5700	8200	128.0	105.7	152.1
	410	350	470	19.9	17.0	22.8
	5700	4700	6800	160.8	132.6	191.8
	1	1	1	3.1	2.8	3.7
	110	94	120	17.4	14.9	19.0
	140000	120000	160000	98.0	84.0	112.0
	0	0	1	1.4	1.3	1.6
	1600	1400	1800	16.2	14.2	18.3
	370	330	420	4.8	4.3	5.5
	13000	11000	16000	186.3	157.7	229.3
	18000	15000	20000	24.4	20.4	27.2
	3800	3100	4600	74.4	60.7	90.1
	40000	33000	47000	88.5	73.0	104.0
	28000	23000	33000	100.9	82.9	118.9
	<b>307117</b>	<b>259080</b>	<b>355558</b>	<b>78.3</b>	<b>66.0</b>	<b>90.6</b>
	<b>378147</b>	<b>320748</b>	<b>436662</b>	<b>42.0</b>	<b>35.7</b>	<b>48.5</b>
	<b>328960</b>	<b>277010</b>	<b>381480</b>	<b>84.6</b>	<b>71.3</b>	<b>98.1</b>

Table 2: Estimates of TB/HIV and MDR-TB 2011, European Region

Country	Estimated HIV-infection among TB incidence (new and relapses)						Estimated MDR-TB among notified new TB cases						
	Number			%			Number			%			
	Best	Low	High	Best	Low	High	Best	Low	High	Best	Low	High	
<b>EU/EEA</b>													
Austria	15	11	18	4.7	3.7	5.8	8	3	18	2.5	0.8	5.7	
Belgium	40	29	52	4.6	3.5	5.8	8	3	16	1.5	0.6	3.1	
<i>Bulgaria</i>	8	2	17	0.3	0.1	0.7	28	16	46	2.0	1.1	3.2	
Cyprus	0	0	0	-	-	-	0	0	6	0.0	0.0	23.0	
Czech Republic	3	2	5	0.5	0.3	0.7	10	4	20	2.0	0.8	4.1	
Denmark	16	12	21	4.5	3.3	5.8	2	0	8	0.5	0.0	2.6	
<i>Estonia</i>	50	36	66	15.0	11.0	19.0	56	43	72	23.0	17.0	29.0	
Finland	5	4	7	1.3	0.9	1.8	5	1	12	2.2	0.6	5.5	
France	220	180	280	8.3	6.6	10.0	9	5	15	0.5	0.2	0.8	
Germany	76	54	100	2.1	1.5	2.7	69	33	130	2.5	1.2	4.5	
Greece	10	7	13	2.2	1.6	2.9	3	0	19	0.9	0.0	4.7	
Hungary	15	10	21	0.9	0.6	1.2	25	12	45	2.1	1.0	3.8	
Iceland	1	0	1	3.4	2.6	4.3	0	0	2	0.0	0.0	60.0	
Ireland	13	10	17	3.9	3.0	4.9	0	0	4	0.0	0.0	2.2	
Italy	88	67	110	5.1	4.1	6.3	45	31	62	3.2	2.3	4.5	
<i>Latvia</i>	83	66	100	8.9	7.4	11.0	89	70	110	13.0	10.0	16.0	
<i>Lithuania</i>	17	11	25	0.9	0.6	1.2	170	140	200	13.0	11.0	15.0	
Luxembourg	0	0	0	3.7	2.9	4.7	0	0	0	1.8	1.0	2.5	
Malta	6	2	13	17.0	5.2	33.0	0	0	0	1.8	1.0	2.5	
Netherlands	35	26	46	3.1	2.4	4.0	9	5	16	1.7	0.9	3.0	
Norway	6	4	8	2.0	1.5	2.6	5	1	13	2.9	0.8	7.2	
Poland	140	99	190	1.6	1.2	2.2	35	21	53	0.5	0.3	0.8	
Portugal	370	290	460	14.0	12.0	17.0	21	11	36	1.2	0.6	2.1	
<i>Romania</i>	350	240	490	1.6	1.2	2.2	340	220	500	2.8	1.8	4.2	
Slovakia	0	0	0	-	-	-	4	0	13	1.4	0.2	4.8	
Slovenia	1	1	1	0.4	0.3	0.6	0	0	5	0.0	0.0	3.0	
Spain	660	560	760	9.1	8.3	10.0	10	1	35	0.2	0.0	0.8	
Sweden	13	10	18	2.1	1.5	2.8	9	4	16	3.1	1.4	5.8	
United Kingdom	300	220	380	3.4	2.6	4.2	54	42	70	1.3	1.0	1.7	
<b>Subtotal EU/EEA</b>	<b>2541</b>	<b>1952</b>	<b>3219</b>	<b>3.6</b>	<b>3.2</b>	<b>4.0</b>	<b>1013</b>	<b>667</b>	<b>1543</b>	<b>1.8</b>	<b>1.2</b>	<b>2.7</b>	
<b>Non-EU/EEA</b>													
Albania	0	0	0	-	-	-	3	0	10	1.0	0.1	3.7	
Andorra	0	0	0	-	-	-	0	0	2	0.0	0.0	60.0	
Armenia	55	38	75	3.3	2.4	4.2	86	65	110	9.4	7.1	12.0	
<i>Azerbaijan</i>	160	110	220	1.5	1.1	2.0	930	790	1100	22.0	19.0	26.0	
<i>Belarus</i>	250	180	340	3.8	3.0	4.7	1200	1100	1300	32.0	30.0	35.0	
Bosnia and Herzegovina	0	0	0	-	-	-	2	0	11	0.2	0.0	0.9	
Croatia	5	3	7	0.6	0.4	0.9	1	0	5	0.2	0.0	0.9	
Georgia	80	58	110	1.5	1.1	1.9	340	300	390	11.0	9.6	12.0	
Israel	27	17	40	6.3	4.0	9.0	13	6	23	3.7	1.8	6.7	
<i>Kazakhstan</i>	330	270	390	1.6	1.4	1.7	3800	3600	3900	30.0	29.0	32.0	
<i>Kyrgyzstan</i>	120	87	160	1.7	1.4	2.2	970	830	1100	26.0	23.0	31.0	
Macedonia, the former Yugoslav Republic of	0	0	0	-	-	-	0	0	7	0.0	0.0	2.8	
<i>Moldova</i>	320	260	400	5.7	5.1	6.3	660	570	760	19.0	17.0	22.0	
Monaco	0	0	0	-	-	-	0	0	0	1.8	1.0	2.5	
Montenegro	0	0	0	-	-	-	2	0	8	1.8	0.0	9.4	
<i>Russia</i>	9300	7400	11000	6.7	5.7	7.7	19000	17000	21000	20.0	18.0	22.0	
San Marino	0	0	0	-	-	-	0	0	0	1.8	1.0	2.5	
Serbia	11	5	22	7.1	3.1	13	8	2	21	0.5	0.1	1.3	
Switzerland	19	14	24	5.1	4.0	6.2	1	0	5	0.3	0.0	1.8	
<i>Tajikistan</i>	250	190	320	1.8	1.5	2.2	540	420	670	13.0	9.8	16.0	
Turkey	27	15	44	0.2	0.1	0.2	83	10	300	0.9	0.1	3.3	
<i>Turkmenistan</i>	0	0	0	-	-	-	0	0	0	3.8	1.0	9.5	
<i>Ukraine</i>	8100	6700	9600	20.0	20.0	21.0	4400	3800	5100	16.0	14.0	18.0	
<i>Uzbekistan</i>	960	780	1200	3.4	3.2	3.7	2400	1800	3000	23.0	18.0	29.0	
<b>Subtotal non-EU/EEA</b>	<b>20014</b>	<b>16127</b>	<b>23952</b>	<b>6.5</b>	<b>6.2</b>	<b>6.7</b>	<b>34438</b>	<b>30294</b>	<b>38821</b>	<b>16.1</b>	<b>14.2</b>	<b>18.2</b>	
<b>Total European Region</b>	<b>22554</b>	<b>18079</b>	<b>27171</b>	<b>6.0</b>	<b>5.6</b>	<b>6.2</b>	<b>35451</b>	<b>30960</b>	<b>40364</b>	<b>13.1</b>	<b>11.4</b>	<b>14.9</b>	
<b>Subtotal 18 HPC</b>	<b>20460</b>	<b>16443</b>	<b>24557</b>	<b>6.2</b>	<b>5.9</b>	<b>6.4</b>	<b>35092</b>	<b>30774</b>	<b>39658</b>	<b>15.4</b>	<b>13.5</b>	<b>17.5</b>	

'European Region' comprises the 53 countries of the WHO European Region. WHO European Region 18 TB High Priority Countries presented in italics.

	Estimated MDR-TB among notified previously treated TB cases						Estimated MDR-TB among all notified TB cases		
	Number			%			Number		
	Best	Low	High	Best	Low	High	Best	Low	High
	4	1	10	20.0	4.3	48.0	12	4	19
	10	5	18	17.0	8.2	30.0	18	10	26
	91	66	120	26.0	19.0	33.0	120	90	150
	0	0	0	12.0	10.0	15.0	0	0	0
	2	0	7	7.1	0.9	24.0	12	4	20
	0	0	3	0.0	0.0	12.0	2	0	4
	44	33	54	58.0	43.0	71.0	100	83	120
	2	0	8	14.0	0.4	58.0	7	1	13
	34	19	55	13.0	7.4	21.0	43	26	61
	37	23	55	12.0	7.6	18.0	110	61	150
	2	0	11	6.7	0.2	32.0	6	0	14
	19	8	38	8.8	3.6	17.0	44	24	64
	0	0	0	12.0	10.0	15.0	0	0	0
	3	0	11	9.1	0.2	41.0	3	0	7
	13	9	17	13.0	8.8	17.0	57	42	72
	28	19	39	29.0	20.0	40.0	120	96	140
	190	170	210	50.0	45.0	56.0	360	320	390
	0	0	1	0.0	0.0	98.0	0	0	0
	0	0	0	12.0	10.0	15.0	1	1	1
	2	0	9	4.5	0.1	23.0	11	5	17
	4	0	11	9.5	1.2	30.0	9	2	15
	33	20	52	3.5	2.1	5.4	68	46	89
	11	4	26	5.3	1.7	12.0	32	17	47
	510	380	680	11.0	8.0	15.0	850	650	1000
	2	0	9	3.4	0.1	18.0	5	0	11
	0	0	4	0.0	0.0	34.0	0	0	0
	26	12	49	7.1	3.3	13.0	36	15	58
	9	3	19	21.0	7.1	42.0	18	9	27
	16	9	27	5.8	3.1	9.6	71	55	87
	<b>1092</b>	<b>782</b>	<b>1542</b>	<b>12.7</b>	<b>9.1</b>	<b>17.9</b>	<b>2114</b>	<b>1560</b>	<b>2603</b>
	5	1	11	27.0	6.0	61.0	8	2	14
	0	0	1	0.0	0.0	98.0	0	0	0
	170	140	190	43.0	38.0	49.0	250	220	280
	2500	2300	2700	56.0	52.0	60.0	3400	3200	3700
	810	780	850	75.0	72.0	79.0	2000	1900	2100
	1	0	7	2.1	0.1	11.0	3	0	8
	0	0	0	2.4	0.3	8.5	1	0	5
	420	370	460	32.0	28.0	35.0	760	700	820
	1	0	5	13.0	0.3	53.0	14	6	22
	4500	4300	4600	51.0	50.0	53.0	8200	8000	8400
	550	490	620	52.0	45.0	58.0	1500	1400	1700
	2	0	11	4.0	0.1	20.0	2	0	6
	940	890	980	64.0	60.0	67.0	1600	1500	1700
	0	0	0	12.0	10.0	15.0	0	0	0
	0	0	3	0.0	0.0	25.0	2	0	5
	25000	23000	29000	46.0	41.0	52.0	44000		48000
	0	0	0	12.0	10.0	15.0	0	0	0
	11	5	22	7.1	3.1	13	20	9	31
	5	2	13	10.0	2.8	24.0	6	1	12
	500	450	550	54.0	48.0	59.0	1000	910	1200
	470	190	810	38.0	15.0	65.0	560	240	880
	0	0	0	18.0	11.0	27.0	0	0	0
	5100	4600	5600	44.0	40.0	49.0	9500	8700	10000
	670	560	760	62.0	52.0	71.0	3000	2700	3400
	<b>41656</b>	<b>38078</b>	<b>47194</b>	<b>47.3</b>	<b>43.3</b>	<b>53.6</b>	<b>75826</b>	<b>29487</b>	<b>82283</b>
	<b>42748</b>	<b>38860</b>	<b>48736</b>	<b>44.2</b>	<b>40.2</b>	<b>50.4</b>	<b>77940</b>	<b>31047</b>	<b>84886</b>
	<b>42493</b>	<b>38738</b>	<b>48223</b>	<b>45.5</b>	<b>41.5</b>	<b>51.7</b>	<b>77940</b>	<b>30709</b>	<b>83980</b>

**Table 3: Tuberculosis cases, notification rates per 100 000 population and mean annual change in rates, European Region, 2007–2011**

Country	Trends in TB notification rate, 2007–2011	2007		2008		2009		2010		2011		M:F ratio 2011	Mean annual % change in rate, 2007–2011
		N	Rate	N	Rate	N	Rate	N	Rate	N	Rate		
<b>EU/EEA</b>													
Austria		874	10.6	817	9.8	696	8.3	691	8.3	687	8.2	1.6	-6.0
Belgium		1020	9.6	990	9.3	994	9.2	1086	10.0	1044	9.5	1.8	-0.1
Bulgaria		3038	39.6	3150	41.2	2910	38.3	2649	35.0	2407	32.1	2.0	-5.0
Cyprus		42	5.4	50	6.3	55	6.9	61	7.6	54	6.7	1.5	6.2
Czech Republic		846	8.2	864	8.3	694	6.6	669	6.4	600	5.7	2.5	-8.4
Denmark <sup>a</sup>		391	7.2	380	6.9	334	6.1	366	6.6	381	6.9	1.5	-0.8
Estonia		491	36.6	444	33.1	411	30.7	333	24.8	341	25.4	2.5	-8.4
Finland		348	6.6	344	6.5	417	7.8	325	6.1	325	6.0	1.3	-1.0
France <sup>b</sup>		5574	8.8	5758	9.0	5276	8.2	5116	7.9	4942	7.6	1.5	-3.4
Germany		5000	6.1	4523	5.5	4427	5.4	4388	5.4	4316	5.3	1.4	-3.4
Greece		639	5.7	664	5.9	589	5.2	487	4.3	489	4.3	2.4	-6.4
Hungary		1685	16.7	1619	16.1	1407	14.0	1741	17.4	1445	14.5	1.9	-2.4
Iceland		14	4.6	6	1.9	9	2.8	22	6.9	9	2.8	0.3	19.1
Ireland		480	11.1	468	10.6	479	10.8	420	9.4	425	9.5	1.3	-3.8
Italy <sup>c</sup>		4525	7.7	4418	7.4	4244	7.1	4692	7.8	3521	5.8	1.4	-5.8
Latvia		1255	55.0	1070	47.1	977	43.2	935	41.6	885	39.7	2.0	-7.7
Liechtenstein		5	14.2	-	-	-	-	-	-	-	-	-	-
Lithuania		2408	71.1	2250	66.8	2081	62.1	1938	58.2	1904	58.7	2.3	-4.6
Luxembourg		39	8.2	28	5.8	27	5.5	29	5.8	26	5.1	1.4	-10.3
Malta		38	9.3	53	12.9	44	10.6	32	7.7	33	7.9	2.3	-1.0
Netherlands		998	6.1	1015	6.2	1158	7.0	1065	6.4	1007	6.0	1.3	0.1
Norway		302	6.5	313	6.6	358	7.5	336	6.9	361	7.3	1.2	3.5
Poland		8614	22.6	8080	21.2	8236	21.6	7509	19.7	8478	22.2	2.1	-0.1
Portugal		3139	29.6	3002	28.3	2871	27.0	2626	24.7	2540	23.9	2.0	-5.2
Romania		24 837	115.2	24 680	114.6	23 164	107.7	21 059	98.1	19 212	89.7	2.2	-6.0
Slovakia		682	12.6	633	11.7	506	9.3	439	8.1	399	7.3	1.7	-12.6
Slovenia		218	10.8	213	10.6	188	9.3	172	8.4	192	9.4	1.4	-3.2
Spain		7768	17.5	8 216	18.1	7592	16.6	7239	15.7	6762	14.7	1.6	-4.2
Sweden		482	5.3	546	5.9	617	6.7	668	7.2	586	6.2	1.5	4.7
United Kingdom <sup>d</sup>		8329	13.7	8 606	14.1	8917	14.5	8483	13.7	8963	14.3	1.3	1.2
<b>Subtotal EU/EEA</b>		<b>84 081</b>	<b>16.8</b>	<b>83 200</b>	<b>16.5</b>	<b>79 678</b>	<b>15.8</b>	<b>75 576</b>	<b>14.9</b>	<b>72 334</b>	<b>14.2</b>	<b>1.8</b>	<b>-4.0</b>

<sup>a</sup> 'European Region' comprises the 53 countries of the WHO European Region and Liechtenstein.

WHO European Region 18 TB High Priority Countries presented in italics.

Note: For TB cases and case rates by country and year for the period 1995–2011 see [http://ecdc.europa.eu/en/healthtopics/Tuberculosis/epidemiological\\_data/Pages/tuberculosis\\_surveillance\\_Europe.aspx](http://ecdc.europa.eu/en/healthtopics/Tuberculosis/epidemiological_data/Pages/tuberculosis_surveillance_Europe.aspx)

Note: The data published in this report might differ from figures in national reports due to reporting taking place at different times. The deadline for correcting and updating the data used in this report in the joint database was 31 October 2012.

<sup>b</sup> Excluding Greenland (115 cases in 2011, see Chapter 1.1)

<sup>c</sup> France Overseas territories have been included. Provisional data for 2011 from France.

<sup>d</sup> Provisional data for 2011 from Italy.

<sup>e</sup> Data before 2007 differ from those published in the UK due to a revision of the UK surveillance system.

Country	Trends in TB notification rate, 2007–2011	2007		2008		2009		2010		2011		M:F ratio 2011	Mean annual % change in rate, 2007–2011
		N	Rate	N	Rate	N	Rate	N	Rate	N	Rate		
<b>Non-EU/EEA</b>													
Albania		447	14.1	434	13.6	447	14.0	445	13.9	431	13.4	2.2	-1.2%
Andorra		6	7.4	4	4.8	9	10.8	7	8.2	4	4.6	1.0	5.2%
Armenia		2129	69.3	2125	69.0	2006	65.0	1780	57.6	1582	51.0	2.9	-7.2%
Azerbaijan		7347	83.3	10078	112.7	10417	114.9	8394	91.4	10100	108.5	-	8.9%
Belarus		5756	59.2	5483	56.6	5511	57.2	5554	57.9	5118	53.5	2.7	-2.4%
Bosnia and Herzegovina		2400	63.5	1736	46.0	1772	47.0	1390	37.0	1385	36.9	1.3	-11.7%
Croatia		982	22.2	980	22.2	855	19.4	695	15.8	619	14.1	1.4	-10.5%
Georgia		5912	133.9	5836	132.8	5978	136.7	5796	133.2	5533	127.8	2.9	-1.1%
Israel		397	5.7	322	4.5	347	4.8	343	4.6	418	5.5	2.5	0.2%
Kazakhstan		37658	243.3	28913	184.7	30578	193.0	28550	178.1	26211	161.7	1.5	-9.1%
Kyrgyzstan		6707	130.5	7127	136.9	6358	120.6	6295	118.0	6666	123.6	1.3	-1.1%
Macedonia, the former Yugoslav Republic of		563	27.5	483	23.5	473	23.0	420	20.4	362	17.5	1.4	-10.5%
Moldova		6367	173.4	5838	160.6	5591	155.2	5447	152.5	5341	150.7	-	-3.4%
Monaco		-	-	-	-	-	-	1	2.8	-	-	-	-
Montenegro		159	25.3	133	21.1	120	19.0	114	18.1	112	17.7	1.4	-8.4%
Russia		214924	150.0	214905	150.1	156222	109.2	162553	113.7	159479	111.7	2.2	-6.2%
San Marino		-	-	-	-	-	-	-	-	-	-	-	-
Serbia		2981	24.9	2813	23.5	2595	21.5	2385	19.8	2216	18.4	-	-7.2%
Serbia excluding UN Administered Province of Kosovo <sup>d</sup>		1020	10.4	1091	11.1	970	9.8	1501	15.2	1341	13.6	-	10.0%
UN Administered Province of Kosovo <sup>d</sup>		1961	92.2	1722	80.0	1625	74.5	884	40.1	875	41.1	-	-16.3%
Switzerland		472	6.3	516	6.8	554	7.3	548	7.2	578	7.5	1.4	4.6%
Tajikistan		8081	122.4	7996	119.5	7482	110.3	7641	111.1	7609	109.1	1.3	-2.8%
Turkey		19694	28.1	18452	26.0	17402	24.2	16551	22.7	15679	21.3	1.4	-6.7%
Turkmenistan		3698	76.1	3909	79.5	3157	63.4	3230	64.1	-	-	-	-4.9%
Ukraine		40643	87.8	37832	82.3	38901	85.1	36409	80.1	42676	94.4	2.2	2.3%
Uzbekistan		23390	88.2	21194	79.0	21453	79.1	20330	74.1	15913	57.3	1.4	-9.8%
<b>Subtotal non-EU/EEA</b>		<b>390713</b>	<b>100.6</b>	<b>377109</b>	<b>96.7</b>	<b>318228</b>	<b>81.3</b>	<b>314878</b>	<b>80.1</b>	<b>308032</b>	<b>78.1</b>	<b>1.9</b>	<b>-5.9%</b>
<b>Total European Region</b>		<b>474794</b>	<b>53.6</b>	<b>460309</b>	<b>51.7</b>	<b>397906</b>	<b>44.5</b>	<b>390454</b>	<b>43.6</b>	<b>380366</b>	<b>42.2</b>	<b>1.9</b>	<b>-5.7%</b>
<b>Subtotal 18 HPC</b>		<b>414335</b>	<b>107.9</b>	<b>401282</b>	<b>104.2</b>	<b>340599</b>	<b>88.1</b>	<b>335444</b>	<b>86.5</b>	<b>326656</b>	<b>84.0</b>	<b>2.0</b>	<b>-5.9%</b>

<sup>d</sup> This designation is without prejudice to positions on status and is in line with UNSCR 1244 and the ICJ opinion on the Kosovo Declaration of Independence.

**Table 4:** Tuberculosis cases and age-standardised rates per 100 000 population, European Region, 2007–2011

Country	2007			2008			2009		
	N	Crude rate	Standardised rate	N	Crude rate	Standardised rate	N	Crude rate	Standardised rate
<b>EU/EEA</b>									
Austria	874	10.6	10.5	817	9.8	9.7	696	8.3	8.2
Belgium	1020	9.6	9.8	990	9.3	9.4	994	9.2	9.4
Bulgaria	3038	39.6	38.8	3150	41.2	40.6	2910	38.3	37.6
Cyprus	42	5.4	4.5	50	6.3	5.8	55	6.9	6.5
Czech Republic	846	8.2	8.3	864	8.3	8.3	694	6.6	6.7
Denmark <sup>b</sup>	391	7.2	7.4	380	6.9	7.1	334	6.1	6.3
Estonia	491	36.6	36.9	444	33.1	33.4	411	30.7	30.9
Finland	348	6.6	6.5	344	6.5	6.4	417	7.8	7.7
France	5574	8.8	8.9	5758	9.0	9.1	5276	8.2	8.3
Germany	5000	6.1	5.9	4523	5.5	5.3	4427	5.4	5.2
Greece	639	5.7	5.5	664	5.9	5.8	589	5.2	5.1
Hungary	1685	16.7	16.6	1619	16.1	16.0	1407	14.0	13.9
Iceland	14	4.6	4.7	6	1.9	1.7	9	2.8	2.7
Ireland	480	11.1	11.4	468	10.6	11.1	479	10.8	11.4
Italy	4525	7.7	7.5	4418	7.4	7.3	4244	7.1	6.9
Latvia	1255	55.0	55.2	1070	47.1	47.2	977	43.2	42.9
Liechtenstein	5	14.2	-	-	-	-	-	-	-
Lithuania	2408	71.1	72.5	2250	66.8	67.9	2081	62.1	62.7
Luxembourg	39	8.2	8.3	28	5.8	5.8	27	5.5	5.4
Malta	38	9.3	9.5	53	12.9	13.1	44	10.6	10.3
Netherlands	998	6.1	6.3	1015	6.2	6.4	1158	7.0	7.3
Norway	302	6.5	6.7	313	6.6	6.8	358	7.5	7.8
Poland	8614	22.6	23.5	8080	21.2	21.9	8236	21.6	22.2
Portugal	3139	29.6	29.2	3002	28.3	27.9	2871	27.0	26.7
Romania	24837	115.2	114.3	24680	114.6	113.8	23164	107.7	106.5
Slovakia	682	12.6	14.1	633	11.7	13.0	506	9.3	10.2
Slovenia	218	10.8	10.9	213	10.6	10.4	188	9.3	9.1
Spain	7768	17.5	16.8	8216	18.1	17.5	7592	16.6	16.1
Sweden	482	5.3	5.4	546	5.9	6.2	617	6.7	6.9
United Kingdom	8329	13.7	14.0	8606	14.1	14.4	8917	14.5	14.9
<b>Total EU/EEA</b>	<b>84081</b>	<b>16.8</b>	<b>16.7</b>	<b>83200</b>	<b>16.5</b>	<b>16.4</b>	<b>79678</b>	<b>15.8</b>	<b>15.7</b>
<b>Non-EU/EEA</b>									
Albania	422	13.3	15.9	402	12.6	14.6	416	13.0	15.5
Andorra	5	6.1	7.2	4	4.8	4.8	7	8.4	8.0
Armenia	1533	49.9	-	1507	48.9	50.6	1464	47.5	48.8
Azerbaijan	4444	50.4	-	5130	57.4	-	5872	64.8	-
Belarus	4872	50.1	49.8	4634	47.9	47.3	4633	48.1	-
Bosnia and Herzegovina	2217	58.7	-	1663	44.1	46.6	1659	44.0	45.8
Croatia	884	20.0	-	944	21.4	20.6	793	18.0	17.5
Georgia	4065	92.1	90.1	4148	94.4	93.5	4457	101.9	101.2
Israel	389	5.6	6.8	318	4.5	5.5	338	4.7	5.6
Kazakhstan	21557	139.3	131.3	19684	125.7	123.1	16810	106.1	103.1
Kyrgyzstan	5667	110.3	-	6230	119.7	114.5	5434	103.1	115.0
Macedonia, the former Yugoslav Republic of	494	24.1	25.0	427	20.8	21.3	417	20.3	20.6
Moldova	4166	113.5	113.1	3951	108.7	107.9	3804	105.6	104.2
Monaco	0	0.0	0.0	0	0.0	0.0	0	0.0	0.0
Montenegro	137	21.8	23.0	123	19.5	20.7	108	17.1	18.1
Russia	118367	82.6	82.1	120835	84.4	81.8	117227	81.9	79.1
San Marino	0	-	-	0	-	-	0	-	-
Serbia	2667	27.1	-	2526	25.7	-	1740	17.7	18.3
Serbia excluding UN Administered Province of Kosovo <sup>c</sup>	-	-	-	-	-	-	-	-	-
UN Administered Province of Kosovo <sup>c</sup>	-	-	-	-	-	-	-	-	-
Switzerland	313	4.2	4.2	319	4.2	4.2	334	4.4	4.4
Tajikistan	6078	92.0	112.0	6150	91.9	114.5	5864	86.4	108.4
Turkey	17809	25.4	30.3	16760	23.6	28.2	15943	22.2	26.8
Turkmenistan	3347	68.9	-	3628	73.8	-	3157	63.4	-
Ukraine	34891	75.4	-	35739	77.7	76.4	33424	73.1	71.6
Uzbekistan	18773	70.8	91.1	15971	59.6	80.8	16569	61.1	80.5
<b>Total non-EU/EEA</b>	<b>200114</b>	<b>55.4</b>	<b>66.8</b>	<b>239809</b>	<b>65.9</b>	<b>65.8</b>	<b>226808</b>	<b>62.0</b>	<b>62.6</b>

<sup>a</sup> 'European Region' comprises the 53 countries of the WHO European Region and Liechtenstein.

WHO European Region 18 TB High Priority Countries presented in *italics*.

Note: For TB cases and case rates by country and year for the period 1995–2011, see [http://ecdc.europa.eu/en/healthtopics/Tuberculosis/epidemiological\\_data/Pages/epidemiological\\_data.aspx](http://ecdc.europa.eu/en/healthtopics/Tuberculosis/epidemiological_data/Pages/epidemiological_data.aspx)

<sup>b</sup> The standard population based on the average of the EU Member States population by age group, 2000–2010

<sup>c</sup> Excluding Greenland (115 cases in 2011, see Chapter 1.1).

<sup>d</sup> In accordance with the UN Security Council Resolution No. 1244 (1999). For EU/EEA countries all notified TB cases are presented and for non-EU/EEA countries only new cases notified in a particular year



	2010			2011		
	N	Crude rate	Standardised rate	N	Crude rate	Standardised rate
	691	8.3	8.2	687	8.2	8.1
	1086	10.0	10.2	1044	9.5	9.7
	2649	35.0	34.5	2407	32.1	31.4
	61	7.6	6.8	54	6.7	6.5
	669	6.4	6.4	600	5.7	5.7
	366	6.6	6.9	381	6.9	7.1
	333	24.8	25.0	341	25.4	25.5
	325	6.1	6.0	325	6.0	5.8
	5116	7.9	8.1	4942	7.6	7.7
	4388	5.4	5.2	4316	5.3	5.0
	487	4.3	4.2	489	4.3	4.2
	1741	17.4	17.1	1445	14.5	14.1
	22	6.9	7.2	9	2.8	2.8
	420	9.4	9.9	425	9.5	10.0
	4692	7.8	7.7	3521	5.8	5.8
	935	41.6	41.4	885	39.7	39.4
	-	-	-	-	-	-
	1938	58.2	58.5	1904	58.7	58.8
	29	5.8	5.8	26	5.1	5.2
	32	7.7	7.7	33	7.9	8.0
	1065	6.4	6.7	1007	6.0	6.3
	336	6.9	7.2	361	7.3	7.7
	7509	19.7	20.0	8478	22.2	22.4
	2626	24.7	24.3	2540	23.9	23.4
	21059	98.1	96.9	19212	89.7	88.5
	439	8.1	8.7	399	7.3	7.8
	172	8.4	8.2	192	9.4	9.0
	7239	15.7	15.3	6762	14.7	14.3
	668	7.2	7.4	586	6.2	6.5
	8483	13.7	14.0	8963	14.3	14.7
	<b>75576</b>	<b>14.9</b>	<b>14.8</b>	<b>72334</b>	<b>14.2</b>	<b>14.1</b>
	415	13.0	14.7	413	12.8	14.6
	7	8.2	8.3	3	3.5	3.3
	1329	43.0	44.4	1200	38.7	40.2
	5237	57.0	-	5296	56.9	-
	4345	45.3	44.3	4043	42.3	41.1
	1289	34.3	35.4	1320	35.2	36.9
	652	14.8	14.4	619	14.1	13.6
	4383	100.7	100.1	4223	97.6	97.5
	339	4.6	5.2	408	5.4	5.8
	15641	97.59541885	94.9	14396	88.8	88.1
	5308	99.5	111.9	5180	96.1	-
	368	17.9	18.3	307	14.9	15.2
	3745	104.8	103.6	3836	108.2	106.6
	1	2.8	2.7	0	-	-
	102	16.2	17.2	100	15.8	16.2
	109904	76.9	69.2	104320	73.0	70.4
	0	-	-	0	-	-
	2178	22.1	-	1205	12.2	12.7
	-	-	-	-	-	-
	-	-	0.0	846	2.6	-
	322	4.2	4.2	379	4.9	4.9
	5959	86.6	110.1	5935	85.1	110.7
	15183	20.9	25.5	14417	19.6	24.2
	3148	62.4	-	0	-	-
	31295	68.9	-	31188	69.0	-
	15734	57.3	76.2	13995	50.4	68.2
	<b>185026</b>	<b>57.6</b>	<b>56.1</b>	<b>171119</b>	<b>52.3</b>	<b>47.4</b>

**Table 5: New TB cases and relapses, notification rates per 100 000 population, European Region, 2002–2011<sup>a</sup>**

Country	Trends in TB notification rate, 2002–2011 <sup>a</sup>	2002		2003		2004		2005		2006		2007	
		N	Rate	N	Rate	N	Rate	N	Rate	N	Rate	N	Rate
<b>EU/EEA</b>													
Austria		992	12.3	916	11.3	1017	12.5	936	11.4	856	10.4	818	9.9
Belgium		952	9.2	695	6.7	860	8.3	851	8.1	825	7.8	819	7.7
Bulgaria		2962	37.5	2952	37.6	2923	37.5	3101	40.0	3011	39.0	2821	36.7
Cyprus		19	2.7	34	4.8	29	4.0	33	4.4	35	4.6	41	5.3
Czech Republic		1156	11.3	1110	10.9	1027	10.1	886	8.7	872	8.5	770	7.5
Denmark <sup>b</sup>		386	7.2	368	6.8	355	6.6	392	7.2	350	6.4	355	6.5
Estonia		621	45.6	559	41.2	540	40.0	480	35.6	426	31.7	457	34.0
Finland		476	9.2	412	7.9	329	6.3	354	6.8	281	5.3	333	6.3
France		4314	7.0	4292	6.9	4523	7.3	4443	7.1	4193	6.6	3871	6.1
Germany		5062	6.1	4985	6.0	5149	6.2	4825	5.8	4469	5.4	4185	5.1
Greece		281	2.6	552	5.0	600	5.4	583	5.3	567	5.1	530	4.7
Hungary		2505	24.6	2297	22.6	2087	20.6	1721	17.0	1627	16.1	1467	14.6
Iceland		8	2.8	5	1.7	12	4.1	10	3.4	13	4.3	12	3.9
Ireland		306	7.8	288	7.3	304	7.5	311	7.6	314	7.5	350	8.1
Italy		2903	5.1	3570	6.2	3183	5.5	3005	5.1	3295	5.6	3378	5.7
Latvia		1803	76.9	1686	72.3	1571	67.7	1404	60.9	1285	56.0	1226	53.7
Liechtenstein		-	-	-	-	-	-	-	-	-	-	5	14.2
Lithuania		2097	60.3	2553	73.7	2030	58.9	2371	69.2	2365	69.5	2232	65.9
Luxembourg		31	7.0	53	11.8	31	6.8	36	7.8	33	7.0	0	0.0
Malta		24	6.1	6	1.5	19	4.8	24	6.0	30	7.4	37	9.1
Netherlands		1191	7.4	1101	6.8	1128	6.9	1071	6.6	980	6.0	947	5.8
Norway		207	4.6	246	5.4	240	5.2	238	5.2	223	4.8	224	4.8
Poland		9212	24.1	8901	23.3	8337	21.8	8586	22.5	7980	20.9	8033	21.1
Portugal		4170	40.4	3870	37.2	3588	34.3	3206	30.4	3253	30.8	2962	27.9
Romania		30065	137.7	27741	127.4	27652	127.4	25916	119.7	23774	110.0	22128	102.6
Slovakia		964	17.9	893	16.6	653	12.1	685	12.7	657	12.2	610	11.3
Slovenia		338	17.0	278	13.9	252	12.6	271	13.6	208	10.4	214	10.6
Spain		5229	12.8	4594	11.0	5516	13.0	6185	14.4	6101	13.9	6154	13.8
Sweden		371	4.2	385	4.3	429	4.8	531	5.9	476	5.3	446	4.9
United Kingdom <sup>c</sup>		5290	8.9	5135	8.6	5308	8.9	6015	10.0	6270	10.4	5987	9.9
<b>Subtotal EU/EEA</b>		<b>83935</b>	<b>17.1</b>	<b>80477</b>	<b>16.4</b>	<b>79692</b>	<b>16.1</b>	<b>78470</b>	<b>15.8</b>	<b>74769</b>	<b>15.0</b>	<b>71412</b>	<b>14.3</b>

<sup>a</sup> 'European Region' comprises the 53 countries of the WHO European Region and Liechtenstein.

WHO European Region 18 TB High Priority Countries presented in *italics*.

Note: For TB cases and case rates by country and year for the period 1995–2011, see [http://ecdc.europa.eu/en/healthtopics/Tuberculosis/epidemiological\\_data/Pages/epidemiological\\_data.aspx](http://ecdc.europa.eu/en/healthtopics/Tuberculosis/epidemiological_data/Pages/epidemiological_data.aspx)

<sup>b</sup> Cases with missing information on previous history of TB treatment are not included. For countries with no information on relapse, only new cases included.

<sup>c</sup> Excluding Greenland (115 cases in 2011, see Chapter 1.1).

<sup>d</sup> Data before 2007 differ from those published in the UK due to a revision of the UK surveillance system.

	2008		2009		2010		2011	
	N	Rate	N	Rate	N	Rate	N	Rate
	737	8.9	438	5.2	360	4.3	401	4.8
	787	7.4	787	7.3	790	7.3	705	6.4
	2945	38.5	2657	34.9	2413	31.9	2173	29.0
	18	2.3	43	5.4	33	4.1	31	3.9
	806	7.8	632	6.0	620	5.9	569	5.4
	331	6.0	292	5.3	331	6.0	359	6.5
	400	29.8	358	26.7	289	21.6	297	22.2
	328	6.2	403	7.6	312	5.8	312	5.8
	3328	5.2	2873	4.5	2752	4.3	2639	4.1
	3773	4.6	3757	4.6	3627	4.4	3577	4.4
	535	4.8	466	4.1	354	3.1	452	4.0
	1433	14.3	1265	12.6	1543	15.4	1278	12.8
	5	1.6	8	2.5	22	6.9	8	2.5
	360	8.2	364	8.2	327	7.3	280	6.2
	3409	5.7	2540	4.2	2751	4.6	2018	3.3
	1048	46.1	948	41.9	915	40.7	866	38.8
	-	-	-	-	-	-	-	-
	2097	62.3	1898	56.7	1754	52.7	1748	53.9
	0	0.0	0	0.0	24	4.8	11	2.1
	48	11.7	41	9.9	20	4.8	22	5.3
	962	5.9	1109	6.7	1025	6.2	974	5.8
	237	5.0	275	5.7	276	5.7	314	6.4
	7419	19.5	7646	20.0	7009	18.4	7950	20.8
	2840	26.7	2722	25.6	2497	23.5	2413	22.7
	21646	100.5	20643	96.0	18590	86.6	16992	79.4
	562	10.4	433	8.0	389	7.2	352	6.5
	208	10.3	187	9.2	159	7.8	181	8.8
	6770	15.0	6687	14.6	6534	14.2	6044	13.1
	452	4.9	508	5.5	547	5.9	457	4.9
	6505	10.6	7058	11.5	7219	11.6	7850	12.6
	<b>69989</b>	<b>13.9</b>	<b>67038</b>	<b>13.3</b>	<b>63482</b>	<b>12.5</b>	<b>61273</b>	<b>12.1</b>

Country	Trends in TB notification rate, 2002–2011 <sup>a</sup>	2002		2003		2004		2005		2006		2007	
		N	Rate	N	Rate	N	Rate	N	Rate	N	Rate	N	Rate
<b>Non-EU/EEA</b>													
Albania		594	19.2	543	17.5	547	17.5	506	16.1	469	14.9	438	13.8
Andorra		5	7.2	10	13.8	7	9.3	10	12.8	12	15.0	5	6.1
Armenia		1433	46.8	1538	50.3	1660	54.2	2206	72.0	1767	57.6	1682	54.7
Azerbaijan		5142	62.1	3840	45.8	5404	63.7	6034	70.3	5705	65.6	5521	62.6
Belarus		5139	51.6	5106	51.5	5443	55.1	5308	54.0	5142	52.6	5351	55.0
Bosnia and Herzegovina		1691	44.8	1740	46.0	2353	62.2	2111	55.8	1778	47.0	2373	62.8
Croatia		1443	32.3	1356	30.4	1170	26.3	1050	23.6	1029	23.2	951	21.5
Georgia		4490	97.1	4212	92.2	4011	88.7	4501	100.5	4554	102.5	4310	97.6
Israel		466	7.5	472	7.4	456	7.0	371	5.6	340	5.0	396	5.7
Kazakhstan		27546	184.9	27069	181.0	26349	175.0	25512	168.2	23796	155.4	24752	159.9
Kyrgyzstan		6613	132.2	6172	123.2	6104	121.6	6329	125.5	6174	121.4	6098	118.7
Macedonia, the former Yugoslav Republic of		686	33.9	653	32.2	644	31.7	598	29.3	561	27.5	526	25.7
Moldova		3769	95.0	3619	92.9	4806	125.6	5141	136.5	4990	134.3	4857	132.3
Monaco		-	-	-	-	-	-	-	-	-	-	-	-
Montenegro		-	-	-	-	-	-	156	24.9	167	26.6	147	23.4
Russia		128873	88.6	124041	85.6	121426	84.1	127930	88.9	124689	86.9	127338	88.9
San Marino		1	3.5	1	3.4	-	-	-	-	-	-	-	-
Serbia		-	-	-	-	-	-	3208	26.9	3146	26.3	2891	24.1
Serbia excluding UN Administered Province of Kosovo <sup>d</sup>		-	-	-	-	-	-	2106	21.4	2024	20.6	1961	19.9
UN Administered Province of Kosovo <sup>d</sup>		-	-	-	-	-	-	1102	53.8	1122	53.4	930	43.7
Switzerland		438	6.0	401	5.5	407	5.5	381	5.1	341	4.6	313	4.2
Tajikistan		4052	64.5	4260	67.2	4529	70.9	5460	84.6	5362	82.2	6297	95.3
Turkey		18043	27.6	17923	27.0	17543	26.1	19744	29.4	19629	28.4	18878	27.0
Turkmenistan		3671	79.8	3771	81.1	3382	72.0	3191	67.2	3223	67.1	3428	70.6
Ukraine		40175	83.6	37043	77.8	38403	81.2	39608	84.4	41265	88.6	37517	81.1
Uzbekistan		20588	81.5	20700	81.2	20289	78.9	21513	82.9	23900	91.2	19779	74.6
<b>Subtotal non-EU/EEA</b>		<b>274858</b>	<b>71.1</b>	<b>264470</b>	<b>68.4</b>	<b>264933</b>	<b>68.4</b>	<b>280868</b>	<b>73.3</b>	<b>278039</b>	<b>72.2</b>	<b>273848</b>	<b>70.9</b>
<b>Total European Region</b>		<b>358793</b>	<b>41.1</b>	<b>344947</b>	<b>39.5</b>	<b>344625</b>	<b>39.3</b>	<b>359338</b>	<b>40.8</b>	<b>352808</b>	<b>40.0</b>	<b>345260</b>	<b>39.0</b>
<b>Subtotal 18 HPC</b>		<b>307082</b>	<b>80.4</b>	<b>294785</b>	<b>77.2</b>	<b>294065</b>	<b>76.9</b>	<b>305749</b>	<b>79.9</b>	<b>301057</b>	<b>78.6</b>	<b>294672</b>	<b>76.7</b>

<sup>a</sup> 'European Region' comprises the 53 countries of the WHO European Region and Liechtenstein.

WHO European Region 18 TB High Priority Countries presented in *italics*.

Note: For TB cases and case rates by country and year for the period 1995–2011, see [http://ecdc.europa.eu/en/healthtopics/Tuberculosis/epidemiological\\_data/Pages/epidemiological\\_data.aspx](http://ecdc.europa.eu/en/healthtopics/Tuberculosis/epidemiological_data/Pages/epidemiological_data.aspx)

<sup>d</sup> In accordance with the UN Security Council Resolution No. 1244 (1999).

	2008		2009		2010		2011	
	N	Rate	N	Rate	N	Rate	N	Rate
	427	13.4	435	13.6	431	13.5	422	13.1
	4	4.8	8	9.6	7	8.2	3	3.5
	1655	53.7	1560	50.6	1410	45.6	1261	40.7
	6417	71.7	7301	80.5	6390	69.5	6515	70.0
	5126	53.0	5250	54.5	5003	52.1	4697	49.1
	1713	45.4	1725	45.8	1321	35.1	1360	36.2
	980	22.2	832	18.9	688	15.6	619	14.1
	4412	100.4	4732	108.2	4674	107.4	4547	105.0
	322	4.5	347	4.8	340	4.6	412	5.4
	23140	147.8	20508	129.5	19703	122.9	19135	118.1
	6628	127.4	5765	109.4	5652	106.0	5529	102.5
	450	21.9	450	21.9	384	18.6	335	16.2
	4442	122.2	4347	120.7	4122	115.4	4208	118.7
	-	-	-	-	1	2.8	-	-
	131	20.8	113	17.9	110	17.4	110	17.4
	128263	89.6	126227	88.2	118641	83.0	112910	79.0
	-	-	-	-	-	-	-	-
	2714	22.6	2526	21.0	2326	19.3	2171	19.2
	1722	17.5	1625	16.5	1442	14.6	1296	14.7
	992	46.1	901	41.3	884	40.1	875	50.3
	319	4.2	334	4.4	322	4.2	379	4.9
	6396	95.6	6125	90.3	6297	91.5	6290	90.2
	17600	24.8	16757	23.3	15879	21.8	15054	20.4
	3757	76.4	3157	63.4	3230	64.1	-	-
	37832	82.3	36075	78.9	33857	74.5	34237	75.8
	17040	63.6	17540	64.7	16883	61.5	14501	52.2
	<b>269768</b>	<b>69.6</b>	<b>262114</b>	<b>67.3</b>	<b>247671</b>	<b>63.4</b>	<b>234695</b>	<b>58.3</b>
	<b>339757</b>	<b>38.2</b>	<b>329152</b>	<b>36.8</b>	<b>311153</b>	<b>34.7</b>	<b>295968</b>	<b>32.8</b>
	<b>290844</b>	<b>75.5</b>	<b>281848</b>	<b>72.9</b>	<b>265702</b>	<b>68.6</b>	<b>250960</b>	<b>64.3</b>

Table 6: Tuberculosis cases by history of previous TB treatment, European Region, 2011

Country	New		Unknown previous TB history		Previously treated total		Previous treatment completed		Previous treatment failed		Previous treatment defaulted		Other retreatment			
	N	(%) <sup>a</sup>	N	(%) <sup>a</sup>	N	(%) <sup>a</sup>	N	(%) <sup>b</sup>	N	(%) <sup>b</sup>	N	(%) <sup>b</sup>	N	(%) <sup>b</sup>	N	
<b>EU/EEA</b>																
Austria	396	(57.6)	271	(39.4)	20	(2.9)	12	(60.0)	0	(0.0)	0	(0.0)	8	(40.0)	687	
Belgium <sup>c</sup>	705	(67.5)	280	(26.8)	59	(5.7)	-	(0.0)	-	(0.0)	-	(0.0)	59	(100.0)	1044	
Bulgaria	2 052	(85.3)	-	(0.0)	355	(14.7)	262	(73.8)	37	(10.4)	56	(15.8)	0	(0.0)	2 407	
Cyprus	31	(57.4)	20	(37.0)	3	(5.6)	1	(33.3)	0	(0.0)	0	(0.0)	2	(66.7)	54	
Czech Republic	569	(94.8)	-	(0.0)	31	(5.2)	0	(0.0)	0	(0.0)	0	(0.0)	31	(100.0)	600	
Denmark <sup>cd</sup>	359	(94.2)	-	(0.0)	22	(5.8)	-	(0.0)	-	(0.0)	-	(0.0)	22	(100.0)	381	
Estonia	265	(77.7)	-	(0.0)	76	(22.3)	53	(69.7)	11	(14.5)	12	(15.8)	0	(0.0)	341	
Finland	312	(96.0)	-	(0.0)	13	(4.0)	0	(0.0)	0	(0.0)	0	(0.0)	13	(100.0)	325	
France	2 639	(53.4)	2 042	(41.3)	261	(5.3)	0	(0.0)	0	(0.0)	0	(0.0)	261	(100.0)	4 942	
Germany	3 490	(80.9)	526	(12.2)	300	(7.0)	159	(53.0)	7	(2.3)	42	(14.0)	92	(30.7)	4 316	
Greece	452	(92.4)	2	(0.4)	35	(7.2)	0	(0.0)	0	(0.0)	0	(0.0)	35	(100.0)	489	
Hungary	1 223	(84.6)	1	(0.1)	221	(15.3)	153	(69.2)	0	(0.0)	56	(25.3)	12	(5.4)	1 445	
Iceland	8	(88.9)	0	(0.0)	1	(11.1)	1	(100.0)	0	(0.0)	0	(0.0)	0	(0.0)	9	
Ireland <sup>d</sup>	280	(65.9)	118	(27.8)	27	(6.4)	-	(0.0)	-	(0.0)	-	(0.0)	27	(100.0)	425	
Italy	2 018	(57.3)	1 403	(39.8)	100	(2.8)	0	(0.0)	0	(0.0)	0	(0.0)	100	(100.0)	3 521	
Latvia	788	(89.0)	0	(0.0)	97	(11.0)	83	(85.6)	0	(0.0)	14	(14.4)	0	(0.0)	885	
Liechtenstein	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Lithuania	1 532	(80.5)	3	(0.2)	369	(19.4)	216	(58.5)	47	(12.7)	106	(28.7)	0	(0.0)	1 904	
Luxembourg	11	(42.3)	14	(53.8)	1	(3.8)	0	(0.0)	0	(0.0)	0	(0.0)	1	(100.0)	26	
Malta	22	(66.7)	8	(24.2)	3	(9.1)	2	(66.7)	0	(0.0)	1	(33.3)	0	(0.0)	33	
Netherlands	958	(95.1)	11	(1.1)	38	(3.8)	27	(71.1)	0	(0.0)	10	(26.3)	1	(2.6)	1 007	
Norway <sup>e</sup>	314	(87.0)	10	(2.8)	37	(10.2)	-	(0.0)	-	(0.0)	-	(0.0)	37	(100.0)	361	
Poland	7 515	(88.6)	0	(0.0)	963	(11.4)	660	(68.5)	0	(0.0)	0	(0.0)	303	(31.5)	8 478	
Portugal	2 325	(91.5)	0	(0.0)	215	(8.5)	147	(68.4)	2	(0.9)	23	(10.7)	43	(20.0)	2 540	
Romania	14 543	(75.7)	0	(0.0)	4 669	(24.3)	3 139	(67.2)	801	(17.2)	729	(15.6)	0	(0.0)	19 212	
Slovakia	323	(81.0)	26	(6.5)	50	(12.5)	48	(96.0)	0	(0.0)	0	(0.0)	2	(4.0)	399	
Slovenia	181	(94.3)	0	(0.0)	11	(5.7)	9	(81.8)	0	(0.0)	1	(9.1)	1	(9.1)	192	
Spain	6 044	(89.4)	348	(5.1)	370	(5.5)	0	(0.0)	0	(0.0)	0	(0.0)	370	(100.0)	6 762	
Sweden	454	(77.5)	87	(14.8)	45	(7.7)	7	(15.6)	0	(0.0)	1	(2.2)	37	(82.2)	586	
United Kingdom <sup>c</sup>	7 850	(87.6)	589	(6.6)	524	(5.8)	-	(0.0)	-	(0.0)	-	(0.0)	524	(100.0)	8 963	
<b>Subtotal EU/EEA</b>	<b>57 659</b>	<b>(79.7)</b>	<b>5 759</b>	<b>(8.0)</b>	<b>8 916</b>	<b>(12.3)</b>	<b>4 979</b>	<b>(55.8)</b>	<b>905</b>	<b>(10.2)</b>	<b>1 051</b>	<b>(11.8)</b>	<b>1 981</b>	<b>(22.2)</b>	<b>72 334</b>	
<b>Non-EU/EEA</b>																
Albania	413	(95.8)	0	0	18	(4.2)	9	(50.0)	0	(0.0)	0	(0.0)	9	(50.0)	431	
Andorra	3	(75.0)	0	0	1	(25.0)	0	(0.0)	0	(0.0)	0	(0.0)	1	(100.0)	4	
Armenia	1 200	(75.9)	0	0	382	(24.1)	61	(16.0)	10	(2.6)	13	(3.4)	298	(78.0)	1 582	
Azerbaijan	5 296	(54.0)	0	(0.0)	4 804	(47.6)	1 219	(25.4)	13	(0.3)	67	(1.4)	3 505	(73.0)	10 100	
Belarus	4 043	(79.0)	0	0	1 075	(21.0)	654	(60.8)	228	(21.2)	26	(2.4)	167	(15.5)	5 118	
Bosnia and Herzegovina	1 320	(95.3)	0	0	65	(4.7)	40	(61.5)	0	(0.0)	0	(0.0)	25	(38.5)	1 385	
Croatia	619	(100.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	619	
Georgia	4 223	(76.3)	0	0	1 310	(23.7)	324	(24.7)	60	(4.6)	100	(7.6)	826	(63.1)	5 533	
Israel	408	(97.6)	0	0	10	(2.4)	4	(40.0)	2	(20.0)	2	(20.0)	2	(20.0)	418	
Kazakhstan	14 396	(54.9)	0	(0.0)	11 815	(45.1)	4 739	(40.1)	622	(5.3)	608	(5.1)	5 846	(49.5)	26 211	
Kyrgyzstan	5 180	(77.7)	0	0	1 486	(22.3)	349	(23.5)	0	(0.0)	0	(0.0)	1 137	(76.5)	6 666	
Macedonia, the former Yugoslav Republic of	307	(84.8)	0	0	55	(15.2)	28	(50.9)	0	(0.0)	0	(0.0)	27	(49.1)	362	
Moldova	3 836	(71.8)	25	(0.5)	1 480	(27.7)	372	(25.1)	145	(9.8)	285	(19.3)	678	(45.8)	5 341	
Monaco	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Montenegro	100	(89.3)	0	0	12	(10.7)	10	(83.3)	0	(0.0)	2	(16.7)	0	(0.0)	112	
Russia	104 320	(65.4)	0	0	55 159	(34.6)	8 590	(15.6)	9 879	(17.9)	2 745	(5.0)	33 945	(61.5)	159 479	
San Marino	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Serbia	2 051	(92.6)	3	(0.1)	162	(7.3)	120	(74.1)	6	(3.7)	9	(5.6)	27	(16.7)	2 216	
Serbia excluding UN Administered Province of Kosovo <sup>e</sup>	1 205	(89.9)	3	(0.2)	133	(9.9)	91	(68.4)	6	(4.5)	9	(6.8)	27	(20.3)	1 341	
UN Administered Province of Kosovo <sup>e</sup>	846	(96.7)	0	0	29	(3.3)	29	(100.0)	0	(0.0)	0	(0.0)	0	(0.0)	875	
Switzerland	379	(65.6)	145	(25.1)	54	(9.3)	0	(0.0)	0	(0.0)	0	(0.0)	54	(100.0)	578	
Tajikistan	5 935	(78.0)	745	(9.8)	929	(12.2)	355	(38.2)	198	(21.3)	67	(7.2)	309	(33.3)	7 609	
Turkey	14 417	(92.0)	0	0	1 262	(8.0)	637	(50.5)	85	(6.7)	125	(9.9)	415	(32.9)	15 679	
Turkmenistan	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Ukraine	3 118	(73.1)	0	0	11 488	(26.9)	3 049	(26.5)	0	(0.0)	0	(0.0)	8 439	(73.5)	42 676	
Uzbekistan	13 995	(87.9)	844	(5.3)	1 074	(6.7)	506	(47.1)	175	(16.3)	36	(3.4)	357	(33.2)	15 913	
<b>Subtotal non-EU/EEA</b>	<b>213 629</b>	<b>(69.4)</b>	<b>1 762</b>	<b>(0.6)</b>	<b>92 641</b>	<b>(30.1)</b>	<b>21 066</b>	<b>(22.7)</b>	<b>11 423</b>	<b>(12.3)</b>	<b>4 085</b>	<b>(4.4)</b>	<b>56 067</b>	<b>(60.5)</b>	<b>308 032</b>	
<b>Total European Region</b>	<b>271 288</b>	<b>(71.3)</b>	<b>7 521</b>	<b>(2.0)</b>	<b>101 557</b>	<b>(26.7)</b>	<b>26 045</b>	<b>(25.6)</b>	<b>12 328</b>	<b>(12.1)</b>	<b>5 136</b>	<b>(5.1)</b>	<b>58 048</b>	<b>(57.2)</b>	<b>380 366</b>	
<b>Subtotal 18 HPC</b>	<b>227 209</b>	<b>(69.6)</b>	<b>1 617</b>	<b>(0.5)</b>	<b>97 830</b>	<b>(29.9)</b>	<b>24 608</b>	<b>(25.2)</b>	<b>12 311</b>	<b>(12.6)</b>	<b>4 989</b>	<b>(5.1)</b>	<b>55 922</b>	<b>(57.2)</b>	<b>326 656</b>	

<sup>a</sup> 'European Region' comprises the 53 countries of the WHO European Region and Liechtenstein.

<sup>b</sup> WHO European Region 18 TB High Priority Countries presented in italics.

<sup>c</sup> Percentages among all TB cases.

<sup>d</sup> Percentages among previously treated TB cases.

<sup>e</sup> Distribution by previous diagnosis.

<sup>f</sup> Excluding Greenland (see Chapter 1.1).

<sup>g</sup> In accordance with the UN Security Council Resolution No. 1244 (1999).

Table 7: Tuberculosis cases by site of disease, European Region, 2011

Country	Pulmonary						Extrapulmonary		No site reported		Total
	Pulmonary only		Pulmonary + extrapulmonary		Total pulmonary		N	(%)	N	(%)	
	N	(%)	N	(%)	N	(%)					
<b>EU/EEA</b>											
Austria	490	(71.3)	50	(7.3)	540	(78.6)	136	(19.8)	11	(1.6)	687
Belgium	645	(61.8)	102	(9.8)	747	(71.6)	297	(28.4)	0	(0.0)	1044
Bulgaria	1636	(68.0)	88	(3.7)	1724	(71.6)	683	(28.4)	0	(0.0)	2407
Cyprus	42	(77.8)	2	(3.7)	44	(81.5)	8	(14.8)	2	(3.7)	54
Czech Republic	493	(82.2)	29	(4.8)	522	(87.0)	78	(13.0)	0	(0.0)	600
Denmark <sup>a</sup>	232	(60.9)	8	(2.1)	240	(63.0)	47	(12.3)	94	(24.7)	381
Estonia	269	(78.9)	52	(15.2)	321	(94.1)	20	(5.9)	0	(0.0)	341
Finland	236	(72.6)	0	(0.0)	236	(72.6)	89	(27.4)	0	(0.0)	325
France	2874	(58.2)	726	(14.7)	3600	(72.8)	1289	(26.1)	53	(1.1)	4942
Germany	2880	(66.7)	466	(10.8)	3346	(77.5)	926	(21.5)	44	(1.0)	4316
Greece	371	(75.9)	55	(11.2)	426	(87.1)	60	(12.3)	3	(0.6)	489
Hungary	1357	(93.9)	32	(2.2)	1389	(96.1)	56	(3.9)	0	(0.0)	1445
Iceland	2	(22.2)	1	(11.1)	3	(33.3)	6	(66.7)	0	(0.0)	9
Ireland	263	(61.9)	30	(7.1)	293	(68.9)	121	(28.5)	11	(2.6)	425
Italy	2349	(66.7)	233	(6.6)	2582	(73.3)	939	(26.7)	0	(0.0)	3521
Latvia	730	(82.5)	66	(7.5)	796	(89.9)	89	(10.1)	0	(0.0)	885
Liechtenstein	-	-	-	-	-	-	-	-	-	-	-
Lithuania	1714	(90.0)	0	(0.0)	1714	(90.0)	190	(10.0)	0	(0.0)	1904
Luxembourg	21	(80.8)	1	(3.8)	22	(84.6)	4	(15.4)	0	(0.0)	26
Malta	17	(51.5)	5	(15.2)	22	(66.7)	11	(33.3)	0	(0.0)	33
Netherlands	431	(42.8)	132	(13.1)	563	(55.9)	441	(43.8)	3	(0.3)	1007
Norway	146	(40.4)	54	(15.0)	200	(55.4)	158	(43.8)	3	(0.8)	361
Poland	7828	(92.3)	51	(0.6)	7879	(92.9)	599	(7.1)	0	(0.0)	8478
Portugal	1647	(64.8)	210	(8.3)	1857	(73.1)	675	(26.6)	8	(0.3)	2540
Romania	15245	(79.4)	1186	(6.2)	16431	(85.5)	2781	(14.5)	0	(0.0)	19212
Slovakia	320	(80.2)	17	(4.3)	337	(84.5)	62	(15.5)	0	(0.0)	399
Slovenia	133	(69.3)	32	(16.7)	165	(85.9)	27	(14.1)	0	(0.0)	192
Spain	4979	(73.6)	0	(0.0)	4979	(73.6)	1783	(26.4)	0	(0.0)	6762
Sweden	298	(50.9)	60	(10.2)	358	(61.1)	228	(38.9)	0	(0.0)	586
United Kingdom	3705	(41.3)	898	(10.0)	4603	(51.4)	4313	(48.1)	47	(0.5)	8963
<b>Subtotal EU/EEA</b>	<b>51353</b>	<b>(71.0)</b>	<b>4586</b>	<b>(6.3)</b>	<b>55939</b>	<b>(77.3)</b>	<b>16116</b>	<b>(22.3)</b>	<b>279</b>	<b>(0.4)</b>	<b>72334</b>
<b>Non-EU/EEA</b>											
Albania	-	-	-	-	294	(68.2)	128	(29.7)	9	(2.1)	431
Andorra	-	-	-	-	3	(75.0)	1	(25.0)	0	(0.0)	4
Armenia	-	-	-	-	1056	(66.8)	289	(18.3)	237	(15.0)	1582
Azerbaijan	-	-	-	-	8938	(88.5)	1131	(11.2)	31	(0.3)	10100
Belarus	-	-	-	-	4634	(90.5)	404	(7.9)	80	(1.6)	5118
Bosnia and Herzegovina	-	-	-	-	1259	(88.4)	166	(11.6)	0	(0.0)	1425
Croatia	-	-	-	-	602	(88.7)	77	(11.3)	0	(0.0)	679
Georgia	-	-	-	-	3676	(66.4)	1065	(19.2)	792	(14.3)	5533
Israel	-	-	-	-	351	(84.0)	67	(16.0)	0	(0.0)	418
Kazakhstan	-	-	-	-	23806	(90.8)	2405	(9.2)	0	(0.0)	26211
Kyrgyzstan	-	-	-	-	4835	(72.5)	1613	(24.2)	218	(3.3)	6666
Macedonia, the former Yugoslav Republic of	-	-	-	-	271	(74.9)	76	(21.0)	15	(4.1)	362
Moldova	-	-	-	-	4876	(91.3)	460	(8.6)	5	(0.1)	5341
Monaco	-	-	-	-	-	-	-	-	-	-	-
Montenegro	-	-	-	-	107	(89.9)	12	(10.1)	0	(0.0)	119
Russia	-	-	-	-	136775	(85.8)	10670	(6.7)	12035	(7.5)	159480
San Marino	-	-	-	-	-	-	-	-	-	-	-
Serbia	-	-	-	-	1175	(53.0)	166	(7.5)	875	(39.5)	2216
Serbia excluding UN Administered Province of Kosovo <sup>b</sup>	-	-	-	-	1175	(87.7)	166	(12.3)	0	(0.0)	1341
UN Administered Province of Kosovo <sup>b</sup>	-	-	-	-	-	-	-	-	875	-	875
Switzerland	-	-	-	-	359	(62.1)	165	(28.5)	54	(9.3)	578
Tajikistan	-	-	-	-	5996	(78.8)	1613	(21.2)	0	(0.0)	7609
Turkey	-	-	-	-	9909	(63.2)	5770	(36.8)	0	(0.0)	15679
Turkmenistan	-	-	-	-	-	-	-	-	-	-	-
Ukraine	-	-	-	-	33165	(77.7)	3737	(8.8)	5774	(13.5)	42676
Uzbekistan	-	-	-	-	11824	(74.3)	4089	(25.7)	0	(0.0)	15913
<b>Subtotal non-EU/EEA</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>253911</b>	<b>(82.4)</b>	<b>34104</b>	<b>(11.1)</b>	<b>20125</b>	<b>(6.5)</b>	<b>308140</b>
<b>Total European Region</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>309850</b>	<b>(81.4)</b>	<b>50220</b>	<b>(13.2)</b>	<b>20404</b>	<b>(5.4)</b>	<b>380474</b>
<b>Subtotal 18 HPC</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>270476</b>	<b>(82.8)</b>	<b>37009</b>	<b>(11.3)</b>	<b>19172</b>	<b>(5.9)</b>	<b>326657</b>

<sup>a</sup>European Region<sup>a</sup> comprises the 53 countries of the WHO European Region and Liechtenstein. WHO European Region 18 TB High Priority Countries presented in italics.

<sup>b</sup>Excluding Greenland (see Chapter 1.1).

<sup>c</sup>In accordance with the UN Security Council Resolution No. 1244 (1999).

Table 8: New pulmonary tuberculosis cases by laboratory confirmation, European Region, 2011

Country	New pulmonary TB cases												
	N	(%) <sup>a</sup>	Laboratory confirmed		Culture positive						Total	N	(%) <sup>b</sup>
			N	(%)	Smear positive		Smear negative		Smear unknown				
					N	(%) <sup>c</sup>	N	(%) <sup>c</sup>	N	(%) <sup>c</sup>			
<b>EU/EEA</b>													
Austria	311	(57.6)	227	(73.0)	88	(28.3)	44	(14.1)	89	(28.6)	221	(71.1)	
Belgium	513	(68.7)	423	(82.5)	226	(44.1)	171	(33.3)	12	(2.3)	409	(79.7)	
Bulgaria	1424	(82.6)	920	(64.6)	649	(45.6)	203	(14.3)	1	(0.1)	853	(59.9)	
Cyprus	25	(56.8)	22	(88.0)	11	(44.0)	8	(32.0)	3	(12.0)	22	(88.0)	
Czech Republic	495	(94.8)	378	(76.4)	186	(37.6)	190	(38.4)	0	(0.0)	376	(76.0)	
Denmark <sup>d</sup>	224	(93.3)	219	(97.8)	124	(55.4)	58	(25.9)	37	(16.5)	219	(97.8)	
Estonia	247	(76.9)	203	(82.2)	122	(49.4)	80	(32.4)	0	(0.0)	202	(81.8)	
Finland	225	(95.3)	184	(81.8)	80	(35.6)	87	(38.7)	15	(6.7)	182	(80.9)	
France	1922	(53.4)	1437	(74.8)	409	(21.3)	494	(25.7)	37	(1.9)	940	(48.9)	
Germany	2738	(81.8)	2165	(79.1)	880	(32.1)	0	(0.0)	1214	(44.3)	2094	(76.5)	
Greece	392	(92.0)	313	(79.8)	154	(39.3)	58	(14.8)	19	(4.8)	231	(58.9)	
Hungary	1170	(84.2)	556	(47.5)	208	(17.8)	248	(21.2)	48	(4.1)	504	(43.1)	
Iceland	3	(100.0)	1	(33.3)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	
Ireland	195	(66.6)	156	(80.0)	83	(42.6)	37	(19.0)	34	(17.4)	154	(79.0)	
Italy	1377	(53.3)	823	(59.8)	252	(18.3)	160	(11.6)	76	(5.5)	488	(35.4)	
Latvia	703	(88.3)	563	(80.1)	289	(41.1)	270	(38.4)	0	(0.0)	559	(79.5)	
Liechtenstein	-	-	0	-	-	-	-	-	-	-	-	-	
Lithuania	1345	(78.5)	1000	(74.3)	681	(50.6)	319	(23.7)	0	(0.0)	1000	(74.3)	
Luxembourg	8	(36.4)	6	(75.0)	4	(50.0)	1	(12.5)	1	(12.5)	6	(75.0)	
Malta	15	(68.2)	12	(80.0)	7	(46.7)	3	(20.0)	2	(13.3)	12	(80.0)	
Netherlands	530	(94.1)	442	(83.4)	169	(31.9)	142	(26.8)	123	(23.2)	434	(81.9)	
Norway	174	(87.0)	143	(82.2)	37	(21.3)	50	(28.7)	53	(30.5)	140	(80.5)	
Poland	6931	(88.0)	4759	(68.7)	2527	(36.5)	1908	(27.5)	264	(3.8)	4699	(67.8)	
Portugal	1689	(91.0)	1384	(81.9)	761	(45.1)	224	(13.3)	284	(16.8)	1269	(75.1)	
Romania	11914	(72.5)	9294	(78.0)	6775	(56.9)	1908	(16.0)	0	(0.0)	8683	(72.9)	
Slovakia	266	(78.9)	149	(56.0)	85	(32.0)	53	(19.9)	0	(0.0)	138	(51.9)	
Slovenia	155	(93.9)	151	(97.4)	82	(52.9)	57	(36.8)	12	(7.7)	151	(97.4)	
Spain	4428	(88.9)	3538	(79.9)	1849	(41.8)	1270	(28.7)	82	(1.9)	3201	(72.3)	
Sweden	281	(78.5)	248	(88.3)	98	(34.9)	120	(42.7)	29	(10.3)	247	(87.9)	
United Kingdom	4031	(87.6)	2923	(72.5)	1112	(27.6)	753	(18.7)	966	(24.0)	2831	(70.2)	
<b>Subtotal EU/EEA</b>	<b>43731</b>	<b>(78.2)</b>	<b>32639</b>	<b>(74.6)</b>	<b>17948</b>	<b>(41.0)</b>	<b>8916</b>	<b>(20.4)</b>	<b>3401</b>	<b>(7.8)</b>	<b>30265</b>	<b>(69.2)</b>	
<b>Non-EU/EEA</b>													
Albania	285	(96.9)	209	(73.3)	151	(53.0)	29	(10.2)	0	(0.0)	180	(63.2)	
Andorra	3	(100.0)	1	(33.3)	1	(33.3)	0	(0.0)	0	(0.0)	1	(33.3)	
Armenia	911	(86.3)	437	(48.0)	313	(34.4)	108	(11.9)	0	(0.0)	421	(46.2)	
Azerbaijan	4166	(46.6)	2260	(54.2)	1174	(28.2)	834	(20.0)	0	(0.0)	2008	(48.2)	
Belarus	3656	(78.9)	2179	(59.6)	1056	(28.9)	962	(26.3)	0	(0.0)	2018	(55.2)	
Bosnia and Herzegovina	1194	(94.8)	708	(59.3)	542	(45.4)	161	(13.5)	0	(0.0)	703	(58.9)	
Croatia	544	(90.4)	347	(63.8)	198	(36.4)	83	(15.3)	63	(11.6)	344	(63.2)	
Georgia	3167	(86.2)	2501	(79.0)	1781	(56.2)	463	(14.6)	12	(0.4)	2256	(71.2)	
Israel	342	(97.4)	241	(70.5)	131	(38.3)	106	(31.0)	0	(0.0)	237	(69.3)	
Kazakhstan	12399	(52.1)	6161	(49.7)	3289	(26.5)	1915	(15.4)	89	(0.7)	5293	(42.7)	
Kyrgyzstan	3662	(75.7)	1537	(42.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	
Macedonia, the former Yugoslav Republic of	231	(85.2)	176	(76.2)	94	(40.7)	44	(19.0)	0	(0.0)	138	(59.7)	
Moldova	3412	(70.0)	1821	(53.4)	977	(28.6)	543	(15.9)	6	(0.2)	1526	(44.7)	
Monaco	-	-	0	-	-	-	-	-	-	-	-	-	
Montenegro	88	(82.2)	56	(63.6)	48	(54.5)	8	(9.1)	0	(0.0)	56	(63.6)	
Russia	94297	(68.9)	43761	(46.4)	22095	(23.4)	14570	(15.5)	0	(0.0)	36665	(38.9)	
San Marino	-	-	0	-	-	-	-	-	-	-	-	-	
Serbia	1050	(89.4)	914	87	625	60	254	24	6	1	885	84	
Serbia excluding UN Administered Province of Kosovo <sup>e</sup>	1050	(89.4)	914	(87.0)	625	(59.5)	254	(24.2)	6	(0.6)	885	(84.3)	
UN Administered Province of Kosovo <sup>e</sup>	-	-	0	-	-	-	-	-	-	-	-	-	
Switzerland	260	(72.4)	224	(86.2)	86	(33.1)	28	(10.8)	106	(40.8)	220	(84.6)	
Tajikistan	4322	(72.1)	2174	(50.3)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	
Turkey	8852	(89.3)	6398	(72.3)	3638	(41.1)	1071	(12.1)	400	(4.5)	5109	(57.7)	
Turkmenistan	-	-	0	-	-	-	-	-	-	-	-	-	
Ukraine	27821	(83.9)	13715	(49.3)	13715	(49.3)	0	(0.0)	0	(0.0)	13715	(49.3)	
Uzbekistan	10156	(85.9)	5066	(49.9)	266	(2.6)	868	(8.5)	0	(0.0)	1134	(11.2)	
<b>Subtotal non-EU/EEA</b>	<b>180818</b>	<b>(71.2)</b>	<b>90886</b>	<b>(50.3)</b>	<b>50180</b>	<b>(27.8)</b>	<b>22047</b>	<b>(12.2)</b>	<b>682</b>	<b>(0.4)</b>	<b>72909</b>	<b>(40.3)</b>	
<b>Total European Region</b>	<b>224549</b>	<b>(72.5)</b>	<b>123525</b>	<b>(55.0)</b>	<b>68128</b>	<b>(30.3)</b>	<b>30963</b>	<b>(13.8)</b>	<b>4083</b>	<b>(1.8)</b>	<b>103174</b>	<b>(45.9)</b>	
<b>Subtotal 18 HPC</b>	<b>192454</b>	<b>(71.2)</b>	<b>99990</b>	<b>(52.0)</b>	<b>56820</b>	<b>(29.5)</b>	<b>24114</b>	<b>(12.5)</b>	<b>508</b>	<b>(0.3)</b>	<b>81442</b>	<b>(42.3)</b>	

<sup>a</sup>European Region\* comprises the 53 countries of the WHO European Region and Liechtenstein.

<sup>b</sup>WHO European Region 18 TB High Priority Countries presented in italics.

<sup>c</sup>Percentage among pulmonary TB cases.

<sup>d</sup>Percentage among new pulmonary TB cases.

<sup>e</sup>Percentage among all TB cases.

<sup>f</sup>Excluding Greenland (see Chapter 1.1).

<sup>g</sup>In accordance with the UN Security Council Resolution No. 1244 (1999).



	New pulmonary TB cases								All pulmonary TB cases		All TB cases
	Culture negative/not done								N	(%) <sup>c</sup>	N
	Smear positive		Smear negative		Smear unknown		Total				
N	(%) <sup>a</sup>	N	(%) <sup>b</sup>	N	(%) <sup>b</sup>	N	(%) <sup>b</sup>	N	(%) <sup>c</sup>	N	
	6	(1.9)	25	(8.0)	59	(19.0)	90	(28.9)	540	(78.6)	687
	14	(2.7)	70	(13.6)	20	(3.9)	104	(20.3)	747	(71.6)	1044
	67	(4.7)	443	(31.1)	61	(4.3)	571	(40.1)	1724	(71.6)	2407
	0	(0.0)	3	(12.0)	0	(0.0)	3	(12.0)	44	(81.5)	54
	2	(0.4)	117	(23.6)	0	(0.0)	119	(24.0)	522	(87.0)	600
	0	(0.0)	3	(1.3)	2	(0.9)	5	(2.2)	240	(63.0)	381
	1	(0.4)	38	(15.4)	6	(2.4)	45	(18.2)	321	(94.1)	341
	2	(0.9)	34	(15.1)	7	(3.1)	43	(19.1)	236	(72.6)	325
	497	(25.9)	411	(21.4)	74	(3.9)	982	(51.1)	3600	(72.8)	4942
	71	(2.6)	0	(0.0)	573	(20.9)	644	(23.5)	3346	(77.5)	4316
	82	(20.9)	42	(10.7)	37	(9.4)	161	(41.1)	426	(87.1)	489
	52	(4.4)	445	(38.0)	169	(14.4)	666	(56.9)	1389	(96.1)	1445
	1	(33.3)	1	(33.3)	1	(33.3)	3	(100.0)	3	(33.3)	9
	2	(1.0)	16	(8.2)	23	(11.8)	41	(21.0)	293	(68.9)	425
	335	(24.3)	222	(16.1)	332	(24.1)	889	(64.6)	2582	(73.3)	3521
	4	(0.6)	130	(18.5)	10	(1.4)	144	(20.5)	796	(89.9)	885
	-	-	-	-	-	-	-	-	-	-	-
	0	(0.0)	345	(25.7)	0	(0.0)	345	(25.7)	1714	(90.0)	1904
	0	(0.0)	1	(12.5)	1	(12.5)	2	(25.0)	22	(84.6)	26
	0	(0.0)	0	(0.0)	3	(20.0)	3	(20.0)	22	(66.7)	33
	8	(1.5)	42	(7.9)	46	(8.7)	96	(18.1)	563	(55.9)	1007
	3	(1.7)	1	(0.6)	30	(17.2)	34	(19.5)	200	(55.4)	361
	60	(0.9)	1983	(28.6)	189	(2.7)	2232	(32.2)	7879	(92.9)	8478
	115	(6.8)	82	(4.9)	223	(13.2)	420	(24.9)	1857	(73.1)	2540
	611	(5.1)	2499	(21.0)	121	(1.0)	3231	(27.1)	16431	(85.5)	19212
	11	(4.1)	117	(44.0)	0	(0.0)	128	(48.1)	337	(84.5)	399
	0	(0.0)	1	(0.6)	3	(1.9)	4	(2.6)	165	(85.9)	192
	337	(7.6)	644	(14.5)	246	(5.6)	1227	(27.7)	4979	(73.6)	6762
	1	(0.4)	23	(8.2)	10	(3.6)	34	(12.1)	358	(61.1)	586
	92	(2.3)	402	(10.0)	706	(17.5)	1200	(29.8)	4603	(51.4)	8963
	<b>2374</b>	<b>(5.4)</b>	<b>8140</b>	<b>(18.6)</b>	<b>2952</b>	<b>(6.8)</b>	<b>13466</b>	<b>(30.8)</b>	<b>55939</b>	<b>(77.3)</b>	<b>72334</b>
	29	(10.2)	69	(24.2)	7	(2.5)	105	(36.8)	294	(68.2)	431
	0	(0.0)	1	(33.3)	1	(33.3)	2	(66.7)	3	(75.0)	4
	16	(1.8)	474	(52.0)	0	(0.0)	490	(53.8)	1056	(66.8)	1582
	252	(6.0)	1906	(45.8)	0	(0.0)	2158	(51.8)	8938	(88.5)	10100
	161	(4.4)	1442	(39.4)	35	(1.0)	1638	(44.8)	4634	(90.5)	5118
	5	(0.4)	485	(40.6)	1	(0.1)	491	(41.1)	1259	(88.4)	1425
	3	(0.6)	72	(13.2)	125	(23.0)	200	(36.8)	602	(88.7)	679
	245	(7.7)	631	(19.9)	35	(1.1)	911	(28.8)	3676	(66.4)	5533
	4	(1.2)	42	(12.3)	59	(17.3)	105	(30.7)	351	(84.0)	418
	868	(7.0)	6177	(49.8)	61	(0.5)	7106	(57.3)	23806	(90.8)	26211
	1537	(42.0)	2125	(58.0)	0	(0.0)	3662	(100.0)	4835	(72.5)	6666
	38	(16.5)	51	(22.1)	4	(1.7)	93	(40.3)	271	(74.9)	362
	295	(8.6)	1428	(41.9)	163	(4.8)	1886	(55.3)	4876	(91.3)	5341
	-	-	-	-	-	-	-	-	-	-	0
	0	(0.0)	29	(33.0)	3	(3.4)	32	(36.4)	107	(89.9)	119
	7096	(7.5)	49347	(52.3)	1189	(1.3)	57632	(61.1)	136775	(85.8)	159480
	-	-	-	-	-	-	-	-	-	-	0
	29	3	118	11	18	2	165	16	1175	88	
	29	(2.8)	118	(11.2)	18	(1.7)	165	(15.7)	1175	(87.6)	1341
	-	-	-	-	-	-	-	-	-	-	-
	4	(1.5)	0	(0.0)	36	(13.8)	40	(15.4)	359	(62.1)	578
	2174	(50.3)	2148	(49.7)	0	(0.0)	4322	(100.0)	5996	(78.8)	7609
	1289	(14.6)	1301	(14.7)	1153	(13.0)	3743	(42.3)	9909	(63.2)	15679
	-	-	-	-	-	-	-	-	-	-	0
	0	(0.0)	14106	(50.7)	0	(0.0)	14106	(50.7)	33165	(77.7)	42676
	3932	(38.7)	5090	(50.1)	0	(0.0)	9022	(88.8)	11824	(74.3)	15913
	<b>17977</b>	<b>(9.9)</b>	<b>87042</b>	<b>(48.1)</b>	<b>2890</b>	<b>(1.6)</b>	<b>107909</b>	<b>(59.7)</b>	<b>253911</b>	<b>(82.6)</b>	<b>307265</b>
	<b>20351</b>	<b>(9.1)</b>	<b>95182</b>	<b>(42.4)</b>	<b>5842</b>	<b>(2.6)</b>	<b>121375</b>	<b>(54.1)</b>	<b>309850</b>	<b>(81.6)</b>	<b>379599</b>
	<b>18548</b>	<b>(9.6)</b>	<b>89630</b>	<b>(46.6)</b>	<b>2834</b>	<b>(1.5)</b>	<b>111012</b>	<b>(57.7)</b>	<b>270476</b>	<b>(82.8)</b>	<b>326657</b>

**Table 9: Laboratory-confirmed tuberculosis cases by confirmation method, EU/EEA, 2011**

Country	Smear-positive and nucleic-acid-test-positive only <sup>a</sup>		Culture-positive only		Meeting both criteria		All laboratory-confirmed cases		All tuberculosis cases (N)
	N	(%) <sup>b</sup>	N	(%) <sup>b</sup>	N	(%) <sup>b</sup>	N	(%) <sup>c</sup>	
Austria	3	(0.6)	384	(82.4)	79	(17.0)	466	(67.8)	687
Belgium	5	(0.6)	633	(79.4)	159	(19.9)	797	(76.3)	1044
<i>Bulgaria</i>	0	(0.0)	1070	(99.9)	1	(0.1)	1071	(44.5)	2407
Cyprus	0	(0.0)	44	(100.0)	0	(0.0)	44	(81.5)	54
Czech Republic	1	(0.2)	409	(96.0)	16	(3.8)	426	(71.0)	600
Denmark <sup>d</sup>	0	(0.0)	182	(66.9)	90	(33.1)	272	(71.4)	381
Estonia	2	(0.8)	180	(68.2)	82	(31.1)	264	(77.4)	341
Finland	1	(0.4)	233	(92.5)	18	(7.1)	252	(77.5)	325
France	0	(0.0)	2309	(100.0)	0	(0.0)	2309	(46.7)	4942
Germany	25	(0.8)	2308	(75.2)	738	(24.0)	3071	(71.2)	4316
Greece	3	(1.1)	275	(98.9)	0	(0.0)	278	(56.9)	489
Hungary	0	(0.0)	597	(100.0)	0	(0.0)	597	(41.3)	1445
Iceland	0	(0.0)	4	(100.0)	0	(0.0)	4	(44.4)	9
Ireland	1	(0.3)	272	(94.4)	15	(5.2)	288	(67.8)	425
Italy <sup>e</sup>	0	(0.0)	982	(100.0)	0	(0.0)	982	(27.9)	3521
Latvia	0	(0.0)	671	(100.0)	0	(0.0)	671	(75.8)	885
Liechtenstein	-	-	-	-	-	-	-	-	-
<i>Lithuania</i>	0	(0.0)	1403	(100.0)	0	(0.0)	1403	(73.7)	1904
Luxembourg	0	(0.0)	19	(100.0)	0	(0.0)	19	(73.1)	26
Malta	0	(0.0)	24	(100.0)	0	(0.0)	24	(72.7)	33
Netherlands	6	(0.8)	583	(79.6)	143	(19.5)	732	(72.7)	1007
Norway	0	(0.0)	224	(85.5)	38	(14.5)	262	(72.6)	361
Poland	0	(0.0)	5581	(100.0)	0	(0.0)	5581	(65.8)	8478
Portugal	0	(0.0)	1588	(100.0)	0	(0.0)	1588	(62.5)	2540
<i>Romania</i>	0	(0.0)	12446	(100.0)	0	(0.0)	12446	(64.8)	19212
Slovakia	2	(1.1)	180	(95.7)	6	(3.2)	188	(47.1)	399
Slovenia	0	(0.0)	111	(61.0)	71	(39.0)	182	(94.8)	192
Spain	0	(0.0)	4383	(100.0)	0	(0.0)	4383	(64.8)	6762
Sweden	1	(0.2)	381	(80.0)	94	(19.7)	476	(81.2)	586
United Kingdom	1	(0.0)	5257	(99.5)	27	(0.5)	5285	(59.0)	8963
<b>Total EU/EEA</b>	<b>51</b>	<b>(0.1)</b>	<b>42733</b>	<b>(96.3)</b>	<b>1577</b>	<b>(3.6)</b>	<b>44361</b>	<b>(61.3)</b>	<b>72334</b>

WHO European Region 18 TB High Priority Countries presented in italics.

<sup>a</sup> Only data on microscopy sputum smear results are collected in TESSy.

<sup>b</sup> Percentage among all laboratory-confirmed TB cases.

<sup>c</sup> Percentage among all TB cases.

<sup>d</sup> Excluding Greenland (see Chapter 1.1).

<sup>e</sup> Italy reported culture results only for cases with positive sputum smear.

**Table 10: Classification of tuberculosis cases according to EU case definition, EU/EEA, 2011**

Country	Confirmed		Probable		Possible		All tuberculosis cases (N)
	N	(%)	N	(%)	N	(%)	
Austria	466	(67.8)	72	(10.5)	149	(21.7)	687
Belgium	797	(76.3)	88	(8.4)	159	(15.2)	1044
<i>Bulgaria</i>	1071	(44.5)	187	(7.8)	1149	(47.7)	2407
Cyprus	44	(81.5)	1	(1.9)	9	(16.7)	54
Czech Republic	426	(71.0)	72	(12.0)	102	(17.0)	600
Denmark <sup>a</sup>	272	(71.4)	19	(5.0)	90	(23.6)	381
<i>Estonia</i>	264	(77.4)	17	(5.0)	60	(17.6)	341
Finland	252	(77.5)	25	(7.7)	48	(14.8)	325
France	2309	(46.7)	922	(18.7)	1711	(34.6)	4942
Germany	3071	(71.2)	301	(7.0)	944	(21.9)	4316
Greece	278	(56.9)	96	(19.6)	115	(23.5)	489
Hungary	597	(41.3)	60	(4.2)	788	(54.5)	1445
Iceland	4	(44.4)	1	(11.1)	4	(44.4)	9
Ireland	288	(67.8)	41	(9.6)	96	(22.6)	425
Italy <sup>b</sup>	982	(27.9)	540	(15.3)	1999	(56.8)	3521
<i>Latvia</i>	671	(75.8)	81	(9.2)	133	(15.0)	885
Liechtenstein	-	-	-	-	-	-	-
<i>Lithuania</i>	1403	(73.7)	0	(0.0)	501	(26.3)	1904
Luxembourg	19	(73.1)	0	(0.0)	7	(26.9)	26
Malta	24	(72.7)	0	(0.0)	9	(27.3)	33
Netherlands	732	(72.7)	80	(7.9)	195	(19.4)	1007
Norway	262	(72.6)	19	(5.3)	80	(22.2)	361
Poland	5581	(65.8)	73	(0.9)	2824	(33.3)	8478
Portugal	1588	(62.5)	138	(5.4)	814	(32.0)	2540
<i>Romania</i>	12446	(64.8)	1535	(8.0)	5231	(27.2)	19212
Slovakia	188	(47.1)	67	(16.8)	144	(36.1)	399
Slovenia	182	(94.8)	3	(1.6)	7	(3.6)	192
Spain	4383	(64.8)	394	(5.8)	1985	(29.4)	6762
Sweden	476	(81.2)	27	(4.6)	83	(14.2)	586
United Kingdom	5285	(59.0)	387	(4.3)	3291	(36.7)	8963
<b>Total EU/EEA</b>	<b>44361</b>	<b>(61.3)</b>	<b>5246</b>	<b>(7.3)</b>	<b>22727</b>	<b>(31.4)</b>	<b>72334</b>

WHO European Region 18 TB High Priority Countries presented in italics.

<sup>a</sup> Excluding Greenland (see Chapter 1.1).

<sup>b</sup> Italy reported laboratory confirmation only for sputum smear positive cases.

Table 11: New TB cases by age group, European Region, 2011

Country	0-4			5-14			15-24			25-44			45-64		
	N	(%)	Rate	N	(%)	Rate	N	(%)	Rate	N	(%)	Rate	N	(%)	Rate
<b>EU/EEA</b>															
Austria	12	(3.0)	3.1	7	(1.8)	0.8	54	(13.6)	5.3	134	(33.8)	5.7	105	(26.5)	4.6
Belgium	40	(5.7)	6.4	30	(4.3)	2.5	119	(16.9)	9.1	266	(37.7)	9.1	122	(17.3)	4.2
<i>Bulgaria</i>	58	(2.8)	15.5	115	(5.6)	17.4	194	(9.5)	21.8	637	(31.0)	29.3	656	(32.0)	31.7
Cyprus	0	(0.0)	0.0	0	(0.0)	0.0	5	(16.1)	4.2	19	(61.3)	7.8	1	(3.2)	0.5
Czech Republic	5	(0.9)	0.9	1	(0.2)	0.1	33	(5.8)	2.6	148	(26.0)	4.6	213	(37.4)	7.4
Denmark <sup>a</sup>	5	(1.4)	1.5	10	(2.8)	1.5	32	(8.9)	4.6	141	(39.3)	9.7	126	(35.1)	8.5
<i>Estonia</i>	0	(0.0)	0.0	1	(0.4)	0.8	18	(6.8)	10.0	117	(44.2)	31.0	93	(35.1)	26.7
Finland	3	(1.0)	1.0	8	(2.6)	1.4	24	(7.7)	3.6	54	(17.3)	4.0	70	(22.4)	4.6
France	82	(3.1)	2.0	70	(2.7)	0.9	320	(12.1)	4.0	977	(37.0)	5.8	622	(23.6)	3.6
Germany	83	(2.4)	2.4	80	(2.3)	1.1	283	(8.1)	3.1	1053	(30.2)	4.9	997	(28.6)	4.3
Greece	15	(3.3)	2.6	21	(4.6)	2.0	62	(13.7)	5.3	146	(32.3)	4.3	88	(19.5)	3.0
Hungary	2	(0.2)	0.4	1	(0.1)	0.1	61	(5.0)	5.0	289	(23.6)	9.7	558	(45.6)	21.2
Iceland	0	(0.0)	0.0	1	(12.5)	2.3	1	(12.5)	2.1	4	(50.0)	4.5	1	(12.5)	1.3
Ireland	4	(1.4)	1.1	9	(3.2)	1.5	34	(12.1)	6.5	133	(47.5)	9.3	71	(25.4)	6.9
Italy	51	(2.5)	1.8	70	(3.5)	1.2	250	(12.4)	4.1	828	(41.0)	4.8	398	(19.7)	2.4
<i>Latvia</i>	25	(3.2)	22.4	36	(4.6)	18.5	78	(9.9)	25.2	331	(42.0)	51.7	252	(32.0)	43.0
Liechtenstein	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
<i>Lithuania</i>	26	(1.7)	15.6	62	(4.0)	19.3	116	(7.6)	24.4	533	(34.8)	59.4	557	(36.4)	65.7
Luxembourg	0	(0.0)	0.0	0	(0.0)	0.0	3	(27.3)	4.9	4	(36.4)	2.6	4	(36.4)	3.0
Malta	0	(0.0)	0.0	0	(0.0)	0.0	6	(27.3)	10.4	10	(45.5)	8.7	2	(9.1)	1.7
Netherlands	17	(1.8)	1.8	38	(4.0)	1.9	144	(15.0)	7.1	396	(41.3)	9.0	234	(24.4)	5.0
Norway	3	(1.0)	1.0	13	(4.1)	2.1	89	(28.3)	13.8	148	(47.1)	10.9	39	(12.4)	3.1
Poland	30	(0.4)	1.5	81	(1.1)	2.2	382	(5.1)	7.3	1724	(22.9)	15.1	3339	(44.4)	31.7
Portugal	18	(0.8)	3.5	25	(1.1)	2.3	233	(10.0)	20.0	838	(36.0)	26.6	767	(33.0)	27.6
<i>Romania</i>	298	(2.0)	27.4	462	(3.2)	21.3	2455	(16.9)	82.1	5137	(35.3)	76.2	4119	(28.3)	78.1
Slovakia	10	(3.1)	3.5	7	(2.2)	1.3	29	(9.0)	3.8	63	(19.5)	3.7	120	(37.2)	8.2
Slovenia	2	(1.1)	1.9	2	(1.1)	1.1	6	(3.3)	2.6	64	(35.4)	10.6	51	(28.2)	8.7
Spain	295	(4.9)	11.9	229	(3.8)	5.1	635	(10.5)	13.4	2401	(39.7)	16.1	1339	(22.2)	11.5
Sweden	7	(1.5)	1.2	23	(5.1)	2.3	102	(22.5)	8.2	219	(48.2)	8.9	64	(14.1)	2.7
United Kingdom	132	(1.7)	3.4	255	(3.2)	3.6	1221	(15.6)	14.9	3628	(46.2)	21.3	1610	(20.5)	10.1
<b>Subtotal EU/EEA</b>	<b>1223</b>	<b>(2.1)</b>	<b>4.5</b>	<b>1657</b>	<b>(2.9)</b>	<b>3.2</b>	<b>6989</b>	<b>(12.1)</b>	<b>11.5</b>	<b>20442</b>	<b>(35.4)</b>	<b>14.3</b>	<b>16618</b>	<b>(28.8)</b>	<b>12.2</b>
<b>Non-EU/EEA</b>															
Albania	1	(0.2)	0.5	6	(1.5)	1.2	83	(20.1)	14.0	103	(24.9)	11.3	134	(32.4)	19.4
Andorra	0	(0.0)	0.0	0	(0.0)	0.0	0	(0.0)	0.0	2	(66.7)	7.2	1	(33.3)	4.6
<i>Armenia</i>	18	(1.5)	8.0	29	(2.4)	7.3	206	(17.2)	37.4	416	(34.7)	50.6	413	(34.4)	54.2
<i>Azerbaijan</i>	55	(1.0)	6.5	131	(2.5)	11.7	388	(7.3)	20.7	336	(6.3)	12.0	200	(3.8)	9.6
<i>Belarus</i>	10	(0.2)	1.9	16	(0.4)	1.7	373	(9.2)	28.0	1755	(43.4)	61.3	1506	(37.2)	57.3
Bosnia and Herzegovina	5	(0.4)	3.0	15	(1.1)	3.9	113	(8.3)	22.5	290	(21.3)	26.2	453	(33.3)	42.9
Croatia	3	(0.5)	1.4	10	(1.6)	2.3	48	(7.8)	9.1	132	(21.3)	10.9	235	(38.0)	19.0
<i>Georgia</i>	47	(1.1)	18.2	155	(3.7)	33.9	885	(21.0)	129.9	1916	(45.4)	163.1	894	(21.2)	78.6
Israel	9	(2.2)	1.2	11	(2.7)	0.8	98	(24.0)	8.7	179	(43.9)	8.7	64	(15.7)	4.3
<i>Kazakhstan</i>	159	(1.1)	9.2	463	(3.2)	19.9	4148	(28.8)	142.5	6332	(44.0)	132.5	2787	(19.4)	82.4
<i>Kyrgyzstan</i>	-	-	-	-	-	-	425	(8.2)	35.5	658	(12.7)	44.1	355	(6.9)	41.7
Macedonia, the former Yugoslav Republic of	5	(1.6)	4.5	28	(9.1)	11.4	55	(17.9)	17.8	79	(25.7)	12.6	86	(28.0)	16.5
<i>Moldova</i>	51	(1.3)	22.9	108	(2.8)	29.4	546	(14.2)	89.1	1713	(44.7)	173.8	1247	(32.5)	130.2
Monaco	0	(0.0)	0.0	0	(0.0)	0.0	0	(0.0)	0.0	0	(0.0)	0.0	0	(0.0)	0.0
Montenegro	1	(1.0)	2.6	2	(2.0)	2.4	14	(14.0)	15.6	32	(32.0)	17.9	38	(38.0)	23.3
<i>Russia</i>	1214	(1.2)	14.7	2331	(2.2)	17.2	13382	(12.8)	69.1	53200	(51.0)	122.8	28845	(27.7)	72.1
San Marino	0	(0.0)	0.0	0	(0.0)	0.0	0	(0.0)	0.0	0	(0.0)	0.0	0	(0.0)	0.0
Serbia	6	(0.3)	0.7	7	(0.3)	0.4	146	(7.1)	8.4	366	(17.8)	11.3	483	(23.5)	16.5
Serbia excluding UN Administered Province of Kosovo <sup>b</sup>	6	(0.5)	1.1	7	(0.6)	0.6	86	(7.1)	6.4	287	(23.8)	10.1	446	(37.0)	17.6
UN Administered Province of Kosovo <sup>b</sup>	0	(0.0)	0.0	0	(0.0)	0.0	60	(7.1)	14.9	79	(9.3)	19.6	37	(4.4)	9.2
Switzerland	11	(2.9)	2.9	8	(2.1)	1.0	55	(14.5)	6.0	156	(41.2)	7.1	96	(25.3)	4.5
<i>Tajikistan</i>	136	(2.3)	15.4	433	(7.3)	26.0	1801	(30.3)	110.9	2178	(36.7)	128.0	1013	(17.1)	117.4
<i>Turkey</i>	196	(1.4)	3.0	548	(3.8)	4.3	2725	(18.9)	21.2	5001	(34.7)	21.5	3973	(27.6)	28.8
<i>Turkmenistan</i>	0	(0.0)	0.0	0	(0.0)	0.0	0	(0.0)	0.0	0	0.0	0.0	0	(0.0)	0.0
<i>Ukraine</i>	5	(0.0)	0.2	14	(0.0)	0.3	887	(2.8)	14.6	5544	(17.8)	41.4	3295	(10.6)	26.9
<i>Uzbekistan</i>	290	(2.1)	10.3	1302	(9.3)	24.9	2380	(17.0)	38.7	4903	(35.0)	60.8	3571	(25.5)	82.5
<b>Subtotal non-EU/EEA</b>	<b>2222</b>	<b>(1.0)</b>	<b>7.8</b>	<b>5617</b>	<b>(2.6)</b>	<b>11</b>	<b>28758</b>	<b>(13.5)</b>	<b>46.3</b>	<b>85291</b>	<b>(39.9)</b>	<b>72.4</b>	<b>49689</b>	<b>(23.3)</b>	<b>52.8</b>
<b>Total European Region</b>	<b>3445</b>	<b>(1.3)</b>	<b>6.2</b>	<b>7274</b>	<b>(2.7)</b>	<b>7</b>	<b>35747</b>	<b>(13.2)</b>	<b>29.4</b>	<b>105733</b>	<b>(39.0)</b>	<b>40.6</b>	<b>66307</b>	<b>(24.4)</b>	<b>28.9</b>
<b>Subtotal 18 HPC</b>	<b>2588</b>	<b>(1.1)</b>	<b>9.4</b>	<b>6206</b>	<b>(2.7)</b>	<b>13</b>	<b>31007</b>	<b>(13.6)</b>	<b>50.9</b>	<b>90707</b>	<b>(39.9)</b>	<b>77.4</b>	<b>53776</b>	<b>(23.7)</b>	<b>57.8</b>

\*European Region\* comprises the 53 countries of the WHO European Region and Liechtenstein.  
WHO European Region 18 TB High Priority Countries presented in italics.

<sup>a</sup> Excluding Greenland (see Chapter 1.1).

<sup>b</sup> In accordance with the UN Security Council Resolution No. 1244 (1999).

	> 64			Unknown		Total
	N	(%)	Rate	N	(%)	
	84	(21.2)	5.7	0	(0.0)	396
	128	(18.2)	6.9	0	(0.0)	705
	392	(19.1)	29.4	0	(0.0)	2052
	6	(19.4)	5.7	0	(0.0)	31
	169	(29.7)	10.3	0	(0.0)	569
	45	(12.5)	4.8	0	(0.0)	359
	36	(13.6)	15.8	0	(0.0)	265
	153	(49.0)	16.3	0	(0.0)	312
	567	(21.5)	5.2	1	(0.0)	2639
	993	(28.5)	5.9	1	(0.0)	3490
	116	(25.7)	5.3	4	(0.9)	452
	312	(25.5)	18.7	0	(0.0)	1223
	1	(12.5)	2.6	0	(0.0)	8
	29	(10.4)	5.6	0	(0.0)	280
	411	(20.4)	3.3	10	(0.5)	2018
	66	(8.4)	17.0	0	(0.0)	788
	-	-	-	-	-	-
	238	(15.5)	44.4	0	(0.0)	1532
	0	(0.0)	0.0	0	(0.0)	11
	4	(18.2)	6.2	0	(0.0)	22
	129	(13.5)	5.0	0	(0.0)	958
	22	(7.0)	3.0	0	(0.0)	314
	1959	(26.1)	37.8	0	(0.0)	7515
	436	(18.8)	22.6	8	(0.3)	2325
	2072	(14.2)	64.6	0	(0.0)	14543
	94	(29.1)	14.0	0	(0.0)	323
	56	(30.9)	16.5	0	(0.0)	181
	1137	(18.8)	14.4	8	(0.1)	6044
	39	(8.6)	2.2	0	(0.0)	454
	1004	(12.8)	9.7	0	(0.0)	7850
	<b>10698</b>	<b>(18.6)</b>	<b>12.1</b>	<b>32</b>	<b>(0.1)</b>	<b>57659</b>
	86	(20.8)	27.2	0	(0.0)	413
	0	(0.0)	0.0	0	(0.0)	3
	118	(9.8)	34.6	0	(0.0)	1200
	20	(0.4)	3.4	4166	(78.7)	5296
	383	(9.5)	29.6	0	(0.0)	4043
	482	(35.4)	90.5	2	(0.1)	1320
	191	(30.9)	25.0	0	(0.0)	619
	326	(7.7)	52.5	0	(0.0)	4223
	47	(11.5)	5.9	0	(0.0)	408
	507	(3.5)	46.5	0	(0.0)	14396
	80	(1.5)	34.2	3662	(70.7)	5180
	54	(17.6)	21.8	0	(0.0)	307
	171	(4.5)	42.9	0	(0.0)	3836
	0	(0.0)	0.0	0	(0.0)	0
	13	(13.0)	16.3	0	(0.0)	100
	5348	(5.1)	29.2	0	(0.0)	104320
	0	(0.0)	0.0	0	(0.0)	0
	413	(20.1)	26.8	630	(30.7)	2051
	373	(31.0)	26.3	0	(0.0)	1205
	40	(4.7)	32.7	630	(74.5)	846
	53	(14.0)	4.0	0	(0.0)	379
	374	(6.3)	156.5	0	(0.0)	5935
	1974	(13.7)	44.1	0	(0.0)	14417
	0	(0.0)	0.0	0	(0.0)	0
	757	(2.4)	10.9	20686	(66.3)	31188
	1549	(11.1)	129.4	0	(0.0)	13995
	<b>12946</b>	<b>(6.1)</b>	<b>31.1</b>	<b>29146</b>	<b>(13.6)</b>	<b>213629</b>
	<b>23644</b>	<b>(8.7)</b>	<b>18.1</b>	<b>29178</b>	<b>(10.8)</b>	<b>271288</b>
	<b>14411</b>	<b>(6.3)</b>	<b>35</b>	<b>28514</b>	<b>(12.5)</b>	<b>227209</b>



Table 12 Tuberculosis cases in children and adults, European Region, 2011

Country	Age < 15			Age ≥ 15		
	N	(%) <sup>a</sup>	Rate	N	(%) <sup>a</sup>	Rate
<b>EU/EEA</b>						
Austria	24	(3.5)	1.9	663	(96.5)	9.2
Belgium	85	(8.1)	4.6	959	(91.9)	10.6
Bulgaria	176	(7.3)	17.0	2 231	(92.7)	34.5
Cyprus	0	(0.0)	0.0	54	(100.0)	8.1
Czech Republic	6	(1.0)	0.4	594	(99.0)	6.6
Denmark <sup>b</sup>	16	(4.2)	1.6	365	(95.8)	8.0
Estonia	1	(0.3)	0.5	340	(99.7)	30.0
Finland	11	(3.4)	1.2	314	(96.6)	7.0
France	255	(5.2)	2.1	4 685	(94.8)	8.8
Germany	179	(4.1)	1.6	4 134	(95.8)	5.8
Greece	38	(7.8)	2.3	447	(91.4)	4.6
Hungary	4	(0.3)	0.3	1 441	(99.7)	16.9
Iceland	1	(11.1)	1.5	8	(88.9)	3.2
Ireland	20	(4.7)	2.0	404	(95.1)	11.5
Italy	209	(5.9)	2.5	3 281	(93.2)	6.3
Latvia	61	(6.9)	19.9	824	(93.1)	42.8
Liechtenstein	-	-	-	-	-	-
Lithuania	88	(4.6)	18.0	1 816	(95.4)	65.9
Luxembourg	1	(3.8)	1.1	25	(96.2)	5.9
Malta	0	(0.0)	0.0	33	(100.0)	9.3
Netherlands	56	(5.6)	1.9	951	(94.4)	6.9
Norway	17	(4.7)	1.8	344	(95.3)	8.6
Poland	111	(1.3)	1.9	8 367	(98.7)	25.8
Portugal	44	(1.7)	2.7	2 487	(97.9)	27.5
Romania	776	(4.0)	23.9	18 436	(96.0)	101.2
Slovakia	17	(4.3)	2.0	382	(95.7)	8.3
Slovenia	4	(2.1)	1.4	188	(97.9)	10.7
Spain	541	(8.0)	7.8	6 211	(91.9)	15.8
Sweden	36	(6.1)	2.3	550	(93.9)	7.0
United Kingdom	413	(4.6)	3.8	8 550	(95.4)	16.6
<b>Subtotal EU/EEA</b>	<b>3 190</b>	<b>(4.4)</b>	<b>4.0</b>	<b>69 084</b>	<b>(95.5)</b>	<b>16.1</b>
<b>Non-EU/EEA</b>						
Albania	7	(1.6)	1.0	424	(98.4)	16.9
Andorra	0	(0.0)	0.0	4	(100.0)	5.5
Armenia	51	(3.2)	8.2	1 531	(96.8)	61.8
Azerbaijan	0	-	-	0	-	-
Belarus	27	(0.5)	1.9	4 720	(92.2)	58.2
Bosnia and Herzegovina	17	(1.2)	3.1	1 406	(101.5)	44.0
Croatia	13	(2.1)	2.0	666	(107.6)	17.8
Georgia	206	(3.7)	28.8	5 327	(96.3)	147.4
Israel	20	(4.8)	1.0	403	(96.4)	7.3
Kazakhstan	659	(2.9)	16.3	22 417	(97.1)	184.3
Kyrgyzstan	504	(8.1)	31.1	4 739	(75.8)	125.6
Macedonia, the former Yugoslav Republic of	33	(9.1)	9.2	330	(91.2)	19.3
Moldova	0	-	-	0	-	-
Monaco	0	-	-	0	-	-
Montenegro	3	(2.7)	2.5	116	(103.6)	22.7
Russia	3 545	(2.2)	16.2	100 842	(63.2)	83.4
San Marino	0	-	-	0	-	-
Serbia	50	(2.3)	2.3	2 137	(96.4)	22.6
Serbia excluding UN Administered Province of Kosovo <sup>c</sup>	13	(1.0)	0.8	1 328	(99.0)	16.3
UN Administered Province of Kosovo <sup>c</sup>	37	(4.2)	7.5	809	(92.5)	60.8
Switzerland	26	(4.5)	2.2	556	(96.2)	8.5
Tajikistan	569	(7.5)	22.3	5 366	(70.5)	121.2
Turkey	761	(4.9)	4.0	14 918	(95.1)	27.4
Turkmenistan	0	-	-	0	-	-
Ukraine	520	(1.2)	8.0	30 139	(70.6)	77.9
Uzbekistan	1 751	(11.0)	21.8	14 165	(89.0)	71.8
<b>Subtotal non-EU/EEA</b>	<b>8 762</b>	<b>(2.9)</b>	<b>11.2</b>	<b>210 206</b>	<b>(69.1)</b>	<b>66.6</b>
<b>Total European Region</b>	<b>11 952</b>	<b>(3.2)</b>	<b>7.6</b>	<b>279 290</b>	<b>(75.2)</b>	<b>37.6</b>
<b>Subtotal 18 HPC</b>	<b>9 695</b>	<b>(3.0)</b>	<b>12.8</b>	<b>227 811</b>	<b>(70.6)</b>	<b>72.8</b>

<sup>a</sup> 'European Region' comprises the 53 countries of the WHO European Region and Liechtenstein. WHO European Region 18 TB High Priority Countries presented in italics.

<sup>b</sup> Percentages calculation based on all cases with age notified.

<sup>c</sup> Excluding Greenland (see Chapter 1.1).

<sup>d</sup> In accordance with the UN Security Council Resolution No. 1244 (1999).

Table 13: Tuberculosis cases by origin and sex ratio, European Region, 2011

Country	Criterion	Native						Foreign					
		Male	Female	Gender unknown	Total	(%)	Sex ratio (M:F)	Male	Female	Gender unknown	Total	(%)	Sex ratio (M:F)
<b>EU/EEA</b>													
Austria	citizenship	223	131	0	354	(51.5)	1.7	194	132	0	326	(47.5)	1.5
Belgium	citizenship	323	177	0	500	(47.9)	1.8	346	198	0	544	(52.1)	1.7
Bulgaria	birthplace	1601	797	0	2398	(99.6)	2.0	7	2	0	9	(0.4)	3.5
Cyprus	birthplace	6	3	0	9	(16.7)	2.0	26	19	0	45	(83.3)	1.4
Czech Republic	birthplace	337	151	0	488	(81.3)	2.2	92	20	0	112	(18.7)	4.6
Denmark <sup>a,b</sup>	birthplace	102	44	0	146	(38.3)	2.3	129	106	0	235	(61.7)	1.2
Estonia	birthplace	214	79	0	293	(85.9)	2.7	29	19	0	48	(14.1)	1.5
Finland	birthplace	123	89	0	212	(65.2)	1.4	37	42	0	79	(24.3)	0.9
France	birthplace	1228	868	12	2108	(42.7)	1.4	1513	926	17	2456	(49.7)	1.6
Germany	birthplace	1312	787	1	2100	(48.8)	1.7	1125	892	8	2025	(46.8)	1.3
Greece	citizenship	185	87	1	273	(55.6)	2.1	156	57	3	216	(44.4)	2.6
Hungary	citizenship	928	490	0	1418	(98.1)	1.9	21	6	0	27	(1.9)	3.5
Iceland	birthplace	1	1	0	2	(22.2)	1.0	1	6	0	7	(77.8)	0.2
Ireland	birthplace	114	75	0	189	(44.5)	1.5	95	84	0	179	(42.1)	1.1
Italy	birthplace	895	682	1	1578	(44.7)	1.3	992	685	0	1677	(47.7)	1.4
Latvia	birthplace	544	273	0	817	(92.3)	2.0	43	16	0	59	(6.7)	2.7
Liechtenstein	-	-	-	-	-	-	-	-	-	-	-	-	-
Lithuania	birthplace	1296	564	0	1860	(97.7)	2.3	39	5	0	44	(2.3)	7.8
Luxembourg	birthplace	4	1	0	5	(19.2)	4.0	11	10	0	21	(80.8)	1.1
Malta	birthplace	3	2	0	5	(15.2)	1.5	20	8	0	28	(84.8)	2.5
Netherlands	birthplace	179	113	0	292	(29.0)	1.6	386	324	0	710	(70.5)	1.2
Norway	birthplace	33	11	0	44	(12.2)	3.0	163	154	0	317	(87.8)	1.1
Poland	citizenship	5683	2757	0	8440	(99.6)	2.1	31	7	0	38	(0.4)	4.4
Portugal	birthplace	1448	703	0	2151	(84.6)	2.1	254	131	0	385	(15.3)	1.9
Romania	birthplace	13123	6039	0	19162	(99.7)	2.2	30	20	0	50	(0.3)	1.5
Slovakia	birthplace	249	147	0	396	(99.2)	1.7	2	1	0	3	(0.8)	2.0
Slovenia	birthplace	70	65	0	135	(70.3)	1.1	41	16	0	57	(29.7)	2.6
Spain	birthplace	2841	1673	14	4528	(67.0)	1.7	1270	865	3	2138	(31.6)	1.5
Sweden	birthplace	38	24	0	62	(10.6)	1.6	311	213	0	524	(89.4)	1.5
United Kingdom	birthplace	1274	934	18	2226	(24.8)	1.4	3584	2688	15	6287	(70.1)	1.3
<b>Subtotal EU/EEA</b>		<b>34377</b>	<b>17767</b>	<b>47</b>	<b>52191</b>	<b>(72.2)</b>	<b>1.9</b>	<b>10948</b>	<b>7652</b>	<b>46</b>	<b>18646</b>	<b>(25.8)</b>	<b>1.4</b>
<b>Non-EU/EEA</b>													
Albania	citizenship	295	136	0	431	(100.0)	2.2	0	0	0	0	(0.0)	-
Andorra	citizenship	2	2	0	4	(100.0)	1.0	0	0	0	0	(0.0)	-
Armenia	citizenship	1167	406	0	1573	(99.4)	2.9	0	0	0	0	(0.0)	-
Azerbaijan	citizenship	-	-	-	-	-	-	-	-	-	-	-	-
Belarus	citizenship	3469	1278	0	4747	(100.0)	2.7	0	0	0	0	(0.0)	-
Bosnia and Herzegovina	citizenship	807	618	0	1425	(100.0)	1.3	0	0	0	0	(0.0)	-
Croatia	birthplace	194	134	0	328	(48.3)	1.4	35	40	0	75	(11.0)	0.9
Georgia	citizenship	4118	1415	0	5533	(100.0)	2.9	0	0	0	0	(0.0)	-
Israel	birthplace	28	16	0	44	(10.5)	1.8	270	104	0	374	(89.5)	2.6
Kazakhstan	citizenship	13815	9261	0	23076	(100.0)	1.5	0	0	0	0	(0.0)	-
Kyrgyzstan	birthplace	2969	2274	0	5243	(100.0)	1.3	0	0	0	0	(0.0)	-
Macedonia, the former Yugoslav Republic of	birthplace	206	141	0	347	(95.9)	1.5	8	7	0	15	(4.1)	1.1
Moldova	citizenship	-	-	-	-	-	-	-	-	-	-	-	-
Monaco	birthplace	-	-	-	-	-	-	-	-	-	-	-	-
Montenegro	citizenship	70	49	0	119	(100.0)	1.4	0	0	0	0	(0.0)	-
Russia	citizenship	69693	31806	0	101499	(97.3)	2.2	2156	665	0	2821	(2.7)	3.2
San Marino	-	-	-	-	-	-	-	-	-	-	-	-	-
Serbia	-	1237	944	-	2181	(99.7)	1.3	2	4	-	6	(0.3)	0.5
Serbia excluding UN Administered Province of Kosovo <sup>c</sup>	citizenship	801	534	0	1335	(99.6)	1.5	2	4	0	6	(0.4)	0.5
UN Administered Province of Kosovo <sup>c</sup>	birthplace	436	410	0	846	(100.0)	1.1	0	0	0	0	(0.0)	-
Switzerland	birthplace	79	48	0	127	(22.0)	1.6	250	178	0	428	(74.0)	1.4
Tajikistan	birthplace	3347	2588	0	5935	(100.0)	1.3	0	0	0	0	(0.0)	-
Turkey	birthplace	9083	6394	0	15477	(98.7)	1.4	99	103	0	202	(1.3)	1.0
Turkmenistan	citizenship	-	-	-	-	-	-	-	-	-	-	-	-
Ukraine	citizenship	-	-	-	-	-	-	-	-	-	-	-	-
Uzbekistan	birthplace	9170	6700	0	15870	(99.7)	1.4	10	14	0	24	(0.2)	0.7
<b>Subtotal non-EU/EEA</b>		<b>119749</b>	<b>64210</b>	<b>-</b>	<b>183959</b>	<b>(97.7)</b>	<b>1.9</b>	<b>2830</b>	<b>1115</b>	<b>-</b>	<b>3945</b>	<b>(2.1)</b>	<b>2.5</b>
<b>Total European Region</b>		<b>154126</b>	<b>81977</b>	<b>47</b>	<b>236150</b>	<b>(90.6)</b>	<b>1.9</b>	<b>13778</b>	<b>8767</b>	<b>46</b>	<b>22591</b>	<b>(8.7)</b>	<b>1.6</b>
<b>Subtotal 18 HPC</b>		<b>133609</b>	<b>69874</b>	<b>-</b>	<b>203483</b>	<b>(98.4)</b>	<b>1.9</b>	<b>2413</b>	<b>844</b>	<b>-</b>	<b>3257</b>	<b>(1.6)</b>	<b>2.9</b>

<sup>a</sup> 'European Region' comprises the 53 countries of the WHO European Region and Liechtenstein.

WHO European Region 18 TB High Priority Countries presented in italics.

<sup>b</sup> By birthplace of parents for Danish-born cases under 26 years of age.

<sup>c</sup> Excluding Greenland (see Chapter 1.1).

<sup>d</sup> In accordance with the UN Security Council Resolution No. 1244 (1999).



	Unknown						Total				
	Male	Female	Gender unknown	Total	(%)	Sex ratio (M:F)	Male	Female	Gender unknown	Total	Sex ratio (M:F)
	5	2	0	7	(1.0)	2.5	422	265	0	687	1.6
			0		(0.0)	-	669	375	0	1044	1.8
			0		(0.0)	-	1608	799	0	2407	2.0
			0		(0.0)	-	32	22	0	54	1.5
			0		(0.0)	-	429	171	0	600	2.5
			0		(0.0)	-	231	150	0	381	1.5
			0		(0.0)	-	243	98	0	341	2.5
	25	9	0	34	(10.5)	2.8	185	140	0	325	1.3
	223	154	1	378	(7.6)	1.4	2964	1948	30	4942	1.5
	111	80	0	191	(4.4)	1.4	2548	1759	9	4316	1.5
			0		(0.0)	-	341	144	4	489	2.3
			0		(0.0)	-	949	496	0	1445	1.9
			0		(0.0)	-	2	7	0	9	0.3
	35	22	0	57	(13.4)	1.6	244	181	0	425	1.3
	155	111	0	266	(7.5)	1.4	2042	1478	1	3521	1.4
	7	2	0	9	(1.0)	3.5	594	291	0	885	2.0
			-		-	-	0	0	0	0	-
			0		(0.0)	-	1335	569	0	1904	2.3
			0		(0.0)	-	15	11	0	26	1.4
			0		(0.0)	-	23	10	0	33	2.3
	4	1	0	5	(0.5)	4.0	569	438	0	1007	1.3
			0		(0.0)	-	196	165	0	361	1.2
			0		(0.0)	-	5714	2764	0	8478	2.1
	2	2	0	4	(0.2)	1.0	1704	836	0	2540	2.0
			0		(0.0)	-	13153	6059	0	19212	2.2
			0		(0.0)	-	251	148	0	399	1.7
			0		(0.0)	-	111	81	0	192	1.4
	61	34	1	96	(1.4)	1.8	4172	2572	18	6762	1.6
			0		(0.0)	-	349	237	0	586	1.5
	254	189	7	450	(5.0)	1.3	5112	3811	40	8963	1.3
	<b>882</b>	<b>606</b>	<b>9</b>	<b>1497</b>	<b>(2.1)</b>	<b>1.5</b>	<b>46207</b>	<b>26025</b>	<b>102</b>	<b>72334</b>	<b>1.8</b>
	0	0	0	0	(0.0)	-	295	136	0	431	2.2
	0	0	0	0	(0.0)	-	2	2	0	4	1.0
	8	1	0	9	(0.6)	8.0	1175	407	0	1582	2.9
	-	-	-	-	-	-	-	-	-	-	-
	0	0	0	0	(0.0)	-	3469	1278	0	4747	2.7
	0	0	0	0	(0.0)	-	807	618	0	1425	1.3
	163	113	0	276	(40.6)	1.4	392	287	0	679	1.4
	0	0	0	0	(0.0)	-	4118	1415	0	5533	2.9
	0	0	0	0	(0.0)	-	298	120	0	418	2.5
	0	0	0	0	(0.0)	-	13815	9261	0	23076	1.5
	0	0	0	0	(0.0)	-	2969	2274	0	5243	1.3
	0	0	0	0	(0.0)	-	214	148	0	362	1.4
	-	-	-	-	-	-	-	-	-	-	-
	-	-	-	-	-	-	-	-	-	-	-
	0	0	0	0	(0.0)	-	70	49	0	119	1.4
	0	0	0	0	(0.0)	-	71849	32471	0	104320	2.2
	-	-	-	-	-	-	-	-	-	-	-
	-	0	-	-	-	-	1239	948	-	2187	1.3
	0	0	0	0	(0.0)	-	803	538	0	1341	1.5
	0	0	0	0	(0.0)	-	436	410	0	846	1.1
	13	10	0	23	(4.0)	1.3	342	236	0	578	1.4
	0	0	0	0	(0.0)	-	3347	2588	0	5935	1.3
	0	0	0	0	(0.0)	-	9182	6497	0	15679	1.4
	-	-	-	-	-	-	-	-	-	-	-
	-	-	-	-	-	-	-	-	-	-	-
	15	4	0	19	(0.1)	3.8	9195	6718	0	15913	1.4
	<b>199</b>	<b>128</b>	<b>-</b>	<b>327</b>	<b>(0.2)</b>	<b>2.2</b>	<b>122778</b>	<b>65453</b>	<b>-</b>	<b>188231</b>	<b>1.9</b>
	<b>1081</b>	<b>734</b>	<b>9</b>	<b>1824</b>	<b>(0.7)</b>	<b>2.2</b>	<b>168985</b>	<b>91478</b>	<b>102</b>	<b>260565</b>	<b>1.8</b>
	<b>30</b>	<b>7</b>	<b>-</b>	<b>37</b>	<b>(0.0)</b>	<b>2.2</b>	<b>136052</b>	<b>70725</b>	<b>-</b>	<b>206777</b>	<b>1.9</b>

**Table 14:** Tuberculosis cases in children (<15 years old), by age group and origin, EU/EEA, 2011

Country	Native				Foreign origin				Unknown				Total children			
	0-4		5-14		0-4		5-14		0-4		5-14		0-4		5-14	
	N	(%)	N	(%)	N	(%)	N	(%)	N	(%)	N	(%)	N	(%)	N	(%)
Austria	5	(71.4)	2	(28.6)	10	(58.8)	7	(41.2)	0	(0.0)	0	(0.0)	15	(62.5)	9	(37.5)
Belgium	29	(54.7)	24	(45.3)	19	(59.4)	13	(40.6)	0	(0.0)	0	(0.0)	48	(56.5)	37	(43.5)
Bulgaria	59	(33.5)	117	(66.5)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	59	(33.5)	117	(66.5)
Cyprus	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	-	(0.0)	0	(0.0)
Czech Republic	5	(83.3)	1	(16.7)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	5	(83.3)	1	(16.7)
Denmark <sup>a,b</sup>	5	(41.7)	7	(58.3)	0	(0.0)	4	(100.0)	0	(0.0)	0	(0.0)	5	(31.3)	11	(68.8)
Estonia	0	(0.0)	1	(100.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	-	(0.0)	1	(100.0)
Finland	3	(50.0)	3	(50.0)	0	(0.0)	4	(100.0)	0	(0.0)	1	(100.0)	3	(27.3)	8	(72.7)
France	101	(63.5)	58	(36.5)	20	(23.0)	67	(77.0)	4	(44.4)	5	(55.6)	125	(49.0)	130	(51.0)
Germany	70	(59.3)	48	(40.7)	17	(34.0)	33	(66.0)	5	(45.5)	6	(54.5)	92	(51.4)	87	(48.6)
Greece	9	(39.1)	14	(60.9)	7	(46.7)	8	(53.3)	0	(0.0)	0	(0.0)	16	(42.1)	22	(57.9)
Hungary	3	(75.0)	1	(25.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	3	(75.0)	1	(25.0)
Iceland	0	(0.0)	1	(100.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	-	(0.0)	1	(100.0)
Ireland	5	(41.7)	7	(58.3)	0	(0.0)	7	(100.0)	0	(0.0)	1	(100.0)	5	(25.0)	15	(75.0)
Italy	73	(55.3)	59	(44.7)	19	(26.8)	52	(73.2)	2	(33.3)	4	(66.7)	94	(45.0)	115	(55.0)
Latvia	24	(40.0)	36	(60.0)	1	(100.0)	0	(0.0)	0	(0.0)	0	(0.0)	25	(41.0)	36	(59.0)
Liechtenstein	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Lithuania	26	(29.9)	61	(70.1)	0	(0.0)	1	(100.0)	0	(0.0)	0	(0.0)	26	(29.5)	62	(70.5)
Luxembourg	0	(0.0)	0	(0.0)	0	(0.0)	1	(100.0)	0	(0.0)	0	(0.0)	-	(0.0)	1	(100.0)
Malta	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	-	(0.0)	0	(0.0)
Netherlands	12	(40.0)	18	(60.0)	5	(20.0)	20	(80.0)	0	(0.0)	1	(100.0)	17	(30.4)	39	(69.6)
Norway	1	(50.0)	1	(50.0)	3	(20.0)	12	(80.0)	0	(0.0)	0	(0.0)	4	(23.5)	13	(76.5)
Poland	30	(27.3)	80	(72.7)	0	(0.0)	1	(100.0)	0	(0.0)	0	(0.0)	30	(27.0)	81	(73.0)
Portugal	17	(47.2)	19	(52.8)	1	(12.5)	7	(87.5)	0	(0.0)	0	(0.0)	18	(40.9)	26	(59.1)
Romania	299	(38.8)	472	(61.2)	4	(80.0)	1	(20.0)	0	(0.0)	0	(0.0)	303	(39.0)	473	(61.0)
Slovakia	10	(58.8)	7	(41.2)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	10	(58.8)	7	(41.2)
Slovenia	2	(66.7)	1	(33.3)	0	(0.0)	1	(100.0)	0	(0.0)	0	(0.0)	2	(50.0)	2	(50.0)
Spain	267	(63.0)	157	(37.0)	31	(28.4)	78	(71.6)	3	(37.5)	5	(62.5)	301	(55.6)	240	(44.4)
Sweden	3	(37.5)	5	(62.5)	4	(14.3)	24	(85.7)	0	(0.0)	0	(0.0)	7	(19.4)	29	(80.6)
United Kingdom	116	(44.6)	144	(55.4)	18	(12.9)	121	(87.1)	6	(42.9)	8	(57.1)	140	(33.9)	273	(66.1)
<b>Total EU/EEA</b>	<b>1174</b>	<b>(46.6)</b>	<b>1344</b>	<b>(53.4)</b>	<b>159</b>	<b>(25.6)</b>	<b>462</b>	<b>(74.4)</b>	<b>20</b>	<b>(39.2)</b>	<b>31</b>	<b>(60.8)</b>	<b>1353</b>	<b>(42.4)</b>	<b>1837</b>	<b>(57.6)</b>

WHO European Region 18 TB High Priority Countries presented in italics.

<sup>a</sup> By birthplace of parents for Danish-born cases under 26 years of age.<sup>b</sup> Excluding Greenland (see Chapter 1.1).

**Table 15: Laboratory practices and quality assurance for anti-TB drug susceptibility testing, European Region, 2011**

Country	Labs performing					External quality assurance				External quality assurance for DST								
	Microscopy (N)	Culture (N)	DST (N)	Line Probe Assay (N)	Xpert MTB/RIF (N)	Smear microscopy		Culture		National <sup>a</sup>		International						
						Year <sup>b</sup>	Laboratories with acceptable performance (N)	Year <sup>c</sup>	Laboratories with acceptable performance (N)	EQA available at national level	No. labs	EQA available at international level	Year <sup>d</sup>	% agreement of results for:				
													Isoniazid	Rifampicin				
<b>EU/EEA</b>																		
Austria	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Belgium	115	114	15	8	6	2011	3	2011	3	Yes	14	Yes	2011	100	100			
Bulgaria	34	33	13	3	0	2011	34	2011	29	Yes	3	Yes	2011	100	100			
Cyprus	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Czech Republic	48	48	17	17	-	2011	37	2011	37	Yes	15	Yes	2011	100	100			
Denmark	10	1	1	1	-	2010	-	2010	1	No	-	Yes	2010	100	100			
Estonia	5	2	2	2	2	2011	5	2011	2	Yes	1	Yes	2011	100	100			
Finland	21	11	1	5	3	2011	-	2011	-	Yes	-	Yes	2011	100	100			
France	235	230	70	21	20	2011	-	2011	-	Yes	34	Yes	2011	100	100			
Germany	254	189	84	-	-	-	-	-	-	-	-	Yes	2011	100	100			
Greece	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Hungary	13	13	7	2	2	2011	9	2011	5	Yes	2	Yes	2011	100	100			
Iceland	1	1	1	1	0	2011	1	2011	1	-	-	-	-	-	-	-	-	-
Ireland	13	13	3	3	2	2011	13	2011	13	Yes	2	Yes	2011	100	100			
Italy	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Latvia	16	4	1	1	1	2011	16	2011	4	-	-	Yes	2011	97	100			
Liechtenstein	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Lithuania	13	6	6	1	5	2011	4	2011	6	Yes	3	Yes	2011	90	90			
Luxembourg	1	1	1	1	1	2011	1	2011	1	-	-	Yes	2011	100	100			
Malta	1	1	0	0	-	2011	1	-	-	-	-	-	-	-	-	-	-	-
Netherlands	42	37	4	1	2	2011	-	2011	-	-	-	Yes	2010	100	100			
Norway	18	10	3	4	0	2011	18	2011	10	Yes	2	Yes	2011	100	100			
Poland	85	85	47	11	3	2011	85	2011	85	Yes	46	Yes	2011	100	100			
Portugal	88	88	22	18	-	2010	34	2010	-	Yes	11	Yes	2010	100	100			
Romania	113	70	43	0	0	2011	90	2011	38	Yes	2	Yes	2011	100	100			
Slovakia	5	5	2	0	0	2011	4	2011	4	Yes	1	Yes	2010	90	95			
Slovenia	3	3	1	1	1	2011	3	2011	2	-	-	Yes	2011	100	100			
Spain	-	-	-	-	-	-	-	-	-	-	-	Yes	2011	100	100			
Sweden	5	5	5	5	0	2011	5	2011	4	Yes	4	Yes	2011	100	100			
United Kingdom	193	126	21	12	16	2011	192	2011	126	Yes	20	Yes	2011	-	-			
<b>Subtotal EU/EEA</b>	<b>1332</b>	<b>1096</b>	<b>370</b>	<b>118</b>	<b>64</b>	<b>2010-11</b>	<b>555</b>	<b>2010-11</b>	<b>371</b>	<b>16</b>	<b>160</b>	<b>23</b>	<b>2010-11</b>	<b>99.0</b>	<b>99.3</b>			
<b>Non-EU/EEA</b>																		
Albania	17	1	1	1	0	2011	17	2011	0	Yes	1	Yes	2010	100	100			
Andorra	8	8	8	0	-	-	-	-	-	-	-	No	-	-	-	-	-	-
Armenia	30	1	1	1	0	2011	29	2011	1	Yes	1	Yes	2011	100	100			
Azerbaijan	72	6	2	2	2	2011	1	2011	0	Yes	2	Yes	-	-	-	-	-	-
Belarus	196	41	20	1	0	2011	177	2011	41	Yes	20	Yes	2011	100	100			
Bosnia and Herzegovina	15	13	4	3	0	2011	15	2011	13	Yes	4	Yes	2011	100	100			
Croatia	14	14	6	1	1	-	-	-	-	Yes	0	Yes	2011	100	100			
Georgia	29	2	1	1	1	2011	29	2011	2	Yes	1	Yes	2010	97	100			
Israel	19	19	2	1	1	2011	17	2011	17	Yes	2	Yes	2011	100	100			
Kazakhstan	466	100	22	10	0	2011	466	2011	100	Yes	22	Yes	2011	95	95			
Kyrgyzstan	122	4	3	0	0	-	-	-	-	Yes	-	Yes	2011	97	-			
Macedonia, the former Yugoslav Republic of	8	5	1	0	0	2011	8	2011	5	Yes	1	Yes	2010	100	100			
Moldova	59	4	4	3	-	2011	28	2011	4	Yes	4	Yes	2011	100	100			
Monaco	0	0	0	0	-	2011	-	2011	-	-	0	-	-	-	-	-	-	-
Montenegro	1	1	1	0	0	2011	1	2011	1	Yes	1	Yes	2011	100	100			
Russia	3746	117	0	0	-	2011	828	2011	88	Yes	0	-	-	-	-	-	-	-
San Marino	0	0	0	0	-	2011	-	2011	-	-	-	-	-	-	-	-	-	-
Serbia	43	31	6	1	1	2011	38	2011	0	Yes	3	Yes	2011	100	100			
Serbia excluding UN Administered Province of Kosovo <sup>f</sup>	31	29	4	1	0	2011	26	2011	0	Yes	2	Yes	2011	100	100			
UN Administered Province of Kosovo <sup>f</sup>	12	2	2	0	1	2011	12	2011	0	-	1	-	2010	100	100			
Switzerland	42	24	10	0	14	2011	40	2011	24	Yes	7	Yes	2011	-	-			
Tajikistan	92	3	1	2	2	2011	45	2011	1	Yes	1	Yes	2011	93	89			
Turkey	389	156	71	9	18	-	-	-	-	Yes	0	Yes	2011	100	100			
Turkmenistan	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Ukraine	859	82	42	0	0	-	-	-	-	Yes	23	Yes	2010	100	100			
Uzbekistan	320	7	2	3	0	2011	296	2011	5	Yes	2	Yes	2011	100	100			
<b>Subtotal Non-EU/EEA</b>	<b>6547</b>	<b>639</b>	<b>208</b>	<b>39</b>	<b>40</b>	<b>2011</b>	<b>2035</b>	<b>2011</b>	<b>302</b>	<b>22</b>	<b>95</b>	<b>19</b>	<b>2010-2011</b>	<b>99.0</b>	<b>93.6</b>			
<b>Total European Region</b>	<b>7879</b>	<b>1735</b>	<b>578</b>	<b>157</b>	<b>104</b>	<b>2010-11</b>	<b>2590</b>	<b>2010-11</b>	<b>673</b>	<b>38</b>	<b>255</b>	<b>42</b>	<b>2010-11</b>	<b>96.5</b>	<b>94.2</b>			
<b>Subtotal 18 HPC</b>	<b>6561</b>	<b>638</b>	<b>234</b>	<b>39</b>	<b>31</b>	<b>2011</b>	<b>2048</b>	<b>2011</b>	<b>321</b>	<b>16</b>	<b>85</b>	<b>16</b>	<b>2010-11</b>	<b>97.9</b>	<b>91.6</b>			

<sup>a</sup> 'European Region' comprises the 53 countries of the WHO European Region and Liechtenstein.

WHO European Region 18 TB High Priority Countries presented in *italics*.

<sup>b</sup> For countries with more than one DST laboratory; national reference laboratory not included as these laboratories report to the International EQA result.

<sup>c</sup> Year of participation in external quality assurance for smear microscopy

<sup>d</sup> Year of participation in external quality assurance for isolation of *M. Tuberculosis* complex by culture

<sup>e</sup> Year of participation in external quality assurance for DST for first line anti TB drugs

<sup>f</sup> Excluding Greenland (see Chapter 1.1).

<sup>g</sup> In accordance with the UN Security Council Resolution No. 1244 (1999).

**Table 16: Characteristics of anti-TB drug resistance surveillance of laboratory-confirmed cases, European Region, 2011**

Country	Source of data	Coverage	Laboratory-confirmed TB cases <sup>a</sup>		DST results (isoniazid and rifampicin)		MDR cases		Cases resistant to any anti-TB drug <sup>b</sup>		Reporting completeness <sup>c</sup>
			N	(%)	N	(%)	N	(%)	N	(%)	
<b>EU/EEA</b>											
Austria	TESSy	national	466	(67.8)	450	(96.6)	19	(4.2)	58	(12.9)	Y
Belgium	TESSy	national	797	(76.3)	754	(94.6)	15	(2.0)	57	(7.6)	Y
Bulgaria	TESSy	national	1,071	(44.5)	733	(68.4)	55	(7.5)	124	(16.9)	N
Cyprus	TESSy	national	44	(81.5)	40	(90.9)	1	(2.5)	4	(10.0)	Y
Czech Republic	TESSy	national	426	(71.0)	408	(95.8)	7	(1.7)	28	(6.9)	Y
Denmark <sup>d</sup>	TESSy	national	272	(71.4)	271	(99.6)	3	(1.1)	13	(4.8)	Y
Estonia	TESSy	national	264	(77.4)	262	(99.2)	78	(29.8)	108	(41.2)	Y
Finland	TESSy	national	252	(77.5)	245	(97.2)	5	(2.0)	17	(6.9)	Y
France	NRL-TME <sup>e</sup>	national	2,309	(46.7)	1,568	(67.9)	40	(2.6)	117	(7.5)	N
Germany	TESSy	national	3,071	(71.2)	2,821	(91.9)	56	(2.0)	287	(10.2)	Y
Greece	TESSy	national	278	(56.9)	159	(57.2)	5	(3.1)	31	(19.5)	N
Hungary	TESSy	national	597	(41.3)	479	(80.2)	7	(1.5)	41	(8.6)	N
Iceland	TESSy	national	4	(44.4)	4	(100.0)	0	(0.0)	0	(0.0)	N
Ireland	TESSy	national	288	(67.8)	239	(83.0)	3	(1.3)	20	(8.4)	Y
Italy <sup>f</sup>	NRL-TME <sup>e</sup>	partial national	2,576	(73.2)	2,542	(98.7)	81	(3.2)	386	(15.2)	N
Latvia	TESSy	national	671	(75.8)	644	(96.0)	95	(14.8)	218	(33.9)	Y
Liechtenstein	-	-	-	-	-	-	-	-	-	-	-
Lithuania	TESSy	national	1,403	(73.7)	1,403	(100.0)	296	(21.1)	516	(36.8)	Y
Luxembourg	TESSy	national	19	(73.1)	19	(100.0)	2	(10.5)	4	(21.1)	Y
Malta	TESSy	national	24	(72.7)	22	(91.7)	0	(0.0)	3	(13.6)	Y
Netherlands	TESSy	national	732	(72.7)	726	(99.2)	15	(2.1)	85	(11.7)	Y
Norway	TESSy	national	262	(72.6)	257	(98.1)	4	(1.6)	33	(12.8)	Y
Poland	TESSy	national	5,581	(65.8)	4,993	(89.5)	41	(0.8)	280	(5.6)	Y
Portugal	TESSy	national	1,588	(62.5)	1,252	(78.8)	22	(1.8)	194	(15.5)	N
Romania	TESSy	national	12,446	(64.8)	6,026	(48.4)	530	(8.8)	944	(15.7)	N
Slovakia	TESSy	national	188	(47.1)	185	(98.4)	3	(1.6)	12	(6.5)	N
Slovenia	TESSy	national	182	(94.8)	182	(100.0)	0	(0.0)	7	(3.8)	Y
Spain	NRL-TME <sup>e</sup>	partial national	4,383	(64.8)	1,273	(29.0)	41	(3.2)	112	(8.8)	N
Sweden	TESSy	national	476	(81.2)	475	(99.8)	17	(3.6)	66	(13.9)	Y
United Kingdom	TESSy	national	5,285	(59.0)	5,127	(97.0)	81	(1.6)	524	(10.2)	Y
<b>Subtotal EU/EEA</b>			<b>45,955</b>	<b>(63.5)</b>	<b>33,559</b>	<b>(73.0)</b>	<b>1,522</b>	<b>(4.5)</b>	<b>4,289</b>	<b>(12.8)</b>	<b>19</b>
<b>Non-EU/EEA</b>											
Albania	NRL-TME	national	205	(47.6)	205	(100.0)	5	(2.4)	-	-	N
Andorra	NRL-TME	national	3	(75.0)	2	(66.7)	0	(0.0)	-	-	N
Armenia	NRL-TME	national	529	(33.4)	529	(100.0)	79	(14.9)	-	-	N
Azerbaijan	NRL-TME	partial national	2,176	(21.5)	720	(33.1)	90	(12.5)	-	-	N
Belarus	NRL-TME	national	3,137	(61.3)	3,032	(96.7)	1,594	(52.6)	-	-	Y
Bosnia and Herzegovina	NRL-TME	national	745	(52.3)	745	(100.0)	5	(0.7)	-	-	Y
Croatia	NRL-TME	national	393	(57.9)	393	(100.0)	2	(0.5)	-	-	Y
Georgia	NRL-TME	national	2,955	(53.4)	2,872	(97.2)	453	(15.8)	-	-	Y
Israel	NRL-TME	national	284	(67.9)	284	(100.0)	11	(3.9)	-	-	Y
Kazakhstan	NRL-TME	national	11,555	(44.1)	11,555	(100.0)	4,575	(39.6)	-	-	N
Kyrgyzstan	NRL-TME	partial national	-	-	-	-	-	-	-	-	N
Macedonia, the former Yugoslav Republic of	NRL-TME	national	155	(42.8)	155	(100.0)	1	(0.6)	-	-	N
Moldova	NRL-TME	national	2,561	(47.9)	2,385	(93.1)	1,001	(42.0)	-	-	N
Monaco	-	-	0	-	0	-	0	-	-	-	-
Montenegro	NRL-TME	national	72	(60.5)	72	(100.0)	1	(1.4)	-	-	Y
Russia	NRL-TME	national	51,924	(32.6)	47,627	(91.7)	13,785	(28.9)	-	-	N
San Marino	-	-	0	-	0	-	0	-	-	-	-
Serbia	-	partial national	1,025	(76.4)	966	(94.2)	9	(0.9)	-	-	N
Serbia excluding UN Administered Province of Kosovo <sup>g</sup>	NRL-TME	national	1,025	(76.4)	966	(94.2)	9	(0.9)	-	-	Y
UN Administered Province of Kosovo <sup>g</sup>	-	national	0	-	0	-	0	-	-	-	N
Switzerland	NRL-TME	national	487	(84.3)	454	(93.2)	8	(1.8)	-	-	Y
Tajikistan	NRL-TME	partial national	1,623	(21.3)	576	(35.5)	380	(66.0)	-	-	N
Turkey	NRL-TME	partial national	4,828	(30.8)	4,823	(99.9)	262	(5.4)	-	-	N
Turkmenistan	NRL-TME	partial national	-	-	-	-	-	-	-	-	-
Ukraine	NRL-TME	national	20,103	(47.1)	14,765	(73.4)	4,305	(29.2)	-	-	N
Uzbekistan	NRL-TME	partial national	4,430	(27.8)	2,217	(50.0)	1,385	(62.5)	-	-	N
<b>Subtotal non-EU/EEA</b>			<b>109,190</b>	<b>(35.4)</b>	<b>94,377</b>	<b>(86.4)</b>	<b>27,951</b>	<b>(25.6)</b>	<b>0</b>	<b>-</b>	<b>0</b>
<b>Total European Region</b>			<b>155,145</b>	<b>(40.8)</b>	<b>127,936</b>	<b>(82.5)</b>	<b>29,473</b>	<b>(19.0)</b>	<b>0</b>	<b>-</b>	<b>19</b>
<b>Subtotal 18 HPC</b>			<b>121,676</b>	<b>(37.2)</b>	<b>100,169</b>	<b>(82.3)</b>	<b>28,963</b>	<b>(23.8)</b>	<b>0</b>	<b>-</b>	<b>0</b>

<sup>a</sup> 'European Region' comprises the 53 countries of the WHO European Region and Liechtenstein.

WHO European Region 18 TB High Priority Countries presented in italics.

<sup>b</sup> Lab-confirmed cases consists culture positive or nucleic acid amplification and sputum smear positive cases for EU/EEA countries. Only culture positive cases for non-EU countries.

<sup>c</sup> Any resistance to isoniazid, rifampicin, ethambutol or streptomycin expressed as a percentage of cases with DST results available at least for isoniazid and rifampicin. No routine testing for ethambutol and streptomycin in all countries.

<sup>d</sup> Data considered complete when national coverage 100% or culture results available for 90% of all cases, and 50% of all cases culture-positive, 75% of them with DST results and EQA results accurate in 95% of samples for reported year.

<sup>e</sup> Excluding Greenland (see Chapter 1.1).

<sup>f</sup> NRL: National reference laboratory; TME: WHO Tuberculosis Monitoring and Evaluation Database.

<sup>g</sup> Data from Italy reported from NRL; data may differ from data shown elsewhere in this report.

<sup>h</sup> In accordance with the UN Security Council Resolution No. 1244 (1999).

**Table 17: Multidrug-resistant TB among laboratory-confirmed TB cases by previous history of TB treatment, European Region, 2011**

Country	New			Previously treated			Previous treatment unknown			All TB cases reported <sup>a</sup>		
	Cases with DST results	Multidrug-resistant		Cases with DST results	Multidrug-resistant		Cases with DST results	Multidrug-resistant		Cases with DST results	Multidrug-resistant	
		N	(%)		N	(%)		N	(%)		N	(%)
<b>EU/EEA</b>												
Austria	257	9	(3.5)	11	2	(18.2)	182	8	(4.4)	450	19	(4.2)
Belgium <sup>a</sup>	524	7	(1.3)	35	4	(11.4)	195	4	(2.1)	754	15	(2.0)
Bulgaria	588	18	(3.1)	145	37	(25.5)	0	0	-	733	55	(7.5)
Cyprus	25	1	(4.0)	2	0	(0.0)	13	0	(0.0)	40	1	(2.5)
Czech Republic	392	6	(1.5)	16	1	(6.3)	0	0	-	408	7	(1.7)
Denmark <sup>a,b</sup>	257	3	(1.2)	14	0	(0.0)	0	0	-	271	3	(1.1)
Estonia	210	48	(22.9)	52	30	(57.7)	0	0	-	262	78	(29.8)
Finland	237	5	(2.1)	8	0	(0.0)	0	0	-	245	5	(2.0)
France	1232	25	(2.0)	110	9	(8.2)	226	6	(2.7)	1568	40	(2.6)
Germany	2367	28	(1.2)	146	18	(12.3)	308	10	(3.2)	2821	56	(2.0)
Greece	148	3	(2.0)	11	2	(18.2)	0	0	-	159	5	(3.1)
Hungary	411	2	(0.5)	68	5	(7.4)	0	0	-	479	7	(1.5)
Iceland	4	0	(0.0)	0	0	-	0	0	-	4	0	(0.0)
Ireland <sup>a</sup>	176	0	(0.0)	15	1	(6.7)	48	2	(4.2)	239	3	(1.3)
Italy	760	30	(3.9)	441	24	(5.4)	1341	27	(2.0)	2542	81	(3.2)
Latvia	562	71	(12.6)	82	24	(29.3)	0	0	-	644	95	(14.8)
Liechtenstein	-	-	-	-	-	-	-	-	-	-	-	-
Lithuania	1031	114	(11.1)	369	180	(48.8)	3	2	(66.7)	1403	296	(21.1)
Luxembourg	7	0	(0.0)	1	0	(0.0)	11	2	(18.2)	19	2	(10.5)
Malta	17	0	(0.0)	0	0	-	5	0	(0.0)	22	0	(0.0)
Netherlands	695	12	(1.7)	22	1	(4.5)	9	2	(22.2)	726	15	(2.1)
Norway <sup>a</sup>	229	3	(1.3)	22	0	(0.0)	6	1	(16.7)	257	4	(1.6)
Poland	4416	23	(0.5)	577	18	(3.1)	0	0	-	4993	41	(0.8)
Portugal	1155	17	(1.5)	97	5	(5.2)	0	0	-	1252	22	(1.8)
Romania	3855	117	(3.0)	2171	413	(19.0)	0	0	-	6026	530	(8.8)
Slovakia	147	2	(1.4)	29	1	(3.4)	9	0	(0.0)	185	3	(1.6)
Slovenia	171	0	(0.0)	11	0	(0.0)	0	0	-	182	0	(0.0)
Spain	1013	15	(1.5)	96	16	(16.7)	164	10	(6.1)	1273	41	(3.2)
Sweden	375	9	(2.4)	31	5	(16.1)	69	3	(4.3)	475	17	(3.6)
United Kingdom <sup>a</sup>	4549	61	(1.3)	234	13	(5.6)	344	7	(2.0)	5127	81	(1.6)
<b>Subtotal EU/EEA</b>	<b>25810</b>	<b>629</b>	<b>(2.4)</b>	<b>4816</b>	<b>809</b>	<b>(16.8)</b>	<b>2933</b>	<b>84</b>	<b>(2.9)</b>	<b>33559</b>	<b>1522</b>	<b>(4.5)</b>
<b>Non-EU/EEA</b>												
Albania	194	2	(1.0)	11	3	(27.3)	0	0	-	205	5	(2.4)
Andorra	1	0	(0.0)	1	0	(0.0)	0	0	-	2	0	(0.0)
Armenia	439	66	(15.0)	90	13	(14.4)	0	0	-	529	79	(14.9)
Azerbaijan	569	55	(9.7)	151	35	(23.2)	0	0	-	720	90	(12.5)
Belarus	2084	542	(26.0)	948	622	(65.6)	0	430	-	3032	1594	(52.6)
Bosnia and Herzegovina	704	1	(0.1)	41	4	(9.8)	0	0	-	745	5	(0.7)
Croatia	353	1	(0.3)	40	1	(2.5)	0	0	-	393	2	(0.5)
Georgia	2197	239	(10.9)	675	214	(31.7)	0	0	-	2872	453	(15.8)
Israel	275	10	(3.6)	9	1	(11.1)	0	0	-	284	11	(3.9)
Kazakhstan	5293	1604	(30.3)	4790	2456	(51.3)	1472	515	(35.0)	11555	4575	(39.6)
Kyrgyzstan	-	-	-	-	-	-	-	-	-	-	-	-
Macedonia, the former Yugoslav Republic of	130	0	(0.0)	25	1	(4.0)	0	0	-	155	1	(0.6)
Moldova	1379	359	(26.0)	1006	642	(63.8)	0	0	-	2385	1001	(42.0)
Monaco	-	-	-	-	-	-	-	-	-	-	-	-
Montenegro	57	1	(1.8)	13	0	(0.0)	2	0	(0.0)	72	1	(1.4)
Russia	34007	6596	(19.4)	13620	7189	(52.8)	0	0	(0.0)	47627	13785	(28.9)
San Marino	-	-	-	-	-	-	-	-	-	-	-	-
Serbia	863	3	(0.3)	100	6	(6.0)	3	0	-	966	9	(0.9)
Serbia excluding UN Administered Province of Kosovo <sup>c</sup>	863	3	(0.3)	100	6	(6.0)	3	0	-	966	9	(0.9)
UN Administered Province of Kosovo <sup>c</sup>	-	-	-	-	-	-	-	-	-	-	-	-
Switzerland	304	1	(0.3)	40	4	(10.0)	110	3	(2.7)	454	8	(1.8)
Tajikistan	161	72	(44.7)	415	308	(74.2)	0	0	-	576	380	(66.0)
Turkey	4221	116	(2.7)	602	146	(24.3)	0	0	-	4823	262	(5.4)
Turkmenistan	-	-	-	-	-	-	-	-	-	-	-	-
Ukraine	10352	1367	(13.2)	4413	2283	(51.7)	0	655	-	14765	4305	(29.2)
Uzbekistan	484	170	(35.1)	123	89	(72.4)	1610	1126	(69.9)	2217	1385	(62.5)
<b>Subtotal non-EU/EEA</b>	<b>64067</b>	<b>11205</b>	<b>(17.5)</b>	<b>27113</b>	<b>14017</b>	<b>(51.7)</b>	<b>3197</b>	<b>2729</b>	<b>(85.4)</b>	<b>94377</b>	<b>27951</b>	<b>(29.6)</b>
<b>Total European Region</b>	<b>89877</b>	<b>11834</b>	<b>(13.2)</b>	<b>31929</b>	<b>14826</b>	<b>(46.4)</b>	<b>6130</b>	<b>2813</b>	<b>(45.9)</b>	<b>127936</b>	<b>29473</b>	<b>(23.0)</b>
<b>Subtotal 18 HPC</b>	<b>67432</b>	<b>11554</b>	<b>(17.1)</b>	<b>29652</b>	<b>14681</b>	<b>(49.5)</b>	<b>3085</b>	<b>2728</b>	<b>(88.4)</b>	<b>100169</b>	<b>28963</b>	<b>(28.9)</b>

<sup>a</sup> 'European Region' comprises the 53 countries of the WHO European Region and Liechtenstein. WHO European Region 18 TB High Priority Countries presented in italics.

DST: Drug Susceptibility Testing; NRL: National Reference Laboratory

<sup>b</sup> Cases classified according to previous TB treatment history. From Belgium, Denmark, Ireland, Norway and United Kingdom previous diagnosis was reported instead and used as a proxy for previous treatment.

<sup>c</sup> Excluding Greenland (see Chapter 1.1).

<sup>d</sup> In accordance with the UN Security Council Resolution No. 1244 (1999).

**Table 18: Anti-TB drug resistance among new laboratory-confirmed pulmonary TB cases, European Region, 2011<sup>a</sup>**

Country	Cases resistant to at least <sup>b</sup> :								New laboratory-confirmed pulmonary TB cases		New pulmonary TB cases
	Cases with DST results		Isoniazid		Rifampicin		Isoniazid and rifampicin (multidrug resistant)		N	(%) <sup>f</sup>	N
	N	(%) <sup>e</sup>	N	(%) <sup>d</sup>	N	(%) <sup>d</sup>	N	(%) <sup>d</sup>			
<b>EU/EEA</b>											
Austria	214	(96.0)	21	(9.8)	10	(4.7)	8	(3.7)	223	(71.7)	311
Belgium	397	(95.9)	21	(5.3)	5	(1.3)	4	(1.0)	414	(80.7)	513
<i>Bulgaria</i>	579	(67.9)	42	(7.3)	23	(4.0)	17	(2.9)	853	(59.9)	1424
Cyprus	21	(95.5)	0	(0.0)	0	(0.0)	0	(0.0)	22	(88.0)	25
Czech Republic	365	(96.8)	11	(3.0)	11	(3.0)	6	(1.6)	377	(76.2)	495
Denmark <sup>f</sup>	218	(99.5)	9	(4.1)	2	(0.9)	2	(0.9)	219	(97.8)	224
<i>Estonia</i>	202	(100.0)	63	(31.2)	48	(23.8)	47	(23.3)	202	(81.8)	247
Finland	176	(96.2)	14	(8.0)	5	(2.8)	5	(2.8)	183	(81.3)	225
France	-	-	-	-	-	-	-	-	-	-	-
Germany	1961	(92.9)	128	(6.5)	30	(1.5)	26	(1.3)	2111	(77.1)	2738
Greece	139	(59.4)	17	(12.2)	4	(2.9)	3	(2.2)	234	(59.7)	392
Hungary	407	(80.8)	22	(5.4)	2	(0.5)	2	(0.5)	504	(43.1)	1170
Iceland	0	-	0	-	0	-	0	-	0	(0.0)	3
Ireland	135	(87.1)	4	(3.0)	0	(0.0)	0	(0.0)	155	(79.5)	195
Italy	-	-	-	-	-	-	-	-	-	-	-
<i>Latvia</i>	543	(97.1)	155	(28.5)	70	(12.9)	69	(12.7)	559	(79.5)	703
Liechtenstein	-	-	-	-	-	-	-	-	-	-	-
<i>Lithuania</i>	1000	(100.0)	231	(23.1)	116	(11.6)	111	(11.1)	1000	(74.3)	1345
Luxembourg	6	(100.0)	0	(0.0)	0	(0.0)	0	(0.0)	6	(75.0)	8
Malta	11	(91.7)	0	(0.0)	0	(0.0)	0	(0.0)	12	(80.0)	15
Netherlands	434	(98.9)	40	(9.2)	9	(2.1)	9	(2.1)	439	(82.8)	530
Norway	136	(97.1)	11	(8.1)	2	(1.5)	2	(1.5)	140	(80.5)	174
Poland	4210	(89.6)	139	(3.3)	28	(0.7)	23	(0.5)	4699	(67.8)	6931
Portugal	1018	(80.2)	71	(7.0)	15	(1.5)	14	(1.4)	1269	(75.1)	1689
<i>Romania</i>	3855	(44.4)	275	(7.1)	145	(3.8)	117	(3.0)	8683	(72.9)	11914
Slovakia	138	(98.6)	5	(3.6)	3	(2.2)	2	(1.4)	140	(52.6)	266
Slovenia	151	(100.0)	1	(0.7)	0	(0.0)	0	(0.0)	151	(97.4)	155
Spain	-	-	-	-	-	-	-	-	-	-	-
Sweden	247	(99.6)	30	(12.1)	6	(2.4)	5	(2.0)	248	(88.3)	281
United Kingdom	2751	(97.1)	188	(6.8)	39	(1.4)	35	(1.3)	2832	(70.3)	4031
<b>Subtotal EU/EEA</b>	<b>19314</b>	<b>(75.2)</b>	<b>1498</b>	<b>(7.8)</b>	<b>573</b>	<b>(3.0)</b>	<b>507</b>	<b>(2.6)</b>	<b>25675</b>	<b>(71.3)</b>	<b>36004</b>
<b>Non-EU/EEA</b>											
Albania	194	(100.0)	21	(10.8)	8	(4.1)	2	(1.0)	194	(68.1)	285
Andorra	1	(50.0)	0	(0.0)	0	(0.0)	0	(0.0)	2	(66.7)	3
<i>Armenia</i>	439	(100.0)	139	(31.7)	76	(17.3)	66	(15.0)	439	(48.2)	911
<i>Azerbaijan</i>	569	(28.3)	114	(20.0)	59	(10.4)	55	(9.7)	2009	(48.2)	4166
<i>Belarus</i>	2084	(95.6)	627	(30.1)	568	(27.3)	542	(26.0)	2179	(59.6)	3656
Bosnia and Herzegovina	704	(100.0)	2	(0.3)	1	(0.1)	1	(0.1)	704	(59.0)	1194
Croatia	353	(100.0)	11	(3.1)	2	(0.6)	1	(0.3)	353	(64.9)	544
<i>Georgia</i>	2197	(97.3)	513	(23.4)	262	(11.9)	239	(10.9)	2257	(71.3)	3167
Israel	275	(100.0)	25	(9.1)	10	(3.6)	10	(3.6)	275	(80.4)	342
<i>Kazakhstan</i>	5293	(100.0)	1714	(32.4)	1629	(30.8)	1604	(30.3)	5293	(42.7)	12399
<i>Kyrgyzstan</i>	-	-	-	-	-	-	-	-	-	-	-
Macedonia, the former Yugoslav Republic of	130	(100.0)	5	(3.8)	3	(2.3)	0	(0.0)	130	(56.3)	231
<i>Moldova</i>	1379	(92.5)	503	(36.5)	374	(27.1)	359	(26.0)	1491	(43.7)	3412
Monaco	-	-	-	-	-	-	-	-	-	-	-
Montenegro	57	(100.0)	2	(3.5)	1	(1.8)	1	(1.8)	57	(64.8)	88
<i>Russia</i>	34007	(92.8)	6596	(19.4)	6596	(19.4)	6596	(19.4)	36665	(38.9)	94297
San Marino	-	-	-	-	-	-	-	-	-	-	-
Serbia	863	(94.1)	17	(2.0)	3	(0.3)	3	(0.3)	917	(87.3)	1050
Serbia excluding UN Administered Province of Kosovo <sup>g</sup>	863	(94.1)	17	(2.0)	3	(0.3)	3	(0.3)	917	(87.3)	1050
UN Administered Province of Kosovo <sup>g</sup>	-	-	-	-	-	-	-	-	-	-	-
Switzerland	304	(95.0)	15	(4.9)	3	(1.0)	1	(0.3)	320	(123.1)	260
<i>Tajikistan</i>	161	(15.9)	86	(53.4)	81	(50.3)	72	(44.7)	1010	(23.4)	4322
<i>Turkey</i>	4221	(99.9)	474	(11.2)	157	(3.7)	116	(2.7)	4226	(47.7)	8852
<i>Turkmenistan</i>	-	-	-	-	-	-	-	-	-	-	-
<i>Ukraine</i>	10352	(75.5)	1658	(16.0)	1498	(14.5)	1367	(13.2)	13715	(49.3)	27821
<i>Uzbekistan</i>	484	(42.6)	285	(58.9)	174	(36.0)	170	(35.1)	1135	(11.2)	10156
<b>Subtotal non-EU/EEA</b>	<b>64067</b>	<b>(87.3)</b>	<b>12807</b>	<b>(20.0)</b>	<b>11505</b>	<b>(18.0)</b>	<b>11205</b>	<b>(17.5)</b>	<b>73371</b>	<b>(41.4)</b>	<b>177156</b>
<b>Total European Region</b>	<b>83381</b>	<b>(84.2)</b>	<b>14305</b>	<b>(17.2)</b>	<b>12078</b>	<b>(14.5)</b>	<b>11712</b>	<b>(14.0)</b>	<b>99046</b>	<b>(46.5)</b>	<b>213160</b>
<b>Subtotal 18 HPC</b>	<b>67365</b>	<b>(82.4)</b>	<b>13475</b>	<b>(20.0)</b>	<b>11876</b>	<b>(17.6)</b>	<b>11547</b>	<b>(17.1)</b>	<b>81716</b>	<b>(43.3)</b>	<b>188792</b>

<sup>a</sup>European Region<sup>a</sup> comprises the 53 countries of the WHO European Region and Liechtenstein. WHO European Region 18 TB High Priority Countries presented in italics.

DST: Drug Susceptibility Testing

<sup>b</sup>Cases classified according to previous TB treatment history. From Belgium, Denmark, Ireland, Norway and United Kingdom previous diagnosis was reported instead and used as a proxy for previous treatment.

<sup>c</sup>Any resistance to isoniazid, rifampicin; expressed as a percentage of cases with DST results available at least for isoniazid and rifampicin.

<sup>d</sup>Percentage among new laboratory-confirmed pulmonary TB cases.

<sup>e</sup>Percentage among new laboratory-confirmed pulmonary TB cases with DST results.

<sup>f</sup>Percentage among new pulmonary TB cases with DST results.

<sup>g</sup>Excluding Greenland (see Chapter 1.1).

<sup>h</sup>In accordance with the UN Security Council Resolution No. 1244 (1999).

**Table 19: Anti-TB drug resistance among previously treated laboratory-confirmed pulmonary TB cases, European Region, 2011<sup>a</sup>**

Country	Cases resistant to at least <sup>b</sup> :								Previously treated laboratory-confirmed pulmonary TB cases		Total previously treated pulmonary TB cases
	Cases with DST results		Isoniazid		Rifampicin		Isoniazid and rifampicin (multidrug resistant)				
	N	(%) <sup>c</sup>	N	(%) <sup>d</sup>	N	(%) <sup>d</sup>	N	(%) <sup>d</sup>	N	(%) <sup>e</sup>	N
<b>EU/EEA</b>											
Austria	9	(81.8)	3	(33.3)	2	(22.2)	2	(22.2)	11	(64.7)	17
Belgium	31	(93.9)	5	(16.1)	4	(12.9)	4	(12.9)	33	(71.7)	46
<i>Bulgaria</i>	145	(76.3)	55	(37.9)	41	(28.3)	37	(25.5)	190	(63.3)	300
Cyprus	2	(100.0)	0	(0.0)	0	(0.0)	0	(0.0)	2	(66.7)	3
Czech Republic	15	(83.3)	1	(6.7)	2	(13.3)	1	(6.7)	18	(66.7)	27
Denmark <sup>f</sup>	12	(100.0)	0	(0.0)	0	(0.0)	0	(0.0)	12	(75.0)	16
Estonia	51	(96.2)	33	(64.7)	30	(58.8)	30	(58.8)	53	(71.6)	74
Finland	6	(100.0)	0	(0.0)	0	(0.0)	0	(0.0)	6	(54.5)	11
France	0	(0.0)	0	-	0	-	0	-	105	(50.5)	208
Germany	124	(91.9)	23	(18.5)	19	(15.3)	16	(12.9)	135	(56.5)	239
Greece	11	(57.9)	3	(27.3)	2	(18.2)	2	(18.2)	19	(57.6)	33
Hungary	68	(79.1)	8	(11.8)	6	(8.8)	5	(7.4)	86	(39.4)	218
Iceland	0	-	0	-	0	-	0	-	0	-	0
Ireland	14	(93.3)	3	(21.4)	1	(7.1)	1	(7.1)	15	(71.4)	21
Italy	0	(0.0)	0	-	0	-	0	-	31	(39.2)	79
Latvia	80	(88.9)	40	(50.0)	23	(28.8)	23	(28.8)	90	(96.8)	93
Liechtenstein	-	-	-	-	-	-	-	-	-	-	-
Lithuania	366	(100.0)	206	(56.3)	184	(50.3)	179	(48.9)	366	(100.0)	366
Luxembourg	1	(100.0)	0	(0.0)	0	(0.0)	0	(0.0)	1	(100.0)	1
Malta	0	-	0	-	0	-	0	-	0	(0.0)	2
Netherlands	17	(94.4)	1	(5.9)	1	(5.9)	1	(5.9)	18	(75.0)	24
Norway	16	(100.0)	0	(0.0)	0	(0.0)	0	(0.0)	16	(72.7)	22
Poland	570	(90.8)	44	(7.7)	21	(3.7)	18	(3.2)	628	(66.2)	948
Portugal	88	(75.9)	12	(13.6)	5	(5.7)	4	(4.5)	116	(69.0)	168
Romania	2171	(57.7)	592	(27.3)	452	(20.8)	413	(19.0)	3763	(83.3)	4517
Slovakia	29	(100.0)	4	(13.8)	1	(3.4)	1	(3.4)	29	(60.4)	48
Slovenia	10	(100.0)	1	(10.0)	0	(0.0)	0	(0.0)	10	(100.0)	10
Spain	0	(0.0)	0	-	0	-	0	-	220	(74.6)	295
Sweden	21	(100.0)	6	(28.6)	5	(23.8)	5	(23.8)	21	(67.7)	31
United Kingdom	165	(95.4)	22	(13.3)	12	7	11	(6.7)	173	(61.8)	280
<b>Subtotal EU/EEA</b>	<b>4022</b>	<b>(65.2)</b>	<b>1062</b>	<b>(26.4)</b>	<b>811</b>	<b>(20.2)</b>	<b>753</b>	<b>(18.7)</b>	<b>6167</b>	<b>(76.2)</b>	<b>8097</b>
<b>Non-EU/EEA</b>											
Albania	11	(100.0)	6	(54.5)	3	(27.3)	3	(27.3)	11	(122.2)	9
Andorra	0	-	0	-	0	-	0	-	0	-	0
Armenia	90	(100.0)	25	(27.8)	18	(20.0)	13	(14.4)	90	(62.1)	145
Azerbaijan	151	(90.4)	64	(42.4)	41	(27.2)	35	(23.2)	167	(7.9)	2124
Belarus	948	(99.0)	656	(69.2)	639	(67.4)	622	(65.6)	958	(98.0)	978
Bosnia and Herzegovina	41	(100.0)	5	(12.2)	4	(9.8)	4	(9.8)	41	(63.1)	65
Croatia	40	(100.0)	3	(7.5)	2	(5.0)	1	(2.5)	40	(69.0)	58
Georgia	675	(96.7)	297	(44.0)	223	(33.0)	214	(31.7)	698	(53.3)	1310
Israel	9	(100.0)	2	(22.2)	2	(22.2)	1	(11.1)	9	(100.0)	9
Kazakhstan	4790	(100.0)	2564	(53.5)	2486	(51.9)	2456	(51.3)	4790	(56.9)	8417
Kyrgyzstan	-	-	-	-	-	-	-	-	-	-	-
Macedonia, the former Yugoslav Republic of	25	(100.0)	2	(8.0)	4	(16.0)	1	(4.0)	25	(62.5)	40
Moldova	1006	(94.0)	711	(70.7)	652	(64.8)	642	(63.8)	1070	(74.4)	1439
Monaco	-	-	-	-	-	-	-	-	-	-	-
Montenegro	13	(100.0)	0	(0.0)	1	(7.7)	0	(0.0)	13	(68.4)	19
Russia	13620	(89.3)	7189	(52.8)	7189	(52.8)	7189	(52.8)	15259	(35.9)	42478
San Marino											
Serbia	100	(95.2)	7	(7.0)	6	(6.0)	6	(6.0)	105	(86.1)	122
Serbia excluding UN Administered Province of Kosovo <sup>g</sup>	100	(95.2)	7	(7.0)	6	(6.0)	6	(6.0)	105	(86.1)	122
UN Administered Province of Kosovo <sup>g</sup>	-	-	-	-	-	-	-	-	-	-	-
Switzerland	40	(88.9)	7	(17.5)	4	(10.0)	4	(10.0)	45	(83.3)	54
Tajikistan	415	(67.7)	319	(76.9)	314	(75.7)	308	(74.2)	613	(95.8)	640
Turkey	602	(100.0)	186	(30.9)	168	(27.9)	146	(24.3)	602	(57.0)	1057
Turkmenistan	-	-	-	-	-	-	-	-	-	-	-
Ukraine	4413	(69.1)	2406	(54.5)	2377	(53.9)	2283	(51.7)	6388	(55.6)	11488
Uzbekistan	123	(27.0)	113	(91.9)	99	(80.5)	89	(72.4)	455	(46.6)	977
<b>Subtotal non-EU/EEA</b>	<b>27112</b>	<b>(86.4)</b>	<b>14562</b>	<b>(53.7)</b>	<b>14232</b>	<b>(52.5)</b>	<b>14017</b>	<b>(51.7)</b>	<b>31379</b>	<b>(43.9)</b>	<b>71438</b>
<b>Total European Region</b>	<b>31134</b>	<b>(82.9)</b>	<b>15624</b>	<b>(50.2)</b>	<b>15043</b>	<b>(48.3)</b>	<b>14770</b>	<b>(47.4)</b>	<b>37546</b>	<b>(47.2)</b>	<b>79535</b>
<b>Subtotal 18 HPC</b>	<b>29646</b>	<b>(83.4)</b>	<b>15456</b>	<b>(52.1)</b>	<b>14936</b>	<b>(50.4)</b>	<b>14679</b>	<b>(49.5)</b>	<b>35552</b>	<b>(46.5)</b>	<b>76403</b>

<sup>a</sup> 'European Region' comprises the 53 countries of the WHO European Region and Liechtenstein.

WHO European Region 18 TB High Priority Countries presented in italics.

DST: Drug Susceptibility Testing<sup>h</sup>

<sup>b</sup> Cases classified according to previous TB treatment history. From Belgium, Denmark, Ireland, Norway and United Kingdom previous diagnosis was reported instead and used as a proxy for previous treatment.

<sup>c</sup> Any resistance to isoniazid, rifampicin; expressed as a percentage of cases with DST results available at least for isoniazid and rifampicin.

<sup>d</sup> Percentage among previously treated laboratory-confirmed pulmonary TB cases.

<sup>e</sup> Percentage among previously treated laboratory-confirmed pulmonary TB cases with DST results.

<sup>f</sup> Excluding Greenland (see Chapter 1.1).

<sup>g</sup> In accordance with the UN Security Council Resolution No. 1244 (1999).

**Table 20: Number and proportion of notified XDR-TB cases among MDR-TB cases with second-line drug susceptibility testing, European Region, 2009–2011**

Country	2009						2010						
	Total laboratory-confirmed with FLD DST (N) <sup>a</sup>	Total MDR-TB		Total MDR with SLD DST (N)	Total XDR-TB		Total laboratory-confirmed with FLD DST (N) <sup>a</sup>	Total MDR-TB		Total MDR with SLD DST (N)	Total XDR-TB		
		N	(%)		N	(%)		N	(%)		N	(%)	
<b>EU/EEA</b>													
Austria	436	23	(5.3)	21	2	(9.5)	474	16	(3.4)	16	1	(6.3)	
Belgium	760	10	(1.3)	10	3	(30.0)	822	19	(2.3)	19	2	(10.5)	
Bulgaria	845	43	(5.1)	24	1	(4.2)	968	56	(5.8)	35	1	(2.9)	
Cyprus	31	4	(12.9)	2	0	(0.0)	-	-	-	-	-	-	
Czech Republic	452	8	(1.8)	7	1	(14.3)	419	9	(2.1)	4	1	(25.0)	
Denmark <sup>b</sup>	241	2	(0.8)	2	0	(0.0)	283	2	(0.7)	2	0	(0.0)	
Estonia	304	85	(28.0)	79	8	(10.1)	262	65	(24.8)	61	10	(16.4)	
Finland	-	-	-	-	-	-	-	-	-	-	-	-	
France	-	-	-	-	-	-	-	-	-	-	-	-	
Germany	-	-	-	-	-	-	-	-	-	-	-	-	
Greece	169	12	(7.1)	11	2		93	2	(2.2)	2	0	(0.0)	
Hungary	-	-	-	-	-	-	570	19	(3.3)	18	2	(11.1)	
Iceland	-	-	-	-	-	-	-	-	-	-	-	-	
Ireland	-	-	-	-	-	-	-	-	-	-	-	-	
Italy	2511	82	(3.3)	32	1	(3.1)	2597	87	(3.4)	10	0	(0.0)	
Latvia	752	131	(17.4)	130	16	(12.3)	716	88	(12.3)	87	13	(14.9)	
Liechtenstein	-	-	-	-	-	-	-	-	-	-	-	-	
Lithuania	1478	322	(21.8)	4	4	(100.0)	1363	310	(22.7)	310	50	(16.1)	
Luxembourg	-	-	-	-	-	-	-	-	-	-	-	-	
Malta	-	-	-	-	-	-	16	1	(6.3)	1	0	(0.0)	
Netherlands	-	-	-	-	-	-	-	-	-	-	-	-	
Norway	283	8	(2.8)	4	0	(0.0)	275	8	(2.9)	8	0	(0.0)	
Poland	3858	21	(0.5)	5	1	(20.0)	3706	30	(0.8)	12	1	(8.3)	
Portugal	-	-	-	-	-	-	-	-	-	-	-	-	
Romania	6266	624	(10.0)	217	26	(12.0)	6129	574	(9.4)	215	27	(12.6)	
Slovakia	235	1	(0.4)	1	0	(0.0)	234	1	(0.4)	1	0	(0.0)	
Slovenia	-	-	-	-	-	-	-	-	-	-	-	-	
Spain	1750	56	(3.2)	-	5	-	1416	49	(3.5)	49	3	(6.1)	
Sweden	515	13	(2.5)	13	0	(0.0)	-	-	-	-	-	-	
United Kingdom	4955	60	(1.2)	52	1	(1.9)	4603	60	(1.3)	57	3	(5.3)	
<b>Subtotal EU/EEA</b>	<b>25841</b>	<b>1505</b>	<b>(5.8)</b>	<b>614</b>	<b>71</b>	<b>(11.6)</b>	<b>24946</b>	<b>1396</b>	<b>(5.6)</b>	<b>907</b>	<b>114</b>	<b>(12.6)</b>	
<b>Non-EU/EEA</b>													
Albania	128	0	(0.0)	-	-	-	205	2	(1.0)	2	0	(0.0)	
Andorra	3	0	(0.0)	-	-	-	-	-	-	-	-	-	
Armenia	680	156	(22.9)	-	-	-	691	177	(25.6)	177	21	(11.9)	
Azerbaijan	0	0	-	-	-	-	-	-	-	-	-	-	
Belarus	3985	1342	(33.7)	-	-	-	-	-	-	-	-	-	
Bosnia and Herzegovina	920	2	(0.2)	-	-	-	-	-	-	-	-	-	
Croatia	517	7	(1.4)	-	-	-	-	-	-	-	-	-	
Georgia	2372	369	(15.6)	306	32	(10.5)	2545	359	(14.1)	313	30	(9.6)	
Israel	266	6	(2.3)	6	0	(0.0)	247	12	(4.9)	12	1	(8.3)	
Kazakhstan	9578	3644	(38.0)	282	216	(76.6)	-	-	-	0	-	-	
Kyrgyzstan	1930	785	(40.7)	-	-	-	941	489	(52.0)	32	32	(100.0)	
Macedonia, the former Yugoslav Republic of	219	1	(0.5)	0	0	-	181	7	(3.9)	5	1	(20.0)	
Moldova	2413	1069	(44.3)	0	0	-	-	-	-	-	-	-	
Monaco	0	0	-	0	0	-	-	-	-	-	-	-	
Montenegro	89	1	(1.1)	1	0	(0.0)	-	-	-	-	-	-	
Russia	58716	14 686	(25.0)	-	-	-	-	-	-	-	-	-	
San Marino	-	-	-	-	-	-	0	0	-	-	-	-	
Serbia	-	-	-	-	-	-	-	-	-	-	-	-	
Serbia excluding UN Administered Province of Kosovo <sup>c</sup>	-	-	-	-	-	-	-	-	-	-	-	-	
UN Administered Province of Kosovo <sup>c</sup>	-	-	-	-	-	-	-	-	-	-	-	-	
Switzerland	453	5	(1.1)	-	-	-	454	9	(2.0)	9	0	(0.0)	
Tajikistan	1413	319	(22.6)	52	11	(21.2)	-	-	-	-	-	-	
Turkey	4313	222	(5.1)	0	0		4957	250	(5.0)	5	3	(60.0)	
Turkmenistan	275	39	(14.2)	0	0		-	-	-	-	-	-	
Ukraine	18355	3482	(19.0)	0	0		-	-	-	-	-	-	
Uzbekistan	1303	654	(50.2)	58	13	(22.4)	4025	1023	(25.4)	364	16	(4.4)	
<b>Subtotal non-EU/EEA</b>	<b>107928</b>	<b>26789</b>	<b>(24.8)</b>	<b>705</b>	<b>272</b>	<b>(38.6)</b>	<b>14246</b>	<b>2328</b>	<b>(16.3)</b>	<b>919</b>	<b>104</b>	<b>(11.3)</b>	
<b>Total European Region</b>	<b>133769</b>	<b>28294</b>	<b>(21.2)</b>	<b>1319</b>	<b>343</b>	<b>(26.0)</b>	<b>39192</b>	<b>3724</b>	<b>(9.5)</b>	<b>1826</b>	<b>218</b>	<b>(11.9)</b>	
<b>Subtotal 18 HPC</b>	<b>114978</b>	<b>27972</b>	<b>(24.3)</b>	<b>1152</b>	<b>327</b>	<b>(28.4)</b>	<b>22597</b>	<b>3391</b>	<b>(15.0)</b>	<b>1599</b>	<b>203</b>	<b>(12.7)</b>	

<sup>a</sup> 'European Region' comprises the 53 countries of the WHO European Region and Liechtenstein.

WHO European Region TB High Priority Countries presented in *italics*.

FLD DST - drug susceptibility testing for first line TB drugs, SLD DST - drug susceptibility testing for second line TB drugs.

<sup>b</sup> Includes only countries reporting second-line anti-TB drug susceptibility testing.

<sup>c</sup> Excluding Greenland (see Chapter 1.1).

<sup>d</sup> In accordance with the UN Security Council Resolution No. 1244 (1999).



	2011					
	Total laboratory-confirmed with FLD DST (N) <sup>a</sup>	Total MDR-TB		Total MDR with SLD DST (N)	Total XDR-TB	
		N	(%)		N	(%)
	450	19	(4.2)	19	6	(31.6)
	754	15	(2.0)	15	3	(20.0)
	733	55	(7.5)	46	0	(0.0)
	40	1	(2.5)	1	0	(0.0)
	408	7	(1.7)	5	2	(40.0)
	271	3	(1.1)	2	0	(0.0)
	262	78	(29.8)	75	14	(18.7)
	-	-	-	-	-	-
	-	-	-	-	-	-
	2821	56	(2.0)	2	0	(0.0)
	159	5	(3.1)	5	2	(40.0)
	479	7	(1.5)	5	0	(0.0)
	-	-	-	-	-	-
	239	3	(1.3)	1	0	(0.0)
	2542	81	(3.2)	50	6	(12.0)
	644	95	(14.8)	95	12	(12.6)
	-	-	-	-	-	-
	1403	296	(21.1)	295	53	(18.0)
	-	-	-	-	-	-
	-	-	-	-	-	-
	257	4	(1.6)	4	0	(0.0)
	4993	41	(0.8)	9	1	(11.1)
	-	-	-	-	-	-
	6026	530	(8.8)	248	30	(12.1)
	185	3	(1.6)	3	0	(0.0)
	-	-	-	-	-	-
	1273	41	(3.2)	41	1	(2.4)
	475	17	(3.6)	17	0	(0.0)
	5127	81	(1.6)	79	6	(7.6)
	<b>29541</b>	<b>1438</b>	<b>(4.9)</b>	<b>1017</b>	<b>136</b>	<b>(13.4)</b>
	-	-	-	-	-	-
	-	-	-	-	-	-
	529	79	(14.9)	79	0	(0.0)
	720	90	(12.5)	84	3	(3.6)
	-	-	-	-	-	-
	745	5	(0.7)	5	0	(0.0)
	-	-	-	-	-	-
	2872	453	(15.8)	440	28	(6.4)
	284	11	(3.9)	11	0	(0.0)
	11555	4575	(39.6)	825	187	(22.7)
	-	-	-	-	-	-
	-	-	-	-	-	-
	-	-	-	-	-	-
	72	1	(1.4)	1	0	(0.0)
	-	-	-	-	-	-
	966	9	(1.0)	9	2	(22.2)
	966	9	(0.9)	9	2	(22.2)
	-	-	-	-	-	-
	454	8	(1.8)	8	0	(0.0)
	576	380	(66.0)	122	12	(9.8)
	4823	262	(5.4)	13	1	(7.7)
	-	-	-	-	-	-
	-	-	-	-	-	-
	2217	1385	(62.5)	834	12	(1.4)
	<b>25813</b>	<b>7258</b>	<b>(28.1)</b>	<b>2431</b>	<b>245</b>	<b>(10.1)</b>
	<b>55354</b>	<b>8696</b>	<b>(15.7)</b>	<b>3448</b>	<b>381</b>	<b>(11.0)</b>
	<b>32360</b>	<b>8278</b>	<b>(25.6)</b>	<b>3156</b>	<b>352</b>	<b>(11.2)</b>

**Table 21: Anti-TB drug resistance among all TB cases by origin, EU/EEA, 2011<sup>a</sup>**

Country	Criterion	Native								
		All native TB cases (N)	Cases with DST results (N)		Cases resistant to at least:					
			N	(%) <sup>b</sup>	Isoniazid		Rifampicin		Isoniazid and rifampicin (multidrug resistant)	
				N	(%) <sup>c</sup>	N	(%) <sup>c</sup>	N	(%) <sup>c</sup>	
Austria	citizenship	354	232	(65.5)	11	(4.7)	2	(0.9)	0	(0.0)
Belgium	citizenship	500	345	(69.0)	15	(4.3)	0	(0.0)	0	(0.0)
<i>Bulgaria</i>	<i>birthplace</i>	<i>2398</i>	<i>732</i>	<i>(30.5)</i>	<i>98</i>	<i>(13.4)</i>	<i>65</i>	<i>(8.9)</i>	<i>55</i>	<i>(7.5)</i>
Cyprus	birthplace	9	7	(77.8)	0	(0.0)	0	(0.0)	0	(0.0)
Czech Republic	birthplace	488	327	(67.0)	2	(0.6)	7	(2.1)	2	(0.6)
Denmark <sup>f</sup>	birthplace	146	104	(71.2)	2	(1.9)	0	(0.0)	0	(0.0)
<i>Estonia</i>	<i>birthplace</i>	<i>293</i>	<i>231</i>	<i>(78.8)</i>	<i>86</i>	<i>(37.2)</i>	<i>71</i>	<i>(30.7)</i>	<i>70</i>	<i>(30.3)</i>
Finland	birthplace	212	151	(71.2)	6	(4.0)	2	(1.3)	2	(1.3)
France	birthplace	-	-	-	-	-	-	-	-	-
Germany	birthplace	2100	1367	(65.1)	43	(3.1)	12	(0.9)	8	(0.6)
Greece	citizenship	273	69	(25.3)	4	(5.8)	1	(1.4)	0	(0.0)
Hungary	citizenship	1418	469	(33.1)	29	(6.2)	7	(1.5)	6	(1.3)
Iceland	birthplace	2	0	(0.0)	0	-	0	-	0	-
Ireland	birthplace	189	101	(53.4)	3	(3.0)	0	(0.0)	0	(0.0)
Italy	birthplace	1578	899	(57.0)	55	(6.1)	19	(2.1)	13	(1.4)
<i>Latvia</i>	<i>birthplace</i>	<i>817</i>	<i>599</i>	<i>(73.3)</i>	<i>188</i>	<i>(31.4)</i>	<i>90</i>	<i>(15.0)</i>	<i>89</i>	<i>(14.9)</i>
Liechtenstein	-	-	-	-	-	-	-	-	-	-
<i>Lithuania</i>	<i>birthplace</i>	<i>1860</i>	<i>1369</i>	<i>(73.6)</i>	<i>431</i>	<i>(31.5)</i>	<i>296</i>	<i>(21.6)</i>	<i>286</i>	<i>(20.9)</i>
Luxembourg	birthplace	5	4	(80.0)	0	(0.0)	0	(0.0)	0	(0.0)
Malta	birthplace	5	3	(60.0)	0	(0.0)	0	(0.0)	0	(0.0)
Netherlands	birthplace	292	192	(65.8)	10	(5.2)	0	(0.0)	0	(0.0)
Norway	birthplace	44	22	(50.0)	0	(0.0)	0	(0.0)	0	(0.0)
Poland	citizenship	8440	4967	(58.9)	183	(3.7)	48	(1.0)	40	(0.8)
Portugal	birthplace	2151	1068	(49.7)	82	(7.7)	14	(1.3)	12	(1.1)
<i>Romania</i>	<i>birthplace</i>	<i>19162</i>	<i>6019</i>	<i>(31.4)</i>	<i>866</i>	<i>(14.4)</i>	<i>596</i>	<i>(9.9)</i>	<i>529</i>	<i>(8.8)</i>
Slovakia	birthplace	396	184	(46.5)	9	(4.9)	4	(2.2)	3	(1.6)
Slovenia	birthplace	135	125	(92.6)	1	(0.8)	0	(0.0)	0	(0.0)
Spain	birthplace	-	-	-	-	-	-	-	-	-
Sweden	birthplace	62	44	(71.0)	6	(13.6)	0	(0.0)	0	(0.0)
United Kingdom	birthplace	2226	1187	(53.3)	72	(6.1)	6	(0.5)	4	(0.3)
<b>Total EU/EEA</b>		<b>45555</b>	<b>20817</b>	<b>(45.7)</b>	<b>2202</b>	<b>(10.6)</b>	<b>1240</b>	<b>(6.0)</b>	<b>1119</b>	<b>(5.4)</b>

WHO European Region TB High Priority Countries presented in italics.

DST: Drug Susceptibility Testing

<sup>a</sup> Cases with unknown origin are not included.<sup>b</sup> Percentage among all native TB cases.<sup>c</sup> Percentage among all native TB cases with DST results.<sup>d</sup> Percentage among all foreign-origin TB cases.<sup>e</sup> Percentage among all foreign-origin TB cases with DST results.<sup>f</sup> Excluding Greenland (see Chapter 1.1).

	Foreign-origin								
	All foreign TB cases (N)	Cases with DST results (N)		Cases resistant to at least:					
				Isoniazid		Rifampicin		Isoniazid and rifampicin (multidrug resistant)	
		N	(%) <sup>d</sup>	N	(%) <sup>d</sup>	N	(%) <sup>e</sup>	N	(%) <sup>e</sup>
	326	213	(65.3)	37	(17.4)	19	(8.9)	19	(8.9)
	544	409	(75.2)	35	(8.6)	17	(4.2)	15	(3.7)
	9	1	(11.1)	0	(0.0)	0	(0.0)	0	(0.0)
	45	33	(73.3)	3	(9.1)	1	(3.0)	1	(3.0)
	112	81	(72.3)	10	(12.3)	6	(7.4)	5	(6.2)
	235	167	(71.1)	11	(6.6)	3	(1.8)	3	(1.8)
	48	31	(64.6)	11	(35.5)	8	(25.8)	8	(25.8)
	79	68	(86.1)	9	(13.2)	3	(4.4)	3	(4.4)
	-	-	-	-	-	-	-	-	-
	2025	1404	(69.3)	158	(11.3)	51	(3.6)	48	(3.4)
	216	90	(41.7)	16	(17.8)	5	(5.6)	5	(5.6)
	27	10	(37.0)	1	(10.0)	1	(10.0)	1	(10.0)
	7	4	(57.1)	0	(0.0)	0	(0.0)	0	(0.0)
	179	119	(66.5)	10	(8.4)	2	(1.7)	2	(1.7)
	1677	1612	(96.1)	189	(11.7)	79	(4.9)	68	(4.2)
	59	45	(76.3)	15	(33.3)	6	(13.3)	6	(13.3)
	-	-	-	-	-	-	-	-	-
	44	34	(77.3)	15	(44.1)	10	(29.4)	10	(29.4)
	21	15	(71.4)	3	(20.0)	2	(13.3)	2	(13.3)
	28	19	(67.9)	1	(5.3)	0	(0.0)	0	(0.0)
	710	532	(74.9)	51	(9.6)	16	(3.0)	15	(2.8)
	317	235	(74.1)	20	(8.5)	4	(1.7)	4	(1.7)
	38	26	(68.4)	2	(7.7)	1	(3.8)	1	(3.8)
	385	184	(47.8)	16	(8.7)	10	(5.4)	10	(5.4)
	50	7	(14.0)	1	(14.3)	1	(14.3)	1	(14.3)
	3	1	(33.3)	0	(0.0)	0	(0.0)	0	(0.0)
	57	57	(100.0)	2	(3.5)	0	(0.0)	0	(0.0)
	-	-	-	-	-	-	-	-	-
	524	431	(82.3)	53	(12.3)	19	(4.4)	17	(3.9)
	6287	3689	(58.7)	295	(8.0)	82	(2.2)	76	(2.1)
	<b>14052</b>	<b>9517</b>	<b>(67.7)</b>	<b>964</b>	<b>(10.1)</b>	<b>346</b>	<b>(3.6)</b>	<b>320</b>	<b>(3.4)</b>

Table 22: Tuberculosis cases with HIV infection, European Region, 2011

Country	All TB cases (N)	Cases with known HIV status		HIV positive	
		N	(%)	N	(%) <sup>a</sup>
<b>EU/EEA</b>					
Austria	-	-	-	-	-
Belgium	1044	845	(80.9)	44	(5.2)
Bulgaria	2407	1698	(70.5)	5	(0.3)
Cyprus <sup>b</sup>	-	-	-	-	-
Czech Republic	600	153	(25.5)	4	(2.6)
Denmark <sup>b,c</sup>	-	-	-	-	-
Estonia	341	313	(91.8)	47	(15.0)
Finland <sup>c</sup>	-	-	-	-	-
France	4942	1354	(27.4)	95	(7.0)
Germany	-	-	-	-	-
Greece	-	-	-	-	-
Hungary <sup>b</sup>	-	-	-	-	-
Iceland	9	8	(88.9)	0	(0.0)
Ireland	425	94	(22.1)	19	(20.2)
Italy	-	-	-	-	-
Latvia	885	752	(85.0)	71	(9.4)
Liechtenstein	-	-	-	-	-
Lithuania	1904	1352	(71.0)	22	(1.6)
Luxembourg	26	5	(19.2)	2	(40.0)
Malta	33	30	(90.9)	5	(16.7)
Netherlands	1007	460	(45.7)	31	(6.7)
Norway	-	-	-	-	-
Poland <sup>b</sup>	-	-	-	-	-
Portugal	-	-	-	-	-
Romania	19212	9383	(48.8)	243	(2.6)
Slovakia	399	395	(99.0)	0	(0.0)
Slovenia	192	147	(76.6)	0	(0.0)
Spain	6762	4541	(67.2)	415	(9.1)
Sweden	-	-	-	-	-
United Kingdom	-	-	-	-	-
<b>Subtotal EU/EEA</b>	<b>40 188</b>	<b>21530</b>	<b>(53.6)</b>	<b>1003</b>	<b>(4.7)</b>
<b>Non-EU/EEA</b>					
Albania	431	170	(39.4)	2	(1.2)
Andorra	-	-	-	-	-
Armenia	1582	1499	(94.8)	49	(3.3)
Azerbaijan	9805	6179	(63.0)	76	(1.2)
Belarus	5118	4747	(92.8)	217	(4.6)
Bosnia and Herzegovina	-	-	-	-	-
Croatia	-	-	-	-	-
Georgia	5533	2550	(46.1)	50	(2.0)
Israel	418	384	(91.9)	24	(6.3)
Kazakhstan	26211	22480	(85.8)	352	(1.6)
Kyrgyzstan	6666	153	(2.3)	0	(0.0)
Macedonia, the former Yugoslav Republic of	362	45	(12.4)	0	(0.0)
Moldova	5341	5017	(93.9)	285	(5.7)
Monaco	0	0	-	0	-
Montenegro	112	92	(82.1)	0	(0.0)
Russia	159479	79494	(49.8)	4104	(5.2)
San Marino	-	-	-	-	-
Serbia	1341	67	(5.0)	6	(9.0)
Serbia excluding UN Administered Province of Kosovo <sup>d</sup>	1341	67	(5.0)	6	(9.0)
UN Administered Province of Kosovo <sup>d</sup>	-	-	-	-	-
Switzerland	-	-	-	-	-
Tajikistan	7609	6241	(82.0)	115	(1.8)
Turkey	15679	7241	(46.2)	29	(0.4)
Turkmenistan	-	-	-	-	-
Ukraine	42676	31776	(74.5)	5893	(18.5)
Uzbekistan	15913	15913	(100.0)	546	(3.4)
<b>Subtotal non-EU/EEA</b>	<b>304571</b>	<b>184048</b>	<b>(60.4)</b>	<b>11748</b>	<b>(6.4)</b>
<b>Total European Region</b>	<b>344759</b>	<b>205578</b>	<b>(59.6)</b>	<b>12751</b>	<b>(6.2)</b>
<b>Subtotal 18 HPC</b>	<b>326656</b>	<b>196788</b>	<b>(60.2)</b>	<b>12104</b>	<b>(6.2)</b>

<sup>a</sup> 'European Region' comprises the 53 countries of the WHO European Region and Liechtenstein. WHO European Region TB High Priority Countries presented in italics.

Case-based reporting of HIV-coinfection highlighted.

<sup>b</sup> % of HIV-positive cases were calculated if total cases tested for HIV was provided.

<sup>c</sup> Cyprus, Denmark, Finland, Hungary and Poland reported HIV positive cases, but not the number of tested cases for HIV and are therefore excluded from the current analysis.

<sup>d</sup> Excluding Greenland (see Chapter 1.1).

<sup>e</sup> In accordance with the UN Security Council Resolution No. 1244 (1999).

**Table 23: Treatment outcome of new laboratory-confirmed pulmonary TB cases after 12 months, European Region, 2010**

Country	Cases notified in 2010	Success		Died		Failed		Defaulted		Still on treatment		Transferred or unknown	
		N	(%)	N	(%)	N	(%)	N	(%)	N	(%)	N	(%)
<b>EU/EEA<sup>a</sup></b>													
Austria	206	133	(64.6)	13	(6.3)	0	(0.0)	13	(6.3)	31	(15.0)	16	(7.8)
Belgium	474	357	(75.3)	33	(7.0)	0	(0.0)	53	(11.2)	16	(3.4)	15	(3.2)
Bulgaria	946	816	(86.3)	75	(7.9)	15	(1.6)	29	(3.1)	10	(1.1)	1	(0.1)
Cyprus	20	5	(25.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	15	(75.0)
Czech Republic	361	249	(69.0)	61	(16.9)	0	(0.0)	24	(6.6)	14	(3.9)	13	(3.6)
Denmark <sup>b,c</sup>	218	141	(64.7)	23	(10.6)	5	(2.3)	1	(0.5)	7	(3.2)	41	(18.8)
Estonia	192	129	(67.2)	20	(10.4)	3	(1.6)	7	(3.6)	33	(17.2)	0	(0.0)
Finland	185	138	(74.6)	16	(8.6)	0	(0.0)	4	(2.2)	10	(5.4)	17	(9.2)
France	-	-	-	-	-	-	-	-	-	-	-	-	-
Germany	2090	1600	(76.6)	256	(12.2)	3	(0.1)	33	(1.6)	54	(2.6)	144	(6.9)
Greece	-	-	-	-	-	-	-	-	-	-	-	-	-
Hungary	515	355	(68.9)	64	(12.4)	0	(0.0)	51	(9.9)	27	(5.2)	18	(3.5)
Iceland	16	14	(87.5)	1	(6.3)	0	(0.0)	0	(0.0)	0	(0.0)	1	(6.3)
Ireland <sup>b</sup>	164	119	(72.6)	12	(7.3)	0	(0.0)	2	(1.2)	2	(1.2)	29	(17.7)
Italy	-	-	-	-	-	-	-	-	-	-	-	-	-
Latvia	596	451	(75.7)	47	(7.9)	3	(0.5)	37	(6.2)	58	(9.7)	0	(0.0)
Liechtenstein	-	-	-	-	-	-	-	-	-	-	-	-	-
Lithuania	959	656	(68.4)	107	(11.2)	13	(1.4)	104	(10.8)	75	(7.8)	4	(0.4)
Luxembourg	14	0	(0.0)	1	(7.1)	0	(0.0)	0	(0.0)	0	(0.0)	13	(92.9)
Malta	5	4	(80.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	1	(20.0)
Netherlands	470	365	(77.7)	31	(6.6)	0	(0.0)	19	(4.0)	18	(3.8)	37	(7.9)
Norway <sup>b</sup>	139	127	(91.4)	4	(2.9)	1	(0.7)	0	(0.0)	5	(3.6)	2	(1.4)
Poland	3998	2631	(65.8)	242	(6.1)	10	(0.3)	354	(8.9)	15	(0.4)	746	(18.7)
Portugal	-	-	-	-	-	-	-	-	-	-	-	-	-
Romania	9445	7916	(83.8)	441	(4.7)	379	(4.0)	538	(5.7)	171	(1.8)	0	(0.0)
Slovakia	177	149	(84.2)	22	(12.4)	0	(0.0)	5	(2.8)	0	(0.0)	1	(0.6)
Slovenia	121	104	(86.0)	12	(9.9)	0	(0.0)	1	(0.8)	2	(1.7)	2	(1.7)
Spain	3574	2516	(70.4)	211	(5.9)	5	(0.1)	27	(0.8)	31	(0.9)	784	(21.9)
Sweden	289	246	(85.1)	14	(4.8)	1	(0.3)	2	(0.7)	17	(5.9)	9	(3.1)
United Kingdom <sup>b</sup>	2603	2106	(80.9)	135	(5.2)	0	(0.0)	154	(5.9)	118	(4.5)	90	(3.5)
<b>Subtotal EU/EEA</b>	<b>27777</b>	<b>21327</b>	<b>(76.8)</b>	<b>1841</b>	<b>(6.6)</b>	<b>438</b>	<b>(1.6)</b>	<b>1458</b>	<b>(5.3)</b>	<b>714</b>	<b>(2.6)</b>	<b>1999</b>	<b>(7.2)</b>
<b>Non-EU/EEA<sup>a</sup></b>													
Albania	145	132	(91.0)	4	(2.8)	0	(0.0)	4	(2.8)	-	-	5	(3.4)
Andorra	-	-	-	-	-	-	-	-	-	-	-	-	-
Armenia	339	243	(71.7)	15	(4.4)	51	(15.0)	27	(8.0)	-	-	3	(0.9)
Azerbaijan	1919	1470	(76.6)	64	(3.3)	86	(4.5)	188	(9.8)	-	-	111	(5.8)
Belarus	2184	1447	(66.3)	183	(8.4)	491	(22.5)	12	(0.5)	-	-	51	(2.3)
Bosnia and Herzegovina	441	434	(98.4)	5	(1.1)	1	(0.2)	1	(0.2)	-	-	0	(0.0)
Croatia	181	136	(75.1)	25	(13.8)	0	(0.0)	7	(3.9)	-	-	13	(7.2)
Georgia	2500	1908	(76.3)	70	(2.8)	289	(11.6)	173	(6.9)	-	-	60	(2.4)
Israel	99	75	(75.8)	11	(11.1)	0	(0.0)	0	(0.0)	-	-	13	(13.1)
Kazakhstan	4919	2995	(60.9)	158	(3.2)	329	(6.7)	116	(2.4)	-	-	1321	(26.9)
Kyrgyzstan	-	-	-	-	-	-	-	-	-	-	-	-	-
Macedonia, the former Yugoslav Republic of	143	128	(89.5)	6	(4.2)	4	(2.8)	3	(2.1)	-	-	2	(1.4)
Moldova	1267	724	(57.1)	145	(11.4)	67	(5.3)	166	(13.1)	-	-	165	(13.0)
Monaco	-	-	-	-	-	-	-	-	-	-	-	-	-
Montenegro	39	34	(87.2)	2	(5.1)	0	(0.0)	1	(2.6)	-	-	2	(5.1)
Russia	30123	15984	(53.1)	3531	(11.7)	6970	(23.1)	2131	(7.1)	-	-	1507	(5.0)
San Marino	-	-	-	-	-	-	-	-	-	-	-	-	-
Serbia	702	602	(85.8)	48	(6.8)	7	(1.0)	31	(4.4)	-	-	14	(2.0)
Serbia excluding UN Administered Province of Kosovo <sup>e</sup>	702	602	(85.8)	48	(6.8)	7	(1.0)	31	(4.4)	-	-	14	(2.0)
UN Administered Province of Kosovo <sup>e</sup>	-	-	-	-	-	-	-	-	-	-	-	-	-
Switzerland	-	-	-	-	-	-	-	-	-	-	-	-	-
Tajikistan	2290	1834	(80.1)	111	(4.8)	246	(10.7)	72	(3.1)	-	-	27	(1.2)
Turkey	5375	4905	(91.3)	165	(3.1)	40	(0.7)	136	(2.5)	-	-	129	(2.4)
Turkmenistan	-	-	-	-	-	-	-	-	-	-	-	-	-
Ukraine	13279	7935	(59.8)	1665	(12.5)	2212	(16.7)	1009	(7.6)	-	-	458	(3.4)
Uzbekistan	4711	3819	(81.1)	272	(5.8)	276	(5.9)	215	(4.6)	-	-	129	(2.7)
<b>Subtotal non-EU/EEA</b>	<b>70656</b>	<b>44805</b>	<b>(63.4)</b>	<b>6480</b>	<b>(9.2)</b>	<b>11069</b>	<b>(15.7)</b>	<b>4292</b>	<b>(6.1)</b>	-	-	<b>4010</b>	<b>(5.7)</b>
<b>Total European Region</b>	<b>98433</b>	<b>66132</b>	<b>(67.2)</b>	<b>8321</b>	<b>(8.5)</b>	<b>11507</b>	<b>(11.7)</b>	<b>5750</b>	<b>(5.8)</b>	<b>714</b>	<b>(0.7)</b>	<b>6009</b>	<b>(6.1)</b>
<b>Subtotal 18 HPC</b>	<b>81044</b>	<b>53232</b>	<b>(65.7)</b>	<b>7069</b>	<b>(8.7)</b>	<b>11470</b>	<b>(14.2)</b>	<b>4960</b>	<b>(6.1)</b>	<b>347</b>	<b>(0.4)</b>	<b>3966</b>	<b>(4.9)</b>

<sup>a</sup> 'European Region' comprises the 53 countries of the WHO European Region and Liechtenstein.

WHO European Region 18 TB High Priority Countries presented in italics.

<sup>b</sup> For EU/EEA countries: new pulmonary confirmed cases.

<sup>c</sup> Not previously diagnosed cases.

<sup>d</sup> Excluding Greenland (see Chapter 1.1).

<sup>e</sup> For non-EU/EEA countries: new pulmonary smear-positive (and/or culture-positive) cases.

<sup>f</sup> In accordance with the UN Security Council Resolution No. 1244 (1999).

**Table 24:** Treatment outcome of previously treated laboratory-confirmed pulmonary TB cases, European Region, 2010

Country	Cases notified in 2010	Success		Died		Failed		Defaulted		Still on treatment		Transferred or unknown	
		N	(%)	N	(%)	N	(%)	N	(%)	N	(%)	N	(%)
<b>EU/EEA<sup>a</sup></b>													
Austria	15	9	(60.0)	0	(0.0)	0	(0.0)	0	(0.0)	5	(33.3)	1	(6.7)
Belgium <sup>b</sup>	51	32	(62.7)	3	(5.9)	0	(0.0)	5	(9.8)	8	(15.7)	3	(5.9)
Bulgaria	196	101	(51.5)	29	(14.8)	19	(9.7)	29	(14.8)	16	(8.2)	2	(1.0)
Cyprus	0	0	-	0	-	0	-	0	-	0	-	0	-
Czech Republic	30	20	(66.7)	5	(16.7)	0	(0.0)	0	(0.0)	3	(10.0)	2	(6.7)
Denmark <sup>b,c</sup>	26	16	(61.5)	4	(15.4)	1	(3.8)	0	(0.0)	0	(0.0)	5	(19.2)
Estonia	60	24	(40.0)	5	(8.3)	2	(3.3)	7	(11.7)	22	(36.7)	0	(0.0)
Finland	7	6	(85.7)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	1	(14.3)
France	-	-	-	-	-	-	-	-	-	-	-	-	-
Germany	185	131	(70.8)	28	(15.1)	1	(0.5)	9	(4.9)	5	(2.7)	11	(5.9)
Greece	-	-	-	-	-	-	-	-	-	-	-	-	-
Hungary	87	43	(49.4)	9	(10.3)	0	(0.0)	17	(19.5)	12	(13.8)	6	(6.9)
Iceland	0	0	-	0	-	0	-	0	-	0	-	0	-
Ireland <sup>b</sup>	18	11	(61.1)	3	(16.7)	0	(0.0)	0	(0.0)	0	(0.0)	4	(22.2)
Italy	-	-	-	-	-	-	-	-	-	-	-	-	-
Latvia	106	65	(61.3)	7	(6.6)	0	(0.0)	12	(11.3)	22	(20.8)	0	(0.0)
Liechtenstein	-	-	-	-	-	-	-	-	-	-	-	-	-
Lithuania	360	113	(31.4)	64	(17.8)	13	(3.6)	80	(22.2)	89	(24.7)	1	(0.3)
Luxembourg	0	0	-	0	-	0	-	0	-	0	-	0	-
Malta	2	1	(50.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	1	(50.0)
Netherlands	26	15	(57.7)	4	(15.4)	0	(0.0)	1	(3.8)	2	(7.7)	4	(15.4)
Norway <sup>b</sup>	22	14	(63.6)	4	(18.2)	1	(4.5)	0	(0.0)	2	(9.1)	1	(4.5)
Poland	587	350	(59.6)	43	(7.3)	2	(0.3)	66	(11.2)	12	(2.0)	114	(19.4)
Portugal	-	-	-	-	-	-	-	-	-	-	-	-	-
Romania	4228	2236	(52.9)	397	(9.4)	594	(14.0)	741	(17.5)	260	(6.1)	0	(0.0)
Slovakia	29	24	(82.8)	4	(13.8)	0	(0.0)	0	(0.0)	1	(3.4)	0	(0.0)
Slovenia	11	7	(63.6)	4	(36.4)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)
Spain	224	128	(57.1)	19	(8.5)	0	(0.0)	6	(2.7)	7	(3.1)	64	(28.6)
Sweden	24	15	(62.5)	0	(0.0)	0	(0.0)	0	(0.0)	6	(25.0)	3	(12.5)
United Kingdom <sup>b</sup>	187	121	(64.7)	20	(10.7)	0	(0.0)	18	(9.6)	18	(9.6)	10	(5.3)
<b>Subtotal EU/EEA</b>	<b>6481</b>	<b>3482</b>	<b>(53.7)</b>	<b>652</b>	<b>(10.1)</b>	<b>633</b>	<b>(9.8)</b>	<b>991</b>	<b>(15.3)</b>	<b>490</b>	<b>(7.6)</b>	<b>233</b>	<b>(3.6)</b>
<b>Non-EU/EEA<sup>a</sup></b>													
Albania	30	27	(90.0)	1	(3.3)	0	(0.0)	2	(6.7)	-	-	0	(0.0)
Andorra	-	-	-	-	-	-	-	-	-	-	-	-	-
Armenia	451	302	(67.0)	27	(6.0)	46	(10.2)	58	(12.9)	-	-	18	(4.0)
Azerbaijan	4194	2626	(62.6)	135	(3.2)	186	(4.4)	611	(14.6)	-	-	636	(15.2)
Belarus	792	379	(47.9)	82	(10.4)	282	(35.6)	9	(1.1)	-	-	40	(5.1)
Bosnia and Herzegovina	101	96	(95.0)	2	(2.0)	1	(1.0)	1	(1.0)	-	-	1	(1.0)
Croatia	37	28	(75.7)	5	(13.5)	0	(0.0)	1	(2.7)	-	-	3	(8.1)
Georgia	1421	879	(61.9)	73	(5.1)	248	(17.5)	163	(11.5)	-	-	58	(4.1)
Israel	5	4	(80.0)	1	(20.0)	0	(0.0)	0	(0.0)	-	-	0	(0.0)
Kazakhstan	8734	4119	(47.2)	764	(8.7)	389	(4.5)	422	(4.8)	-	-	3040	(34.8)
Kyrgyzstan	-	-	-	-	-	-	-	-	-	-	-	-	-
Macedonia, the former Yugoslav Republic of	52	34	(65.4)	9	(17.3)	2	(3.8)	6	(11.5)	-	-	1	(1.9)
Moldova	1702	545	(32.0)	241	(14.2)	90	(5.3)	288	(16.9)	-	-	538	(31.6)
Monaco	-	-	-	-	-	-	-	-	-	-	-	-	-
Montenegro	14	12	(85.7)	0	(0.0)	0	(0.0)	0	(0.0)	-	-	2	(14.3)
Russia	14609	4984	(34.1)	1751	(12.0)	4884	(33.4)	1703	(11.7)	-	-	1287	(8.8)
San Marino	-	-	-	-	-	-	-	-	-	-	-	-	-
Serbia	172	129	(75.0)	17	(9.9)	1	(0.6)	18	(10.5)	-	-	7	(4.1)
Serbia excluding UN Administered Province of Kosovo <sup>e</sup>	172	129	(75.0)	17	(9.9)	1	(0.6)	18	(10.5)	-	-	7	(4.1)
UN Administered Province of Kosovo <sup>e</sup>	-	-	-	-	-	-	-	-	-	-	-	-	-
Switzerland	-	-	-	-	-	-	-	-	-	-	-	-	-
Tajikistan	1732	1243	(71.8)	189	(10.9)	198	(11.4)	77	(4.4)	-	-	25	(1.4)
Turkey	1368	940	(68.7)	72	(5.3)	29	(2.1)	101	(7.4)	-	-	226	(16.5)
Turkmenistan	-	-	-	-	-	-	-	-	-	-	-	-	-
Ukraine	9812	4540	(46.3)	1388	(14.1)	2242	(22.8)	1003	(10.2)	-	-	639	(6.5)
Uzbekistan	4527	3284	(72.5)	459	(10.1)	225	(5.0)	387	(8.5)	-	-	172	(3.8)
<b>Subtotal non-EU/EEA</b>	<b>49753</b>	<b>24171</b>	<b>(48.6)</b>	<b>5216</b>	<b>(10.5)</b>	<b>8823</b>	<b>(17.7)</b>	<b>4850</b>	<b>(9.7)</b>	<b>-</b>	<b>-</b>	<b>6693</b>	<b>(13.5)</b>
<b>Total European Region</b>	<b>56234</b>	<b>27653</b>	<b>(49.2)</b>	<b>5868</b>	<b>(10.4)</b>	<b>9456</b>	<b>(16.8)</b>	<b>5841</b>	<b>(10.4)</b>	<b>409</b>	<b>(0.7)</b>	<b>6926</b>	<b>(12.3)</b>
<b>Subtotal 18 HPC</b>	<b>54292</b>	<b>26380</b>	<b>(48.6)</b>	<b>5683</b>	<b>(10.5)</b>	<b>9447</b>	<b>(17.4)</b>	<b>5691</b>	<b>(10.5)</b>	<b>409</b>	<b>(0.8)</b>	<b>6682</b>	<b>(12.3)</b>

<sup>a</sup> 'European Region' comprises the 53 countries of the WHO European Region and Liechtenstein.

WHO European Region 18 TB High Priority Countries presented in italics.

<sup>b</sup> Previously treated pulmonary confirmed cases for EU/EEA countries.

<sup>c</sup> Previously diagnosed cases.

<sup>d</sup> Excluding Greenland (see Chapter 1.1).

<sup>e</sup> For non-EU/EEA countries: new pulmonary smear-positive (and/or culture-positive) cases.

<sup>f</sup> In accordance with the UN Security Council Resolution No. 1244 (1999).

Table 25: Treatment outcome of all TB cases, European region, 2010

Country	Cases notified in 2010	Success		Died		Failed		Defaulted		Still on treatment		Transferred or unknown	
		N	(%)	N	(%)	N	(%)	N	(%)	N	(%)	N	(%)
<b>EU/EEA</b>													
Austria	691	423	(61.2)	61	(8.8)	0	(0.0)	41	(5.9)	96	(13.9)	70	(10.1)
Belgium	1086	820	(75.5)	64	(5.9)	0	(0.0)	124	(11.4)	34	(3.1)	44	(4.1)
Bulgaria	2649	2231	(84.2)	239	(9.0)	37	(1.4)	109	(4.1)	27	(1.0)	6	(0.2)
Cyprus	61	13	(21.3)	0	(0.0)	0	(0.0)	1	(1.6)	0	(0.0)	47	(77.0)
Czech Republic	669	486	(72.6)	104	(15.5)	0	(0.0)	36	(5.4)	18	(2.7)	25	(3.7)
Denmark <sup>a</sup>	366	242	(66.1)	31	(8.5)	9	(2.5)	1	(0.3)	15	(4.1)	68	(18.6)
Estonia	333	198	(59.5)	40	(12.0)	6	(1.8)	25	(7.5)	64	(19.2)	0	(0.0)
Finland	325	146	(44.9)	17	(5.2)	0	(0.0)	4	(1.2)	10	(3.1)	148	(45.5)
France	-	-	-	-	-	-	-	-	-	-	-	-	-
Germany	4388	3262	(74.3)	503	(11.5)	6	(0.1)	139	(3.2)	105	(2.4)	373	(8.5)
Greece	-	-	-	-	-	-	-	-	-	-	-	-	-
Hungary	1741	1254	(72.0)	218	(12.5)	0	(0.0)	161	(9.2)	66	(3.8)	42	(2.4)
Iceland	22	20	(90.9)	1	(4.5)	0	(0.0)	0	(0.0)	0	(0.0)	1	(4.5)
Ireland	420	304	(72.4)	27	(6.4)	0	(0.0)	7	(1.7)	2	(0.5)	80	(19.0)
Italy	-	-	-	-	-	-	-	-	-	-	-	-	-
Latvia	935	711	(76.0)	78	(8.3)	3	(0.3)	61	(6.5)	81	(8.7)	1	(0.1)
Liechtenstein	-	-	-	-	-	-	-	-	-	-	-	-	-
Lithuania	1938	1280	(66.0)	214	(11.0)	29	(1.5)	240	(12.4)	170	(8.8)	5	(0.3)
Luxembourg	29	0	(0.0)	1	(3.4)	0	(0.0)	0	(0.0)	0	(0.0)	28	(96.6)
Malta	32	19	(59.4)	1	(3.1)	0	(0.0)	2	(6.3)	0	(0.0)	10	(31.3)
Netherlands	1065	869	(81.6)	54	(5.1)	0	(0.0)	41	(3.8)	31	(2.9)	70	(6.6)
Norway	336	288	(85.7)	15	(4.5)	6	(1.8)	0	(0.0)	18	(5.4)	9	(2.7)
Poland	7509	4976	(66.3)	426	(5.7)	12	(0.2)	653	(8.7)	31	(0.4)	1411	(18.8)
Portugal	-	-	-	-	-	-	-	-	-	-	-	-	-
Romania	21059	16232	(77.1)	1519	(7.2)	1002	(4.8)	1653	(7.8)	653	(3.1)	0	(0.0)
Slovakia	439	384	(87.5)	44	(10.0)	1	(0.2)	7	(1.6)	1	(0.2)	2	(0.5)
Slovenia	172	139	(80.8)	27	(15.7)	0	(0.0)	2	(1.2)	2	(1.2)	2	(1.2)
Spain	7239	4861	(67.2)	420	(5.8)	9	(0.1)	75	(1.0)	60	(0.8)	1814	(25.1)
Sweden	668	567	(84.9)	25	(3.7)	2	(0.3)	6	(0.9)	31	(4.6)	37	(5.5)
United Kingdom	8483	6820	(80.4)	431	(5.1)	0	(0.0)	489	(5.8)	320	(3.8)	423	(5.0)
<b>Subtotal EU/EEA</b>	<b>62655</b>	<b>46545</b>	<b>(74.3)</b>	<b>4560</b>	<b>(7.3)</b>	<b>1122</b>	<b>(1.8)</b>	<b>3877</b>	<b>(6.2)</b>	<b>1835</b>	<b>(2.9)</b>	<b>4716</b>	<b>(7.5)</b>
<b>Non-EU/EEA</b>													
Albania	445	398	(89.4)	10	(2.2)	0	(0.0)	29	(6.5)	-	-	8	(1.8)
Andorra	7	6	(85.7)	0	(0.0)	0	(0.0)	0	(0.0)	-	-	1	(14.3)
Armenia	1780	1389	(78.0)	76	(4.3)	118	(6.6)	148	(8.3)	-	-	49	(2.8)
Azerbaijan	8652	5878	(67.9)	380	(4.4)	435	(5.0)	1154	(13.3)	-	-	805	(9.3)
Belarus	5091	3735	(73.4)	385	(7.6)	780	(15.3)	30	(0.6)	-	-	161	(3.2)
Bosnia and Herzegovina	1071	1051	(98.1)	10	(0.9)	3	(0.3)	4	(0.4)	-	-	3	(0.3)
Croatia	263	199	(75.7)	37	(14.1)	0	(0.0)	9	(3.4)	-	-	18	(6.8)
Georgia	5807	4360	(75.1)	181	(3.1)	577	(9.9)	491	(8.5)	-	-	198	(3.4)
Israel	346	292	(84.4)	22	(6.4)	0	(0.0)	8	(2.3)	-	-	24	(6.9)
Kazakhstan	22183	14388	(64.9)	1045	(4.7)	927	(4.2)	684	(3.1)	-	-	5139	(23.2)
Kyrgyzstan	-	-	-	-	-	-	-	-	-	-	-	-	-
Macedonia, the former Yugoslav Republic of	420	347	(82.6)	38	(9.0)	6	(1.4)	23	(5.5)	-	-	6	(1.4)
Moldova	5447	3064	(56.3)	607	(11.1)	211	(3.9)	633	(11.6)	-	-	932	(17.1)
Monaco	-	-	-	-	-	-	-	-	-	-	-	-	-
Montenegro	116	101	(87.1)	5	(4.3)	0	(0.0)	3	(2.6)	-	-	7	(6.0)
Russia	108604	67384	(62.0)	8170	(7.5)	17801	(16.4)	8118	(7.5)	-	-	7131	(6.6)
San Marino	-	-	-	-	-	-	-	-	-	-	-	-	-
Serbia	1515	1291	(85.2)	100	(6.6)	11	(0.7)	80	(5.3)	-	-	33	(2.2)
Serbia excluding UN Administered Province of Kosovo <sup>b</sup>	1515	1291	(85.2)	100	(6.6)	11	(0.7)	80	(5.3)	-	-	33	(2.2)
UN Administered Province of Kosovo <sup>b</sup>	-	-	-	-	-	-	-	-	-	-	-	-	-
Switzerland	-	-	-	-	-	-	-	-	-	-	-	-	-
Tajikistan	7691	6377	(82.9)	429	(5.6)	495	(6.4)	251	(3.3)	-	-	139	(1.8)
Turkey	16551	14513	(87.7)	505	(3.1)	88	(0.5)	446	(2.7)	-	-	999	(6.0)
Turkmenistan	-	-	-	-	-	-	-	-	-	-	-	-	-
Ukraine	40299	25583	(63.5)	4256	(10.6)	5474	(13.6)	2991	(7.4)	-	-	1995	(5.0)
Uzbekistan	20261	16822	(83.0)	1088	(5.4)	577	(2.8)	1153	(5.7)	-	-	621	(3.1)
<b>Subtotal non-EU/EEA</b>	<b>246549</b>	<b>167178</b>	<b>(67.8)</b>	<b>17344</b>	<b>(7.0)</b>	<b>27503</b>	<b>(11.2)</b>	<b>16255</b>	<b>(6.6)</b>	-	-	<b>18269</b>	<b>(7.4)</b>
<b>Total European Region</b>	<b>309204</b>	<b>213723</b>	<b>(69.1)</b>	<b>21904</b>	<b>(7.1)</b>	<b>28625</b>	<b>(9.3)</b>	<b>20132</b>	<b>(6.5)</b>	<b>1835</b>	<b>(0.6)</b>	<b>22985</b>	<b>(7.4)</b>
<b>Subtotal 18 HPC</b>	<b>269280</b>	<b>184145</b>	<b>(68.4)</b>	<b>19212</b>	<b>(7.1)</b>	<b>28560</b>	<b>(10.6)</b>	<b>18187</b>	<b>(6.8)</b>	<b>995</b>	<b>(0.4)</b>	<b>18181</b>	<b>(6.8)</b>

<sup>a</sup> 'European Region' comprises the 53 countries of the WHO European Region and Liechtenstein.

WHO European Region 18 TB High Priority Countries presented in italics.

<sup>b</sup> Excluding Greenland (see Chapter 1.1).

<sup>c</sup> In accordance with the UN Security Council Resolution No. 1244 (1999).

Table 26: Treatment outcome of all MDR-TB cases after 24 months, European region, 2009

Country	Total number of MDR cases	Success		Died		Failed		Defaulted		Still on treatment		Transferred or unknown	
		N	(%)	N	(%)	N	(%)	N	(%)	N	(%)	N	(%)
<b>EU/EEA</b>													
Austria	23	10	(43.5)	1	(4.3)	0	(0.0)	8	(34.8)	4	(17.4)	0	(0.0)
Belgium	10	4	(40.0)	1	(10.0)	0	(0.0)	2	(20.0)	3	(30.0)	0	(0.0)
Bulgaria	43	8	(18.6)	18	(41.9)	5	(11.6)	5	(11.6)	5	(11.6)	2	(4.7)
Cyprus	-	-	-	-	-	-	-	-	-	-	-	-	-
Czech Republic	8	0	(0.0)	1	(12.5)	0	(0.0)	4	(50.0)	1	(12.5)	2	(25.0)
Denmark <sup>a</sup>	2	1	(50.0)	1	(50.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)
Estonia	85	35	(41.2)	18	(21.2)	5	(5.9)	9	(10.6)	15	(17.6)	3	(3.5)
Finland	-	-	-	-	-	-	-	-	-	-	-	-	-
France	-	-	-	-	-	-	-	-	-	-	-	-	-
Germany	62	38	(61.3)	4	(6.5)	1	(1.6)	4	(6.5)	6	(9.7)	9	(14.5)
Greece	-	-	-	-	-	-	-	-	-	-	-	-	-
Hungary	18	3	(16.7)	3	(16.7)	9	(50.0)	2	(11.1)	1	(5.6)	0	(0.0)
Iceland	-	-	-	-	-	-	-	-	-	-	-	-	-
Ireland	-	-	-	-	-	-	-	-	-	-	-	-	-
Italy	-	-	-	-	-	-	-	-	-	-	-	-	-
Latvia	131	77	(58.8)	25	(19.1)	6	(4.6)	19	(14.5)	3	(2.3)	1	(0.8)
Liechtenstein	-	-	-	-	-	-	-	-	-	-	-	-	-
Lithuania	322	97	(30.1)	93	(28.9)	31	(9.6)	98	(30.4)	2	(0.6)	1	(0.3)
Luxembourg	-	-	-	-	-	-	-	-	-	-	-	-	-
Malta	0	0	-	0	-	0	-	0	-	0	-	0	-
Netherlands	20	12	(60.0)	0	(0.0)	0	(0.0)	4	(20.0)	1	(5.0)	3	(15.0)
Norway	8	5	(62.5)	0	(0.0)	1	(12.5)	0	(0.0)	0	(0.0)	2	(25.0)
Poland	21	12	(57.1)	4	(19.0)	2	(9.5)	1	(4.8)	1	(4.8)	1	(4.8)
Portugal	-	-	-	-	-	-	-	-	-	-	-	-	-
Romania	624	102	(16.3)	118	(18.9)	228	(36.5)	126	(20.2)	50	(8.0)	0	(0.0)
Slovakia	1	0	(0.0)	1	(100.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	-
Slovenia	-	-	-	-	-	-	-	-	-	-	-	-	-
Spain	-	-	-	-	-	-	-	-	-	-	-	-	-
Sweden	13	11	(84.6)	0	(0.0)	1	(7.7)	1	(7.7)	0	(0.0)	0	(0.0)
United Kingdom	60	45	(75.0)	0	(0.0)	0	(0.0)	7	(11.7)	2	(3.3)	6	(10.0)
<b>Subtotal EU/EEA</b>	<b>1451</b>	<b>460</b>	<b>(31.6)</b>	<b>288</b>	<b>(19.8)</b>	<b>289</b>	<b>(19.8)</b>	<b>290</b>	<b>(19.9)</b>	<b>94</b>	<b>(6.5)</b>	<b>30</b>	<b>(2.4)</b>
<b>Non-EU/EEA</b>													
Albania	-	-	-	-	-	-	-	-	-	-	-	-	-
Andorra	-	-	-	-	-	-	-	-	-	-	-	-	-
Armenia	134	69	(51.5)	10	(7.5)	19	(14.2)	31	(23.1)	-	-	5	(3.7)
Azerbaijan	100	74	(74.0)	8	(8.0)	12	(12.0)	6	(6.0)	-	-	0	(0.0)
Belarus	1422	572	(40.2)	214	(15.0)	156	(11.0)	175	(12.3)	-	-	305	(21.4)
Bosnia and Herzegovina	1	1	(100.0)	0	(0.0)	0	(0.0)	0	(0.0)	-	-	0	(0.0)
Croatia	2	1	(50.0)	0	(0.0)	0	(0.0)	0	(0.0)	-	-	1	(50.0)
Georgia	503	270	(53.7)	38	(7.6)	30	(6.0)	141	(28.0)	-	-	24	(4.8)
Israel	6	5	(83.3)	0	(0.0)	0	(0.0)	0	(0.0)	-	-	1	(16.7)
Kazakhstan	3897	2851	(73.2)	254	(6.5)	279	(7.2)	207	(5.3)	-	-	306	(7.9)
Kyrgyzstan	545	193	(35.4)	53	(9.7)	48	(8.8)	208	(38.2)	-	-	43	(7.9)
Macedonia, the former Yugoslav Republic of	1	0	(0.0)	0	(0.0)	0	(0.0)	1	(100.0)	-	-	0	(0.0)
Moldova	-	-	-	-	-	-	-	-	-	-	-	-	-
Monaco	-	-	-	-	-	-	-	-	-	-	-	-	-
Montenegro	1	1	(100.0)	0	(0.0)	0	(0.0)	0	(0.0)	-	-	0	(0.0)
Russia	-	-	-	-	-	-	-	-	-	-	-	-	-
San Marino	-	-	-	-	-	-	-	-	-	-	-	-	-
Serbia	10	6	(60.0)	3	(30.0)	1	(10.0)	0	(0.0)	-	-	0	(0.0)
Serbia excluding UN Administered Province of Kosovo <sup>b</sup>	10	6	(60.0)	3	(30.0)	1	(10.0)	0	(0.0)	-	-	0	(0.0)
UN Administered Province of Kosovo <sup>b</sup>	-	-	-	-	-	-	-	-	-	-	-	-	-
Switzerland	-	-	-	-	-	-	-	-	-	-	-	-	-
Tajikistan	52	37	(71.2)	7	(13.5)	6	(11.5)	2	(3.8)	-	-	0	(0.0)
Turkey	222	147	(66.2)	19	(8.6)	4	(1.8)	12	(5.4)	-	-	40	(18.0)
Turkmenistan	-	-	-	-	-	-	-	-	-	-	-	-	-
Ukraine	3299	906	(27.5)	1030	(31.2)	307	(9.3)	458	(13.9)	-	-	598	(18.1)
Uzbekistan	464	285	(61.4)	43	(9.3)	50	(10.8)	76	(16.4)	-	-	10	(2.2)
<b>Subtotal non-EU/EEA</b>	<b>10 659</b>	<b>5418</b>	<b>(50.8)</b>	<b>1679</b>	<b>(15.8)</b>	<b>912</b>	<b>(8.6)</b>	<b>1317</b>	<b>(12.4)</b>	-	-	<b>1333</b>	<b>(12.5)</b>
<b>Total European Region</b>	<b>12 110</b>	<b>5878</b>	<b>(48.5)</b>	<b>1967</b>	<b>(16.2)</b>	<b>1201</b>	<b>(9.9)</b>	<b>1607</b>	<b>(13.3)</b>	<b>94</b>	<b>(0.8)</b>	<b>1363</b>	<b>(11.3)</b>
<b>Subtotal 18 HPC</b>	<b>11 843</b>	<b>5723</b>	<b>(48.3)</b>	<b>1948</b>	<b>(16.4)</b>	<b>1186</b>	<b>(10.0)</b>	<b>1573</b>	<b>(13.3)</b>	<b>75</b>	<b>(0.6)</b>	<b>1338</b>	<b>(11.3)</b>

<sup>a</sup> 'European Region' comprises the 53 countries of the WHO European Region and Liechtenstein. WHO European Region 18 TB High Priority Countries presented in italics.

<sup>b</sup> Excluding Greenland (see Chapter 1.1).

<sup>c</sup> In accordance with the UN Security Council Resolution No. 1244 (1999).



**Tables on specific topics in the 2013 report:  
TB in prisons and site of the disease**



Table A: TB in Prisons, European Region, 2010

Country	Prison population (N)	New TB cases (all forms) notified in prisons		Proportion of new TB cases in prisons out of the country total <sup>a</sup>	TB relative risk in prisons (RR)
		N	Rate		
<b>EU/EEA</b>					
Austria	-	-	-	-	-
Belgium	18 188	15	82.5	2.1%	12.5
<i>Bulgaria</i>	9 322	42	450.5	2.0%	16.5
Cyprus	-	-	-	-	-
Czech Republic	21 900	38	173.5	6.7%	32.0
Denmark	-	-	-	-	-
<i>Estonia</i>	-	14	-	5.3%	-
Finland	-	-	-	-	-
France	61 473	-	-	-	-
Germany	-	-	-	-	-
Greece	-	-	-	-	-
Hungary	-	-	-	-	-
Iceland	157	-	-	-	-
Ireland	13 758	-	-	-	-
Italy	-	-	-	-	-
<i>Latvia</i>	10 383	56	539.3	7.1%	15.4
Liechtenstein	-	-	-	-	-
<i>Lithuania</i>	8 856	84	948.5	5.5%	20.6
Luxembourg	600	-	-	-	-
Malta	-	-	-	-	-
Netherlands	33 054	21	63.5	2.2%	11.0
Norway	-	-	-	-	-
Poland	80 522	179	222.3	2.4%	11.3
Portugal	-	-	-	-	-
<i>Romania</i>	27 559	122	442.7	0.8%	6.5
Slovakia	7 126	61	856.0	18.9%	144.8
Slovenia	-	-	-	-	-
Spain	-	-	-	-	-
Sweden	-	-	-	-	-
United Kingdom	-	-	-	-	-
<b>Subtotal EU/EEA<sup>b</sup></b>	<b>216 910</b>	<b>618</b>	<b>284.9</b>	<b>2.1%</b>	<b>11.4</b>
<b>Non-EU/EEA</b>					
Albania	6 000	4	66.7	1.0%	5.2
Andorra	0	0	-	-	-
<i>Armenia</i>	4 314	28	649.0	2.3%	16.7
<i>Azerbaijan</i>	16 478	327	1 984.5	6.2%	34.4
<i>Belarus</i>	33 003	146	442.4	3.6%	10.5
Bosnia and Herzegovina	-	-	-	-	-
Croatia	-	-	-	-	-
<i>Georgia</i>	23 684	879	3 711.4	20.8%	38.2
Israel	14 239	45	316.0	11.0%	57.5
<i>Kazakhstan</i>	-	-	-	-	-
<i>Kyrgyzstan</i>	-	-	-	-	-
Macedonia, the former Yugoslav Republic of	-	-	-	-	-
<i>Moldova</i>	22 000	159	722.7	4.1%	6.7
Monaco	-	-	-	-	-
Montenegro	1 500	0	-	-	-
<i>Russia</i>	-	-	-	-	-
San Marino	-	-	-	-	-
Serbia	-	-	-	-	-
Serbia excluding UN Administered Province of Kosovo <sup>c</sup>	-	-	-	-	-
UN Administered Province of Kosovo <sup>c</sup>	-	-	-	-	-
Switzerland	-	-	-	-	-
<i>Tajikistan</i>	10 500	93	885.7	1.6%	10.3
<i>Turkey</i>	120 814	111	91.9	0.8%	4.6
<i>Turkmenistan</i>	-	-	-	-	-
<i>Ukraine</i>	147 272	388	263.5	1.2%	3.8
<i>Uzbekistan</i>	-	-	-	-	-
<b>Subtotal non-EU/EEA</b>	<b>399 804</b>	<b>2 180</b>	<b>545.3</b>	<b>3.1%</b>	<b>12.7</b>
<b>Total European Region</b>	<b>631 229</b>	<b>2 798</b>	<b>443.3</b>	<b>2.8%</b>	<b>12.5</b>
<b>Subtotal 18 HPC</b>	<b>434 185</b>	<b>2 435</b>	<b>560.8</b>	<b>2.7%</b>	<b>11.9</b>

<sup>a</sup> 'European Region' comprises the 53 countries of the WHO European Region.

WHO European Region 18 TB High Priority Countries presented in italics.

<sup>b</sup> The proportion is related to all new TB cases reported by country.

<sup>c</sup> In the calculation of summary results only countries reporting complete data are included.

<sup>d</sup> In accordance with Security Council Resolution 1244(1999)

**Table B: Extrapulmonary TB cases, notification rates per 100 000 population and % of all TB, EU/EEA 2002–2011**

Country	2002				2003				2004				2005				2006			
	Total TB cases notified (N)	Extrapulmonary TB			Total TB cases notified (N)	Extrapulmonary TB			Total TB cases notified (N)	Extrapulmonary TB			Total TB cases notified (N)	Extrapulmonary TB			Total TB cases notified (N)	Extrapulmonary TB		
		N	(%)	Rate		N	(%)	Rate		N	(%)	Rate		N	(%)	Rate		N	(%)	Rate
Austria	1074	212	(19.7)	2.6	990	163	(16.5)	2.0	1075	180	(16.7)	2.2	998	188	(18.8)	2.3	906	145	(16.0)	1.8
Belgium	1294	316	(24.4)	3.1	1117	280	(25.1)	2.7	1198	319	(26.6)	3.1	1107	306	(27.6)	2.9	1117	350	(31.3)	3.3
Bulgaria	3335	393	(11.8)	5.0	3263	424	(13.0)	5.4	3232	345	(10.7)	4.4	3302	376	(11.4)	4.8	3232	327	(10.1)	4.2
Cyprus	20	6	(30.0)	0.9	35	6	(17.1)	0.8	30	3	(10.0)	0.4	37	13	(35.1)	1.7	37	6	(16.2)	0.8
Czech Republic	1200	283	(23.6)	2.8	1162	250	(21.5)	2.5	1057	233	(22.0)	2.3	984	155	(15.8)	1.5	951	159	(16.7)	1.6
Denmark <sup>a</sup>	419	111	(26.5)	2.1	393	107	(27.2)	2.0	385	96	(24.9)	1.8	428	131	(30.6)	2.4	387	106	(27.4)	2.0
Estonia	713	85	(11.9)	6.2	623	66	(10.6)	4.9	594	62	(10.4)	4.6	518	51	(9.8)	3.8	460	36	(7.8)	2.7
Finland	477	177	(37.1)	3.4	415	122	(29.4)	2.3	336	103	(30.7)	2.0	372	99	(26.6)	1.9	297	85	(28.6)	1.6
France	6322	1598	(25.3)	2.6	6098	1553	(25.5)	2.5	5578	1445	(25.9)	2.3	5368	1421	(26.5)	2.3	5323	1300	(24.4)	2.1
Germany	7701	1437	(18.7)	1.7	7166	1390	(19.4)	1.7	6542	1299	(19.9)	1.6	6020	1368	(22.7)	1.7	5378	1168	(21.7)	1.4
Greece	582	78	(13.4)	0.7	620	87	(14.0)	0.8	774	86	(11.1)	0.8	769	116	(15.1)	1.0	681	91	(13.4)	0.8
Hungary	2838	207	(7.3)	2.0	2582	179	(6.9)	1.8	2340	140	(6.0)	1.4	1964	126	(6.4)	1.2	1859	92	(4.9)	0.9
Iceland	8	2	(25.0)	0.7	5	2	(40.0)	0.7	12	7	(58.3)	2.4	11	6	(54.5)	2.0	13	6	(46.2)	2.0
Ireland	408	93	(22.8)	2.4	407	102	(25.1)	2.6	432	118	(27.3)	2.9	450	130	(28.9)	3.2	463	125	(27.0)	3.0
Italy	4212	991	(23.5)	1.7	4518	1159	(25.7)	2.0	4220	1193	(28.3)	2.1	4212	1031	(24.5)	1.8	4503	1167	(25.9)	2.0
Latvia	1855	231	(12.5)	9.8	1726	183	(10.6)	7.8	1610	205	(12.7)	8.8	1443	148	(10.3)	6.4	1328	124	(9.3)	5.4
Liechtenstein	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Lithuania	2844	493	(17.3)	14.2	2821	429	(15.2)	12.4	2514	389	(15.5)	11.3	2574	363	(14.1)	10.6	2559	320	(12.5)	9.4
Luxembourg	32	4	(12.5)	1	54	3	(5.6)	1	31	2	(6.5)	0	37	3	(8.1)	1	33	1	(3.0)	0
Malta	24	5	(20.8)	1.3	7	3	(42.9)	0.8	19	5	(26.3)	1.3	25	6	(24.0)	1.5	30	6	(20.0)	1.5
Netherlands	1401	501	(35.8)	3.1	1321	453	(34.3)	2.8	1344	547	(40.7)	3.4	1128	470	(41.7)	2.9	1031	403	(39.1)	2.5
Norway	251	98	(39.0)	2.2	337	125	(37.1)	2.7	302	102	(33.8)	2.2	288	106	(36.8)	2.3	290	104	(35.9)	2.2
Poland	10475	1031	(9.8)	2.7	10124	913	(9.0)	2.4	9493	802	(8.4)	2.1	9269	820	(8.8)	2.1	8587	708	(8.2)	1.9
Portugal	4501	1192	(26.5)	11.5	4148	1124	(27.1)	10.8	3854	984	(25.5)	9.4	3558	0	(0.0)	0.0	3456	773	(22.4)	7.3
Romania	33595	3699	(11.0)	16.9	31039	4080	(13.1)	18.7	31034	4027	(13.0)	18.5	29288	3757	(12.8)	17.3	26600	3756	(14.1)	17.4
Slovakia	1053	209	(19.8)	3.9	983	206	(21.0)	3.8	705	141	(20.0)	2.6	760	141	(18.6)	2.6	730	133	(18.2)	2.5
Slovenia	350	55	(15.7)	2.8	293	44	(15.0)	2.2	263	51	(19.4)	2.6	278	33	(11.9)	1.7	215	41	(19.1)	2.0
Spain	7626	133	(1.7)	0.3	7467	137	(1.8)	0.3	7766	1006	(13.0)	2.4	7820	979	(12.5)	2.3	8029	1430	(17.8)	3.3
Sweden	407	146	(35.9)	1.6	408	152	(37.3)	1.7	461	149	(32.3)	1.7	559	207	(37.0)	2.3	497	178	(35.8)	2.0
United Kingdom	7330	2903	(39.6)	4.9	7266	2983	(41.1)	5.0	7650	3193	(41.7)	5.3	8349	3683	(44.1)	6.1	8363	3707	(44.3)	6.1
<b>Total EU/EEA</b>	<b>102347</b>	<b>16689</b>	<b>(16.3)</b>	<b>3.4</b>	<b>97388</b>	<b>16725</b>	<b>(17.2)</b>	<b>3.4</b>	<b>94851</b>	<b>17232</b>	<b>(18.2)</b>	<b>3.5</b>	<b>91916</b>	<b>16233</b>	<b>(17.7)</b>	<b>3.3</b>	<b>87355</b>	<b>16847</b>	<b>(19.3)</b>	<b>3.4</b>

<sup>a</sup>European Region<sup>\*</sup> comprises the 53 countries of the WHO European Region.

WHO European Region 18 TB High Priority Countries presented in italics.

<sup>a</sup> Excluding Greenland (see Chapter 1.1).

	2007			2008			2009			2010			2011		
	Total TB cases notified (N)	Extrapulmonary TB		Total TB cases notified (N)	Extrapulmonary TB		Total TB cases notified (N)	Extrapulmonary TB		Total TB cases notified (N)	Extrapulmonary TB		Total TB cases notified (N)	Extrapulmonary TB	
		N	(%)		Rate	N		(%)	Rate		N	(%)		Rate	N
	874	144 (16.5)	1.7	817	137 (16.8)	1.6	696	121 (17.4)	1.4	691	133 (19.2)	1.6	687	136 (19.8)	1.6
	1020	281 (27.5)	2.7	990	271 (27.4)	2.5	994	274 (27.6)	2.5	1086	303 (27.9)	2.8	1044	297 (28.4)	2.7
	3038	298 (9.8)	3.9	3150	743 (23.6)	9.7	2910	787 (27.0)	10.3	2649	798 (30.1)	10.6	2407	683 (28.4)	9.1
	42	6 (14.3)	0.8	50	8 (16.0)	1.0	55	19 (34.5)	2.4	61	19 (31.1)	2.4	54	8 (14.8)	1.0
	846	124 (14.7)	1.2	864	131 (15.2)	1.3	694	106 (15.3)	1.0	669	97 (14.5)	0.9	600	78 (13.0)	0.7
	391	91 (23.3)	1.7	380	95 (25.0)	1.7	334	70 (21.0)	1.3	366	44 (12.0)	0.8	381	47 (12.3)	0.8
	491	34 (6.9)	2.5	444	34 (7.7)	2.5	411	22 (5.4)	1.6	333	21 (6.3)	1.6	341	20 (5.9)	1.5
	348	111 (31.9)	2.1	344	125 (36.3)	2.4	417	118 (28.3)	2.2	325	92 (28.3)	1.7	325	89 (27.4)	1.7
	5574	1356 (24.3)	2.1	5758	1603 (27.8)	2.5	5276	1395 (26.4)	2.2	5116	1361 (26.6)	2.1	4942	1289 (26.1)	2.0
	5000	1043 (20.9)	1.3	4523	995 (22.0)	1.2	4427	933 (21.1)	1.1	4388	979 (22.3)	1.2	4316	926 (21.5)	1.1
	639	86 (13.5)	0.8	664	86 (13.0)	0.8	589	84 (14.3)	0.7	487	69 (14.2)	0.6	489	60 (12.3)	0.5
	1685	100 (5.9)	1.0	1619	86 (5.3)	0.9	1407	71 (5.0)	0.7	1741	74 (4.3)	0.7	1445	56 (3.9)	0.6
	14	5 (35.7)	1.6	6	3 (50.0)	1.0	9	2 (22.2)	0.6	22	4 (18.2)	1.3	9	6 (66.7)	1.9
	480	131 (27.3)	3.0	468	130 (27.8)	3.0	479	164 (34.2)	3.7	420	150 (35.7)	3.4	425	121 (28.5)	2.7
	4525	1091 (24.1)	1.8	4418	1131 (25.6)	1.9	4244	1156 (27.2)	1.9	4692	1316 (28.0)	2.2	3521	939 (26.7)	1.5
	1255	141 (11.2)	6.2	1070	120 (11.2)	5.3	977	89 (9.1)	3.9	935	88 (9.4)	3.9	885	89 (10.1)	4.0
	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	2408	280 (11.6)	8.3	2250	266 (11.8)	7.9	2081	236 (11.3)	7.0	1938	225 (11.6)	6.8	1904	190 (10.0)	5.9
	39	3 (7.7)	1	-	-	-	27	2 (7.4)	0	29	6 (20.7)	1	26	4 (15.4)	1
	38	11 (28.9)	2.7	53	13 (24.5)	3.2	44	18 (40.9)	4.4	32	13 (40.6)	3.1	33	11 (33.3)	2.6
	998	402 (40.3)	2.5	1015	417 (41.1)	2.5	1158	517 (44.6)	3.1	1065	475 (44.6)	2.9	1007	441 (43.8)	2.6
	302	123 (40.7)	2.6	313	128 (40.9)	2.7	358	132 (36.9)	2.8	336	137 (40.8)	2.8	361	158 (43.8)	3.2
	8614	628 (7.3)	1.6	8080	597 (7.4)	1.6	8236	582 (7.1)	1.5	7509	517 (6.9)	1.4	8478	599 (7.1)	1.6
	3139	728 (23.2)	6.9	3002	753 (25.1)	7.1	2871	763 (26.6)	7.2	2626	727 (27.7)	6.8	2540	675 (26.6)	6.3
	24837	3351 (13.5)	15.5	24680	3310 (13.4)	15.4	23164	3351 (14.5)	15.6	21059	3058 (14.5)	14.2	19212	2781 (14.5)	13.0
	682	134 (19.6)	2.5	633	111 (17.5)	2.1	506	92 (18.2)	1.7	439	67 (15.3)	1.2	399	62 (15.5)	1.1
	218	38 (17.4)	1.9	213	33 (15.5)	1.6	188	26 (13.8)	1.3	172	30 (17.4)	1.5	192	27 (14.1)	1.3
	7768	1501 (19.3)	3.4	8216	1901 (23.1)	4.2	7592	1814 (23.9)	4.0	7239	1933 (26.7)	4.2	6762	1783 (26.4)	3.9
	482	180 (37.3)	2.0	546	236 (43.2)	2.6	617	264 (42.8)	2.9	668	252 (37.7)	2.7	586	228 (38.9)	2.4
	8329	3777 (45.3)	6.2	8606	3921 (45.6)	6.4	8917	4082 (45.8)	6.6	8483	3949 (46.6)	6.4	8963	4313 (48.1)	6.9
	<b>84076</b>	<b>16198 (19.3)</b>	<b>3.2</b>	<b>83172</b>	<b>17384 (20.9)</b>	<b>3.5</b>	<b>79678</b>	<b>17290 (21.7)</b>	<b>3.4</b>	<b>75576</b>	<b>16937 (22.4)</b>	<b>3.3</b>	<b>72334</b>	<b>16116 (22.3)</b>	<b>3.2</b>

Table C: All tuberculosis cases by site of disease, EU/EEA, 2011

Country	Total TB cases notified (N)	Pulmonary TB		Extrapulmonary		Extrapulmonary TB							
						Lymphatic		Pleural		Urogenital		Bone	
		N	(%) <sup>b</sup>	N	(%) <sup>b</sup>	N	(%) <sup>c</sup>	N	(%) <sup>c</sup>	N	(%) <sup>c</sup>	N	(%) <sup>c</sup>
Austria	687	540	(78.6)	136	(19.8)	65	(47.8)	20	(14.7)	16	(11.8)	8	(5.9)
Belgium	1044	747	(71.6)	297	(28.4)	150	(50.5)	72	(24.2)	14	(4.7)	11	(3.7)
Bulgaria	2407	1724	(71.6)	683	(28.4)	273	(40.0)	216	(31.6)	29	(4.2)	17	(2.5)
Cyprus	54	44	(81.5)	8	(14.8)	5	(62.5)	2	(25.0)	0	(0.0)	0	(0.0)
Czech Republic	600	522	(87.0)	78	(13.0)	34	(43.6)	16	(20.5)	6	(7.7)	2	(2.6)
Denmark <sup>d</sup>	381	240	(63.0)	47	(12.3)	31	(66.0)	6	(12.8)	4	(8.5)	0	(0.0)
Estonia	341	321	(94.1)	20	(5.9)	5	(25.0)	6	(30.0)	2	(10.0)	2	(10.0)
Finland	325	236	(72.6)	89	(27.4)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)
France	4942	3600	(72.8)	1289	(26.1)	577	(44.8)	229	(17.8)	47	(3.6)	116	(9.0)
Germany	4316	3346	(77.5)	926	(21.5)	431	(46.5)	147	(15.9)	90	(9.7)	67	(7.2)
Greece	489	426	(87.1)	60	(12.3)	22	(36.7)	8	(13.3)	3	(5.0)	1	(1.7)
Hungary	1445	1389	(96.1)	56	(3.9)	6	(10.7)	9	(16.1)	11	(19.6)	13	(23.2)
Iceland	9	3	(33.3)	6	(66.7)	3	(50.0)	1	(16.7)	0	(0.0)	0	(0.0)
Ireland	425	293	(68.9)	121	(28.5)	46	(38.0)	24	(19.8)	5	(4.1)	6	(5.0)
Italy	3521	2582	(73.3)	939	(26.7)	385	(41.0)	111	(11.8)	79	(8.4)	33	(3.5)
Latvia	885	796	(89.9)	89	(10.1)	47	(52.8)	26	(29.2)	5	(5.6)	0	(0.0)
Liechtenstein	-	-	-	-	-	-	-	-	-	-	-	-	-
Lithuania	1904	1714	(90.0)	190	(10.0)	51	(26.8)	58	(30.5)	17	(8.9)	20	(10.5)
Luxembourg	26	22	(84.6)	4	(15.4)	4	(100.0)	0	(0.0)	0	(0.0)	0	(0.0)
Malta	33	22	(66.7)	11	(33.3)	6	(54.5)	1	(9.1)	1	(9.1)	0	(0.0)
Netherlands	1007	563	(55.9)	441	(43.8)	225	(51.0)	64	(14.5)	19	(4.3)	11	(2.5)
Norway	361	200	(55.4)	158	(43.8)	87	(55.1)	16	(10.1)	5	(3.2)	15	(9.5)
Poland	8478	7879	(92.9)	599	(7.1)	149	(24.9)	214	(35.7)	68	(11.4)	40	(6.7)
Portugal	2540	1857	(73.1)	675	(26.6)	215	(31.9)	188	(27.9)	48	(7.1)	11	(1.6)
Romania	19212	16431	(85.5)	2781	(14.5)	535	(19.2)	1606	(57.7)	117	(4.2)	89	(3.2)
Slovakia	399	337	(84.5)	62	(15.5)	20	(32.3)	18	(29.0)	7	(11.3)	0	(0.0)
Slovenia	192	165	(85.9)	27	(14.1)	10	(37.0)	11	(40.7)	1	(3.7)	1	(3.7)
Spain	6762	4979	(73.6)	1783	(26.4)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)
Sweden	586	358	(61.1)	228	(38.9)	139	(61.0)	15	(6.6)	2	(0.9)	11	(4.8)
United Kingdom	8963	4603	(51.4)	4313	(48.1)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)
<b>Total EU/EEA</b>	<b>72334</b>	<b>55939</b>	<b>(77.3)</b>	<b>16116</b>	<b>(22.3)</b>	<b>3521</b>	<b>(21.8)</b>	<b>3084</b>	<b>(19.1)</b>	<b>596</b>	<b>(3.7)</b>	<b>474</b>	<b>(2.9)</b>

<sup>a</sup> 'European Region' comprises the 53 countries of the WHO European Region. WHO European Region 18 TB High Priority Countries presented in italics.

<sup>b</sup> CNS - central nervous system.

<sup>c</sup> Percentages among all notified TB cases.

<sup>d</sup> Percentages among extrapulmonary cases.

<sup>e</sup> Excluding Greenland (see Chapter 1.1).

	Extrapulmonary TB														Unknown	
	Spinal		Gastrointestinal		Meningitis		Disseminated		CNS <sup>a</sup> /other		Other extrapulmonary		Extrapulmonary no site specified			
	N	(%) <sup>c</sup>	N	(%) <sup>c</sup>	N	(%) <sup>c</sup>	N	(%) <sup>c</sup>	N	(%) <sup>c</sup>	N	(%) <sup>c</sup>	N	(%) <sup>c</sup>	N	(%) <sup>b</sup>
3	(2.2)	8	(5.9)	1	(0.7)	2	(1.5)	2	(1.5)	11	(8.1)	0	(0.0)	11	(1.6)	
18	(6.1)	8	(2.7)	7	(2.4)	3	(1.0)	1	(0.3)	13	(4.4)	0	(0.0)	0	(0.0)	
21	(3.1)	12	(1.8)	5	(0.7)	4	(0.6)	3	(0.4)	103	(15.1)	0	(0.0)	0	(0.0)	
0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	1	(12.5)	0	(0.0)	2	(3.7)	
6	(7.7)	0	(0.0)	0	(0.0)	0	(0.0)	2	(2.6)	12	(15.4)	0	(0.0)	0	(0.0)	
0	(0.0)	2	(4.3)	0	(0.0)	1	(2.1)	0	(0.0)	3	(6.4)	0	(0.0)	94	(24.7)	
4	(20.0)	0	(0.0)	1	(5.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	
0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	89	(100.0)	0	(0.0)	
0	(0.0)	0	(0.0)	46	(3.6)	26	(2.0)	0	(0.0)	248	(19.2)	0	(0.0)	53	(1.1)	
34	(3.7)	43	(4.6)	22	(2.4)	13	(1.4)	9	(1.0)	70	(7.6)	0	(0.0)	44	(1.0)	
2	(3.3)	4	(6.7)	2	(3.3)	7	(11.7)	1	(1.7)	10	(16.7)	0	(0.0)	3	(0.6)	
0	(0.0)	0	(0.0)	2	(3.6)	0	(0.0)	0	(0.0)	15	(26.8)	0	(0.0)	0	(0.0)	
0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	1	(16.7)	1	(16.7)	0	(0.0)	0	(0.0)	
5	(4.1)	4	(3.3)	3	(2.5)	1	(0.8)	0	(0.0)	21	(17.4)	6	(5.0)	11	(2.6)	
72	(7.7)	56	(6.0)	14	(1.5)	18	(1.9)	14	(1.5)	157	(16.7)	0	(0.0)	0	(0.0)	
4	(4.5)	1	(1.1)	0	(0.0)	0	(0.0)	0	(0.0)	6	(6.7)	0	(0.0)	0	(0.0)	
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
0	(0.0)	2	(1.1)	0	(0.0)	0	(0.0)	0	(0.0)	42	(22.1)	0	(0.0)	0	(0.0)	
0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	
1	(9.1)	0	(0.0)	1	(9.1)	0	(0.0)	0	(0.0)	1	(9.1)	0	(0.0)	0	(0.0)	
26	(5.9)	33	(7.5)	3	(0.7)	0	(0.0)	7	(1.6)	53	(12.0)	0	(0.0)	3	(0.3)	
12	(7.6)	0	(0.0)	3	(1.9)	2	(1.3)	2	(1.3)	16	(10.1)	0	(0.0)	3	(0.8)	
35	(5.8)	12	(2.0)	10	(1.7)	16	(2.7)	2	(0.3)	53	(8.8)	0	(0.0)	0	(0.0)	
36	(5.3)	30	(4.4)	16	(2.4)	32	(4.7)	9	(1.3)	90	(13.3)	0	(0.0)	8	(0.3)	
129	(4.6)	65	(2.3)	129	(4.6)	0	(0.0)	3	(0.1)	108	(3.9)	0	(0.0)	0	(0.0)	
13	(21.0)	1	(1.6)	0	(0.0)	0	(0.0)	0	(0.0)	3	(4.8)	0	(0.0)	0	(0.0)	
1	(3.7)	3	(11.1)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	
0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	1783	(100.0)	0	(0.0)	
19	(8.3)	20	(8.8)	5	(2.2)	0	(0.0)	3	(1.3)	14	(6.1)	0	(0.0)	0	(0.0)	
0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	4313	(100.0)	47	(0.5)	
<b>441</b>	<b>(2.7)</b>	<b>304</b>	<b>(1.9)</b>	<b>270</b>	<b>(1.7)</b>	<b>125</b>	<b>(0.8)</b>	<b>59</b>	<b>(0.4)</b>	<b>1051</b>	<b>(6.5)</b>	<b>6191</b>	<b>(38.4)</b>	<b>279</b>	<b>(0.4)</b>	

**Table D1: All tuberculosis cases by site of disease in children, EU/EEA, 2011**

Country	Total TB cases notified (N)	Pulmonary TB		Extrapulmonary		Extrapulmonary TB							
						Lymphatic		Pleural		Urogenital		Bone	
		N	(%) <sup>b</sup>	N	(%) <sup>b</sup>	N	(%) <sup>c</sup>	N	(%) <sup>c</sup>	N	(%) <sup>c</sup>	N	(%) <sup>c</sup>
Austria	24	21	(87.5)	3	(12.5)	1	(33.3)	0	(0.0)	0	(0.0)	1	(33.3)
Belgium	85	60	(70.6)	25	(29.4)	19	(76.0)	2	(8.0)	0	(0.0)	0	(0.0)
<i>Bulgaria</i>	176	16	(9.1)	160	(90.9)	158	(98.8)	1	(0.6)	0	(0.0)	0	(0.0)
Cyprus	0	0	-	0	-	0	-	0	-	0	-	0	-
Czech Republic	6	5	(83.3)	1	(16.7)	1	(100.0)	0	(0.0)	0	(0.0)	0	(0.0)
Denmark <sup>d</sup>	16	8	(50.0)	3	(18.8)	1	(33.3)	0	(0.0)	0	(0.0)	0	(0.0)
<i>Estonia</i>	1	1	(100.0)	0	(0.0)	0	-	0	-	0	-	0	-
Finland	11	9	(81.8)	2	(18.2)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)
France	255	140	(54.9)	95	(37.3)	55	(57.9)	2	(2.1)	1	(1.1)	8	(8.4)
Germany	179	142	(79.3)	32	(17.9)	18	(56.3)	0	(0.0)	0	(0.0)	7	(21.9)
Greece	38	32	(84.2)	3	(7.9)	1	(33.3)	0	(0.0)	0	(0.0)	0	(0.0)
Hungary	4	4	(100.0)	0	(0.0)	0	-	0	-	0	-	0	-
Iceland	1	1	(100.0)	0	(0.0)	0	-	0	-	0	-	0	-
Ireland	20	11	(55.0)	9	(45.0)	5	(55.6)	1	(11.1)	0	(0.0)	0	(0.0)
Italy	209	169	(80.9)	40	(19.1)	21	(52.5)	5	(12.5)	0	(0.0)	3	(7.5)
<i>Latvia</i>	61	25	(41.0)	36	(59.0)	32	(88.9)	4	(11.1)	0	(0.0)	0	(0.0)
Liechtenstein	88	7	(8.0)	81	(92.0)	40	(49.4)	3	(3.7)	0	(0.0)	1	(1.2)
<i>Lithuania</i>	-	-	-	-	-	-	-	-	-	-	-	-	-
Luxembourg	1	1	(100.0)	0	(0.0)	0	-	0	-	0	-	0	-
Malta	0	0	-	0	-	0	-	0	-	0	-	0	-
Netherlands	56	22	(39.3)	34	(60.7)	29	(85.3)	2	(5.9)	0	(0.0)	1	(2.9)
Norway	17	9	(52.9)	8	(47.1)	4	(50.0)	0	(0.0)	0	(0.0)	0	(0.0)
Poland	111	60	(54.1)	51	(45.9)	40	(78.4)	6	(11.8)	1	(2.0)	1	(2.0)
Portugal	44	29	(65.9)	15	(34.1)	4	(26.7)	6	(40.0)	0	(0.0)	0	(0.0)
<i>Romania</i>	776	317	(40.9)	459	(59.1)	286	(62.3)	113	(24.6)	1	(0.2)	6	(1.3)
Slovakia	17	11	(64.7)	6	(35.3)	4	(66.7)	1	(16.7)	0	(0.0)	0	(0.0)
Slovenia	4	2	(50.0)	2	(50.0)	2	(100.0)	0	(0.0)	0	(0.0)	0	(0.0)
Spain	541	417	(77.1)	124	(22.9)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)
Sweden	36	28	(77.8)	8	(22.2)	4	(50.0)	1	(12.5)	0	(0.0)	0	(0.0)
United Kingdom	413	251	(60.8)	150	(36.3)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)
<b>Total EU/EEA</b>	<b>3190</b>	<b>1798</b>	<b>(56.4)</b>	<b>1347</b>	<b>(42.2)</b>	<b>725</b>	<b>(53.8)</b>	<b>147</b>	<b>(10.9)</b>	<b>3</b>	<b>(0.2)</b>	<b>28</b>	<b>(2.1)</b>

<sup>a</sup> 'European Region' comprises the 53 countries of the WHO European Region. WHO European Region 18 TB High Priority Countries presented in italics.

<sup>b</sup> CNS - central nervous system.

<sup>c</sup> Percentages among all notified TB cases.

<sup>d</sup> Percentages among extrapulmonary cases.

<sup>e</sup> Excluding Greenland (see Chapter 1.1).



	Extrapulmonary TB														Unknown		
	Spinal		Gastrointestinal		Meningitis		Disseminated		CNS <sup>a</sup> /other		Other extrapulmonary		Extrapulmonary no site specified				
	N	(%) <sup>c</sup>	N	(%) <sup>c</sup>	N	(%) <sup>c</sup>	N	(%) <sup>c</sup>	N	(%) <sup>c</sup>	N	(%) <sup>c</sup>	N	(%) <sup>c</sup>	N	(%) <sup>b</sup>	
0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	1	(33.3)	0	(0.0)	0	(0.0)	0	(0.0)
0	(0.0)	1	(4.0)	2	(8.0)	0	(0.0)	0	(0.0)	0	(0.0)	1	(4.0)	0	(0.0)	0	(0.0)
0	(0.0)	0	(0.0)	1	(0.6)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)
0	-	0	-	0	-	0	-	0	-	0	-	0	-	0	-	0	-
0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)
0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	1	(33.3)	0	(0.0)	1	(33.3)	0	(0.0)	5	(31.3)
0	-	0	-	0	-	0	-	0	-	0	-	0	-	0	-	0	(0.0)
0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	2	(100.0)	0	(0.0)
0	(0.0)	0	(0.0)	3	(3.2)	0	(0.0)	0	(0.0)	0	(0.0)	26	(27.4)	0	(0.0)	20	(7.8)
1	(3.1)	0	(0.0)	2	(6.3)	0	(0.0)	0	(0.0)	0	(0.0)	4	(12.5)	0	(0.0)	5	(2.8)
0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	2	(66.7)	0	(0.0)	3	(7.9)
0	-	0	-	0	-	0	-	0	-	0	-	0	-	0	-	0	(0.0)
0	-	0	-	0	-	0	-	0	-	0	-	0	-	0	-	0	(0.0)
0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	1	(11.1)	2	(22.2)	0	(0.0)
0	(0.0)	1	(2.5)	0	(0.0)	0	(0.0)	1	(2.5)	2	(5.0)	7	(17.5)	0	(0.0)	0	(0.0)
0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)
0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	37	(45.7)	0	(0.0)	0	(0.0)
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
0	-	0	-	0	-	0	-	0	-	0	-	0	-	0	-	0	(0.0)
0	-	0	-	0	-	0	-	0	-	0	-	0	-	0	-	0	-
0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	2	(5.9)	0	(0.0)	0	(0.0)
0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	1	(12.5)	0	(0.0)	3	(37.5)	0	(0.0)	0	(0.0)
1	(2.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	2	(3.9)	0	(0.0)	0	(0.0)
0	(0.0)	1	(6.7)	1	(6.7)	0	(0.0)	0	(0.0)	0	(0.0)	3	(20.0)	0	(0.0)	0	(0.0)
4	(0.9)	5	(1.1)	31	(6.8)	0	(0.0)	0	(0.0)	0	(0.0)	13	(2.8)	0	(0.0)	0	(0.0)
0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	1	(16.7)	0	(0.0)	0	(0.0)
0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)
0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	124	(100.0)	0	(0.0)
1	(12.5)	1	(12.5)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	1	(12.5)	0	(0.0)	0	(0.0)
0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	150	(100.0)	12	(2.9)
<b>7</b>	<b>(0.5)</b>	<b>9</b>	<b>(0.7)</b>	<b>40</b>	<b>(3.0)</b>	<b>3</b>	<b>(0.2)</b>	<b>3</b>	<b>(0.2)</b>	<b>104</b>	<b>7.7</b>	<b>278</b>	<b>(20.6)</b>	<b>45</b>	<b>(1.4)</b>		

**Table D2: All tuberculosis cases by site of disease in adults, EU/EEA, 2011**

Country	Total TB cases notified (N)	Pulmonary TB		Extrapulmonary		Extrapulmonary TB							
						Lymphatic		Pleural		Urogenital		Bone	
		N	(%) <sup>b</sup>	N	(%) <sup>b</sup>	N	(%) <sup>c</sup>	N	(%) <sup>c</sup>	N	(%) <sup>c</sup>	N	(%) <sup>c</sup>
Austria	663	519	(78.3)	133	(20.1)	64	(48.1)	20	(15.0)	16	(12.0)	7	(5.3)
Belgium	959	687	(71.6)	272	(28.4)	131	(48.2)	70	(25.7)	14	(5.1)	11	(4.0)
<i>Bulgaria</i>	2231	1708	(76.6)	523	(23.4)	115	(22.0)	215	(41.1)	29	(5.5)	17	(3.3)
Cyprus	54	44	(81.5)	8	(14.8)	5	(62.5)	2	(25.0)	0	(0.0)	0	(0.0)
Czech Republic	594	517	(87.0)	77	(13.0)	33	(42.9)	16	(20.8)	6	(7.8)	2	(2.6)
Denmark <sup>d</sup>	365	232	(63.6)	44	(12.1)	30	(68.2)	6	(13.6)	4	(9.1)	0	(0.0)
Estonia	340	320	(94.1)	20	(5.9)	5	(25.0)	6	(30.0)	2	(10.0)	2	(10.0)
Finland	314	227	(72.3)	87	(27.7)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)
France	4 685	3 459	(73.8)	1 193	(25.5)	522	(43.8)	227	(19.0)	46	(3.9)	108	(9.1)
Germany	4 134	3 204	(77.5)	892	(21.6)	413	(46.3)	145	(16.3)	90	(10.1)	60	(6.7)
Greece	447	390	(87.2)	57	(12.8)	21	(36.8)	8	(14.0)	3	(5.3)	1	(1.8)
Hungary	1 441	1 385	(96.1)	56	(3.9)	6	(10.7)	9	(16.1)	11	(19.6)	13	(23.2)
Iceland	8	2	(25.0)	6	(75.0)	3	(50.0)	1	(16.7)	0	(0.0)	0	(0.0)
Ireland	404	281	(69.6)	112	(27.7)	41	(36.6)	23	(20.5)	5	(4.5)	6	(5.4)
Italy	3 281	2 383	(72.6)	898	(27.4)	364	(40.5)	105	(11.7)	79	(8.8)	30	(3.3)
Latvia	824	771	(93.6)	53	(6.4)	15	(28.3)	22	(41.5)	5	(9.4)	0	(0.0)
Liechtenstein	-	-	-	-	-	-	-	-	-	-	-	-	-
Lithuania	1 816	1 707	(94.0)	109	(6.0)	11	(10.1)	55	(50.5)	17	(15.6)	19	(17.4)
Luxembourg	25	21	(84.0)	4	(16.0)	4	(100.0)	0	(0.0)	0	(0.0)	0	(0.0)
Malta	33	22	(66.7)	11	(33.3)	6	(54.5)	1	(9.1)	1	(9.1)	0	(0.0)
Netherlands	951	541	(56.9)	407	(42.8)	196	(48.2)	62	(15.2)	19	(4.7)	10	(2.5)
Norway	344	191	(55.5)	150	(43.6)	83	(55.3)	16	(10.7)	5	(3.3)	15	(10.0)
Poland	8 367	7 819	(93.5)	548	(6.5)	109	(19.9)	208	(38.0)	67	(12.2)	39	(7.1)
Portugal	2 487	1 822	(73.3)	657	(26.4)	211	(32.1)	180	(27.4)	48	(7.3)	11	(1.7)
Romania	18 436	16 114	(87.4)	2 322	(12.6)	249	(10.7)	1 493	(64.3)	116	(5.0)	83	(3.6)
Slovakia	382	326	(85.3)	56	(14.7)	16	(28.6)	17	(30.4)	7	(12.5)	0	(0.0)
Slovenia	188	163	(86.7)	25	(13.3)	8	(32.0)	11	(44.0)	1	(4.0)	1	(4.0)
Spain	6 211	4 553	(73.3)	1 658	(26.7)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)
Sweden	550	330	(60.0)	220	(40.0)	135	(61.4)	14	(6.4)	2	(0.9)	11	(5.0)
United Kingdom	8 550	4 352	(50.9)	4 163	(48.7)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)
<b>Total EU/EEA</b>	<b>69 084</b>	<b>54 090</b>	<b>(78.3)</b>	<b>14 761</b>	<b>(21.4)</b>	<b>2 796</b>	<b>18.9</b>	<b>2 932</b>	<b>(19.9)</b>	<b>593</b>	<b>(4.0)</b>	<b>446</b>	<b>(3.0)</b>

<sup>a</sup> 'European Region' comprises the 53 countries of the WHO European Region. WHO European Region 18 TB High Priority Countries presented in italics.

<sup>b</sup> CNS - central nervous system.

<sup>c</sup> Percentages among all notified TB cases.

<sup>d</sup> Percentages among extrapulmonary cases.

<sup>e</sup> Excluding Greenland (see Chapter 1.1).

	Extrapulmonary TB														Unknown	
	Spinal		Gastrointestinal		Meningitis		Disseminated		CNS <sup>a</sup> /other		Other extrapulmonary		Extrapulmonary no site specified			
	N	(%) <sup>c</sup>	N	(%) <sup>c</sup>	N	(%) <sup>c</sup>	N	(%) <sup>c</sup>	N	(%) <sup>c</sup>	N	(%) <sup>c</sup>	N	(%) <sup>c</sup>	N	(%) <sup>b</sup>
3	(2.3)	8	(6.0)	1	(0.8)	2	(1.5)	1	(0.8)	11	(8.3)	0	(0.0)	11	(1.7)	
18	(6.6)	7	(2.6)	5	(1.8)	3	(1.1)	1	(0.4)	12	(4.4)	0	(0.0)	0	(0.0)	
21	(4.0)	12	(2.3)	4	(0.8)	4	(0.8)	3	(0.6)	103	(19.7)	0	(0.0)	0	(0.0)	
0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	1	(12.5)	0	(0.0)	2	(3.7)	
6	(7.8)	0	(0.0)	0	(0.0)	0	(0.0)	2	(2.6)	12	(15.6)	0	(0.0)	0	(0.0)	
0	(0.0)	2	(4.5)	0	(0.0)	0	(0.0)	0	(0.0)	2	(4.5)	0	(0.0)	89	(24.4)	
4	(20.0)	0	(0.0)	1	(5.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	
0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	87	(100.0)	0	(0.0)	
0	(0.0)	0	(0.0)	42	(3.5)	26	(2.2)	0	(0.0)	222	(18.6)	0	(0.0)	33	(0.7)	
33	(3.7)	43	(4.8)	20	(2.2)	13	(1.5)	9	(1.0)	66	(7.4)	0	(0.0)	38	(0.9)	
2	(3.5)	4	(7.0)	2	(3.5)	7	(12.3)	1	(1.8)	8	(14.0)	0	(0.0)	0	(0.0)	
0	(0.0)	0	(0.0)	2	(3.6)	0	(0.0)	0	(0.0)	15	(26.8)	0	(0.0)	0	(0.0)	
0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	1	(16.7)	1	(16.7)	0	(0.0)	0	(0.0)	
5	(4.5)	4	(3.6)	3	(2.7)	1	(0.9)	0	(0.0)	20	(17.9)	4	(3.6)	11	(2.7)	
72	(8.0)	55	(6.1)	14	(1.6)	17	(1.9)	12	(1.3)	150	(16.7)	0	(0.0)	0	(0.0)	
4	(7.5)	1	(1.9)	0	(0.0)	0	(0.0)	0	(0.0)	6	(11.3)	0	(0.0)	0	(0.0)	
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
0	(0.0)	2	(1.8)	0	(0.0)	0	(0.0)	0	(0.0)	5	(4.6)	0	(0.0)	0	(0.0)	
0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	
1	(9.1)	0	(0.0)	1	(9.1)	0	(0.0)	0	(0.0)	1	(9.1)	0	(0.0)	0	(0.0)	
26	(6.4)	33	(8.1)	3	(0.7)	0	(0.0)	7	(1.7)	51	(12.5)	0	(0.0)	3	(0.3)	
12	(8.0)	0	(0.0)	3	(2.0)	1	(0.7)	2	(1.3)	13	(8.7)	0	(0.0)	3	(0.9)	
34	(6.2)	12	(2.2)	10	(1.8)	16	(2.9)	2	(0.4)	51	(9.3)	0	(0.0)	0	(0.0)	
35	(5.3)	29	(4.4)	15	(2.3)	32	(4.9)	9	(1.4)	87	(13.2)	0	(0.0)	8	(0.3)	
125	(5.4)	60	(2.6)	98	(4.2)	0	(0.0)	3	(0.1)	95	(4.1)	0	(0.0)	0	(0.0)	
13	(23.2)	1	(1.8)	0	(0.0)	0	(0.0)	0	(0.0)	2	(3.6)	0	(0.0)	0	(0.0)	
1	(4.0)	3	(12.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	
0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	1658	(100.0)	0	(0.0)	
18	(8.2)	19	(8.6)	5	(2.3)	0	(0.0)	3	(1.4)	13	(5.9)	0	(0.0)	0	(0.0)	
0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	4163	(100.0)	35	(0.4)	
<b>433</b>	<b>(2.9)</b>	<b>295</b>	<b>(2.0)</b>	<b>229</b>	<b>(1.6)</b>	<b>122</b>	<b>(0.8)</b>	<b>56</b>	<b>(0.4)</b>	<b>947</b>	<b>(6.4)</b>	<b>5912</b>	<b>(40.1)</b>	<b>233</b>	<b>(0.3)</b>	



**Table E: Extrapulmonary TB cases by laboratory confirmation and multidrug resistance, EU/EEA, 2011**

Country	Total (N)	Culture positive		Culture negative		Culture unknown/ not available		MDR-TB	
		N	(%)	N	(%)	N	(%)	N	(%) <sup>a</sup>
Austria	136	74	(54.4)	35	(25.7)	27	(19.9)	1	(1.4)
Belgium	297	205	(69.0)	55	(18.5)	37	(12.5)	3	(1.5)
<i>Bulgaria</i>	683	28	(4.1)	295	(43.2)	360	(52.7)	1	(3.6)
Cyprus	8	6	(75.0)	0	(0.0)	2	(25.0)	1	(16.7)
Czech Republic	78	31	(39.7)	40	(51.3)	7	(9.0)	0	(0.0)
Denmark <sup>b</sup>	47	38	(80.9)	8	(17.0)	1	(2.1)	1	(2.6)
Estonia	20	9	(45.0)	9	(45.0)	2	(10.0)	1	(11.1)
Finland	89	63	(70.8)	0	(0.0)	26	(29.2)	0	(0.0)
France	1289	504	(39.1)	162	(12.6)	623	(48.3)	0	(0.0)
Germany	926	542	(58.5)	180	(19.4)	204	(22.0)	5	(0.9)
Greece	60	24	(40.0)	2	(3.3)	34	(56.7)	0	(0.0)
Hungary	56	7	(12.5)	22	(39.3)	27	(48.2)	0	(0.0)
Iceland	6	4	(66.7)	1	(16.7)	1	(16.7)	0	(0.0)
Ireland	121	62	(51.2)	15	(12.4)	44	(36.4)	0	(0.0)
Italy	939	13	(1.4)	250	(26.6)	676	(72.0)	0	(0.0)
<i>Latvia</i>	89	22	(24.7)	67	(75.3)	0	(0.0)	3	(13.6)
Liechtenstein	-	-	-	-	-	-	-	-	-
<i>Lithuania</i>	190	34	(17.9)	156	(82.1)	0	(0.0)	4	(11.8)
Luxembourg	4	2	(50.0)	1	(25.0)	1	(25.0)	0	(0.0)
Malta	11	9	(81.8)	1	(9.1)	1	(9.1)	0	(0.0)
Netherlands	441	267	(60.5)	69	(15.6)	105	(23.8)	3	(1.1)
Norway	158	103	(65.2)	6	(3.8)	49	(31.0)	1	(1.0)
Poland	599	254	(42.4)	255	(42.6)	90	(15.0)	0	(0.0)
Portugal	675	203	(30.1)	63	(9.3)	409	(60.6)	4	(2.0)
<i>Romania</i>	2781	0	(0.0)	0	(0.0)	2781	(100.0)	0	-
Slovakia	62	10	(16.1)	37	(59.7)	15	(24.2)	0	(0.0)
Slovenia	27	21	(77.8)	4	(14.8)	2	(7.4)	0	(0.0)
Spain	1783	799	(44.8)	523	(29.3)	461	(25.9)	0	(0.0)
Sweden	228	170	(74.6)	35	(15.4)	23	(10.1)	6	(3.5)
United Kingdom	4313	2067	(47.9)	0	(0.0)	2246	(52.1)	29	(1.4)
<b>Total EU/EEA</b>	<b>16 116</b>	<b>5571</b>	<b>(34.6)</b>	<b>2291</b>	<b>(14.2)</b>	<b>8 254</b>	<b>(51.2)</b>	<b>63</b>	<b>(1.1)</b>

<sup>a</sup> 'European Region' comprises the 53 countries of the WHO European Region.

WHO European Region 18 TB High Priority Countries presented in italics.

<sup>b</sup> Percentage of MDR-TB culture-positive extrapulmonary cases, with available DST results.

<sup>c</sup> Excluding Greenland (see Chapter 1.1).

**Table F1:** All TB cases by site and origin, EU/EEA, 2011

Country	Total TB cases notified (N)	Native											
		Pulmonary TB		Extrapulmonary		Lymphatic		Pleural		Urogenital		Bone	
		N	(%) <sup>b</sup>	N	(%) <sup>b</sup>	N	(%) <sup>c</sup>	N	(%) <sup>c</sup>	N	(%) <sup>c</sup>	N	(%) <sup>c</sup>
Austria	354	270	(76.3)	77	(21.8)	31	(40.3)	14	(18.2)	12	(15.6)	2	(2.6)
Belgium	500	366	(73.2)	134	(26.8)	60	(44.8)	41	(30.6)	12	(9.0)	6	(4.5)
Bulgaria	2398	1717	(71.6)	681	(28.4)	272	(39.9)	216	(31.7)	29	(4.3)	17	(2.5)
Cyprus	9	7	(77.8)	2	(22.2)	1	(50.0)	0	(0.0)	0	(0.0)	0	(0.0)
Czech Republic	488	425	(87.1)	63	(12.9)	26	(41.3)	13	(20.6)	5	(7.9)	1	(1.6)
Denmark <sup>d</sup>	146	96	(65.8)	11	(7.5)	4	(36.4)	4	(36.4)	2	(18.2)	0	(0.0)
Estonia	293	278	(94.9)	15	(5.1)	4	(26.7)	4	(26.7)	2	(13.3)	2	(13.3)
Finland	212	162	(76.4)	50	(23.6)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)
France	2108	1620	(76.9)	465	(22.1)	185	(39.8)	90	(19.4)	20	(4.3)	50	(10.8)
Germany	2100	1735	(82.6)	353	(16.8)	116	(32.9)	73	(20.7)	53	(15.0)	27	(7.6)
Greece	273	241	(88.3)	30	(11.0)	10	(33.3)	5	(16.7)	2	(6.7)	1	(3.3)
Hungary	1418	1363	(96.1)	55	(3.9)	6	(10.9)	8	(14.5)	11	(20.0)	13	(23.6)
Iceland	2	2	(100.0)	0	(0.0)	0	-	0	-	0	-	0	-
Ireland	189	142	(75.1)	42	(22.2)	10	(23.8)	15	(35.7)	4	(9.5)	2	(4.8)
Italy	1578	1151	(72.9)	427	(27.1)	138	(32.3)	61	(14.3)	57	(13.3)	15	(3.5)
Latvia	817	735	(90.0)	82	(10.0)	45	(54.9)	22	(26.8)	5	(6.1)	0	(0.0)
Liechtenstein	-	-	-	-	-	-	-	-	-	-	-	-	-
Lithuania	1860	1673	(89.9)	187	(10.1)	49	(26.2)	57	(30.5)	17	(9.1)	20	(10.7)
Luxembourg	5	5	(100.0)	0	(0.0)	0	-	0	-	0	-	0	-
Malta	5	2	(40.0)	3	(60.0)	0	(0.0)	0	(0.0)	1	(33.3)	0	(0.0)
Netherlands	292	200	(68.5)	91	(31.2)	43	(47.3)	22	(24.2)	5	(5.5)	2	(2.2)
Norway	44	32	(72.7)	12	(27.3)	4	(33.3)	3	(25.0)	0	(0.0)	1	(8.3)
Poland	8440	7845	(93.0)	595	(7.0)	147	(24.7)	213	(35.8)	68	(11.4)	39	(6.6)
Portugal	2151	1598	(74.3)	545	(25.3)	174	(31.9)	148	(27.2)	44	(8.1)	8	(1.5)
Romania	19162	16390	(85.5)	2772	(14.5)	528	(19.0)	1605	(57.9)	116	(4.2)	89	(3.2)
Slovakia	396	335	(84.6)	61	(15.4)	19	(31.1)	18	(29.5)	7	(11.5)	0	(0.0)
Slovenia	135	116	(85.9)	19	(14.1)	7	(36.8)	7	(36.8)	1	(5.3)	1	(5.3)
Spain	4528	3363	(74.3)	1165	(25.7)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)
Sweden	62	44	(71.0)	18	(29.0)	6	(33.3)	5	(27.8)	0	(0.0)	1	(5.6)
United Kingdom	2226	1550	(69.6)	649	(29.2)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)
<b>Total EU/EEA</b>	<b>52191</b>	<b>43463</b>	<b>(83.3)</b>	<b>8604</b>	<b>(16.5)</b>	<b>1885</b>	<b>(21.9)</b>	<b>2644</b>	<b>(30.7)</b>	<b>473</b>	<b>(5.5)</b>	<b>297</b>	<b>(3.5)</b>

<sup>a</sup> 'European Region' comprises the 53 countries of the WHO European Region. WHO European Region 18 TB High Priority Countries presented in italics.

<sup>b</sup> CNS - central nervous system.

<sup>c</sup> Percentages among all notified TB cases.

<sup>d</sup> Percentages among extrapulmonary cases.

<sup>e</sup> Excluding Greenland (see Chapter 1.1).

	Native														Site unknown	
	Spinal		Gastrointestinal		Meningitis		Disseminated		CNS <sup>a</sup> /other		Other extrapulmonary		Extrapulmonary no site specified			
	N	(%) <sup>c</sup>	N	(%) <sup>c</sup>	N	(%) <sup>c</sup>	N	(%) <sup>c</sup>	N	(%) <sup>c</sup>	N	(%) <sup>c</sup>	N	(%) <sup>c</sup>	N	(%) <sup>b</sup>
1	(1.3)	4	(5.2)	1	(1.3)	2	(2.6)	2	(2.6)	8	(10.4)	0	(0.0)	7	(2.0)	
2	(1.5)	3	(2.2)	2	(1.5)	0	(0.0)	1	(0.7)	7	(5.2)	0	(0.0)	0	(0.0)	
21	(3.1)	12	(1.8)	5	(0.7)	4	(0.6)	3	(0.4)	102	(15.0)	0	(0.0)	0	(0.0)	
0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	1	(50.0)	0	(0.0)	0	(0.0)	
6	(9.5)	0	(0.0)	0	(0.0)	0	(0.0)	2	(3.2)	10	(15.9)	0	(0.0)	0	(0.0)	
0	(0.0)	1	(9.1)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	39	(26.7)	
2	(13.3)	0	(0.0)	1	(6.7)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	
0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	50	(100.0)	0	(0.0)	
0	(0.0)	0	(0.0)	16	(3.4)	9	(1.9)	0	(0.0)	95	(20.4)	0	(0.0)	23	(1.1)	
8	(2.3)	13	(3.7)	14	(4.0)	6	(1.7)	6	(1.7)	37	(10.5)	0	(0.0)	12	(0.6)	
1	(3.3)	3	(10.0)	0	(0.0)	4	(13.3)	1	(3.3)	3	(10.0)	0	(0.0)	2	(0.7)	
0	(0.0)	0	(0.0)	2	(3.6)	0	(0.0)	0	(0.0)	15	(27.3)	0	(0.0)	0	(0.0)	
0	-	0	-	0	-	0	-	0	-	0	-	0	-	0	-	
1	(2.4)	1	(2.4)	3	(7.1)	0	(0.0)	0	(0.0)	6	(14.3)	0	(0.0)	5	(2.6)	
28	(6.6)	21	(4.9)	5	(1.2)	9	(2.1)	6	(1.4)	87	(20.4)	0	(0.0)	0	(0.0)	
4	(4.9)	1	(1.2)	0	(0.0)	0	(0.0)	0	(0.0)	5	(6.1)	0	(0.0)	0	(0.0)	
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
0	(0.0)	2	(1.1)	0	(0.0)	0	(0.0)	0	(0.0)	42	(22.5)	0	(0.0)	0	(0.0)	
0	-	0	-	0	-	0	-	0	-	0	-	0	-	0	-	
1	(33.3)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	1	(33.3)	0	(0.0)	0	(0.0)	
1	(1.1)	2	(2.2)	2	(2.2)	0	(0.0)	1	(1.1)	13	(14.3)	0	(0.0)	1	(0.3)	
2	(16.7)	0	(0.0)	0	(0.0)	0	(0.0)	1	(8.3)	1	(8.3)	0	(0.0)	0	(0.0)	
35	(5.9)	12	(2.0)	10	(1.7)	16	(2.7)	2	(0.3)	53	(8.9)	0	(0.0)	0	(0.0)	
30	(5.5)	28	(5.1)	13	(2.4)	15	(2.8)	9	(1.7)	76	(13.9)	0	(0.0)	8	(0.4)	
129	(4.7)	65	(2.3)	129	(4.7)	0	(0.0)	3	(0.1)	108	(3.9)	0	(0.0)	0	(0.0)	
13	(21.3)	1	(1.6)	0	(0.0)	0	(0.0)	0	(0.0)	3	(4.9)	0	(0.0)	0	(0.0)	
0	(0.0)	3	(15.8)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	
0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	1165	(100.0)	0	(0.0)	
0	(0.0)	3	(16.7)	0	(0.0)	0	(0.0)	0	(0.0)	3	(16.7)	0	(0.0)	0	(0.0)	
0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	649	(100.0)	27	(1.2)	
<b>285</b>	<b>(3.3)</b>	<b>175</b>	<b>(2.0)</b>	<b>203</b>	<b>(2.4)</b>	<b>65</b>	<b>(0.8)</b>	<b>37</b>	<b>(0.4)</b>	<b>676</b>	<b>(7.9)</b>	<b>1864</b>	<b>(21.7)</b>	<b>124</b>	<b>0.2</b>	

Table F2: All TB cases by site and origin, EU/EEA, 2011

Country	Total TB cases notified (N)	Foreign origin											
		Pulmonary TB		Extrapulmonary		Lymphatic		Pleural		Urogenital		Bone	
		N	(%) <sup>b</sup>	N	(%) <sup>b</sup>	N	(%) <sup>c</sup>	N	(%) <sup>c</sup>	N	(%) <sup>c</sup>	N	(%) <sup>c</sup>
Austria	326	264	(81.0)	58	(17.8)	33	(56.9)	6	(10.3)	4	(6.9)	6	(10.3)
Belgium	544	381	(70.0)	163	(30.0)	90	(55.2)	31	(19.0)	2	(1.2)	5	(3.1)
<i>Bulgaria</i>	9	7	(77.8)	2	(22.2)	1	(50.0)	0	(0.0)	0	(0.0)	0	(0.0)
Cyprus	45	37	(82.2)	6	(13.3)	4	(66.7)	2	(33.3)	0	(0.0)	0	(0.0)
Czech Republic	112	97	(86.6)	15	(13.4)	8	(53.3)	3	(20.0)	1	(6.7)	1	(6.7)
Denmark <sup>d</sup>	235	144	(61.3)	36	(15.3)	27	(75.0)	2	(5.6)	2	(5.6)	0	(0.0)
<i>Estonia</i>	48	43	(89.6)	5	(10.4)	1	(20.0)	2	(40.0)	0	(0.0)	0	(0.0)
Finland	79	48	(60.8)	31	(39.2)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)
France	2456	1711	(69.7)	728	(29.6)	341	(46.8)	121	(16.6)	24	(3.3)	60	(8.2)
Germany	2025	1481	(73.1)	528	(26.1)	294	(55.7)	71	(13.4)	30	(5.7)	37	(7.0)
Greece	216	185	(85.6)	30	(13.9)	12	(40.0)	3	(10.0)	1	(3.3)	0	(0.0)
Hungary	27	26	(96.3)	1	(3.7)	0	(0.0)	1	(100.0)	0	(0.0)	0	(0.0)
Iceland	7	1	(14.3)	6	(85.7)	3	(50.0)	1	(16.7)	0	(0.0)	0	(0.0)
Ireland	179	110	(61.5)	66	(36.9)	29	(43.9)	8	(12.1)	0	(0.0)	4	(6.1)
Italy	1677	1230	(73.3)	447	(26.7)	221	(49.4)	50	(11.2)	22	(4.9)	16	(3.6)
<i>Latvia</i>	59	52	(88.1)	7	(11.9)	2	(28.6)	4	(57.1)	0	(0.0)	0	(0.0)
Liechtenstein	-	-	-	-	-	-	-	-	-	-	-	-	-
<i>Lithuania</i>	44	41	(93.2)	3	(6.8)	2	(66.7)	1	(33.3)	0	(0.0)	0	(0.0)
Luxembourg	21	17	(81.0)	4	(19.0)	4	(100.0)	0	(0.0)	0	(0.0)	0	(0.0)
Malta	28	20	(71.4)	8	(28.6)	6	(75.0)	1	(12.5)	0	(0.0)	0	(0.0)
Netherlands	710	362	(51.0)	347	(48.9)	180	(51.9)	42	(12.1)	14	(4.0)	9	(2.6)
Norway	317	168	(53.0)	146	(46.1)	83	(56.8)	13	(8.9)	5	(3.4)	14	(9.6)
Poland	38	34	(89.5)	4	(10.5)	2	(50.0)	1	(25.0)	0	(0.0)	1	(25.0)
Portugal	385	255	(66.2)	130	(33.8)	41	(31.5)	40	(30.8)	4	(3.1)	3	(2.3)
<i>Romania</i>	50	41	(82.0)	9	(18.0)	7	(77.8)	1	(11.1)	1	(11.1)	0	(0.0)
Slovakia	3	2	(66.7)	1	(33.3)	1	(100.0)	0	(0.0)	0	(0.0)	0	(0.0)
Slovenia	57	49	(86.0)	8	(14.0)	3	(37.5)	4	(50.0)	0	(0.0)	0	(0.0)
Spain	2138	1560	(73.0)	578	(27.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)
Sweden	524	314	(59.9)	210	(40.1)	133	(63.3)	10	(4.8)	2	(1.0)	10	(4.8)
United Kingdom	6287	2812	(44.7)	3462	(55.1)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)
<b>Total EU/EEA</b>	<b>18 646</b>	<b>11492</b>	<b>(61.6)</b>	<b>7039</b>	<b>(37.8)</b>	<b>1528</b>	<b>(21.7)</b>	<b>418</b>	<b>(5.9)</b>	<b>112</b>	<b>(1.6)</b>	<b>166</b>	<b>(2.4)</b>

<sup>a</sup> 'European Region' comprises the 53 countries of the WHO European Region. WHO European Region 18 TB High Priority Countries presented in italics.

<sup>b</sup> CNS - central nervous system.

<sup>c</sup> Percentages among all notified TB cases.

<sup>d</sup> Percentages among extrapulmonary cases.

<sup>e</sup> Excluding Greenland (see Chapter 1.1).



	Foreign origin														Site unknown	
	Spinal		Gastrointestinal		Meningitis		Disseminated		CNS <sup>a</sup> /other		Other extrapulmonary		Extrapulmonary no site specified			
	N	(%) <sup>c</sup>	N	(%) <sup>c</sup>	N	(%) <sup>c</sup>	N	(%) <sup>c</sup>	N	(%) <sup>c</sup>	N	(%) <sup>c</sup>	N	(%) <sup>c</sup>	N	(%) <sup>b</sup>
2	(3.4)	4	(6.9)	0	(0.0)	0	(0.0)	0	(0.0)	3	(5.2)	0	(0.0)	4	(1.2)	
16	(9.8)	5	(3.1)	5	(3.1)	3	(1.8)	0	(0.0)	6	(3.7)	0	(0.0)	0	(0.0)	
0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	1	(50.0)	0	(0.0)	0	(0.0)	
0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	2	(4.4)	
0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	2	(13.3)	0	(0.0)	0	(0.0)	
0	(0.0)	1	(2.8)	0	(0.0)	1	(2.8)	0	(0.0)	3	(8.3)	0	(0.0)	55	(23.4)	
2	(40.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	
0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	31	(100.0)	0	(0.0)	
0	(0.0)	0	(0.0)	29	(4.0)	17	(2.3)	0	(0.0)	136	(18.7)	0	(0.0)	17	(0.7)	
25	(4.7)	27	(5.1)	7	(1.3)	7	(1.3)	3	(0.6)	27	(5.1)	0	(0.0)	16	(0.8)	
1	(3.3)	1	(3.3)	2	(6.7)	3	(10.0)	0	(0.0)	7	(23.3)	0	(0.0)	1	(0.5)	
0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	
0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	1	(16.7)	1	(16.7)	0	(0.0)	0	(0.0)	
4	(6.1)	3	(4.5)	0	(0.0)	1	(1.5)	0	(0.0)	13	(19.7)	4	(6.1)	3	(1.7)	
40	(8.9)	31	(6.9)	9	(2.0)	7	(1.6)	8	(1.8)	43	(9.6)	0	(0.0)	0	(0.0)	
0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	1	(14.3)	0	(0.0)	0	(0.0)	
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	
0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	
0	(0.0)	0	(0.0)	1	(12.5)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	
25	(7.2)	31	(8.9)	1	(0.3)	0	(0.0)	6	(1.7)	39	(11.2)	0	(0.0)	1	(0.1)	
10	(6.8)	0	(0.0)	3	(2.1)	2	(1.4)	1	(0.7)	15	(10.3)	0	(0.0)	3	(0.9)	
0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	
6	(4.6)	2	(1.5)	3	(2.3)	17	(13.1)	0	(0.0)	14	(10.8)	0	(0.0)	0	(0.0)	
0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	
0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	
1	(12.5)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	
0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	578	(100.0)	0	(0.0)	
19	(9.0)	17	(8.1)	5	(2.4)	0	(0.0)	3	(1.4)	11	(5.2)	0	(0.0)	0	(0.0)	
0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	3 462	(100.0)	13	(0.2)	
<b>151</b>	<b>(2.1)</b>	<b>122</b>	<b>(1.7)</b>	<b>65</b>	<b>(0.9)</b>	<b>58</b>	<b>(0.8)</b>	<b>22</b>	<b>(0.3)</b>	<b>322</b>	<b>(4.6)</b>	<b>4 075</b>	<b>(57.9)</b>	<b>115</b>	<b>(0.6)</b>	

Table F3: All TB cases by site and origin, EU/EEA, 2011

Country	Total TB cases notified (N)	Unknown origin											
		Pulmonary TB		Extrapulmonary		Lymphatic		Pleural		Urogenital		Bone	
		N	(%) <sup>b</sup>	N	(%) <sup>b</sup>	N	(%) <sup>c</sup>	N	(%) <sup>c</sup>	N	(%) <sup>c</sup>	N	(%) <sup>c</sup>
Austria	7	6	(85.7)	1	(14.3)	1	(100.0)	0	(0.0)	0	(0.0)	0	(0.0)
Belgium	0	0	-	0	-	0	-	0	-	0	-	0	-
Bulgaria	0	0	-	0	-	0	-	0	-	0	-	0	-
Cyprus	0	0	-	0	-	0	-	0	-	0	-	0	-
Czech Republic	0	0	-	0	-	0	-	0	-	0	-	0	-
Denmark <sup>d</sup>	0	0	-	0	-	0	-	0	-	0	-	0	-
Estonia	0	0	-	0	-	0	-	0	-	0	-	0	-
Finland	34	26	(76.5)	8	(23.5)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)
France	378	269	(71.2)	96	(25.4)	51	(53.1)	18	(18.8)	3	(3.1)	6	(6.3)
Germany	191	130	(68.1)	45	(23.6)	21	(46.7)	3	(6.7)	7	(15.6)	3	(6.7)
Greece	0	0	-	0	-	0	-	0	-	0	-	0	-
Hungary	0	0	-	0	-	0	-	0	-	0	-	0	-
Iceland	0	0	-	0	-	0	-	0	-	0	-	0	-
Ireland	57	41	(71.9)	13	(22.8)	7	(53.8)	1	(7.7)	1	(7.7)	0	(0.0)
Italy	266	201	(75.6)	65	(24.4)	26	(40.0)	0	(0.0)	0	(0.0)	2	(3.1)
Latvia	9	9	(100.0)	0	(0.0)	0	-	0	-	0	-	0	-
Liechtenstein	-	-	-	-	-	-	-	-	-	-	-	-	-
Lithuania	0	0	-	0	-	0	-	0	-	0	-	0	-
Luxembourg	0	0	-	0	-	0	-	0	-	0	-	0	-
Malta	0	0	-	0	-	0	-	0	-	0	-	0	-
Netherlands	5	1	(20.0)	3	(60.0)	2	(66.7)	0	(0.0)	0	(0.0)	0	(0.0)
Norway	0	0	-	0	-	0	-	0	-	0	-	0	-
Poland	0	0	-	0	-	0	-	0	-	0	-	0	-
Portugal	4	4	(100.0)	0	(0.0)	0	-	0	-	0	-	0	-
Romania	0	0	-	0	-	0	-	0	-	0	-	0	-
Slovakia	0	0	-	0	-	0	-	0	-	0	-	0	-
Slovenia	0	0	-	0	-	0	-	0	-	0	-	0	-
Spain	96	56	(58.3)	40	(41.7)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)
Sweden	0	0	-	0	-	0	-	0	-	0	-	0	-
United Kingdom	450	241	(53.6)	202	(44.9)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)
<b>Total EU/EEA</b>	<b>1497</b>	<b>984</b>	<b>(65.7)</b>	<b>473</b>	<b>(31.6)</b>	<b>108</b>	<b>(22.8)</b>	<b>22</b>	<b>(4.7)</b>	<b>11</b>	<b>(2.3)</b>	<b>11</b>	<b>(2.3)</b>

<sup>a</sup> 'European Region' comprises the 53 countries of the WHO European Region. WHO European Region 18 TB High Priority Countries presented in italics.

<sup>b</sup> CNS - central nervous system.

<sup>c</sup> Percentages among all notified TB cases.

<sup>d</sup> Percentages among extrapulmonary cases.

<sup>e</sup> Excluding Greenland (see Chapter 1.1).

	Unknown origin														Site unknown		
	Spinal		Gastrointestinal		Meningitis		Disseminated		CNS <sup>a</sup> /other		Other extrapulmonary		Extrapulmonary no site specified				
	N	(%) <sup>c</sup>	N	(%) <sup>c</sup>	N	(%) <sup>c</sup>	N	(%) <sup>c</sup>	N	(%) <sup>c</sup>	N	(%) <sup>c</sup>	N	(%) <sup>c</sup>	N	(%) <sup>b</sup>	
0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)
0	-	0	-	0	-	0	-	0	-	0	-	0	-	0	-	0	-
0	-	0	-	0	-	0	-	0	-	0	-	0	-	0	-	0	-
0	-	0	-	0	-	0	-	0	-	0	-	0	-	0	-	0	-
0	-	0	-	0	-	0	-	0	-	0	-	0	-	0	-	0	-
0	-	0	-	0	-	0	-	0	-	0	-	0	-	0	-	0	-
0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	8	(100.0)	0	(0.0)
0	(0.0)	0	(0.0)	1	(1.0)	0	(0.0)	0	(0.0)	17	(17.7)	0	(0.0)	13	(3.4)	13	(3.4)
1	(2.2)	3	(6.7)	1	(2.2)	0	(0.0)	0	(0.0)	6	(13.3)	0	(0.0)	16	(8.4)	16	(8.4)
0	-	0	-	0	-	0	-	0	-	0	-	0	-	0	-	0	-
0	-	0	-	0	-	0	-	0	-	0	-	0	-	0	-	0	-
0	-	0	-	0	-	0	-	0	-	0	-	0	-	0	-	0	-
0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	2	(15.4)	2	(15.4)	3	(5.3)	3	(5.3)
4	(6.2)	4	(6.2)	0	(0.0)	2	(3.1)	0	(0.0)	27	(41.5)	0	(0.0)	0	(0.0)	0	(0.0)
0	-	0	-	0	-	0	-	0	-	0	-	0	-	0	-	0	(0.0)
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
0	-	0	-	0	-	0	-	0	-	0	-	0	-	0	-	0	-
0	-	0	-	0	-	0	-	0	-	0	-	0	-	0	-	0	-
0	-	0	-	0	-	0	-	0	-	0	-	0	-	0	-	0	-
0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	1	(33.3)	0	(0.0)	1	(20.0)	1	(20.0)
0	-	0	-	0	-	0	-	0	-	0	-	0	-	0	-	0	-
0	-	0	-	0	-	0	-	0	-	0	-	0	-	0	-	0	-
0	-	0	-	0	-	0	-	0	-	0	-	0	-	0	-	0	(0.0)
0	-	0	-	0	-	0	-	0	-	0	-	0	-	0	-	0	-
0	-	0	-	0	-	0	-	0	-	0	-	0	-	0	-	0	-
0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	40	(100.0)	0	(0.0)	0	(0.0)
0	-	0	-	0	-	0	-	0	-	0	-	0	-	0	-	0	-
0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	202	(100.0)	7	(1.6)	7	(1.6)
<b>5</b>	<b>(1.1)</b>	<b>7</b>	<b>(1.5)</b>	<b>2</b>	<b>(0.4)</b>	<b>2</b>	<b>(0.4)</b>	<b>0</b>	<b>(0.0)</b>	<b>53</b>	<b>(11.2)</b>	<b>252</b>	<b>(53.3)</b>	<b>40</b>	<b>2.7</b>	<b>40</b>	<b>2.7</b>

**Table G: Treatment success for all TB cases by site of disease, EU/EEA, 2010**

Country	Total extrapulmonary (N)	Treatment success		Extrapulmonary TB by site														
		N	%	Lymphatic (N)	Treatment success		Pleural (N)	Treatment success		Urogenital (N)	Treatment success		Bone (N)	Treatment success		Spinal (N)	Treatment success	
					N	%		N	%		N	%		N	%		N	%
Austria	133	85	(63.9)	76	54	(71.1)	15	10	(66.7)	5	4	(80.0)	6	2	(33.3)	4	1	(25.0)
Belgium	303	244	(80.5)	174	143	(82.2)	41	36	(87.8)	18	17	(94.4)	10	5	(50.0)	17	15	(88.2)
Bulgaria	798	738	(92.5)	305	296	(97.0)	238	212	(89.1)	20	20	(100.0)	23	21	(91.3)	25	20	(80.0)
Cyprus	19	4	(21.1)	9	1	(11.1)	4	2	(50.0)	2	1	(50.0)	0	0	(0.0)	1	0	(0.0)
Czech Republic	97	79	(81.4)	30	23	(76.7)	32	25	(78.1)	5	5	(100.0)	9	7	(77.8)	8	7	(87.5)
Denmark <sup>a</sup>	44	31	(70.5)	18	13	(72.2)	6	4	(66.7)	3	3	(100.0)	1	1	(100.0)	6	4	(66.7)
Estonia	21	13	(61.9)	5	3	(60.0)	7	5	(71.4)	5	4	(80.0)	1	1	(100.0)	2	0	(0.0)
Finland	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
France	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Germany	979	752	(76.8)	459	369	(80.4)	157	120	(76.4)	83	74	(89.2)	66	47	(71.2)	37	28	(75.7)
Greece	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Hungary	74	62	(83.8)	6	5	(83.3)	32	27	(84.4)	5	4	(80.0)	15	11	(73.3)	0	0	(0.0)
Iceland	4	4	(100.0)	2	2	(100.0)	0	0	(0.0)	0	0	(0.0)	0	0	(0.0)	0	0	(0.0)
Ireland	150	117	(78.0)	61	52	(85.2)	24	18	(75.0)	4	2	(50.0)	8	6	(75.0)	5	2	(40.0)
Italy	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Latvia	88	80	(90.9)	43	41	(95.3)	30	26	(86.7)	7	7	(100.0)	4	2	(50.0)	1	1	(100.0)
Liechtenstein	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Lithuania	225	209	(92.9)	87	82	(94.3)	69	63	(91.3)	20	19	(95.0)	21	18	(85.7)	0	0	(0.0)
Luxembourg	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Malta	13	8	(61.5)	9	6	(66.7)	1	0	(0.0)	0	0	(0.0)	1	1	(100.0)	0	0	(0.0)
Netherlands	475	406	(85.5)	237	213	(89.9)	54	47	(87.0)	22	17	(77.3)	26	23	(88.5)	33	30	(90.9)
Norway	137	117	(85.4)	80	73	(91.3)	10	9	(90.0)	2	1	(50.0)	7	5	(71.4)	7	6	(85.7)
Poland	517	386	(74.7)	120	94	(78.3)	199	144	(72.4)	69	54	(78.3)	42	27	(64.3)	24	21	(87.5)
Portugal	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Romania	3058	2734	(89.4)	566	518	(91.5)	1792	1661	(92.7)	114	96	(84.2)	88	70	(79.5)	146	108	(74.0)
Slovakia	67	62	(92.5)	12	11	(91.7)	21	19	(90.5)	12	12	(100.0)	3	3	(100.0)	12	11	(91.7)
Slovenia	30	23	(76.7)	8	7	(87.5)	16	11	(68.8)	2	2	(100.0)	0	0	(0.0)	1	0	(0.0)
Spain	1933	1312	(67.9)	0	0	(0.0)	0	0	(0.0)	0	0	(0.0)	0	0	(0.0)	0	0	(0.0)
Sweden	252	218	(86.5)	141	129	(91.5)	26	19	(73.1)	9	9	(100.0)	15	12	(80.0)	15	11	(73.3)
United Kingdom	3949	3304	(83.7)	0	0	(0.0)	0	0	(0.0)	0	0	(0.0)	0	0	(0.0)	0	0	(0.0)
<b>Total EU/EEA</b>	<b>13366</b>	<b>10988</b>	<b>(82.2)</b>	<b>2448</b>	<b>2135</b>	<b>(87.2)</b>	<b>2774</b>	<b>2458</b>	<b>(88.6)</b>	<b>407</b>	<b>351</b>	<b>(86.2)</b>	<b>346</b>	<b>262</b>	<b>(75.7)</b>	<b>344</b>	<b>265</b>	<b>(77.0)</b>

<sup>a</sup>European Region\* comprises the 53 countries of the WHO European Region.  
WHO European Region 18 TB High Priority Countries presented in italics.

\* Excluding Greenland (see Chapter 1.1).

Extrapulmonary TB by site																	
Gastro-intestinal (N)	Treatment success		Meningitis (N)	Treatment success		Disseminated (N)	Treatment success		CNS/other (N)	Treatment success		Other extrapulmonary (N)	Treatment success		Extrapulmonary no site specified (N)	Treatment success	
	N	(%)		N	(%)		N	(%)		N	(%)		N	(%)		N	(%)
10	6	(60.0)	1	0	(0.0)	5	1	(20.0)	4	2	(50.0)	7	5	(71.4)	0	0	(0.0)
7	5	(71.4)	8	6	(75.0)	3	1	(33.3)	1	1	(100.0)	24	15	(62.5)	0	0	(0.0)
11	10	(90.9)	6	6	(100.0)	8	6	(75.0)	0	0	(0.0)	162	147	(90.7)	0	0	(0.0)
1	0	(0.0)	1	0	(0.0)	0	0	(0.0)	1	0	(0.0)	0	0	(0.0)	0	0	(0.0)
1	1	(100.0)	0	0	(0.0)	0	0	(0.0)	1	1	(100.0)	11	10	(90.9)	0	0	(0.0)
1	0	(0.0)	2	1	(50.0)	1	1	(100.0)	1	0	(0.0)	5	4	(80.0)	0	0	(0.0)
0	0	(0.0)	1	0	(0.0)	0	0	(0.0)	0	0	(0.0)	0	0	(0.0)	0	0	(0.0)
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
42	30	(71.4)	23	10	(43.5)	17	9	(52.9)	11	6	(54.5)	84	59	(70.2)	0	0	(0.0)
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
0	0	(0.0)	1	1	(100.0)	0	0	(0.0)	0	0	(0.0)	15	14	(93.3)	0	0	(0.0)
1	1	(100.0)	0	0	(0.0)	0	0	(0.0)	0	0	(0.0)	1	1	(100.0)	0	0	(0.0)
0	0	(0.0)	8	2	(25.0)	1	1	(100.0)	4	2	(50.0)	35	32	(91.4)	0	0	(0.0)
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
0	0	(0.0)	1	1	(100.0)	0	0	(0.0)	0	0	(0.0)	2	2	(100.0)	0	0	(0.0)
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
3	2	(66.7)	2	2	(100.0)	0	0	(0.0)	0	0	(0.0)	23	23	(100.0)	0	0	(0.0)
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
2	1	(50.0)	0	0	(0.0)	0	0	(0.0)	0	0	(0.0)	0	0	(0.0)	0	0	(0.0)
30	21	(70.0)	8	1	(12.5)	0	0	(0.0)	11	8	(72.7)	54	46	(85.2)	0	0	(0.0)
0	0	(0.0)	2	1	(50.0)	4	2	(50.0)	2	2	(100.0)	23	18	(78.3)	0	0	(0.0)
13	8	(61.5)	5	3	(60.0)	4	2	(50.0)	4	3	(75.0)	37	30	(81.1)	0	0	(0.0)
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
78	63	(80.8)	128	91	(71.1)	0	0	(0.0)	4	3	(75.0)	142	124	(87.3)	0	0	(0.0)
2	1	(50.0)	0	0	(0.0)	1	1	(100.0)	0	0	(0.0)	4	4	(100.0)	0	0	(0.0)
0	0	(0.0)	0	0	(0.0)	0	0	(0.0)	0	0	(0.0)	3	3	(100.0)	0	0	(0.0)
0	0	(0.0)	0	0	(0.0)	0	0	(0.0)	0	0	(0.0)	0	0	(0.0)	1933	1312	(67.9)
19	17	(89.5)	5	2	(40.0)	3	1	(33.3)	6	6	(100.0)	13	12	(92.3)	0	0	(0.0)
0	0	(0.0)	0	0	(0.0)	0	0	(0.0)	0	0	(0.0)	0	0	(0.0)	3949	3304	(83.7)
<b>221</b>	<b>166</b>	<b>(75.1)</b>	<b>202</b>	<b>127</b>	<b>(62.9)</b>	<b>47</b>	<b>25</b>	<b>(53.2)</b>	<b>50</b>	<b>34</b>	<b>(68.0)</b>	<b>645</b>	<b>549</b>	<b>(85.1)</b>	<b>5882</b>	<b>4616</b>	<b>(78.5)</b>

**Table H: Tuberculosis cases with HIV infection by site of disease, EU/EEA, 2011**

Country	Pulmonary					Extrapulmonary				
	Total (N) <sup>a</sup>	Cases with known HIV status		HIV positive		Total (N) <sup>a</sup>	Cases with known HIV status		HIV positive	
		N	(%)	N	(%)		N	(%)	N	(%)
Austria	-	-	-	-	-	-	-	-	-	-
Belgium	747	592	(79.3)	34	(5.7)	297	253	(85.2)	10	(4.0)
<i>Bulgaria</i>	1724	1408	(81.7)	4	(0.3)	683	290	(42.5)	1	(0.3)
Cyprus	-	-	-	-	-	-	-	-	-	-
Czech Republic	522	136	(26.1)	3	(2.2)	78	17	(21.8)	1	(5.9)
Denmark <sup>b</sup>	-	-	-	-	-	-	-	-	-	-
<i>Estonia</i>	321	296	(92.2)	45	(15.2)	20	17	(85.0)	2	(11.8)
Finland	-	-	-	-	-	-	-	-	-	-
France	-	-	-	-	-	-	-	-	-	-
Germany	-	-	-	-	-	-	-	-	-	-
Greece	-	-	-	-	-	-	-	-	-	-
Hungary	-	-	-	-	-	-	-	-	-	-
Iceland	3	2	(66.7)	0	(0.0)	3	2	(66.7)	0	(0.0)
Ireland	293	63	(21.5)	16	(25.4)	121	31	(25.6)	3	(9.7)
Italy	-	-	-	-	-	-	-	-	-	-
<i>Latvia</i>	-	-	-	-	-	-	-	-	-	-
Liechtenstein	-	-	-	-	-	-	-	-	-	-
<i>Lithuania</i>	1714	1286	(75.0)	21	(1.6)	190	66	(34.7)	1	(1.5)
Luxembourg	-	-	-	-	-	-	-	-	-	-
Malta	22	21	(95.5)	5	(23.8)	11	9	(81.8)	0	(0.0)
Netherlands	-	-	-	-	-	-	-	-	-	-
Norway	-	-	-	-	-	-	-	-	-	-
Poland	-	-	-	-	-	-	-	-	-	-
Portugal	-	-	-	-	-	-	-	-	-	-
<i>Romania</i>	16431	8188	(49.8)	191	(2.3)	2781	1195	(43.0)	52	(4.4)
Slovakia	337	336	(99.7)	0	(0.0)	62	59	(95.2)	0	(0.0)
Slovenia	165	132	(80.0)	0	(0.0)	27	15	(55.6)	0	(0.0)
Spain	4979	3398	(68.2)	295	(8.7)	1783	1143	(64.1)	120	(10.5)
Sweden	-	-	-	-	-	-	-	-	-	-
United Kingdom	-	-	-	-	-	-	-	-	-	-
<b>Subtotal EU/EEA</b>	<b>27258</b>	<b>15858</b>	<b>(58.2)</b>	<b>614</b>	<b>(3.9)</b>	<b>6056</b>	<b>3097</b>	<b>(51.1)</b>	<b>190</b>	<b>(6.1)</b>

<sup>a</sup> 'European Region' comprises the 53 countries of the WHO European Region.

WHO European Region 18 TB High Priority Countries presented in italics.

<sup>b</sup> Excluding cases from countries not reporting positive and negative HIV status

<sup>c</sup> Excluding Greenland (see Chapter 1.1).

## Trend tables

**Table 1: All notified TB cases, rates per 100 000 population and mean annual change in rates, European Region, 1995–2011**

Country	Trend in rate, 1995–2011	1995		1996		1997		1998		1999		2000		2001	
		N	Rate	N	Rate	N	Rate	N	Rate	N	Rate	N	Rate	N	Rate
<b>EU/EEA</b>															
Austria		1479	18.6	1488	19	1396	17.5	1316	16.5	1245	15.6	1225	15.3	1075	13.4
Belgium		1380	13.6	1352	13	1263	12.4	1203	11.8	1270	12.4	1313	12.8	1321	12.9
<i>Bulgaria</i>		3245	38.5	3109	37	3437	41.2	4117	49.7	3530	42.9	3349	40.9	3862	47.4
Cyprus		36	5.6	24	4	47	7.1	45	6.7	39	5.7	33	4.8	40	5.7
Czech Republic		1851	17.9	1936	19	1834	17.8	1805	17.5	1631	15.9	1442	14.0	1350	13.1
Denmark <sup>a</sup>		448	8.6	484	9.2	554	10.5	529	10.0	536	10.1	548	10.3	511	9.6
<i>Estonia</i>		608	42.0	683	47.9	744	52.9	818	58.7	754	54.7	791	57.7	812	59.4
Finland		654	12.8	635	12.4	557	10.9	612	11.9	594	11.5	546	10.6	501	9.7
France		8723	14.7	7656	12.9	6832	11.4	6651	11.1	6674	11.1	6714	11.1	6465	10.6
Germany		12198	15.0	11814	14.4	11163	13.6	10440	12.7	9974	12.2	9064	11.0	7539	9.2
Greece		939	8.9	945	8.9	767	7.1	1152	10.7	952	8.8	703	6.4	617	5.6
Hungary		4339	42.0	4278	41.4	4240	41.2	3999	38.9	3914	38.2	3598	35.2	3150	30.9
Iceland		12	4.5	11	4.1	10	3.7	17	6.2	12	4.4	13	4.7	13	4.6
Ireland		458	12.7	434	12.0	416	11.4	424	11.5	469	12.6	403	10.7	406	10.6
Italy		5225	9.2	5152	9.1	5176	9.1	4795	8.4	4429	7.8	4759	8.4	4505	7.9
<i>Latvia</i>		1541	61.6	1761	71.3	2003	81.9	2182	90.1	1968	82.0	2063	86.6	2082	88.1
Liechtenstein		-	-	-	-	-	-	-	-	-	-	-	-	-	-
<i>Lithuania</i>		2362	64.8	2608	72.1	2926	81.5	3016	84.7	2903	82.1	2981	84.9	2989	85.7
Luxembourg		32	7.9	36	8.7	38	9.1	44	10.4	42	9.8	44	10.1	32	7.3
Malta		10	2.7	29	7.8	11	2.9	16	4.2	22	5.8	18	4.7	16	4.1
Netherlands		1619	10.5	1678	10.8	1486	9.5	1341	8.6	1535	9.7	1404	8.9	1436	9.0
Norway		236	5.4	217	5.0	205	4.7	244	5.5	273	6.1	237	5.3	288	6.4
Poland		15959	41.4	15358	39.8	13967	36.1	13302	34.4	12179	31.5	11477	29.7	10672	27.9
Portugal		5577	55.7	5248	52.3	5112	50.8	5260	52.0	5160	50.8	4494	44.1	4399	42.9
<i>Romania</i>		23271	102.5	24113	106.4	23903	105.9	25758	114.3	26870	119.5	27667	123.2	30440	135.7
Slovakia		1537	28.7	1499	27.9	1298	24.1	1282	23.8	1218	22.6	1111	20.6	1076	20.0
Slovenia		525	26.4	563	28.3	481	24.2	449	22.6	438	22.1	380	19.1	371	18.6
Spain		8764	22.3	8331	21.1	9347	23.6	9111	23.0	8393	21.1	8395	21.0	7453	18.4
Sweden		564	6.4	493	5.6	456	5.2	446	5.0	493	5.6	458	5.2	428	4.8
United Kingdom		6161	10.6	6240	10.7	6355	10.9	5719	9.8	5701	9.7	6724	11.4	6864	11.6
<b>Subtotal EU/EEA</b>		<b>109753</b>	<b>22.7</b>	<b>108175</b>	<b>22.3</b>	<b>106024</b>	<b>21.9</b>	<b>106093</b>	<b>21.8</b>	<b>103218</b>	<b>21.2</b>	<b>101954</b>	<b>20.9</b>	<b>100713</b>	<b>20.6</b>

\*European Region\* comprises the 53 countries of the WHO European Region and Liechtenstein.

WHO European Region 18 TB High Priority Countries presented in italics.

Note: The data published in this report might differ from figures in national reports due to different times of reporting. The deadline for correcting and updating the data used in this report in the joint database was 31 October 2012.

<sup>a</sup> Excluding Greenland data (see Chapter 1.1).



	2002		2003		2004		2005		2006		2007		2008		2009		2010		2011		Mean annual % change in rate, 1995–2011	Slope of trendline 1995–2011
	N	Rate	N	Rate	N	Rate	N	Rate	N	Rate	N	Rate	N	Rate	N	Rate	N	Rate				
	1074	13.3	990	12.2	1075	13.2	998	12.2	906	11.0	874	10.6	817	9.8	696	8.3	691	8.3	687	8.2	-4.9%	-0.69
	1294	12.6	1117	10.8	1198	11.5	1107	10.6	1117	10.6	1020	9.6	990	9.3	994	9.2	1086	10.0	1044	9.5	-2.0%	-0.27
	3335	42.3	3263	41.6	3232	41.4	3302	42.5	3232	41.9	3038	39.6	3150	41.2	2910	38.3	2649	35.0	2407	32.1	-0.7%	-0.36
	20	2.8	35	4.9	30	4.1	37	4.9	37	4.8	42	5.4	50	6.3	55	6.9	61	7.6	54	6.7	6.4%	0.08
	1200	11.8	1162	11.4	1057	10.4	984	9.6	951	9.3	846	8.2	864	8.3	694	6.6	669	6.4	600	5.7	-6.7%	-0.86
	419	7.8	393	7.3	385	7.1	428	7.9	387	7.1	391	7.2	380	6.9	334	6.1	366	6.6	381	6.9	-1.0%	-0.24
	713	52.4	623	45.9	594	44.0	518	38.4	460	34.2	491	36.6	444	33.1	411	30.7	333	24.8	341	25.4	-2.6%	-1.83
	477	9.2	415	8.0	336	6.4	372	7.1	297	5.7	348	6.6	344	6.5	417	7.8	325	6.1	325	6.0	-3.8%	-0.46
	6322	10.3	6098	9.9	5578	9.0	5368	8.6	5323	8.4	5574	8.8	5758	9.0	5276	8.2	5116	7.9	4942	7.6	-3.9%	-0.35
	7701	9.3	7166	8.7	6542	7.9	6020	7.3	5378	6.5	5000	6.1	4523	5.5	4427	5.4	4388	5.4	4316	5.3	-6.2%	-0.66
	582	5.3	620	5.6	774	7.0	769	6.9	681	6.1	639	5.7	664	5.9	589	5.2	487	4.3	489	4.3	-2.9%	-0.27
	2838	27.9	2582	25.5	2340	23.1	1964	19.5	1859	18.4	1685	16.7	1619	16.1	1407	14.0	1741	17.4	1445	14.5	-6.0%	-2.03
	8	2.8	5	1.7	12	4.1	11	3.7	13	4.3	14	4.6	6	1.9	9	2.8	22	6.9	9	2.8	10.9%	-0.05
	408	10.5	407	10.3	432	10.7	450	10.9	463	11.0	480	11.1	468	10.6	479	10.8	420	9.4	425	9.5	-1.6%	-0.14
	4212	7.4	4518	7.9	4220	7.3	4212	7.2	4503	7.7	4525	7.7	4418	7.4	4244	7.1	4692	7.8	3521	5.8	-2.5%	-0.14
	1855	79.1	1726	74.0	1610	69.4	1443	62.6	1328	57.9	1255	55.0	1070	47.1	977	43.2	935	41.6	885	39.7	-2.3%	-2.66
	-	-	-	-	-	-	-	-	-	-	5	14.2	-	-	-	-	-	-	-	-	-	-
	2844	81.8	2821	81.5	2514	73.0	2574	75.1	2559	75.2	2408	71.1	2250	66.8	2081	62.1	1938	58.2	1904	58.7	-0.4%	-1.12
	32	7.2	54	12.0	31	6.8	37	8.0	33	7.0	39	8.2	28	5.8	27	5.5	29	5.8	26	5.1	0.1%	-0.25
	24	6.1	7	1.8	19	4.8	25	6.2	30	7.4	38	9.3	53	12.9	44	10.6	32	7.7	33	7.9	24.6%	0.38
	1401	8.7	1321	8.2	1344	8.3	1128	6.9	1031	6.3	998	6.1	1015	6.2	1158	7.0	1065	6.4	1007	6.0	-3.1%	-0.29
	251	5.5	337	7.4	302	6.6	288	6.3	290	6.2	302	6.5	313	6.6	358	7.5	336	6.9	361	7.3	2.7%	0.14
	10475	27.4	10124	26.5	9493	24.9	9269	24.3	8587	22.5	8614	22.6	8080	21.2	8236	21.6	7509	19.7	8478	22.2	-3.7%	-1.26
	4501	43.6	4148	39.9	3854	36.8	3558	33.8	3456	32.7	3139	29.6	3002	28.3	2871	27.0	2626	24.7	2540	23.9	-5.1%	-2.09
	33595	153.9	31039	142.6	31034	142.9	29288	135.2	26600	123.1	24837	115.2	24680	114.6	23164	107.7	21059	98.1	19212	89.7	-0.6%	-0.43
	1053	19.6	983	18.3	705	13.1	760	14.1	730	13.5	682	12.6	633	11.7	506	9.3	439	8.1	399	7.3	-7.8%	-1.32
	350	17.6	293	14.7	263	13.2	278	13.9	215	10.7	218	10.8	213	10.6	188	9.3	172	8.4	192	9.4	-5.8%	-1.25
	7626	18.6	7467	17.9	7766	18.3	7820	18.2	8029	18.3	7768	17.5	8216	18.1	7592	16.6	7239	15.7	6762	14.7	-2.4%	-0.46
	407	4.6	408	4.6	461	5.1	559	6.2	497	5.5	482	5.3	546	5.9	617	6.7	668	7.2	586	6.2	0.4%	0.06
	7330	12.4	7266	12.2	7650	12.8	8349	13.9	8363	13.8	8329	13.7	8606	14.1	8917	14.5	8483	13.7	8963	14.3	2.1%	0.30
	<b>102347</b>	<b>20.9</b>	<b>97388</b>	<b>19.8</b>	<b>94851</b>	<b>19.2</b>	<b>91916</b>	<b>18.5</b>	<b>87355</b>	<b>17.5</b>	<b>84081</b>	<b>16.8</b>	<b>83200</b>	<b>16.5</b>	<b>79678</b>	<b>15.8</b>	<b>75576</b>	<b>14.9</b>	<b>72334</b>	<b>14.2</b>	<b>-2.9%</b>	<b>-0.53</b>

Country	Trend in rate, 1995–2011	1995		1996		1997		1998		1999		2000		2001	
		N	Rate	N	Rate	N	Rate	N	Rate	N	Rate	N	Rate	N	Rate
<b>Non-EU/EEA</b>															
Albania		641	20.4	738	23.7	655	21.2	694	22.5	743	24.2	612	19.9	555	18.0
Andorra		0	-	17	26.1	23	35.4	8	12.5	10	15.6	12	18.6	10	15.1
Armenia		1000	31.0	928	29.3	1051	33.5	1381	44.4	1510	48.9	1355	44.0	1389	45.3
Azerbaijan		1429	18.4	2480	31.6	4635	58.6	4672	58.6	4690	58.3	5187	64.0	4898	59.8
Belarus		4854	47.2	5598	54.6	5832	57.2	6150	60.5	7339	72.6	6799	67.6	2341	23.4
Bosnia and Herzegovina		2132	64.0	2220	67.2	2695	80.1	2785	80.0	2955	82.1	2500	67.7	2469	65.9
Croatia		2114	45.3	2174	46.7	2054	44.4	2118	46.2	1765	38.9	-	-	1376	30.7
Georgia		1625	32.1	3522	70.5	8446	171.5	5098	104.8	5837	121.5	4819	101.5	4006	85.5
Israel		0	0.0	369	6.7	422	7.5	643	11.2	522	8.9	537	8.9	512	8.4
Kazakhstan		11310	71.0	13944	88.7	17060	110.2	20623	135.1	24979	165.6	27875	186.4	26224	176.0
Kyrgyzstan		3393	73.9	4093	87.9	5346	112.8	3214	66.6	6376	130.2	6463	130.4	-	-
Macedonia, the former Yugoslav Republic of		786	40.0	724	36.7	693	34.9	620	31.1	591	29.5	641	31.9	648	32.1
Moldova		2925	67.4	2922	67.8	2908	68.1	2625	62.2	2711	65.1	2935	71.5	3608	89.3
Monaco		-	-	-	-	-	-	-	-	3	8.6	-	-	-	-
Montenegro		-	-	-	-	-	-	-	-	-	-	-	-	-	-
Russia		84980	57.1	111075	74.8	121765	82.2	121434	82.2	134360	91.2	153155	104.4	132477	90.6
San Marino		-	-	-	-	1	3.8	-	-	-	-	1	3.7	-	-
Serbia		-	-	-	-	-	-	-	-	-	-	-	-	-	-
Serbia excluding UN Administered Province of Kosovo <sup>b</sup>		-	-	-	-	-	-	-	-	-	-	-	-	-	-
UN Administered Province of Kosovo <sup>b</sup>		-	-	-	-	-	-	-	-	-	-	-	-	-	-
Switzerland		831	11.8	764	10.8	747	10.5	749	10.5	789	11.1	640	8.9	617	8.6
Tajikistan		2029	35.1	1647	28.1	1858	31.3	2448	40.6	-	-	2779	45.0	3508	56.3
Turkey		22981	39.0	20212	33.8	20778	34.2	22509	36.5	22088	35.2	18038	28.3	4444	6.9
Turkmenistan		1939	46.3	2072	48.6	3357	77.4	3839	87.3	4092	92.0	5932	131.8	3948	86.7
Ukraine		21459	42.0	23414	46.1	27204	54.0	31318	62.8	32879	66.6	32945	67.4	3150	6.5
Uzbekistan		9866	43.0	11919	51.1	12954	54.5	14558	60.3	15318	62.6	16074	64.9	7095	28.3
<b>Subtotal non-EU/EEA</b>		<b>176294</b>	<b>46.6</b>	<b>210832</b>	<b>55.5</b>	<b>240484</b>	<b>63.2</b>	<b>247486</b>	<b>64.9</b>	<b>269557</b>	<b>70.6</b>	<b>289299</b>	<b>75.7</b>	<b>203573</b>	<b>53.2</b>
<b>Total European Region</b>		<b>286047</b>	<b>33.2</b>	<b>319007</b>	<b>37.0</b>	<b>346508</b>	<b>40.1</b>	<b>353579</b>	<b>40.8</b>	<b>372775</b>	<b>43.0</b>	<b>391253</b>	<b>45.1</b>	<b>304286</b>	<b>35.0</b>
<b>Subtotal 18 HPC</b>		<b>200817</b>	<b>52.7</b>	<b>236100</b>	<b>61.8</b>	<b>266207</b>	<b>69.7</b>	<b>275760</b>	<b>72.2</b>	<b>298204</b>	<b>78.0</b>	<b>321207</b>	<b>84.0</b>	<b>237571</b>	<b>62.2</b>

<sup>b</sup> In accordance with the UN Security Council Resolution No. 1244 (1999).

	2002		2003		2004		2005		2006		2007		2008		2009		2010		2011		Mean annual % change in rate, 1995-2011	Slope of trendline 1995-2011
	N	Rate	N	Rate	N	Rate	N	Rate	N	Rate	N	Rate	N	Rate	N	Rate	N	Rate				
	594	19.2	561	18.1	581	18.6	540	17.2	502	15.9	447	14.1	434	13.6	447	14.0	445	13.9	431	13.4	-2.2%	-0.65
	5	7.2	11	15.2	7	9.3	10	12.8	13	16.3	6	7.4	4	4.8	9	10.8	7	8.2	4	4.6	3.1%	-0.77
	1433	46.8	1570	51.3	1701	55.5	2322	75.7	2155	70.2	2129	69.3	2125	69.0	2006	65.0	1780	57.6	1582	51.0	4.0%	2.21
	5142	62.1	3931	46.9	6501	76.7	7920	92.2	7498	86.2	7347	83.3	10078	112.7	10417	114.9	8394	91.4	10100	108.5	15.5%	4.89
	-	-	5963	60.1	6490	65.7	6357	64.7	6065	62.0	5756	59.2	5483	56.6	5511	57.2	5554	57.9	5118	53.5	-9.1%	0.32
	1691	44.8	1780	47.1	2382	63.0	2160	57.1	1800	47.6	2400	63.5	1736	46.0	1772	47.0	1390	37.0	1385	36.9	-1.6%	-2.28
	1443	32.3	1494	33.5	1297	29.1	1144	25.8	1135	25.6	982	22.2	980	22.2	855	19.4	695	15.8	619	14.1	-12.3%	-1.81
	4490	97.1	5993	131.1	5967	132.0	6448	144.0	6311	142.0	5912	133.9	5836	132.8	5978	136.7	5796	133.2	5533	127.8	15.9%	3.58
	466	7.5	472	7.4	456	7.0	372	5.6	340	5.0	397	5.7	322	4.5	347	4.8	343	4.6	418	5.5	0.1%	-0.12
	27546	184.9	44868	299.9	39380	261.6	40429	266.5	38556	251.8	37658	243.3	28913	184.7	30578	193.0	28550	178.1	26211	161.7	7.0%	7.01
	6613	132.2	8670	173.1	6591	131.3	6765	134.2	6656	130.9	6707	130.5	7127	136.9	6358	120.6	6295	118.0	6666	123.6	7.4%	2.95
	686	33.9	697	34.4	680	33.4	658	32.3	627	30.7	563	27.5	483	23.5	473	23.0	420	20.4	362	17.5	-4.8%	-1.02
	1146	28.9	6241	160.2	6008	157.0	6278	166.7	6118	164.7	6367	173.4	5838	160.6	5591	155.2	5447	152.5	5341	150.7	25.8%	8.01
	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1	2.8	-	-	-	-0.04
	-	-	-	-	-	-	170	27.1	171	27.3	159	25.3	133	21.1	120	19.0	114	18.1	112	17.7	-6.7%	1.78
	128873	88.6	152244	105.1	152438	105.6	154379	107.3	152265	106.1	214924	150.0	214905	150.1	156222	109.2	162553	113.7	159479	111.7	5.4%	3.68
	1	3.5	1	3.4	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-0.09
	-	-	-	-	-	-	3468	35.2	3272	33.3	2981	24.9	2813	23.5	2595	21.6	2385	19.9	2216	18.5	-7.2%	-1.64
	-	-	-	-	-	-	3468	35.2	3272	33.3	1020	10.4	1091	11.1	970	9.8	1501	15.2	1341	13.6	-9.9%	-1.05
	-	-	-	-	-	-	-	-	-	-	1961	92.2	1722	80.0	1625	74.5	884	41.6	875	41.1	-16.3%	-14.06
	671	9.2	630	8.6	602	8.2	563	7.6	519	6.9	472	6.3	516	6.8	554	7.3	548	7.2	578	7.5	-2.5%	-0.31
	687	10.9	4883	77.1	5122	80.1	7526	116.6	6671	102.2	8081	122.4	7996	119.5	7482	110.3	7641	111.1	7609	109.1	34.4%	7.09
	-	-	6032	9.1	8444	12.6	21303	31.3	20526	29.7	19694	28.1	18452	26.0	17402	24.2	16551	22.7	15679	21.3	3.3%	-0.72
	3671	79.8	4759	102.4	4182	89.0	3291	69.3	3369	70.2	3698	76.1	3909	79.5	3157	63.4	3230	64.1	0	-	-1.8%	-1.62
	-	-	53444	112.2	-	-	-	-	41265	88.6	40643	87.8	37832	82.3	38901	85.1	36409	80.1	42676	94.4	-2.9%	2.64
	20588	81.5	26172	102.7	25714	100.0	28891	111.3	25310	96.6	23390	88.3	21194	79.0	21453	79.1	20330	74.1	15913	57.3	9.3%	2.20
	<b>205746</b>	<b>79.4</b>	<b>330416</b>	<b>88.6</b>	<b>274543</b>	<b>81.7</b>	<b>300994</b>	<b>89.3</b>	<b>331144</b>	<b>86.0</b>	<b>390713</b>	<b>100.6</b>	<b>377109</b>	<b>97.2</b>	<b>318228</b>	<b>81.3</b>	<b>314878</b>	<b>80.1</b>	<b>308032</b>	<b>78.1</b>	<b>4.6%</b>	<b>2.25</b>
	<b>308093</b>	<b>35.3</b>	<b>427804</b>	<b>48.9</b>	<b>369394</b>	<b>44.5</b>	<b>392910</b>	<b>47.2</b>	<b>418499</b>	<b>47.4</b>	<b>474789</b>	<b>53.6</b>	<b>460309</b>	<b>51.7</b>	<b>397906</b>	<b>44.5</b>	<b>390454</b>	<b>43.6</b>	<b>380366</b>	<b>40.8</b>	<b>2.1%</b>	<b>0.66</b>
	<b>242531</b>	<b>97.6</b>	<b>364242</b>	<b>95.3</b>	<b>307522</b>	<b>91.8</b>	<b>329034</b>	<b>98.0</b>	<b>356944</b>	<b>93.1</b>	<b>414335</b>	<b>107.9</b>	<b>401282</b>	<b>104.2</b>	<b>340599</b>	<b>88.1</b>	<b>335444</b>	<b>86.5</b>	<b>326656</b>	<b>84.0</b>	<b>5.2%</b>	<b>2.20</b>

Table II: All laboratory confirmed tuberculosis cases, European Region, 1995–2011

Country	Trend in percentage, 1995–2011	1995		1996		1997		1998		1999		2000		2001	
		N	% among all TB cases	N	% among all TB cases	N	% among all TB cases	N	% among all TB cases	N	% among all TB cases	N	% among all TB cases	N	% among all TB cases
<b>EU/EEA</b>															
Austria		945	(63.9)	910	(61.2)	853	(61.1)	864	(65.7)	852	(68.4)	802	(65.5)	696	(64.7)
Belgium		742	(53.8)	731	(54.1)	641	(50.8)	813	(67.6)	926	(72.9)	969	(73.8)	958	(72.5)
Bulgaria		-	-	-	-	-	-	-	-	-	-	1408	(42.0)	1323	(34.3)
Cyprus		-	-	-	-	-	-	-	-	-	-	-	-	-	-
Czech Republic		-	-	1002	(51.8)	907	(49.5)	951	(52.7)	830	(50.9)	875	(60.7)	854	(63.3)
Denmark <sup>a</sup>		406	(90.6)	427	(88.2)	459	(82.9)	445	(84.1)	428	(79.9)	430	(78.5)	383	(75.0)
Estonia		181	(29.8)	440	(64.4)	595	(80.0)	536	(65.5)	528	(70.0)	541	(68.4)	591	(72.8)
Finland		477	(72.9)	513	(80.8)	447	(80.3)	499	(81.5)	511	(86.0)	460	(84.2)	419	(83.6)
France		-	-	1563	(20.4)	1576	(23.1)	1631	(24.5)	1683	(25.2)	1756	(26.2)	1744	(27.0)
Germany		-	-	-	-	-	-	-	-	-	-	-	-	4670	(61.9)
Greece		-	-	-	-	-	-	-	-	396	(41.6)	287	(40.8)	268	(43.4)
Hungary		-	-	-	-	-	-	-	-	1206	(30.8)	912	(25.3)	940	(29.8)
Iceland		9	(75.0)	6	(54.5)	9	(90.0)	11	(64.7)	8	(66.7)	9	(69.2)	12	(92.3)
Ireland		-	-	-	-	-	-	243	(57.3)	260	(55.4)	229	(56.8)	149	(36.7)
Italy		1860	(35.6)	2111	(41.0)	2193	(42.4)	2261	(47.2)	2164	(48.9)	1778	(37.4)	1616	(35.9)
Latvia		-	-	-	-	-	-	-	-	-	-	1298	(62.9)	1288	(61.9)
Liechtenstein		-	-	-	-	-	-	-	-	-	-	-	-	-	-
Lithuania		-	-	-	-	-	-	-	-	-	-	1556	(52.2)	1771	(59.3)
Luxembourg		24	(75.0)	22	(61.1)	6	(15.8)	44	(100.0)	42	(100.0)	44	(100.0)	32	(100.0)
Malta		4	(40.0)	9	(31.0)	2	(18.2)	4	(25.0)	13	(59.1)	10	(55.6)	10	(62.5)
Netherlands		808	(49.9)	1225	(73.0)	1049	(70.6)	692	(51.6)	943	(61.4)	863	(61.5)	915	(63.7)
Norway		150	(63.6)	149	(68.7)	139	(67.8)	176	(72.1)	186	(68.1)	170	(71.7)	220	(76.4)
Poland		-	-	-	-	-	-	-	-	6700	(55.0)	6377	(55.6)	5965	(55.9)
Portugal		-	-	-	-	-	-	-	-	-	-	2281	(50.8)	2290	(52.1)
Romania		8582	(36.9)	5630	(23.3)	13726	(57.4)	13158	(51.1)	13495	(50.2)	13708	(49.5)	13816	(45.4)
Slovakia		-	-	811	(54.1)	748	(57.6)	737	(57.5)	645	(53.0)	596	(53.6)	575	(53.4)
Slovenia		307	(58.5)	423	(75.1)	356	(74.0)	346	(77.1)	350	(79.9)	324	(85.3)	308	(83.0)
Spain		-	-	-	-	-	-	-	-	-	-	3436	(40.9)	2693	(36.1)
Sweden		460	(81.6)	417	(84.6)	380	(83.3)	368	(82.5)	412	(83.6)	371	(81.0)	359	(83.9)
United Kingdom		-	-	-	-	-	-	3104	(54.3)	2904	(50.9)	3231	(48.1)	3551	(51.7)
<b>Subtotal EU/EEA</b>		<b>14955</b>	<b>(32.1)</b>	<b>16389</b>	<b>(34.1)</b>	<b>24086</b>	<b>(52.1)</b>	<b>26883</b>	<b>(50.3)</b>	<b>35482</b>	<b>(49.8)</b>	<b>44721</b>	<b>(48.2)</b>	<b>48416</b>	<b>(44.1)</b>

<sup>a</sup> 'European Region' comprises the 53 countries of the WHO European Region and Liechtenstein. WHO European Region 18 TB High Priority Countries presented in italics.

<sup>a</sup> Excluding Greenland data (see Chapter 1.1).

	2002		2003		2004		2005		2006		2007		2008		2009		2010		2011	
	N	% among all TB cases	N	% among all TB cases	N	% among all TB cases	N	% among all TB cases	N	% among all TB cases	N	% among all TB cases	N	% among all TB cases	N	% among all TB cases	N	% among all TB cases	N	% among all TB cases
	703	(65.5)	636	(64.2)	675	(62.8)	654	(65.5)	569	(62.8)	541	(61.9)	488	(59.7)	445	(63.9)	480	(69.5)	466	(67.8)
	1014	(78.4)	868	(77.7)	937	(78.2)	834	(75.3)	884	(79.1)	800	(78.4)	810	(81.8)	802	(80.7)	854	(78.6)	797	(76.3)
	1626	(48.8)	1377	(42.2)	1283	(39.7)	1254	(38.0)	1360	(42.1)	1385	(45.6)	1360	(43.2)	1281	(44.0)	1174	(44.3)	1071	(44.5)
	13	(65.0)	23	(65.7)	19	(63.3)	19	(51.4)	23	(62.2)	33	(78.6)	36	(72.0)	41	(74.5)	59	(96.7)	44	(81.5)
	758	(63.2)	756	(65.1)	666	(63.0)	644	(65.4)	621	(65.3)	557	(65.8)	560	(64.8)	477	(68.7)	434	(64.9)	426	(71.0)
	311	(74.2)	299	(76.1)	291	(75.6)	328	(76.6)	301	(77.8)	293	(74.9)	291	(76.6)	242	(72.5)	287	(78.4)	272	(71.4)
	534	(74.9)	466	(74.8)	452	(76.1)	389	(75.1)	352	(76.5)	385	(78.4)	348	(78.4)	308	(74.9)	264	(79.3)	264	(77.4)
	395	(82.8)	351	(84.6)	293	(87.2)	326	(87.6)	272	(91.6)	252	(72.4)	249	(72.4)	307	(73.6)	255	(78.5)	252	(77.5)
	1725	(27.3)	2394	(39.3)	2570	(46.1)	2412	(44.9)	2412	(45.3)	2535	(45.5)	2532	(44.0)	2427	(46.0)	2386	(46.6)	2309	(46.7)
	4966	(64.5)	4704	(65.6)	4362	(66.7)	4142	(68.8)	3814	(70.9)	3503	(70.1)	3194	(70.6)	3208	(72.5)	3108	(70.8)	3071	(71.2)
	271	(46.6)	229	(36.9)	206	(26.6)	214	(27.8)	210	(30.8)	210	(32.9)	248	(37.3)	303	(51.4)	189	(38.8)	278	(56.9)
	959	(33.8)	929	(36.0)	990	(42.3)	777	(39.6)	832	(44.8)	772	(45.8)	760	(46.9)	706	(50.2)	623	(35.8)	597	(41.3)
	6	(75.0)	4	(80.0)	8	(66.7)	8	(72.7)	12	(92.3)	11	(78.6)	5	(83.3)	8	(88.9)	19	(86.4)	4	(44.4)
	253	(62.0)	261	(64.1)	279	(64.6)	283	(62.9)	316	(68.3)	315	(65.6)	312	(66.7)	341	(71.2)	281	(66.9)	288	(67.8)
	1600	(38.0)	2554	(56.5)	1954	(46.3)	1662	(39.5)	1735	(38.5)	1840	(40.7)	1529	(34.6)	1381	(32.5)	1651	(35.2)	982	(27.9)
	1296	(69.9)	1263	(73.2)	1157	(71.9)	1109	(76.9)	995	(74.9)	994	(79.2)	838	(78.3)	773	(79.1)	733	(78.4)	671	(75.8)
	-	-	-	-	-	-	-	-	-	-	5	(100.0)	-	-	-	-	-	-	-	-
	1544	(54.3)	1680	(59.6)	1598	(63.6)	1739	(67.6)	1787	(69.8)	1686	(70.0)	1616	(71.8)	1478	(71.0)	1363	(70.3)	1403	(73.7)
	32	(100.0)	54	(100.0)	31	(100.0)	37	(100.0)	33	(100.0)	26	(66.7)	0	(0.0)	27	(100.0)	20	(69.0)	19	(73.1)
	14	(58.3)	3	(42.9)	8	(42.1)	11	(44.0)	15	(50.0)	19	(50.0)	25	(47.2)	20	(45.5)	16	(50.0)	24	(72.7)
	768	(54.8)	756	(57.2)	759	(56.5)	852	(75.5)	755	(73.2)	721	(72.2)	745	(73.4)	760	(65.6)	787	(73.9)	732	(72.7)
	192	(76.5)	273	(81.0)	246	(81.5)	214	(74.3)	225	(77.6)	245	(81.1)	226	(72.2)	287	(80.2)	276	(82.1)	262	(72.6)
	5663	(54.1)	5553	(54.8)	5049	(53.2)	5399	(58.2)	5229	(60.9)	5410	(62.8)	5093	(63.0)	5223	(63.4)	4756	(63.3)	5581	(65.8)
	2571	(57.1)	2296	(55.4)	2317	(60.1)	2193	(61.6)	2234	(64.6)	2076	(66.1)	2085	(69.5)	1981	(69.0)	1605	(61.1)	1588	(62.5)
	18547	(55.2)	17012	(54.8)	18605	(60.0)	18483	(63.1)	16844	(63.3)	16189	(65.2)	14741	(59.7)	15243	(65.8)	13673	(64.9)	12446	(64.8)
	504	(47.9)	406	(41.3)	357	(50.6)	357	(47.0)	401	(54.9)	397	(58.2)	383	(60.5)	235	(46.4)	234	(53.3)	188	(47.1)
	292	(83.4)	259	(88.4)	231	(87.8)	245	(88.1)	184	(85.6)	189	(86.7)	201	(94.4)	179	(95.2)	155	(90.1)	182	(94.8)
	3837	(50.3)	3572	(47.8)	3457	(44.5)	3686	(47.1)	3651	(45.5)	3950	(50.8)	4493	(54.7)	4095	(53.9)	4890	(67.6)	4383	(64.8)
	353	(86.7)	349	(85.5)	370	(80.3)	444	(79.4)	397	(79.9)	365	(75.7)	436	(79.9)	515	(83.5)	524	(78.4)	476	(81.2)
	4025	(54.9)	4163	(57.3)	4501	(58.8)	4849	(58.1)	4963	(59.3)	4775	(57.3)	4852	(56.4)	5035	(56.5)	4909	(57.9)	5285	(59.0)
	<b>54772</b>	<b>(53.5)</b>	<b>53490</b>	<b>(54.9)</b>	<b>53671</b>	<b>(56.6)</b>	<b>53564</b>	<b>(58.3)</b>	<b>51426</b>	<b>(58.9)</b>	<b>50479</b>	<b>(60.0)</b>	<b>48456</b>	<b>(58.2)</b>	<b>48128</b>	<b>(60.4)</b>	<b>46005</b>	<b>(60.9)</b>	<b>44361</b>	<b>(61.3)</b>

Country	Trend in percentage, 1995–2011	1995		1996		1997		1998		1999		2000		2001	
		N	% among all TB cases	N	% among all TB cases	N	% among all TB cases	N	% among all TB cases	N	% among all TB cases	N	% among all TB cases	N	% among all TB cases
<b>Non-EU/EEA</b>															
Albania		-	-	-	-	-	-	-	-	-	-	-	-	-	-
Andorra		-	-	-	-	-	-	-	-	-	-	-	-	-	-
Armenia		-	-	-	-	-	-	-	-	-	-	-	-	-	-
Azerbaijan		-	-	-	-	-	-	-	-	-	-	-	-	-	-
Belarus		-	-	-	-	-	-	-	-	-	-	-	-	-	-
Bosnia and Herzegovina		-	-	-	-	-	-	-	-	-	-	-	-	-	-
Croatia		-	-	-	-	-	-	-	-	-	-	-	-	-	-
Georgia		-	-	-	-	-	-	-	-	-	-	-	-	-	-
Israel		-	-	-	-	-	-	-	-	-	-	-	-	-	-
Kazakhstan		-	-	-	-	-	-	-	-	-	-	-	-	-	-
Kyrgyzstan		-	-	-	-	-	-	-	-	-	-	-	-	-	-
Macedonia, the former Yugoslav Republic of		-	-	-	-	-	-	-	-	-	-	-	-	-	-
Moldova		-	-	-	-	-	-	-	-	-	-	-	-	-	-
Monaco		-	-	-	-	-	-	-	-	-	-	-	-	-	-
Montenegro		-	-	-	-	-	-	-	-	-	-	-	-	-	-
Russia		-	-	-	-	-	-	-	-	-	-	-	-	-	-
San Marino		-	-	-	-	-	-	-	-	-	-	-	-	-	-
Serbia		-	-	-	-	-	-	-	-	-	-	-	-	-	-
Serbia excluding UN Administered Province of Kosovo <sup>b</sup>		-	-	-	-	-	-	-	-	-	-	-	-	-	-
UN Administered Province of Kosovo <sup>b</sup>		-	-	-	-	-	-	-	-	-	-	-	-	-	-
Switzerland		-	-	-	-	-	-	-	-	-	-	-	-	-	-
Tajikistan		-	-	-	-	-	-	-	-	-	-	-	-	-	-
Turkey		-	-	-	-	-	-	-	-	-	-	-	-	-	-
Turkmenistan		-	-	-	-	-	-	-	-	-	-	-	-	-	-
Ukraine		-	-	-	-	-	-	-	-	-	-	-	-	-	-
Uzbekistan		-	-	-	-	-	-	-	-	-	-	-	-	-	-
<b>Subtotal non-EU/EEA</b>		-	-	-	-	-	-	-	-	-	-	-	-	-	-
<b>Total European Region</b>		-	-	-	-	-	-	-	-	-	-	-	-	-	-
<b>Subtotal 18 HPC</b>		-	-	-	-	-	-	-	-	-	-	-	-	-	-

<sup>b</sup> In accordance with the UN Security Council Resolution No. 1244 (1999).

	2002		2003		2004		2005		2006		2007		2008		2009		2010		2011	
	N	% among all TB cases	N	% among all TB cases	N	% among all TB cases	N	% among all TB cases	N	% among all TB cases	N	% among all TB cases	N	% among all TB cases	N	% among all TB cases	N	% among all TB cases	N	% among all TB cases
-	-	-	-	-	-	-	-	-	197	(39.2)	179	(40.0)	-	-	209	(46.8)	205	(46.1)	205	(47.6)
-	-	-	-	-	-	-	-	-	8	(61.5)	3	(50.0)	3	(75.0)	3	(33.3)	4	(57.1)	3	(75.0)
-	-	-	-	-	-	-	-	-	580	(26.9)	497	(23.3)	599	(28.2)	680	(33.9)	691	(38.8)	529	(33.4)
-	-	-	-	-	-	-	-	-	1454	(19.4)	1356	(18.5)	-	-	-	-	2957	(35.2)	2176	(22.2)
-	-	-	-	-	-	-	-	-	2086	(34.4)	1988	(34.5)	1934	(35.3)	2188	(39.7)	3783	(68.1)	3137	(61.3)
-	-	-	-	-	-	-	-	-	993	(55.2)	1266	(52.8)	757	(43.6)	920	(51.9)	647	(46.5)	745	(53.8)
-	-	-	-	-	-	-	-	-	583	(51.4)	575	(58.6)	440	(44.9)	517	(60.5)	492	(70.8)	393	(63.5)
-	-	-	-	-	-	-	-	-	1831	(29.0)	1979	(33.5)	2194	(37.6)	2584	(43.2)	2724	(47.0)	2955	(53.4)
-	-	-	-	-	-	-	-	-	206	(60.6)	242	(61.0)	178	(55.3)	266	(76.7)	247	(72.0)	284	(67.9)
-	-	-	-	-	-	-	-	-	7227	(18.7)	7184	(19.1)	-	-	9774	(32.0)	11571	(40.5)	11555	(50.1)
-	-	-	-	-	-	-	-	-	1833	(27.5)	1720	(25.6)	-	-	1930	(30.4)	941	(14.9)	-	-
-	-	-	-	-	-	-	-	-	212	(33.8)	247	(43.9)	178	(36.9)	238	(50.3)	187	(44.5)	155	(42.8)
-	-	-	-	-	-	-	-	-	1679	(27.4)	1940	(30.5)	2161	(37.0)	2416	(43.2)	2609	(47.9)	2561	(47.9)
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1	(100.0)	-	-	
-	-	-	-	-	-	-	-	-	101	(59.1)	76	(47.8)	74	(55.6)	89	(74.2)	74	(64.9)	72	(64.3)
-	-	-	-	-	-	-	-	-	46491	(30.5)	50262	(23.4)	50168	(23.3)	68963	(44.1)	54208	(33.3)	51924	(32.6)
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
-	-	-	-	-	-	-	-	-	1271	(38.8)	1397	(46.9)	1316	(46.8)	-	-	1122	(47.0)	1025	(76.4)
-	-	-	-	-	-	-	-	-	1271	(38.8)	1397	(46.9)	1316	(46.8)	-	-	1122	(47.0)	1025	(76.4)
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
-	-	-	-	-	-	-	-	-	308	(59.3)	331	(70.1)	185	(35.9)	470	(84.8)	469	(85.6)	487	(84.3)
-	-	-	-	-	-	-	-	-	2051	(30.7)	2228	-	-	-	1413	(18.9)	648	(8.5)	1623	(21.3)
-	-	-	-	-	-	-	-	-	9142	(44.5)	8741	(44.4)	8178	(44.3)	5835	(33.5)	4965	(30.0)	4828	(30.8)
-	-	-	-	-	-	-	-	-	1155	(34.3)	-	-	1331	(34.0)	275	(8.7)	169	(5.2)	-	-
-	-	-	-	-	-	-	-	-	14206	(34.4)	11028	(27.1)	14866	(39.3)	19035	(48.9)	14876	(40.9)	20103	(47.1)
-	-	-	-	-	-	-	-	-	7211	(28.5)	6326	(27.0)	5117	(24.1)	2579	(12.0)	4167	(20.5)	4430	(27.8)
-	-	-	-	-	-	-	-	-	<b>100825</b>	<b>(30.4)</b>	<b>99565</b>	<b>(26.0)</b>	<b>89679</b>	<b>(24.4)</b>	<b>120384</b>	<b>(39.4)</b>	<b>107757</b>	<b>(34.2)</b>	<b>109190</b>	<b>(35.4)</b>
-	-	-	-	-	-	-	-	-	<b>152251</b>	<b>(36.4)</b>	<b>150039</b>	<b>(31.6)</b>	<b>138135</b>	<b>(30.0)</b>	<b>168512</b>	<b>(42.3)</b>	<b>153762</b>	<b>(39.4)</b>	<b>153551</b>	<b>(40.4)</b>
-	-	-	-	-	-	-	-	-	<b>118284</b>	<b>(33.1)</b>	<b>115888</b>	<b>(28.0)</b>	<b>105451</b>	<b>(26.3)</b>	<b>136755</b>	<b>(40.2)</b>	<b>121516</b>	<b>(36.2)</b>	<b>121676</b>	<b>(37.2)</b>

Table III: Tuberculosis cases in children (&lt;15 years old), European Region, 1995–2011

Table IIIa: 1995–2001

Country	Trend in percentage, 1995–2011	1995			1996			1997			1998		
		N	% among all TB cases	Rate	N	% among all TB cases	Rate	N	% among all TB cases	Rate	N	% among all TB cases	Rate
<b>EU/EEA</b>													
Austria		55	(3.7)	3.9	51	(3.4)	3.6	63	(4.5)	4.5	47	(3.6)	3.4
Belgium		87	(6.3)	4.8	69	(5.1)	3.8	67	(5.3)	3.7	78	(6.5)	4.3
<i>Bulgaria</i>		-	-	-	-	-	-	-	-	-	-	-	-
Cyprus		-	-	-	-	-	-	-	-	-	-	-	-
Czech Republic		65	(3.5)	3.3	38	(2.0)	2.0	20	(1.1)	1.1	34	(1.9)	1.9
Denmark <sup>a</sup>		28	(6.3)	3.1	40	(8.3)	4.3	52	(9.4)	5.5	48	(9.1)	5.0
<i>Estonia</i>		18	(3.0)	6.0	18	(2.6)	6.2	28	(3.8)	10.0	10	(1.2)	3.7
Finland		6	(0.9)	0.6	5	(0.8)	0.5	5	(0.9)	0.5	6	(1.0)	0.6
France		426	(4.9)	3.6	383	(5.0)	3.3	308	(4.5)	2.7	333	(5.0)	2.9
Germany		514	(4.2)	3.9	578	(4.9)	4.4	480	(4.3)	3.6	490	(4.7)	3.7
Greece		-	-	-	-	-	-	-	-	-	105	(9.1)	5.9
Hungary		-	-	-	16	(0.4)	0.9	17	(0.4)	0.9	22	(0.6)	1.2
Iceland		-	-	-	1	(9.1)	1.5	0	(0.0)	0.0	1	(5.9)	1.5
Ireland		-	-	-	-	-	-	-	-	-	25	(5.9)	3.0
Italy		196	(3.8)	2.3	174	(3.4)	2.1	154	(3.0)	1.9	147	(3.1)	1.8
<i>Latvia</i>		63	(4.1)	12.1	86	(4.9)	17.0	90	(4.5)	18.4	126	(5.8)	26.8
Liechtenstein		-	-	-	-	-	-	-	-	-	-	-	-
<i>Lithuania</i>		121	(5.1)	15.2	128	(4.9)	16.4	147	(5.0)	19.2	170	(5.6)	22.7
Luxembourg		1	(3.1)	1.3	1	(2.8)	1.3	2	(5.3)	2.6	0	(0.0)	0.0
Malta		1	(10.0)	1.2	3	(10.3)	3.8	1	(9.1)	1.2	1	(6.3)	1.2
Netherlands		93	(5.7)	3.3	98	(5.8)	3.4	91	(6.1)	3.2	81	(6.0)	2.8
Norway		15	(6.4)	1.8	19	(8.8)	2.2	20	(9.8)	2.3	14	(5.7)	1.6
Poland		218	(1.4)	2.4	181	(1.2)	2.1	161	(1.2)	1.9	123	(0.9)	1.5
Portugal		287	(5.1)	16.0	220	(4.2)	12.5	219	(4.3)	12.7	223	(4.2)	13.1
<i>Romania</i>		975	(4.2)	20.6	1195	(5.0)	26.1	1127	(4.7)	25.4	1461	(5.7)	33.7
Slovakia		67	(4.4)	5.5	46	(3.1)	3.8	27	(2.1)	2.3	40	(3.1)	3.5
Slovenia		8	(1.5)	2.2	6	(1.1)	1.7	5	(1.0)	1.4	6	(1.3)	1.8
Spain		-	-	-	-	-	-	-	-	-	491	(5.4)	8.0
Sweden		30	(5.3)	1.8	26	(5.3)	1.6	30	(6.6)	1.8	20	(4.5)	1.2
United Kingdom		426	(6.9)	3.8	410	(6.6)	3.6	481	(7.6)	4.3	371	(6.5)	3.3
<b>Subtotal EU/EEA</b>		<b>3700</b>	<b>(4.0)</b>	<b>4.9</b>	<b>3792</b>	<b>(4.0)</b>	<b>4.9</b>	<b>3595</b>	<b>(3.9)</b>	<b>4.7</b>	<b>4473</b>	<b>(4.4)</b>	<b>5.3</b>

\*European Region\* comprises the 53 countries of the WHO European Region and Liechtenstein.  
 WHO European Region 18 TB High Priority Countries presented in italics.

<sup>a</sup> Excluding Greenland data (see Chapter 1.1).



	1999			2000			2001		
	N	% among all TB cases	Rate	N	% among all TB cases	Rate	N	% among all TB cases	Rate
	50	(4.0)	3.6	72	(5.9)	5.2	66	(6.1)	4.9
	63	(5.0)	3.5	69	(5.3)	3.8	76	(5.8)	4.2
	-	-	-	148	(4.4)	11.4	166	(4.3)	13.1
	-	-	-	-	-	-	-	-	-
	17	(1.0)	1.0	21	(1.5)	1.2	12	(0.9)	0.7
	46	(8.6)	4.8	42	(7.7)	4.3	49	(9.6)	4.9
	14	(1.9)	5.4	18	(2.3)	7.2	15	(1.8)	6.2
	2	(0.3)	0.2	3	(0.5)	0.3	6	(1.2)	0.6
	311	(4.7)	2.7	305	(4.5)	2.6	278	(4.3)	2.4
	425	(4.3)	3.3	446	(4.9)	3.5	300	(4.0)	2.3
	27	(2.8)	1.6	24	(3.4)	1.4	45	(7.3)	2.7
	23	(0.6)	1.3	10	(0.3)	0.6	11	(0.3)	0.7
	0	(0.0)	0.0	0	(0.0)	0.0	0	(0.0)	0.0
	39	(8.3)	4.7	17	(4.2)	2.1	16	(3.9)	1.9
	151	(3.4)	1.8	148	(3.1)	1.8	152	(3.4)	1.9
	-	-	-	145	(7.0)	33.9	158	(7.6)	38.6
	-	-	-	-	-	-	-	-	-
	-	-	-	124	(4.2)	17.5	124	(4.1)	18.1
	3	(7.1)	3.7	4	(9.1)	4.9	0	(0.0)	0.0
	0	(0.0)	0.0	2	(11.1)	2.6	0	(0.0)	0.0
	103	(6.7)	3.5	88	(6.3)	3.0	65	(4.5)	2.2
	25	(9.2)	2.8	18	(7.6)	2.0	24	(8.3)	2.7
	108	(0.9)	1.4	103	(0.9)	1.4	124	(1.2)	1.7
	171	(3.3)	10.2	115	(2.6)	6.9	117	(2.7)	7.1
	1336	(5.0)	31.3	1729	(6.2)	41.6	1911	(6.3)	47.2
	21	(1.7)	1.9	15	(1.4)	1.4	22	(2.0)	2.1
	10	(2.3)	3.0	9	(2.4)	2.8	13	(3.5)	4.1
	628	(7.5)	10.4	526	(6.3)	8.8	493	(6.6)	8.3
	11	(2.2)	0.7	22	(4.8)	1.3	13	(3.0)	0.8
	377	(6.6)	3.3	385	(5.7)	3.4	469	(6.8)	4.2
	<b>3961</b>	<b>(4.2)</b>	<b>4.8</b>	<b>4608</b>	<b>(4.5)</b>	<b>5.5</b>	<b>4725</b>	<b>(4.7)</b>	<b>5.7</b>

Country	Trend in percentage, 1995–2011	1995			1996			1997			1998		
		N	% among all TB cases	Rate	N	% among all TB cases	Rate	N	% among all TB cases	Rate	N	% among all TB cases	Rate
<b>Non-EU/EEA</b>													
Albania		-	-	-	-	-	-	1	(0.2)	0.1	3	(0.4)	0.3
Andorra		-	-	-	-	-	-	-	-	-	-	-	-
Armenia		2	(0.2)	0.2	2	(0.2)	0.2	5	(0.5)	0.6	3	(0.2)	0.4
Azerbaijan		-	-	-	5	(0.2)	0.2	-	-	-	-	-	-
Belarus		-	-	-	-	-	-	-	-	-	-	-	-
Bosnia and Herzegovina		-	-	-	5	(0.2)	0.7	16	(0.6)	2.3	4	(0.1)	0.6
Croatia		16	(0.8)	1.8	-	-	-	25	(1.2)	3.0	33	(1.6)	4.1
Georgia		4	(0.2)	0.3	5	(0.1)	0.4	0	(0.0)	0.0	8	(0.2)	0.7
Israel		-	-	-	3	(0.8)	0.2	7	(1.7)	0.4	2	(0.3)	0.1
Kazakhstan		-	-	-	-	-	-	69	(0.4)	1.5	96	(0.5)	2.2
Kyrgyzstan		4	(0.1)	0.2	12	(0.3)	0.7	5	(0.1)	0.3	7	(0.2)	0.4
Macedonia, the former Yugoslav Republic of		4	(0.5)	0.8	8	(1.1)	1.7	2	(0.3)	0.4	8	(1.3)	1.7
Moldova		2	(0.1)	0.2	2	(0.1)	0.2	0	(0.0)	0.0	4	(0.2)	0.4
Monaco		-	-	-	-	-	-	-	-	-	-	-	-
Montenegro		-	-	-	-	-	-	-	-	-	-	-	-
Russia		-	-	-	-	-	-	-	-	-	2	(0.0)	0.0
San Marino		-	-	-	-	-	-	-	-	-	-	-	-
Serbia		-	-	-	-	-	-	-	-	-	-	-	-
Serbia excluding UN Administered Province of Kosovo <sup>b</sup>		-	-	-	-	-	-	-	-	-	-	-	-
UN Administered Province of Kosovo <sup>b</sup>		-	-	-	-	-	-	-	-	-	-	-	-
Switzerland		1	(0.1)	0.1	1	(0.1)	0.1	0	(0.0)	0.0	1	(0.1)	0.1
Tajikistan		0	(0.0)	0.0	9	(0.5)	0.4	15	(0.8)	0.6	11	(0.4)	0.4
Turkey		0	(0.0)	0.0	0	(0.0)	0.0	0	(0.0)	0.0	0	(0.0)	0.0
Turkmenistan		3	(0.2)	0.2	2	(0.1)	0.1	2	(0.1)	0.1	2	(0.1)	0.1
Ukraine		31	(0.1)	0.3	22	(0.1)	0.2	34	(0.1)	0.4	60	(0.2)	0.6
Uzbekistan		0	(0.0)	0.0	7	(0.1)	0.1	0	(0.0)	0.0	0	(0.0)	0.0
<b>Subtotal non-EU/EEA</b>		<b>67</b>	<b>(0.2)</b>	<b>0.3</b>	<b>83</b>	<b>(0.1)</b>	<b>0.2</b>	<b>181</b>	<b>(0.3)</b>	<b>0.7</b>	<b>244</b>	<b>(0.3)</b>	<b>0.9</b>
<b>Total European Region</b>		<b>3767</b>	<b>(1.3)</b>	<b>2.0</b>	<b>3875</b>	<b>(1.2)</b>	<b>2.1</b>	<b>3776</b>	<b>(1.1)</b>	<b>2.1</b>	<b>4717</b>	<b>(1.4)</b>	<b>2.6</b>
<b>Subtotal 18 HPC</b>		<b>1223</b>	<b>(0.6)</b>	<b>1.3</b>	<b>1493</b>	<b>(0.6)</b>	<b>1.6</b>	<b>1522</b>	<b>(0.6)</b>	<b>1.6</b>	<b>1960</b>	<b>(0.7)</b>	<b>2.1</b>

<sup>b</sup> In accordance with the UN Security Council Resolution No. 1244 (1999).

	1999			2000			2001		
	N	% among all TB cases	Rate	N	% among all TB cases	Rate	N	% among all TB cases	Rate
	0	(0.0)	0.0	5	(0.8)	0.5	4	(0.7)	0.4
	-	-	-	-	-	-	-	-	-
	10	(0.7)	1.2	3	(0.2)	0.4	3	(0.2)	0.4
	-	-	-	-	-	-	5	(0.1)	0.2
	-	-	-	-	-	-	6	(0.3)	0.3
	8	(0.3)	1.1	8	(0.3)	1.1	13	(0.5)	1.8
	3	(0.2)	0.4	-	-	-	2	(0.1)	0.3
	8	(0.1)	0.7	5	(0.1)	0.5	6	(0.1)	0.6
	47	(9.0)	2.8	52	(9.7)	3.1	32	(6.3)	1.9
	94	(0.4)	2.2	120	(0.4)	2.9	126	(0.5)	3.1
	13	(0.2)	0.7	10	(0.2)	0.6	0	(0.0)	0.0
	2	(0.3)	0.4	6	(0.9)	1.3	2	(0.3)	0.5
	4	(0.1)	0.4	3	(0.1)	0.3	7	(0.2)	0.8
	-	-	-	-	-	-	-	-	-
	-	-	-	-	-	-	-	-	-
	50	(0.0)	0.2	2	(0.0)	0.0	63	(0.0)	0.2
	-	-	-	-	-	-	-	-	-
	-	-	-	-	-	-	-	-	-
	-	-	-	-	-	-	-	-	-
	-	-	-	-	-	-	-	-	-
	14	(1.8)	1.1	10	(1.6)	0.8	12	(1.9)	1.0
	-	-	-	0	(0.0)	0.0	8	(0.2)	0.3
	0	(0.0)	0.0	0	(0.0)	0.0	0	(0.0)	0.0
	7	(0.2)	0.4	35	(0.6)	2.1	4	(0.1)	0.2
	36	(0.1)	0.4	62	(0.2)	0.7	27	(0.9)	0.3
	15	(0.1)	0.2	17	(0.1)	0.2	28	(0.4)	0.3
	<b>311</b>	<b>(0.4)</b>	<b>1.3</b>	<b>338</b>	<b>(0.1)</b>	<b>0.6</b>	<b>348</b>	<b>(0.2)</b>	<b>0.5</b>
	<b>4272</b>	<b>(1.2)</b>	<b>2.4</b>	<b>4946</b>	<b>(1.3)</b>	<b>2.9</b>	<b>5073</b>	<b>(1.7)</b>	<b>3.0</b>
	<b>1587</b>	<b>(0.5)</b>	<b>1.8</b>	<b>2421</b>	<b>(0.8)</b>	<b>2.7</b>	<b>2657</b>	<b>(1.1)</b>	<b>3.1</b>



	2007			2008			2009			2010			2011		
	N	% among all TB cases	Rate	N	% among all TB cases	Rate	N	% among all TB cases	Rate	N	% among all TB cases	Rate	N	% among all TB cases	Rate
	25	(2.9)	1.9	39	(4.8)	3.1	18	(2.6)	1.4	25	(3.6)	2.0	24	(3.5)	1.9
	67	(6.6)	3.7	52	(5.3)	2.9	64	(6.4)	3.5	71	(6.5)	3.9	85	(8.1)	4.6
	196	(6.5)	19.0	227	(7.2)	22.2	210	(7.2)	20.6	217	(8.2)	21.1	176	(7.3)	17.0
	1	(2.4)	0.7	3	(6.0)	2.2	2	(3.6)	1.5	2	(3.3)	1.5	0	(0.0)	0.0
	4	(0.5)	0.3	4	(0.5)	0.3	7	(1.0)	0.5	3	(0.4)	0.2	6	(1.0)	0.4
	27	(6.9)	2.7	22	(5.8)	2.2	22	(6.6)	2.2	21	(5.7)	2.1	16	(4.2)	1.6
	1	(0.2)	0.5	2	(0.5)	1.0	3	(0.7)	1.5	6	(1.8)	3.0	1	(0.3)	0.5
	4	(1.1)	0.4	4	(1.2)	0.4	7	(1.7)	0.8	6	(1.8)	0.7	11	(3.4)	1.2
	331	(5.9)	2.8	292	(5.1)	2.5	253	(4.8)	2.1	232	(4.5)	1.9	255	(5.2)	2.1
	180	(3.6)	1.6	124	(2.7)	1.1	146	(3.3)	1.3	160	(3.6)	1.5	179	(4.1)	1.6
	35	(5.5)	2.2	37	(5.6)	2.3	36	(6.1)	2.2	33	(6.8)	2.0	38	(7.8)	2.3
	7	(0.4)	0.5	4	(0.2)	0.3	5	(0.4)	0.3	11	(0.6)	0.7	4	(0.3)	0.3
	0	(0.0)	0.0	0	(0.0)	0.0	1	(11.1)	1.5	0	(0.0)	0.0	1	(11.1)	1.5
	41	(8.5)	4.7	15	(3.2)	1.7	18	(3.8)	1.9	21	(5.0)	2.2	20	(4.7)	2.0
	154	(3.4)	1.9	229	(5.2)	2.7	184	(4.3)	2.2	282	(6.0)	3.3	209	(5.9)	2.5
	57	(4.5)	17.9	48	(4.5)	15.4	40	(4.1)	12.9	46	(4.9)	14.9	61	(6.9)	19.9
	0	(0.0)	0.0	-	-	-	-	-	-	-	-	-	-	-	-
	85	(3.5)	15.8	100	(4.4)	19.3	74	(3.6)	14.7	92	(4.7)	18.4	88	(4.6)	18.0
	2	(5.1)	2.3	0	(0.0)	0.0	1	(3.7)	1.1	1	(3.4)	1.1	1	(3.8)	1.1
	2	(5.3)	2.9	0	(0.0)	0.0	1	(2.3)	1.5	0	(0.0)	0.0	0	(0.0)	0.0
	49	(4.9)	1.7	50	(4.9)	1.7	58	(5.0)	2.0	34	(3.2)	1.2	56	(5.6)	1.9
	19	(6.3)	2.1	23	(7.3)	2.5	14	(3.9)	1.5	13	(3.9)	1.4	17	(4.7)	1.8
	74	(0.9)	1.2	76	(0.9)	1.3	99	(1.2)	1.7	62	(0.8)	1.1	111	(1.3)	1.9
	71	(2.3)	4.3	65	(2.2)	4.0	78	(2.7)	4.8	52	(2.0)	3.2	44	(1.7)	2.7
	1007	(4.1)	30.3	924	(3.7)	28.2	965	(4.2)	29.6	823	(3.9)	25.3	776	(4.0)	23.9
	16	(2.3)	1.8	14	(2.2)	1.6	11	(2.2)	1.3	11	(2.5)	1.3	17	(4.3)	2.0
	6	(2.8)	2.1	3	(1.4)	1.1	6	(3.2)	2.1	3	(1.7)	1.0	4	(2.1)	1.4
	477	(6.1)	7.4	600	(7.3)	9.1	537	(7.1)	7.9	484	(6.7)	7.0	541	(8.0)	7.8
	36	(7.5)	2.3	27	(4.9)	1.8	31	(5.0)	2.0	47	(7.0)	3.0	36	(6.1)	2.3
	490	(5.9)	4.6	497	(5.8)	4.6	428	(4.8)	4.0	386	(4.6)	3.6	413	(4.6)	3.8
	<b>3464</b>	<b>(4.1)</b>	<b>4.4</b>	<b>3481</b>	<b>(4.2)</b>	<b>4.4</b>	<b>3319</b>	<b>(4.2)</b>	<b>4.2</b>	<b>3144</b>	<b>(4.2)</b>	<b>4.0</b>	<b>3190</b>	<b>(4.4)</b>	<b>4.0</b>
	27	(6.0)	3.5	19	(4.4)	2.5	17	(3.8)	2.3	18	(4.0)	2.5	7	(1.6)	1.0
	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	41	(1.9)	6.3	85	(4.0)	13.4	65	(3.2)	10.4	59	(3.3)	9.5	47	(3.0)	7.5
	-	-	-	-	-	-	271	(2.6)	14.0	244	(2.9)	12.7	186	(1.9)	9.5
	31	(0.5)	2.1	38	(0.7)	2.6	11	(0.2)	0.8	31	(0.6)	2.2	26	(0.5)	1.8
	-	-	-	17	(1.0)	2.9	14	(0.8)	2.4	13	(0.9)	2.3	20	(1.4)	3.6
	-	-	-	27	(2.8)	4.0	25	(2.9)	3.7	18	(2.6)	2.7	13	(2.1)	2.0
	306	(5.2)	39.6	267	(4.6)	35.6	281	(4.7)	38.4	249	(4.3)	34.5	202	(3.7)	28.3
	27	(6.8)	1.4	14	(4.3)	0.7	10	(2.9)	0.5	19	(5.5)	0.9	20	(4.8)	1.0
	1884	(5.0)	50.7	981	(3.4)	26.0	818	(2.7)	21.3	733	(2.6)	18.7	622	(2.7)	15.4
	14	(0.2)	0.9	630	(8.8)	39.9	541	(8.5)	34.0	531	(8.4)	33.1	-	-	-
	55	(9.8)	14.2	40	(8.3)	10.6	31	(6.6)	8.4	33	(7.9)	9.1	33	(9.1)	9.2
	176	(2.8)	27.2	160	(2.7)	25.6	161	(2.9)	26.5	137	(2.5)	23.0	159	(3.0)	26.9
	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	2	(1.3)	1.6	1	(0.8)	0.8	2	(1.7)	1.6	3	(2.6)	2.5	3	(2.7)	2.5
	3422	(1.6)	16.2	3203	(1.5)	15.2	3111	(2.0)	14.6	831	(0.5)	3.9	3545	(2.2)	16.2
	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	28	(0.9)	1.6	24	(0.9)	1.4	25	(1.0)	1.4	19	(0.8)	1.1	19	(0.9)	0.8
	28	(0.9)	1.6	24	(0.9)	1.4	25	(1.0)	1.4	19	(0.8)	1.1	19	(0.9)	0.8
	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	15	(3.2)	1.3	11	(2.1)	0.9	16	(2.9)	1.4	12	(2.2)	1.0	19	(3.3)	1.6
	585	(7.2)	23.0	547	(6.8)	21.5	456	(6.1)	17.9	491	(6.4)	19.3	569	(7.5)	22.3
	952	(4.8)	4.9	949	(5.1)	4.9	940	(5.4)	4.9	879	(5.3)	4.6	744	(4.7)	3.9
	8	(0.2)	0.5	7	(0.2)	0.5	5	(0.2)	0.3	3	(0.1)	0.2	-	-	-
	21	(0.1)	0.3	581	(1.5)	8.9	580	(1.5)	9.0	302	(0.8)	4.7	19	(0.0)	0.3
	2583	(11.0)	31.0	2008	(9.5)	24.4	2263	(10.5)	27.8	1878	(9.2)	23.3	1592	(10.0)	19.8
	<b>10177</b>	<b>(2.7)</b>	<b>13.7</b>	<b>9609</b>	<b>(2.6)</b>	<b>12.8</b>	<b>9643</b>	<b>(3.0)</b>	<b>12.5</b>	<b>6503</b>	<b>(2.1)</b>	<b>7.6</b>	<b>7839</b>	<b>(2.6)</b>	<b>9.0</b>
	<b>13641</b>	<b>(2.9)</b>	<b>8.7</b>	<b>13090</b>	<b>(2.8)</b>	<b>8.4</b>	<b>12962</b>	<b>(3.3)</b>	<b>8.3</b>	<b>9647</b>	<b>(2.5)</b>	<b>6.2</b>	<b>11029</b>	<b>(2.9)</b>	<b>6.7</b>
	<b>11369</b>	<b>(2.7)</b>	<b>15.1</b>	<b>10757</b>	<b>(2.7)</b>	<b>14.3</b>	<b>10795</b>	<b>(3.2)</b>	<b>14.3</b>	<b>7552</b>	<b>(2.3)</b>	<b>10.0</b>	<b>8813</b>	<b>(2.7)</b>	<b>11.6</b>

Table IV: Tuberculosis cases of foreign origin, EU/EEA, 1995–2011

Country	Trend in percentage, 1995–2011	1995		1996		1997		1998		1999		2000		2001	
		N	% among all TB cases	N	% among all TB cases	N	% among all TB cases	N	% among all TB cases	N	% among all TB cases	N	% among all TB cases	N	% among all TB cases
Austria		358	(24.2)	350	(23.5)	346	(24.8)	293	(22.3)	319	(25.6)	335	(27.3)	271	(25.2)
Belgium		455	(33.0)	435	(32.2)	414	(32.8)	427	(35.5)	454	(35.7)	508	(38.7)	604	(45.7)
Bulgaria		-	-	-	-	-	-	-	-	-	-	-	-	0	(0.0)
Cyprus		-	-	-	-	-	-	-	-	-	-	-	-	25	(62.5)
Czech Republic		17	(0.9)	0	(0.0)	108	(5.9)	110	(6.1)	135	(8.3)	143	(9.9)	193	(14.3)
Denmark <sup>a</sup>		246	(54.9)	283	(58.5)	380	(68.6)	344	(65.0)	371	(69.2)	350	(63.9)	334	(65.4)
Estonia		0	(0.0)	2	(0.3)	28	(3.8)	114	(13.9)	167	(22.1)	183	(23.1)	182	(22.4)
Finland		38	(5.8)	41	(6.5)	46	(8.3)	58	(9.5)	47	(7.9)	47	(8.6)	66	(13.2)
France		2417	(27.7)	1845	(24.1)	1613	(23.6)	1607	(24.2)	1932	(28.9)	2193	(32.7)	2305	(35.7)
Germany		3532	(29.0)	3474	(29.4)	3427	(30.7)	3291	(31.5)	3305	(33.1)	3047	(33.6)	2741	(36.4)
Greece		-	-	-	-	-	-	126	(10.9)	116	(12.2)	68	(9.7)	104	(16.9)
Hungary		0	(0.0)	42	(1.0)	44	(1.0)	10	(0.3)	64	(1.6)	56	(1.6)	57	(1.8)
Iceland		1	(8.3)	4	(36.4)	2	(20.0)	8	(47.1)	8	(66.7)	5	(38.5)	7	(53.8)
Ireland		-	-	-	-	-	-	35	(8.3)	65	(13.9)	49	(12.2)	65	(16.0)
Italy		525	(10.0)	572	(11.1)	691	(13.4)	797	(16.6)	961	(21.7)	1201	(25.2)	1391	(30.9)
Latvia		-	-	-	-	85	(4.2)	61	(2.8)	-	-	147	(7.1)	122	(5.9)
Liechtenstein		-	-	-	-	-	-	-	-	-	-	-	-	-	-
Lithuania		-	-	-	-	157	(5.4)	231	(7.7)	-	-	160	(5.4)	174	(5.8)
Luxembourg		16	(50.0)	0	(0.0)	17	(44.7)	25	(56.8)	28	(66.7)	21	(47.7)	9	(28.1)
Malta		4	(40.0)	10	(34.5)	3	(27.3)	4	(25.0)	7	(31.8)	5	(27.8)	3	(18.8)
Netherlands		913	(56.4)	833	(49.6)	817	(55.0)	805	(60.0)	898	(58.5)	879	(62.6)	881	(61.4)
Norway		97	(41.1)	102	(47.0)	110	(53.7)	129	(52.9)	180	(65.9)	167	(70.5)	206	(71.5)
Poland		-	-	-	-	-	-	-	-	-	-	-	-	0	(0.0)
Portugal		-	-	-	-	-	-	-	-	325	(6.3)	434	(9.7)	491	(11.2)
Romania		6	(0.0)	-	-	15	(0.1)	0	(0.0)	2	(0.0)	0	(0.0)	4	(0.0)
Slovakia		4	(0.3)	2	(0.1)	0	(0.0)	1	(0.1)	4	(0.3)	8	(0.7)	13	(1.2)
Slovenia		111	(21.1)	106	(18.8)	101	(21.0)	81	(18.0)	103	(23.5)	94	(24.7)	84	(22.6)
Spain		-	-	-	-	-	-	94	(1.0)	151	(1.8)	451	(5.4)	412	(5.5)
Sweden		315	(55.9)	291	(59.0)	300	(65.8)	269	(60.3)	319	(64.7)	305	(66.6)	286	(66.8)
United Kingdom		-	-	-	-	-	-	2987	(52.2)	2959	(51.9)	3458	(51.4)	3588	(52.3)
<b>Total EU/EEA</b>		<b>9055</b>	<b>(14.0)</b>	<b>8392</b>	<b>(21.0)</b>	<b>8704</b>	<b>(13.1)</b>	<b>11907</b>	<b>(14.3)</b>	<b>12920</b>	<b>(15.6)</b>	<b>14314</b>	<b>(16.4)</b>	<b>14618</b>	<b>(14.5)</b>

<sup>a</sup> 'European Region' comprises the 53 countries of the WHO European Region and Liechtenstein. WHO European Region 18 TB High Priority Countries presented in italics.

<sup>a</sup> Excluding Greenland data (see Chapter 1.1).

	2002		2003		2004		2005		2006		2007		2008		2009		2010		2011	
	N	% among all TB cases	N	% among all TB cases	N	% among all TB cases	N	% among all TB cases	N	% among all TB cases	N	% among all TB cases	N	% among all TB cases	N	% among all TB cases	N	% among all TB cases	N	% among all TB cases
	305	(28.4)	343	(34.6)	447	(41.6)	436	(43.7)	335	(37.0)	319	(36.5)	299	(36.6)	230	(33.0)	300	(43.4)	326	(47.5)
	657	(50.8)	605	(54.2)	634	(52.9)	571	(51.6)	574	(51.4)	482	(47.3)	473	(47.8)	485	(48.8)	594	(54.7)	544	(52.1)
	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	5	(0.2)	6	(0.2)	8	(0.3)	2	(0.1)	9	(0.4)
	7	(35.0)	22	(62.9)	23	(76.7)	25	(67.6)	28	(75.7)	31	(73.8)	44	(88.0)	46	(83.6)	50	(82.0)	45	(83.3)
	164	(13.7)	126	(10.8)	149	(14.1)	129	(13.1)	130	(13.7)	151	(17.8)	185	(21.4)	135	(19.5)	117	(17.5)	112	(18.7)
	265	(63.2)	235	(59.8)	237	(61.6)	252	(58.9)	225	(58.1)	242	(61.9)	227	(59.7)	202	(60.5)	220	(60.1)	235	(61.7)
	140	(19.6)	130	(20.9)	138	(23.2)	83	(16.0)	73	(15.9)	80	(16.3)	83	(18.7)	79	(19.2)	61	(18.3)	48	(14.1)
	49	(10.3)	51	(12.3)	42	(12.5)	54	(14.5)	53	(17.8)	74	(21.3)	54	(15.7)	125	(30.0)	107	(32.9)	79	(24.3)
	2564	(40.6)	2572	(42.2)	2526	(45.3)	2422	(45.1)	2310	(43.4)	2498	(44.8)	2587	(44.9)	2427	(46.0)	2469	(48.3)	2456	(49.7)
	2991	(38.8)	3014	(42.1)	2884	(44.1)	2633	(43.7)	2248	(41.8)	2100	(42.0)	1936	(42.8)	1941	(43.8)	2014	(45.9)	2025	(46.9)
	111	(19.1)	155	(25.0)	180	(23.3)	219	(59.3)	-	-	212	(33.2)	249	(37.5)	255	(43.3)	231	(47.4)	216	(44.2)
	47	(1.7)	51	(2.0)	44	(1.9)	62	(3.2)	41	(2.2)	48	(2.8)	47	(2.9)	32	(2.3)	21	(1.2)	27	(1.9)
	3	(37.5)	3	(60.0)	8	(66.7)	7	(63.6)	9	(69.2)	9	(64.3)	4	(66.7)	5	(55.6)	16	(72.7)	7	(77.8)
	123	(30.1)	89	(21.9)	129	(29.9)	152	(33.8)	160	(34.6)	192	(40.0)	203	(43.4)	206	(43.0)	171	(40.7)	179	(42.1)
	1293	(30.7)	1459	(32.3)	1664	(39.4)	1854	(44.0)	2108	(46.8)	1960	(43.3)	2026	(45.9)	2052	(48.4)	2284	(48.7)	1677	(47.6)
	115	(6.2)	93	(5.4)	119	(7.4)	84	(5.8)	69	(5.2)	66	(5.3)	56	(5.2)	60	(6.1)	62	(6.6)	59	(6.7)
	-	-	-	-	-	-	-	-	-	-	1	(20.0)	-	-	-	-	-	-	-	-
	133	(4.7)	128	(4.5)	87	(3.5)	90	(3.5)	74	(2.9)	76	(3.2)	49	(2.2)	61	(2.9)	47	(2.4)	44	(2.3)
	13	(40.6)	36	(66.7)	25	(80.6)	25	(67.6)	20	(60.6)	24	(61.5)	0	(0.0)	16	(59.3)	17	(58.6)	21	(80.8)
	9	(37.5)	4	(57.1)	12	(63.2)	17	(68.0)	17	(56.7)	24	(63.2)	42	(79.2)	34	(77.3)	25	(78.1)	28	(84.8)
	854	(61.0)	749	(56.7)	721	(53.6)	758	(67.2)	659	(63.9)	626	(62.7)	708	(69.8)	842	(72.7)	787	(73.9)	710	(70.5)
	191	(76.1)	267	(79.2)	239	(79.1)	225	(78.1)	235	(81.0)	239	(79.1)	261	(83.4)	323	(90.2)	289	(86.0)	317	(87.8)
	0	(0.0)	0	(0.0)	0	(0.0)	17	(0.2)	47	(0.5)	55	(0.6)	53	(0.7)	53	(0.6)	46	(0.6)	38	(0.4)
	567	(12.6)	503	(12.1)	455	(11.8)	0	(0.0)	398	(11.5)	423	(13.5)	443	(14.8)	441	(15.4)	425	(16.2)	385	(15.2)
	7	(0.0)	0	(0.0)	2	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	35	(0.2)	50	(0.2)	50	(0.3)
	12	(1.1)	16	(1.6)	15	(2.1)	27	(3.6)	11	(1.5)	12	(1.8)	9	(1.4)	7	(1.4)	8	(1.8)	3	(0.8)
	77	(22.0)	43	(14.7)	54	(20.5)	48	(17.3)	34	(15.8)	38	(17.4)	56	(26.3)	55	(29.3)	41	(23.8)	57	(29.7)
	444	(5.8)	603	(8.1)	787	(10.1)	1448	(18.5)	1552	(19.3)	2029	(26.1)	2495	(30.4)	2330	(30.7)	2383	(32.9)	2138	(31.6)
	293	(72.0)	305	(74.8)	343	(74.4)	410	(73.3)	357	(71.8)	374	(77.6)	442	(81.0)	507	(82.2)	572	(85.6)	524	(89.4)
	4294	(58.6)	4538	(62.5)	4825	(63.1)	5445	(65.2)	5455	(65.2)	5481	(65.8)	5819	(67.6)	5996	(67.2)	5816	(68.6)	6287	(70.1)
	<b>15728</b>	<b>(17.1)</b>	<b>16140</b>	<b>(18.5)</b>	<b>16789</b>	<b>(19.7)</b>	<b>17493</b>	<b>(19.9)</b>	<b>17222</b>	<b>(19.9)</b>	<b>17871</b>	<b>(21.3)</b>	<b>18856</b>	<b>(22.7)</b>	<b>18988</b>	<b>(23.8)</b>	<b>19225</b>	<b>(25.4)</b>	<b>18646</b>	<b>(25.8)</b>

**Table V: MDR-TB notification among all laboratory confirmed TB cases, European Region, 2000–2011**

Country	Trend in percentage, 2000–2011	2000		2001		2002		2003		2004		2005	
		N	(%)	N	(%)	N	(%)	N	(%)	N	(%)	N	(%)
<b>EU/EEA</b>													
Austria		5	(0.7)	5	(0.8)	3	(0.4)	12	(2.0)	19	(3.0)	13	(2.1)
Belgium		11	(1.1)	18	(2.4)	21	(2.6)	9	(1.1)	12	(1.4)	11	(1.5)
Bulgaria		-	-	-	-	-	-	44	(3.2)	47	(3.7)	47	(3.7)
Cyprus		-	-	-	-	1	(33.3)	0	(0.0)	0	(0.0)	1	(5.9)
Czech Republic		9	(1.4)	9	(1.3)	10	(2.0)	2	(0.3)	6	(1.2)	13	(2.2)
Denmark <sup>a</sup>		-	-	-	-	1	(0.3)	0	(0.0)	0	(0.0)	5	(1.5)
Estonia		103	(19.5)	158	(27.2)	138	(25.9)	106	(22.8)	90	(19.9)	78	(20.2)
Finland		2	(0.5)	4	(1.1)	3	(0.9)	3	(0.9)	0	(0.0)	2	(0.6)
France		15	(0.8)	15	(0.8)	23	(1.3)	25	(1.2)	26	(1.3)	24	(1.1)
Germany		-	-	105	(2.7)	89	(2.0)	91	(2.1)	98	(2.5)	103	(2.7)
Greece		-	-	-	-	22	(8.1)	22	(9.6)	16	(7.8)	12	(5.6)
Hungary		7	(2.2)	13	(2.9)	17	(3.1)	20	(3.8)	11	(2.2)	17	(4.1)
Iceland		0	(0.0)	0	(0.0)	0	(0.0)	1	(25.0)	0	(0.0)	0	(0.0)
Ireland		3	(1.4)	1	(1.0)	0	(0.0)	1	(0.4)	2	(0.8)	3	(1.1)
Italy		35	(2.0)	38	(2.4)	33	(2.1)	42	(1.6)	24	(1.2)	22	(1.4)
Latvia		150	(11.6)	150	(11.6)	226	(18.2)	174	(14.6)	195	(17.7)	161	(15.3)
Liechtenstein		-	-	-	-	-	-	-	-	-	-	-	-
Lithuania		156	(10.0)	266	(15.0)	297	(19.2)	312	(22.3)	318	(20.0)	338	(19.4)
Luxembourg		-	-	-	-	-	-	1	(1.9)	1	(3.2)	0	(0.0)
Malta		0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)
Netherlands		8	(0.9)	8	(1.6)	2	(0.3)	8	(1.3)	3	(0.4)	8	(0.9)
Norway		3	(1.8)	5	(2.3)	7	(3.6)	3	(1.1)	4	(1.6)	3	(1.4)
Poland		-	-	92	(1.5)	-	-	-	-	51	(1.0)	46	(1.2)
Portugal		30	(3.0)	31	(2.7)	34	(2.2)	23	(1.7)	35	(2.3)	31	(1.9)
Romania		165	(4.1)	198	(6.5)	0	-	585	(18.4)	810	(17.5)	849	(17.1)
Slovakia		7	(1.2)	6	(1.0)	3	(0.6)	6	(1.5)	1	(0.3)	8	(2.6)
Slovenia		0	(0.0)	3	(1.0)	2	(0.7)	1	(0.4)	0	(0.0)	1	(0.4)
Spain		-	-	51	(1.9)	31	(0.8)	47	(1.3)	59	(1.7)	80	(2.2)
Sweden		5	(1.4)	4	(1.1)	4	(1.1)	7	(2.0)	6	(1.6)	4	(0.9)
United Kingdom		28	(0.9)	25	(0.7)	34	(0.9)	52	(1.3)	47	(1.1)	40	(0.8)
<b>Subtotal EU/EEA</b>		<b>742</b>	<b>(3.6)</b>	<b>1205</b>	<b>(3.7)</b>	<b>1001</b>	<b>(4.0)</b>	<b>1597</b>	<b>(5.3)</b>	<b>1881</b>	<b>(5.1)</b>	<b>1920</b>	<b>(5.2)</b>

<sup>a</sup> 'European Region' comprises the 53 countries of the WHO European Region and Liechtenstein. WHO European Region 18 TB High Priority Countries presented in italics.

<sup>a</sup> Excluding Greenland data (see Chapter 1.1).



	2006		2007		2008		2009		2010		2011	
	N	(%)	N	(%)	N	(%)	N	(%)	N	(%)	N	(%)
	10	(1.9)	9	(1.8)	15	(3.1)	23	(5.3)	16	(3.4)	19	(4.2)
	18	(2.2)	14	(1.9)	21	(2.7)	10	(1.3)	19	(2.3)	15	(2.0)
	53	(3.9)	76	(7.5)	31	(3.3)	43	(5.1)	56	(5.8)	55	(7.5)
	0	(0.0)	3	(10.3)	1	(2.8)	4	(12.9)	0	(0.0)	1	(2.5)
	12	(2.1)	8	(1.5)	11	(2.1)	8	(1.8)	9	(2.1)	7	(1.7)
	3	(1.0)	2	(0.7)	0	(0.0)	2	(0.8)	2	(0.7)	3	(1.1)
	55	(15.6)	82	(21.4)	73	(21.0)	85	(28.0)	65	(24.8)	78	(29.8)
	2	(0.7)	2	(0.8)	1	(0.4)	6	(2.0)	6	(2.4)	5	(2.0)
	30	(1.3)	20	(0.8)	27	(1.1)	30	(1.2)	23	(1.0)	40	(2.6)
	82	(2.3)	66	(2.0)	49	(1.6)	62	(2.1)	52	(1.8)	56	(2.0)
	13	(6.2)	14	(2.2)	-	-	12	(7.1)	2	(2.2)	5	(3.1)
	14	(2.6)	12	(2.6)	13	(2.8)	18	(4.0)	19	(3.3)	7	(1.5)
	0	(0.0)	1	(9.1)	1	(20.0)	0	(0.0)	0	(0.0)	0	(0.0)
	4	(1.4)	7	(2.4)	2	(0.7)	1	(0.3)	2	(0.7)	3	(1.3)
	28	(1.8)	56	(3.0)	71	(4.6)	82	(5.9)	87	(3.5)	81	(3.1)
	142	(14.7)	99	(10.1)	128	(15.5)	131	(17.4)	88	(12.3)	95	(14.8)
	-	-	0	(0.0)	-	-	-	-	-	-	-	-
	332	(18.6)	314	(18.6)	276	(17.1)	322	(21.8)	310	(22.7)	296	(21.1)
	0	(0.0)	0	(0.0)	-	-	0	(0.0)	0	(0.0)	2	(10.5)
	2	(14.3)	1	(5.3)	0	(0.0)	0	(0.0)	1	(6.3)	0	(0.0)
	6	(0.8)	6	(0.8)	15	(2.0)	20	(2.6)	11	(1.4)	15	(2.1)
	3	(1.3)	3	(1.2)	4	(1.8)	8	(2.8)	8	(2.9)	4	(1.6)
	32	(0.9)	22	(0.6)	19	(0.5)	21	(0.5)	30	(0.8)	41	(0.8)
	22	(1.3)	34	(2.0)	32	(1.8)	24	(1.4)	19	(1.6)	22	(1.8)
	673	(14.8)	673	(17.6)	792	(14.3)	624	(10.0)	574	(9.4)	530	(8.8)
	7	(1.7)	7	(1.8)	4	(1.0)	1	(0.4)	1	(0.4)	3	(1.6)
	1	(0.5)	0	(0.0)	2	(1.0)	1	(0.6)	0	(0.0)	0	(0.0)
	50	(1.4)	59	(1.5)	76	(1.7)	56	(1.4)	49	(1.2)	41	(3.2)
	3	(0.8)	15	(4.1)	11	(2.6)	13	(2.5)	18	(3.4)	17	(3.6)
	51	(1.0)	56	(1.2)	53	(1.1)	60	(1.2)	60	(1.3)	81	(1.6)
	<b>1648</b>	<b>(4.6)</b>	<b>1661</b>	<b>(4.7)</b>	<b>1728</b>	<b>(4.8)</b>	<b>1667</b>	<b>(4.6)</b>	<b>1527</b>	<b>(4.2)</b>	<b>1522</b>	<b>(4.5)</b>

Country	Trend in percentage, 2000–2011	2000		2001		2002		2003		2004		2005	
		N	(%)	N	(%)	N	(%)	N	(%)	N	(%)	N	(%)
<b>Non-EU/EEA</b>													
Albania		-	-	-	-	-	-	-	-	-	-	1	(0.6)
Andorra		-	-	-	-	-	-	-	-	-	-	-	-
Armenia		-	-	-	-	-	-	-	-	157	(24.8)	162	(21.4)
Azerbaijan		-	-	-	-	-	-	-	-	17	-	800	(97.7)
Belarus		-	-	-	-	-	-	-	-	340	(11.0)	-	-
Bosnia and Herzegovina		5	(0.4)	2	(0.2)	4	(0.4)	2	(0.2)	10	(0.9)	11	(1.0)
Croatia		2	(0.2)	5	(0.6)	6	(0.7)	8	(1.0)	3	(0.4)	6	(0.9)
Georgia		-	-	-	-	-	-	-	-	-	-	195	(14.8)
Israel		44	(10.7)	23	(6.3)	16	(4.5)	20	(5.6)	14	(4.4)	16	(6.0)
Kazakhstan		-	-	-	-	-	-	-	-	4 828	(28.0)	-	-
Kyrgyzstan		-	-	-	-	-	-	-	-	259	(27.5)	989	(100.0)
Macedonia, the former Yugoslav Republic of		-	-	-	-	-	-	-	-	2	(1.4)	4	(3.2)
Moldova		-	-	-	-	-	-	-	-	-	-	338	(28.5)
Monaco		-	-	-	-	-	-	-	-	-	-	-	-
Montenegro		-	-	-	-	-	-	-	-	-	-	2	(2.0)
Russia		-	-	-	-	-	-	-	-	-	-	-	-
San Marino		-	-	-	-	-	-	-	-	-	-	-	-
Serbia		-	-	-	-	-	-	-	-	-	-	9	(0.7)
Serbia excluding UN Administered Province of Kosovo <sup>a</sup>		-	-	-	-	-	-	-	-	-	-	9	(0.7)
UN Administered Province of Kosovo <sup>a</sup>		-	-	-	-	-	-	-	-	-	-	-	-
Switzerland		1	(0.3)	7	(1.4)	11	(2.1)	12	(2.5)	5	(1.1)	5	(1.1)
Tajikistan		-	-	-	-	-	-	-	-	-	-	-	-
Turkey		-	-	-	-	-	-	-	-	-	-	191	(5.1)
Turkmenistan		-	-	-	-	-	-	-	-	-	-	-	-
Ukraine		-	-	-	-	-	-	-	-	-	-	-	-
Uzbekistan		-	-	-	-	-	-	-	-	9	(1.3)	86	(19.8)
<b>Subtotal non-EU/EEA</b>		<b>52</b>	<b>(1.8)</b>	<b>37</b>	<b>(1.2)</b>	<b>37</b>	<b>(1.3)</b>	<b>42</b>	<b>(1.5)</b>	<b>5 644</b>	<b>(22.0)</b>	<b>2 815</b>	<b>(21.0)</b>
<b>Total European Region</b>		<b>794</b>	<b>(4.5)</b>	<b>1 242</b>	<b>(5.0)</b>	<b>1 038</b>	<b>(4.5)</b>	<b>1 639</b>	<b>(7.4)</b>	<b>7 525</b>	<b>(14.8)</b>	<b>4 735</b>	<b>(10.8)</b>
<b>Subtotal 18 HPC</b>		<b>574</b>	<b>(22.1)</b>	<b>772</b>	<b>(24.7)</b>	<b>661</b>	<b>(21.2)</b>	<b>1 221</b>	<b>(40.0)</b>	<b>7 070</b>	<b>(25.4)</b>	<b>4 234</b>	<b>(25.7)</b>

<sup>a</sup> In accordance with the UN Security Council Resolution No. 1244 (1999).

	2006		2007		2008		2009		2010		2011	
	N	(%)	N	(%)	N	(%)	N	(%)	N	(%)	N	(%)
	1	(0.7)	3	(1.6)	2	(0.9)	0	-	2	(1.0)	5	(2.4)
	-	-	-	-	-	-	-	-	-	-	-	-
	215	(24.7)	125	(19.5)	128	(21.1)	156	(22.9)	177	(38.5)	79	(14.9)
	398	(51.5)	196	(41.7)	-	-	-	-	552	(31.3)	90	(12.5)
	651	(20.9)	870	(26.2)	923	(28.5)	1342	(33.7)	1576	(41.7)	1594	(52.6)
	7	(0.6)	8	(0.6)	12	(1.4)	2	(0.2)	2	(0.3)	5	(0.7)
	3	(0.4)	7	(1.0)	4		7	(1.4)	-	-	2	(0.5)
	266	(14.1)	269	(14.0)	481	(20.0)	369	(15.6)	359	(14.1)	453	(15.8)
	19	(7.9)	14	(4.9)	13	(5.7)	6	(2.3)	12	(4.9)	11	(3.9)
	4117	(26.2)	5568	(35.9)	3676	(34.1)	3644	(38.0)	4033	(34.9)	4575	(39.6)
	336	(30.1)	322	(26.4)	269	(33.3)	785	(40.7)	489	(100.0)	-	-
	6	(3.7)	9	(4.7)	2	(1.4)	1	(0.5)	7	(3.9)	1	(0.6)
	1204	(41.8)	896	(39.9)	1048	(43.0)	1069	(44.3)	1082	(42.9)	1001	(42.0)
	-	-	-	-	-	-	-	-	-	-	-	-
	2	(1.9)	2	(2.3)	0	-	1	(1.1)	0	-	1	(1.4)
	-	-	5297	(15.0)	6960	(16.3)	14686	(25.0)	12387	(25.1)	13785	(28.9)
	-	-	-	-	-	-	-	-	-	-	-	-
	10	(0.9)	25	(1.9)	16	(1.5)	-	-	12	(1.3)	9	(0.9)
	10	(0.9)	25	(1.9)	16	(1.5)	-	-	12	(1.3)	9	(0.9)
	-	-	-	-	-	-	-	-	-	-	-	-
	4	(0.9)	8	(2.7)	5	(1.2)	-	-	9	(2.0)	8	(1.8)
	-	-	-	-	-	-	319	(22.6)	266	(69.5)	380	(66.0)
	249	(5.2)	240	(4.9)	263	(5.3)	222	(5.1)	250	(5.0)	262	(5.4)
	16	(15.5)	-	-	-	-	39	(14.2)	38	(26.4)	-	-
	-	-	-	-	-	-	3482	(19.0)	5336	(38.0)	4305	(29.2)
	83	(28.1)	484	(57.1)	342	(46.0)	654	(50.2)	1023	(25.4)	1385	(62.5)
	<b>7587</b>	<b>(21.3)</b>	<b>14343</b>	<b>(20.3)</b>	<b>14144</b>	<b>(19.8)</b>	<b>26784</b>	<b>(24.8)</b>	<b>27612</b>	<b>(28.0)</b>	<b>27951</b>	<b>(25.6)</b>
	<b>9235</b>	<b>(15.9)</b>	<b>16004</b>	<b>(16.1)</b>	<b>15872</b>	<b>(15.4)</b>	<b>28451</b>	<b>(21.1)</b>	<b>29139</b>	<b>(22.5)</b>	<b>29473</b>	<b>(19.0)</b>
	<b>8790</b>	<b>(24.4)</b>	<b>15511</b>	<b>(20.7)</b>	<b>15390</b>	<b>(19.8)</b>	<b>27972</b>	<b>(24.8)</b>	<b>28661</b>	<b>(27.4)</b>	<b>28963</b>	<b>(23.8)</b>

**Table VI: MDR-TB notification among all culture positive TB cases with available DST results, European Region, 2007–2011**

Country	Trend in percentage, 2007–2011	2007			2008			2009			2010			2011			Mean annual % change in rate, 2007–2011
		N	(%)	Rate	N	(%)	Rate	N	(%)	Rate	N	(%)	Rate	N	(%)	Rate	
<b>EU/EEA</b>																	
Austria		9	(1.8)	0.1	15	(3.1)	0.2	23	(5.3)	0.3	16	(3.4)	0.2	19	(4.2)	0.2	26.6%
Belgium		14	(1.9)	0.1	21	(2.7)	0.2	10	(1.3)	0.1	19	(2.3)	0.2	15	(2.0)	0.1	15.7%
Bulgaria		76	(7.5)	1.0	31	(3.3)	0.4	43	(5.1)	0.6	56	(5.8)	0.7	55	(7.5)	0.7	2.6%
Cyprus		3	(10.3)	0.4	1	(2.8)	0.1	4	(12.9)	0.5	0	(0.0)	0.0	1	(2.5)	0.1	-
Czech Republic		8	(1.5)	0.1	11	(2.1)	0.1	8	(1.8)	0.1	9	(2.1)	0.1	7	(1.7)	0.1	-0.5%
Denmark <sup>a</sup>		2	(0.7)	0.0	0	(0.0)	0.0	2	(0.8)	0.0	2	(0.7)	0.0	3	(1.1)	0.1	-
Estonia		82	(21.4)	6.1	73	(21.0)	5.4	85	(28.0)	6.3	65	(24.8)	4.9	78	(29.8)	5.8	0.5%
Finland		2	(0.8)	0.0	1	(0.4)	0.0	6	(2.0)	0.1	6	(2.4)	0.1	5	(2.0)	0.1	107.3%
France		20	(1.3)	0.0	27	(1.7)	0.0	30	(1.2)	0.0	23	(1.6)	0.0	40	(2.6)	0.1	23.5%
Germany		66	(2.0)	0.1	49	(1.6)	0.1	62	(2.1)	0.1	52	(1.8)	0.1	56	(2.0)	0.1	-1.7%
Greece		14	(2.6)	0.1	-	-	-	12	(7.1)	0.1	2	(2.2)	0.0	5	(3.1)	0.0	-
Hungary		12	(2.6)	0.1	13	(2.8)	0.1	18	(4.0)	0.2	19	(3.3)	0.2	7	(1.5)	0.1	-2.5%
Iceland		1	(9.1)	0.3	1	(20.0)	0.3	0	(0.0)	0.0	0	(0.0)	0.0	0	(0.0)	0.0	-
Ireland		7	(2.4)	0.2	2	(0.7)	0.0	1	(0.3)	0.0	2	(0.7)	0.0	3	(1.3)	0.1	6.6%
Italy		56	(3.3)	0.1	71	(3.7)	0.1	82	(3.3)	0.1	87	(3.4)	0.1	81	(3.2)	0.1	9.7%
Latvia		99	(10.1)	4.3	128	(15.5)	5.6	131	(17.4)	5.8	88	(12.3)	3.9	95	(14.8)	4.3	2.3%
Liechtenstein		0	(0.0)	0.0	-	-	-	-	-	-	-	-	-	-	-	-	-
Lithuania		314	(18.6)	9.3	276	(17.1)	8.2	322	(21.8)	9.6	310	(22.7)	9.3	296	(21.1)	9.1	0.1%
Luxembourg		0	(0.0)	0.0	-	-	-	0	(0.0)	0.0	0	(0.0)	0.0	2	(10.5)	0.4	-
Malta		1	(5.3)	0.2	0	(0.0)	0.0	0	(0.0)	0.0	1	(6.3)	0.2	0	(0.0)	0.0	-
Netherlands		6	(0.8)	0.0	15	(2.0)	0.1	20	(2.6)	0.1	11	(1.4)	0.1	15	(2.1)	0.1	43.1%
Norway		3	(1.2)	0.1	4	(1.8)	0.1	8	(2.8)	0.2	8	(2.9)	0.2	4	(1.6)	0.1	19.3%
Poland		22	(0.6)	0.1	19	(0.5)	0.0	21	(0.5)	0.1	30	(0.8)	0.1	41	(0.8)	0.1	19.0%
Portugal		34	(2.0)	0.3	32	(1.8)	0.3	24	(1.4)	0.2	19	(1.6)	0.2	22	(1.8)	0.2	-9.1%
Romania		673	(17.6)	3.1	792	(14.3)	3.7	624	(10.0)	2.9	574	(9.4)	2.7	530	(8.8)	2.5	-4.6%
Slovakia		7	(1.8)	0.1	4	(1.0)	0.1	1	(0.4)	0.0	1	(0.4)	0.0	3	(1.6)	0.1	20.3%
Slovenia		0	(0.0)	0.0	2	(1.0)	0.1	1	(0.6)	0.0	0	(0.0)	0.0	0	(0.0)	0.0	-
Spain		59	(4.3)	0.1	76	(4.7)	0.2	56	(3.2)	0.1	49	(3.5)	0.1	41	(3.2)	0.1	-7.5%
Sweden		15	(4.1)	0.2	11	(2.6)	0.1	13	(2.5)	0.1	18	(3.4)	0.2	17	(3.6)	0.2	5.2%
United Kingdom		56	(1.2)	0.1	53	(1.1)	0.1	60	(1.2)	0.1	60	(1.3)	0.1	81	(1.6)	0.1	9.9%
<b>Subtotal EU/EEA</b>		<b>1661</b>	<b>(5.2)</b>	<b>0.3</b>	<b>1728</b>	<b>(5.3)</b>	<b>0.4</b>	<b>1667</b>	<b>(4.8)</b>	<b>0.3</b>	<b>1527</b>	<b>(4.7)</b>	<b>0.3</b>	<b>1522</b>	<b>(4.5)</b>	<b>0.3</b>	<b>0.0%</b>

<sup>a</sup> 'European Region' comprises the 53 countries of the WHO European Region and Liechtenstein. WHO European Region 18 TB High Priority Countries presented in italics.

<sup>a</sup> Excluding Greenland data (see Chapter 1.1).

Country	Trend in percentage, 2007–2011	2007			2008			2009			2010			2011			Mean annual % change in rate, 2007–2011
		N	(%)	Rate	N	(%)	Rate	N	(%)	Rate	N	(%)	Rate	N	(%)	Rate	
<b>Non-EU/EEA</b>																	
Albania		3	(1.6)	0.1	2	(0.9)	0.1	0	(0.0)	-	2	(1.0)	0.1	5	(2.4)	0.2	-
Andorra		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Armenia		125	(19.5)	4.1	128	(21.1)	4.2	156	(22.9)	5.1	68	(14.8)	2.2	79	(14.9)	2.5	-4.2%
Azerbaijan		196	(41.7)	2.2	-	-	-	-	-	-	552	(31.3)	6.0	90	(12.5)	1.0	-
Belarus		870	(26.2)	8.9	923	(28.5)	9.5	1342	(33.7)	13.9	1576	(41.7)	16.4	1594	(52.6)	16.7	18.0%
Bosnia and Herzegovina		8	(0.6)	0.2	12	(1.4)	0.3	2	(0.2)	0.1	2	(0.3)	0.1	5	(0.7)	0.1	29.4%
Croatia		7	(1.0)	0.2	4	-	0.1	7	(1.4)	0.2	-	-	-	2	(0.5)	0.0	-
Georgia		269	(14.0)	6.1	481	(20.0)	10.9	369	(15.6)	8.4	359	(14.1)	8.2	453	(15.8)	10.5	20.4%
Israel		14	(4.9)	0.2	13	(5.7)	0.2	6	(2.3)	0.1	12	(4.9)	0.2	11	(3.9)	0.1	5.3%
Kazakhstan		5568	(35.9)	36.0	3676	(34.1)	23.5	3644	(38.0)	23.0	4033	(34.9)	25.2	4575	(39.6)	28.2	-3.8%
Kyrgyzstan		322	(26.4)	6.3	269	(33.3)	5.2	785	(40.7)	14.9	489	(100.0)	9.2	-	-	-	8.0%
Macedonia, the former Yugoslav Republic of		9	(4.7)	0.4	2	(1.4)	0.1	1	(0.5)	0.0	7	(3.9)	0.3	1	(0.6)	0.0	96.3%
Moldova		896	(39.9)	24.4	1048	(43.0)	28.8	1069	(44.3)	29.7	1082	(42.9)	30.3	1001	(42.0)	28.2	4.1%
Monaco		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Montenegro		2	(2.3)	0.3	-	-	-	1	(1.1)	0.2	-	-	-	1	(1.4)	0.2	-
Russia		5297	(15.0)	3.7	6960	(16.3)	4.9	14686	(25.0)	10.3	12387	(25.1)	8.7	13785	(28.9)	9.7	34.6%
San Marino		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Serbia		25	(1.9)	0.3	16	(1.5)	0.2	-	-	-	12	(1.3)	0.1	9	(0.9)	0.1	-
Serbia excluding UN Administered Province of Kosovo <sup>b</sup>		25	(1.9)	0.3	16	(1.5)	0.2	-	-	-	12	(1.3)	0.1	9	(0.9)	0.1	-
UN Administered Province of Kosovo <sup>b</sup>		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Switzerland		8	(2.7)	0.1	5	(1.2)	0.1	-	-	-	9	(2.0)	0.1	8	(1.8)	0.1	-
Tajikistan		-	-	-	-	-	-	319	(22.6)	4.7	266	(69.5)	3.9	380	(66.0)	5.4	11.5%
Turkey		240	(4.9)	0.3	263	(5.3)	0.4	222	(5.1)	0.3	250	(5.0)	0.3	262	(5.4)	0.4	1.6%
Turkmenistan		-	-	-	-	-	-	39	(14.2)	0.8	38	(26.4)	0.8	-	-	-	22.6%
Ukraine		-	-	-	-	-	-	3482	(19.0)	7.6	5336	(38.0)	11.7	4305	(29.2)	9.5	11.8%
Uzbekistan		484	(57.1)	1.8	342	(46.0)	1.3	654	(50.2)	2.4	1023	(25.4)	3.7	1385	(62.5)	5.0	36.8%
<b>Subtotal non-EU/EEA</b>		<b>14343</b>	<b>(20.3)</b>	<b>3.7</b>	<b>14144</b>	<b>(19.8)</b>	<b>3.6</b>	<b>26784</b>	<b>(24.8)</b>	<b>6.9</b>	<b>27503</b>	<b>(27.9)</b>	<b>7.0</b>	<b>27951</b>	<b>(25.6)</b>	<b>7.1</b>	<b>22.6%</b>
<b>Total European Region</b>		<b>16004</b>	<b>(16.1)</b>	<b>1.8</b>	<b>15872</b>	<b>(15.4)</b>	<b>1.8</b>	<b>28451</b>	<b>(21.1)</b>	<b>3.2</b>	<b>29030</b>	<b>(22.4)</b>	<b>3.2</b>	<b>29473</b>	<b>(19.0)</b>	<b>3.3</b>	<b>20.0%</b>
<b>Subtotal 18 HPC</b>		<b>15511</b>	<b>(20.7)</b>	<b>4.0</b>	<b>15390</b>	<b>(19.8)</b>	<b>4.0</b>	<b>27972</b>	<b>(24.8)</b>	<b>7.2</b>	<b>28552</b>	<b>(27.3)</b>	<b>7.4</b>	<b>28963</b>	<b>(23.8)</b>	<b>7.5</b>	<b>20.8%</b>

<sup>b</sup> In accordance with the UN Security Council Resolution No. 1244 (1999).

**Table VII: XDR-TB notification among all MDR-TB cases with second line drug sensitivity test results, European Region, 2006–2011<sup>a</sup>**

Country	Trend in percentage, 2006–2011	2006			2007			2008			2009			2010			2011		
		Total MDR TB with SLD DST	XDR-TB		Total MDR TB with SLD DST	XDR-TB		Total MDR TB with SLD DST	XDR-TB		Total MDR TB with SLD DST	XDR-TB		Total MDR TB with SLD DST	XDR-TB		Total MDR TB with SLD DST	XDR-TB	
			N	(%)		N	(%)		N	(%)		N	(%)		N	(%)		N	(%)
<b>EU/EEA</b>																			
Austria		-	-	-	-	-	13	4	(30.8)	21	2	(9.5)	16	1	(6.3)	19	6	(31.6)	
Belgium		18	2	(11.1)	14	1	(7.1)	21	2	(9.5)	10	3	(30.0)	19	2	(10.5)	15	3	(20.0)
Bulgaria		-	-	-	42	6	(14.3)	27	1	(3.7)	24	1	(4.2)	35	1	(2.9)	46	0	(0.0)
Cyprus		-	-	-	2	0	(0.0)	1	0	(0.0)	2	0	(0.0)	0	0	(0.0)	1	0	(0.0)
Czech Republic		4	3	(75.0)	4	0	(0.0)	10	1	(10.0)	7	1	(14.3)	4	1	(25.0)	5	2	(40.0)
Denmark <sup>b</sup>		-	-	-	2	0	(0.0)	0	0	(0.0)	2	0	(0.0)	2	0	(0.0)	2	0	(0.0)
Estonia		52	5	(9.6)	82	14	(17.1)	69	6	(8.7)	79	8	(10.1)	61	10	(16.4)	75	14	(18.7)
Finland		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
France		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Germany		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	2	0	(0.0)
Greece		-	-	-	-	-	-	-	-	-	11	2	(18.2)	2	0	(0.0)	5	2	(40.0)
Hungary		-	-	-	-	-	-	-	-	-	-	-	18	2	(11.1)	5	0	(0.0)	
Iceland		-	-	-	1	0	(0.0)	1	0	(0.0)	0	0	(0.0)	0	0	(0.0)	0	0	(0.0)
Ireland		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1	0	(0.0)
Italy		-	-	-	-	-	-	71	0	(0.0)	32	1	(3.1)	10	0	(0.0)	50	6	(12.0)
Latvia		-	-	-	95	6	(6.3)	127	19	(15.0)	130	16	(12.3)	87	13	(14.9)	95	12	(12.6)
Liechtenstein		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Lithuania		-	-	-	-	-	-	-	-	-	4	4	(100.0)	310	50	(16.1)	295	53	(18.0)
Luxembourg		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Malta		-	-	-	1	0	(0.0)	0	0	(0.0)	0	0	(0.0)	1	0	(0.0)	0	0	(0.0)
Netherlands		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Norway		-	-	-	-	-	-	-	-	-	4	0	(0.0)	8	0	(0.0)	4	0	(0.0)
Poland		-	-	-	-	-	-	4	3	(75.0)	5	1	(20.0)	12	1	(8.3)	9	1	(11.1)
Portugal		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Romania		1	1	(100.0)	48	48	(100.0)	78	53	(67.9)	217	26	(12.0)	215	27	(12.6)	248	30	(12.1)
Slovakia		-	-	-	5	0	(0.0)	4	0	(0.0)	1	0	(0.0)	1	0	(0.0)	3	0	(0.0)
Slovenia		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Spain		-	-	-	-	-	-	73	3	(4.1)	56	5	(8.9)	49	3	(6.1)	41	1	(2.4)
Sweden		-	-	-	14	1	(7.1)	10	1	(10.0)	13	0	(0.0)	0	0	(0.0)	17	0	(0.0)
United Kingdom		-	-	-	-	-	-	-	-	-	52	1	(1.9)	57	3	(5.3)	79	6	(7.6)
<b>Subtotal EU/EEA</b>		<b>75</b>	<b>11</b>	<b>(14.7)</b>	<b>310</b>	<b>76</b>	<b>(24.5)</b>	<b>509</b>	<b>93</b>	<b>(18.3)</b>	<b>670</b>	<b>71</b>	<b>(10.6)</b>	<b>907</b>	<b>114</b>	<b>(12.6)</b>	<b>1017</b>	<b>136</b>	<b>(13.4)</b>

<sup>a</sup> 'European Region' comprises the 53 countries of the WHO European Region and Liechtenstein. WHO European Region 18 TB High Priority Countries presented in *italics*.

<sup>b</sup> Includes countries reporting second-line anti-TB drug susceptibility testing.

<sup>c</sup> Excluding Greenland data (see Chapter 1.1).

Country	Trend in percentage, 2006–2011	2006			2007			2008			2009			2010			2011		
		Total MDR TB with SLD DST	XDR-TB		Total MDR TB with SLD DST	XDR-TB		Total MDR TB with SLD DST	XDR-TB		Total MDR TB with SLD DST	XDR-TB		Total MDR TB with SLD DST	XDR-TB		Total MDR TB with SLD DST	XDR-TB	
			N	(%)		N	(%)		N	(%)		N	(%)		N	(%)		N	(%)
<b>Non-EU/EEA</b>																			
Albania		-	-	-	-	-	-	-	-	-	-	-	2	0	(0.0)	-	-	-	
Andorra		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Armenia		-	-	-	125	10	(8.0)	0	10	-	-	-	177	21	(11.9)	79	0	(0.0)	
Azerbaijan		-	-	-	-	-	-	-	-	-	-	-	-	-	-	84	3	(3.6)	
Belarus		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Bosnia and Herzegovina		-	-	-	-	-	-	-	-	-	-	-	-	-	-	5	0	(0.0)	
Croatia		-	-	-	7	0	(0.0)	-	-	-	-	-	-	-	-	-	-	-	
Georgia		-	-	-	140	13	(9.3)	-	-	-	306	32	(10.5)	313	30	(9.6)	440	28	(6.4)
Israel		19	0	(0.0)	14	0	(0.0)	13	1	(7.7)	6	0	(0.0)	12	1	(8.3)	11	0	(0.0)
Kazakhstan		-	-	-	-	-	-	-	-	-	282	216	(76.6)	0	0	-	825	187	(22.7)
Kyrgyzstan		-	-	-	-	-	-	-	-	-	-	-	32	32	(100.0)	-	-	-	
Macedonia, the former Yugoslav Republic of		-	-	-	-	-	-	-	-	-	-	-	5	1	(20.0)	-	-	-	
Moldova		47	3	(6.4)	319	0	(0.0)	-	-	-	-	-	-	-	-	-	-	-	
Monaco		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Montenegro		-	-	-	2	0	(0.0)	-	-	-	1	0	(0.0)	-	-	-	1	0	(0.0)
Russia		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
San Marino		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Serbia		-	-	-	-	-	-	-	-	-	-	-	-	-	-	9	2	(22.2)	
Serbia excluding UN Administered Province of Kosovo <sup>c</sup>		-	-	-	-	-	-	-	-	-	-	-	-	-	-	9	2	(22.2)	
UN Administered Province of Kosovo <sup>c</sup>		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Switzerland		-	-	-	8	0	(0.0)	5	0	(0.0)	-	-	-	9	0	(0.0)	8	0	(0.0)
Tajikistan		-	-	-	-	-	-	-	-	-	52	11	(21.2)	-	-	-	122	12	(9.8)
Turkey		-	-	-	-	-	-	-	-	-	-	-	5	3	(60.0)	13	1	(7.7)	
Turkmenistan		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Ukraine		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Uzbekistan		-	-	-	19	9	(47.4)	45	8	(17.8)	58	13	(22.4)	364	16	(4.4)	834	12	(1.4)
<b>Subtotal non-EU/EEA</b>		<b>66</b>	<b>3</b>	<b>(4.5)</b>	<b>634</b>	<b>32</b>	<b>(64.7)</b>	<b>63</b>	<b>19</b>	<b>(30.2)</b>	<b>705</b>	<b>272</b>	<b>(36.8)</b>	<b>919</b>	<b>104</b>	<b>(11.3)</b>	<b>2431</b>	<b>245</b>	<b>(10.1)</b>
<b>Total European Region</b>		<b>141</b>	<b>14</b>	<b>(9.9)</b>	<b>944</b>	<b>108</b>	<b>(11.4)</b>	<b>572</b>	<b>112</b>	<b>(19.6)</b>	<b>1375</b>	<b>343</b>	<b>(25.0)</b>	<b>1826</b>	<b>218</b>	<b>(11.9)</b>	<b>3448</b>	<b>381</b>	<b>(11.0)</b>
<b>Subtotal 18 HPC</b>		<b>100</b>	<b>9</b>	<b>(9.0)</b>	<b>870</b>	<b>106</b>	<b>(12.2)</b>	<b>346</b>	<b>97</b>	<b>(28.0)</b>	<b>1152</b>	<b>327</b>	<b>(28.4)</b>	<b>1599</b>	<b>203</b>	<b>(12.7)</b>	<b>3156</b>	<b>352</b>	<b>(11.2)</b>

<sup>c</sup> In accordance with the UN Security Council Resolution No. 1244 (1999).









	2010					2011				
	All TB cases (N)	Cases with known HIV status		HIV positive		All TB cases (N)	Cases with known HIV status		HIV positive	
		N	(%)	N	(%)		N	(%)	N	(%)
-	-	-	-	-	-	-	-	-	-	-
1086	943	(86.8)	62	(6.6)	1044	845	(80.9)	44	(5.2)	
2649	1773	(66.9)	2	(0.1)	2407	1698	(70.5)	5	(0.3)	
-	-	-	-	-	54	1	(1.9)	1	-	
669	176	(26.3)	5	(2.8)	600	153	(25.5)	4	(2.6)	
366	9	(2.5)	9	-	381	9	(2.4)	9	-	
333	298	(89.5)	34	(11.4)	341	313	(91.8)	47	(15.0)	
325	4	(1.2)	4	-	325	3	(0.9)	3	-	
5116	1233	(24.1)	121	(9.8)	4942	1354	(27.4)	95	(7.0)	
-	-	-	-	-	-	-	-	-	-	
-	-	-	-	-	-	-	-	-	-	
-	-	-	-	-	1445	1	(0.1)	1	-	
22	21	(95.5)	1	(4.8)	9	8	(88.9)	0	(0.0)	
420	98	(23.3)	15	(15.3)	425	94	(22.1)	19	(20.2)	
-	-	-	-	-	-	-	-	-	-	
935	748	(80.0)	69	(9.2)	885	752	(85.0)	71	(9.4)	
-	-	-	-	-	-	-	-	-	-	
1938	912	(47.1)	20	(2.2)	1904	1352	(71.0)	22	(1.6)	
29	29	(100.0)	0	(0.0)	26	5	(19.2)	2	(40.0)	
32	26	(81.3)	3	(11.5)	33	30	(90.9)	5	(16.7)	
1065	370	(34.7)	47	(12.7)	1007	460	(45.7)	31	(6.7)	
-	-	-	-	-	-	-	-	-	-	
7509	22	(0.3)	22	-	8478	26	(0.3)	26	-	
2626	1720	(65.5)	229	(13.3)	-	-	-	-	-	
21059	7833	(37.2)	241	(3.1)	19212	9383	(48.8)	243	(2.6)	
439	430	(97.9)	1	(0.2)	399	395	(99.0)	0	(0.0)	
172	131	(76.2)	1	(0.8)	192	147	(76.6)	0	(0.0)	
7239	4909	(67.8)	456	(9.3)	6762	4541	(67.2)	415	(9.1)	
-	-	-	-	-	-	-	-	-	-	
8483	378	(4.5)	378	-	-	-	-	-	-	
<b>37525</b>	<b>21659</b>	<b>(57.7)</b>	<b>1316</b>	<b>(6.1)</b>	<b>40188</b>	<b>21530</b>	<b>(53.6)</b>	<b>1003</b>	<b>(4.7)</b>	
445	186	(41.8)	0	(0.0)	431	170	(39.4)	2	(1.2)	
7	0	(0.0)	0	-	-	-	-	-	-	
1780	1242	(69.8)	17	(1.4)	1582	1499	(94.8)	49	(3.3)	
8394	0	(0.0)	0	-	10100	6179	(61.2)	76	(1.2)	
5554	5153	(92.8)	190	(3.7)	5118	4747	(92.8)	217	(4.6)	
1390	0	(0.0)	0	-	1385	0	(0.0)	0	-	
695	0	(0.0)	1	-	619	0	(0.0)	4	-	
5796	1841	(31.8)	35	(1.9)	5533	2550	(46.1)	50	(2.0)	
343	308	(89.8)	13	(4.2)	418	384	(91.9)	24	(6.3)	
28550	23854	(83.6)	333	(1.4)	26211	22480	(85.8)	352	(1.6)	
6295	6295	(100.0)	183	(2.9)	6254	153	(2.4)	0	(0.0)	
420	39	(9.3)	0	(0.0)	362	45	(12.4)	0	(0.0)	
5447	5192	(95.3)	308	(5.9)	5341	5017	(93.9)	285	(5.7)	
1	0	(0.0)	-	-	-	-	-	-	-	
114	84	(73.7)	1	(1.2)	112	92	(82.1)	0	(0.0)	
162553	162553	(100.0)	8653	(5.3)	159479	79494	(49.8)	4104	(5.2)	
0	0	-	0	-	0	0	-	0	-	
2385	16	(0.7)	12	(75.0)	2216	67	(3.0)	6	(9.0)	
2385	16	(0.7)	12	(75.0)	1341	67	(5.0)	6	(9.0)	
0	0	-	0	-	875	-	-	-	-	
548	0	(0.0)	0	-	578	-	-	-	-	
7641	4049	(53.0)	100	(2.5)	7609	6241	(82.0)	115	(1.8)	
16551	581	(3.5)	14	(2.4)	15679	7241	(46.2)	29	(0.4)	
3230	3230	(100.0)	0	(0.0)	0	0	-	0	-	
36409	34621	(95.1)	5752	(16.6)	42676	31776	(74.5)	5893	(18.5)	
20330	20330	(100.0)	427	(2.1)	15913	15913	(100.0)	546	(3.4)	
<b>314878</b>	<b>269574</b>	<b>(85.6)</b>	<b>16039</b>	<b>(5.9)</b>	<b>304571</b>	<b>184048</b>	<b>(60.4)</b>	<b>11748</b>	<b>(6.4)</b>	
<b>390454</b>	<b>291683</b>	<b>(74.7)</b>	<b>17761</b>	<b>(6.1)</b>	<b>344759</b>	<b>205578</b>	<b>(59.6)</b>	<b>12751</b>	<b>(6.2)</b>	
<b>335444</b>	<b>280551</b>	<b>(83.6)</b>	<b>16380</b>	<b>(5.8)</b>	<b>326656</b>	<b>196788</b>	<b>(60.2)</b>	<b>12104</b>	<b>(6.2)</b>	

Table IX: Treatment success of new laboratory-confirmed pulmonary TB cases, European Region, 2001–2010

Country	Trend in percentage, 2001–2010	2001			2002			2003			2004		
		Cases reported	Success		Cases reported	Success		Cases reported	Success		Cases reported	Success	
			N	(%)		N	(%)		N	(%)		N	(%)
<b>EU/EEA</b>													
Austria		553	449	(81.2)	555	438	(78.9)	514	397	(77.2)	552	422	(76.4)
Belgium		534	336	(62.9)	617	402	(65.2)	437	313	(71.6)	520	380	(73.1)
<i>Bulgaria</i>		-	-	-	-	-	-	1260	1145	(90.9)	-	-	-
Cyprus		-	-	-	11	9	(81.8)	21	17	(81.0)	17	6	(35.3)
Czech Republic		704	487	(69.2)	609	420	(69.0)	620	465	(75.0)	550	381	(69.3)
Denmark <sup>a</sup>		196	173	(88.3)	217	169	(77.9)	213	179	(84.0)	201	171	(85.1)
<i>Estonia</i>		351	238	(67.8)	346	235	(67.9)	332	231	(69.6)	336	239	(71.1)
Finland		-	-	-	-	-	-	-	-	-	-	-	-
France		-	-	-	-	-	-	-	-	-	-	-	-
Germany		2589	1718	(66.4)	2659	1879	(70.7)	2665	1951	(73.2)	2790	1973	(70.7)
Greece		-	-	-	-	-	-	-	-	-	-	-	-
Hungary		732	392	(53.6)	734	433	(59.0)	709	384	(54.2)	787	438	(55.7)
Iceland		7	6	(85.7)	5	5	(100.0)	2	2	(100.0)	4	3	(75.0)
Ireland		129	76	(58.9)	161	121	(75.2)	152	107	(70.4)	162	124	(76.5)
Italy		-	-	-	-	-	-	-	-	-	-	-	-
<i>Latvia</i>		1004	769	(76.6)	943	742	(78.7)	963	749	(77.8)	857	643	(75.0)
Liechtenstein		-	-	-	-	-	-	-	-	-	-	-	-
<i>Lithuania</i>		1142	844	(73.9)	1001	738	(73.7)	1099	836	(76.1)	1092	814	(74.5)
Luxembourg		-	-	-	-	-	-	-	-	-	-	-	-
Malta		9	8	(88.9)	12	11	(91.7)	2	2	(100.0)	5	5	(100.0)
Netherlands		601	519	(86.4)	444	383	(86.3)	441	379	(85.9)	436	368	(84.4)
Norway		145	124	(85.5)	97	81	(83.5)	119	102	(85.7)	132	113	(85.6)
Poland		4905	3734	(76.1)	4594	3476	(75.7)	4578	3646	(79.6)	4246	3358	(79.1)
Portugal		2024	1626	(80.3)	2114	1794	(84.9)	1838	1539	(83.7)	1870	1603	(85.7)
<i>Romania</i>		10960	7779	(71.0)	13116	10363	(79.0)	12272	10079	(82.1)	12937	10622	(82.1)
Slovakia		413	356	(86.2)	364	302	(83.0)	318	280	(88.1)	273	237	(86.8)
Slovenia		250	198	(79.2)	231	188	(81.4)	207	173	(83.6)	169	150	(88.8)
Spain		-	-	-	-	-	-	-	-	-	-	-	-
Sweden		220	143	(65.0)	208	166	(79.8)	208	174	(83.7)	238	146	(61.3)
United Kingdom		1807	1197	(66.2)	2043	1435	(70.2)	2009	1423	(70.8)	2165	1569	(72.5)
<b>Subtotal EU/EEA</b>		<b>29275</b>	<b>21172</b>	<b>(72.3)</b>	<b>31081</b>	<b>23790</b>	<b>(76.5)</b>	<b>30979</b>	<b>24573</b>	<b>(79.3)</b>	<b>30339</b>	<b>23765</b>	<b>(78.3)</b>

<sup>a</sup> 'European Region' comprises the 53 countries of the WHO European Region and Liechtenstein. WHO European Region 18 TB High Priority Countries presented in italics.

<sup>a</sup> Excluding Greenland data (see Chapter 1.1).

	2005			2006			2007			2008			2009			2010		
	Cases reported	Success		Cases reported	Success		Cases reported	Success		Cases reported	Success		Cases reported	Success		Cases reported	Success	
		N	(%)		N	(%)		N	(%)		N	(%)		N	(%)		N	(%)
	511	389	(76.1)	468	322	(68.8)	430	165	(38.4)	381	263	(69.0)	226	155	(68.6)	206	133	(64.6)
	505	351	(69.5)	479	346	(72.2)	501	342	(68.3)	506	380	(75.1)	486	371	(76.3)	474	357	(75.3)
	-	-	-	-	-	-	1233	972	(78.8)	1193	1012	(84.8)	1056	897	(84.9)	946	816	(86.3)
	17	11	(64.7)	20	16	(80.0)	28	-	-	10	7	(70.0)	28	8	(28.6)	20	5	(25.0)
	538	375	(69.7)	528	368	(69.7)	459	331	(72.1)	468	319	(68.2)	402	271	(67.4)	361	249	(69.0)
	-	-	-	201	168	(83.6)	214	173	(80.8)	204	155	(76.0)	172	130	(75.6)	218	141	(64.7)
	295	211	(71.5)	272	193	(71.0)	302	186	(61.6)	257	156	(60.7)	239	141	(59.0)	192	129	(67.2)
	-	-	-	-	-	-	181	130	(71.8)	170	123	(72.4)	227	154	(67.8)	185	138	(74.6)
	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	2665	1882	(70.6)	2558	1950	(76.2)	2447	1876	(76.7)	2178	1705	(78.3)	2250	1732	(77.0)	2090	1600	(76.6)
	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	607	306	(50.4)	687	342	(49.8)	612	311	(50.8)	602	317	(52.7)	597	341	(57.1)	515	355	(68.9)
	5	5	(100.0)	6	4	(66.7)	7	6	(85.7)	1	0	(0.0)	4	3	(75.0)	16	14	(87.5)
	158	117	(74.1)	182	119	(65.4)	181	127	(70.2)	202	156	(77.2)	189	128	(67.7)	164	119	(72.6)
	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	849	649	(76.4)	776	594	(76.5)	772	634	(82.1)	641	484	(75.5)	592	443	(74.8)	596	451	(75.7)
	-	-	-	-	-	-	4	0	(0.0)	-	-	-	-	-	-	-	-	-
	1248	951	(76.2)	1293	988	(76.4)	1209	860	(71.1)	1211	870	(71.8)	1033	740	(71.6)	959	656	(68.4)
	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	9	8	(88.9)	11	11	(100.0)	12	9	(75.0)	13	12	(92.3)	10	8	(80.0)	5	4	(80.0)
	535	442	(82.6)	493	402	(81.5)	460	380	(82.6)	461	370	(80.3)	454	365	(80.4)	470	365	(77.7)
	113	103	(91.2)	111	96	(86.5)	114	103	(90.4)	105	88	(83.8)	146	124	(84.9)	139	127	(91.4)
	4514	3483	(77.2)	4321	3286	(76.0)	4510	3449	(76.5)	4228	3128	(74.0)	4391	2957	(67.3)	3998	2631	(65.8)
	-	-	-	1825	1593	(87.3)	1694	1467	(86.6)	1669	1468	(88.0)	1565	1318	(84.2)	-	-	-
	12650	10676	(84.4)	11688	10026	(85.8)	11247	9532	(84.8)	10085	8504	(84.3)	10737	9165	(85.4)	9445	7916	(83.8)
	263	237	(90.1)	288	238	(82.6)	295	258	(87.5)	269	234	(87.0)	174	143	(82.2)	177	149	(84.2)
	197	158	(80.2)	145	125	(86.2)	150	123	(82.0)	159	127	(79.9)	149	130	(87.2)	121	104	(86.0)
	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	3574	2516	(70.4)
	276	192	(69.6)	249	0	(0.0)	237	193	(81.4)	222	196	(88.3)	255	221	(86.7)	289	246	(85.1)
	2260	1674	(74.1)	2438	1887	(77.4)	2239	1756	(78.4)	2312	1828	(79.1)	2569	2119	(82.5)	2603	2106	(80.9)
	<b>28215</b>	<b>22220</b>	<b>(78.8)</b>	<b>29039</b>	<b>23074</b>	<b>(79.5)</b>	<b>29538</b>	<b>23383</b>	<b>(79.2)</b>	<b>27547</b>	<b>21902</b>	<b>(79.5)</b>	<b>27951</b>	<b>22064</b>	<b>(78.9)</b>	<b>27763</b>	<b>21327</b>	<b>(76.8)</b>

Country	Trend in percentage, 2001–2010	2001			2002			2003			2004		
		Cases reported	Success		Cases reported	Success		Cases reported	Success		Cases reported	Success	
			N	(%)		N	(%)		N	(%)		N	(%)
<b>Non-EU/EEA</b>													
Albania		171	156	(91.2)	225	189	(84.0)	212	186	(87.7)	201	150	(74.6)
Andorra		1	1	(100.0)	3	3	(100.0)	6	6	(100.0)	3	3	(100.0)
Armenia		284	257	(90.5)	295	233	(79.0)	406	312	(76.8)	461	325	(70.5)
Azerbaijan		1421	1093	(76.9)	1149	950	(82.7)	1889	1321	(69.9)	2249	1251	(55.6)
Belarus		-	-	-	-	-	-	2236	1630	(72.9)	2284	1699	(74.4)
Bosnia and Herzegovina		539	529	(98.1)	526	499	(94.9)	272	255	(93.8)	1025	1007	(98.2)
Croatia		0	0	-	204	143	(70.1)	438	168	(38.4)	423	193	(45.6)
Georgia		1014	679	(67.0)	987	643	(65.1)	989	657	(66.4)	1301	880	(67.6)
Israel		313	265	(84.7)	278	238	(85.6)	276	228	(82.6)	248	206	(83.1)
Kazakhstan		8894	6922	(77.8)	9185	7137	(77.7)	8660	6452	(74.5)	7927	5743	(72.4)
Kyrgyzstan		1458	1181	(81.0)	1476	1209	(81.9)	1634	1380	(84.5)	1716	1461	(85.1)
Macedonia, the former Yugoslav Republic of		164	146	(89.0)	200	161	(80.5)	200	167	(83.5)	189	159	(84.1)
Moldova		1060	683	(64.4)	1145	618	(54.0)	1025	668	(65.2)	1530	944	(61.7)
Monaco		-	-	-	-	-	-	-	-	-	-	-	-
Montenegro		-	-	-	-	-	-	-	-	-	-	-	-
Russia		4079	2740	(67.2)	5171	3447	(66.7)	6311	3873	(61.4)	25678	15466	(60.2)
San Marino		-	-	-	-	-	-	-	-	-	-	-	-
Serbia		-	-	-	-	-	-	-	-	-	-	-	-
Serbia excluding UN Administered Province of Kosovo <sup>b</sup>		-	-	-	-	-	-	-	-	-	-	-	-
UN Administered Province of Kosovo <sup>b</sup>		-	-	-	-	-	-	-	-	-	-	-	-
Switzerland		-	-	-	-	-	-	-	-	-	-	-	-
Tajikistan		670	480	(71.6)	107	84	(78.5)	927	423	(45.6)	1055	593	(56.2)
Turkey		4359	3140	(72.0)	5190	3348	(64.5)	6082	4372	(71.9)	5816	4936	(84.9)
Turkmenistan		1243	797	(64.1)	1254	925	(73.8)	1197	844	(70.5)	-	-	-
Ukraine		-	-	-	-	-	-	-	-	-	-	-	-
Uzbekistan		854	649	(76.0)	2544	2030	(79.8)	4674	3971	(85.0)	5034	4139	(82.2)
<b>Subtotal non-EU/EEA</b>		<b>26524</b>	<b>19718</b>	<b>(74.3)</b>	<b>29939</b>	<b>21857</b>	<b>(73.0)</b>	<b>37434</b>	<b>26913</b>	<b>(71.9)</b>	<b>57140</b>	<b>39155</b>	<b>(68.5)</b>
<b>Total European Region</b>		<b>55799</b>	<b>40890</b>	<b>(73.3)</b>	<b>61020</b>	<b>45647</b>	<b>(74.8)</b>	<b>68413</b>	<b>51486</b>	<b>(75.3)</b>	<b>87479</b>	<b>62920</b>	<b>(71.9)</b>
<b>Subtotal 18 HPC</b>		<b>38793</b>	<b>28251</b>	<b>(72.8)</b>	<b>43909</b>	<b>32702</b>	<b>(74.5)</b>	<b>51956</b>	<b>38943</b>	<b>(75.0)</b>	<b>70273</b>	<b>49755</b>	<b>(70.8)</b>

<sup>b</sup> In accordance with the UN Security Council Resolution No. 1244 (1999).

	2005			2006			2007			2008			2009			2010		
	Cases reported	Success		Cases reported	Success		Cases reported	Success		Cases reported	Success		Cases reported	Success		Cases reported	Success	
		N	(%)		N	(%)		N	(%)		N	(%)		N	(%)		N	(%)
	196	154	(78.6)	186	168	(90.3)	181	153	(84.5)	170	154	(90.6)	171	153	(89.5)	145	132	(91.0)
	5	4	(80.0)	8	6	(75.0)	2	2	(100.0)	3	3	(100.0)	3	3	(100.0)	-	-	-
	581	421	(72.5)	580	402	(69.3)	490	343	(70.0)	487	357	(73.3)	440	319	(72.5)	339	243	(71.7)
	1561	922	(59.1)	1454	867	(59.6)	1356	782	(57.7)	1392	782	(56.2)	1480	918	(62.0)	1919	1470	(76.6)
	-	-	-	1072	750	(70.0)	1987	1466	(73.8)	1902	1355	(71.2)	2160	1389	(64.3)	2184	1447	(66.3)
	1035	999	(96.5)	993	960	(96.7)	1267	1227	(96.8)	757	697	(92.1)	852	845	(99.2)	441	434	(98.4)
	391	181	(46.3)	898	265	(29.5)	637	389	(61.1)	602	347	(57.6)	234	148	(63.2)	181	136	(75.1)
	1489	1081	(72.6)	1813	1368	(75.5)	1975	1523	(77.1)	2196	1596	(72.7)	2352	1773	(75.4)	2500	1908	(76.3)
	227	191	(84.1)	206	168	(81.6)	242	194	(80.2)	178	157	(88.2)	202	173	(85.6)	99	75	(75.8)
	6884	4894	(71.1)	6113	4408	(72.1)	6140	4206	(68.5)	6167	3949	(64.0)	5355	3341	(62.4)	4919	2995	(60.9)
	1897	1607	(84.7)	1833	1507	(82.2)	1718	1455	(84.7)	1640	1385	(84.5)	1543	1272	(82.4)	-	-	-
	179	151	(84.4)	178	155	(87.1)	197	172	(87.3)	188	167	(88.8)	199	180	(90.5)	143	128	(89.5)
	1690	1048	(62.0)	1671	1041	(62.3)	1599	991	(62.0)	1533	943	(61.5)	1318	715	(54.2)	1267	724	(57.1)
	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	63	19	(30.2)	58	19	(32.8)	76	60	(78.9)	65	55	(84.6)	78	67	(85.9)	39	34	(87.2)
	25692	14805	(57.6)	30745	17922	(58.3)	31857	18378	(57.7)	32356	18579	(57.4)	32316	17862	(55.3)	30123	15984	(53.1)
	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	(85.8)
	1154	976	(84.6)	1157	971	(83.9)	1145	967	(84.5)	1391	1191	(85.6)	1392	1197	(86.0)	702	602	(85.8)
	1154	976	(84.6)	1157	971	(83.9)	1145	967	(84.5)	1391	1191	(85.6)	1392	1197	(86.0)	702	602	(85.8)
	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	1729	1422	(82.2)	1932	1636	(84.7)	2073	1713	(82.6)	2044	1682	(82.3)	1972	1604	(81.3)	2290	1834	(80.1)
	7450	6653	(89.3)	7865	7132	(90.7)	7510	6870	(91.5)	6993	6408	(91.6)	6007	5456	(90.8)	5375	4905	(91.3)
	995	844	(84.8)	1155	998	(86.4)	1288	1077	(83.6)	1331	1107	(83.2)	1375	1152	(83.8)	-	-	-
	-	-	-	10351	6127	(59.2)	11068	6533	(59.0)	14407	8927	(62.0)	13111	7822	(59.7)	13279	7935	(59.8)
	5336	4296	(80.5)	5642	4550	(80.6)	6326	5010	(79.2)	5117	4158	(81.3)	4959	4037	(81.4)	4711	3819	(81.1)
	<b>58554</b>	<b>40668</b>	<b>(69.5)</b>	<b>75910</b>	<b>51420</b>	<b>(67.7)</b>	<b>79134</b>	<b>53511</b>	<b>(67.6)</b>	<b>80919</b>	<b>53999</b>	<b>(66.7)</b>	<b>77519</b>	<b>50426</b>	<b>(65.0)</b>	<b>70656</b>	<b>44805</b>	<b>(63.4)</b>
	<b>86769</b>	<b>62888</b>	<b>(72.5)</b>	<b>104949</b>	<b>74494</b>	<b>(71.0)</b>	<b>108668</b>	<b>76894</b>	<b>(70.8)</b>	<b>108466</b>	<b>75901</b>	<b>(70.0)</b>	<b>105470</b>	<b>72490</b>	<b>(68.7)</b>	<b>98433</b>	<b>66132</b>	<b>(67.2)</b>
	<b>70346</b>	<b>50480</b>	<b>(71.8)</b>	<b>86255</b>	<b>60509</b>	<b>(70.2)</b>	<b>90150</b>	<b>62531</b>	<b>(69.4)</b>	<b>90952</b>	<b>62254</b>	<b>(68.4)</b>	<b>88045</b>	<b>59046</b>	<b>(67.1)</b>	<b>81044</b>	<b>53232</b>	<b>(65.7)</b>

**Table X: Treatment success of previously treated laboratory confirmed pulmonary TB cases, European Region, 2001–2010**

Country	Trend in percentage, 2001–2010	2001			2002			2003			2004		
		Cases reported	Success		Cases reported	Success		Cases reported	Success		Cases reported	Success	
			N	(%)		N	(%)		N	(%)		N	(%)
<b>EU/EEA</b>													
Austria		15	11	(73.3)	11	10	(90.9)	12	9	(75.0)	16	12	(75.0)
Belgium		80	49	(61.3)	67	49	(73.1)	60	37	(61.7)	58	30	(51.7)
<i>Bulgaria</i>		-	-	-	-	-	-	117	80	(68.4)	-	-	-
Cyprus		-	-	-	2	2	(100.0)	0	0	.	1	1	(100.0)
Czech Republic		25	16	(64.0)	21	10	(47.6)	25	20	(80.0)	13	8	(61.5)
Denmark <sup>a</sup>		17	12	(70.6)	17	14	(82.4)	11	8	(72.7)	18	14	(77.8)
<i>Estonia</i>		206	70	(34.0)	154	60	(39.0)	98	29	(29.6)	90	31	(34.4)
Finland		-	-	-	-	-	-	-	-	-	-	-	-
France		-	-	-	-	-	-	-	-	-	-	-	-
Germany		327	207	(63.3)	288	184	(63.9)	293	183	(62.5)	231	147	(63.6)
Greece		-	-	-	-	-	-	-	-	-	-	-	-
Hungary		165	72	(43.6)	157	73	(46.5)	183	87	(47.5)	163	68	(41.7)
Iceland		0	0	-	0	0	.	0	0	.	0	0	.
Ireland		21	10	(47.6)	17	10	(58.8)	23	13	(56.5)	16	8	(50.0)
Italy		33	13	(39.4)	21	13	(61.9)	15	15	(100.0)	-	-	-
<i>Latvia</i>		331	149	(45.0)	298	121	(40.6)	245	113	(46.1)	229	106	(46.3)
Liechtenstein		-	-	-	-	-	-	-	-	-	-	-	-
<i>Lithuania</i>		556	242	(43.5)	486	204	(42.0)	497	164	(33.0)	449	137	(30.5)
Luxembourg		-	-	-	-	-	-	-	-	-	-	-	-
Malta		0	0	.	0	0	.	0	0	.	0	0	.
Netherlands		21	17	(81.0)	25	18	(72.0)	21	15	(71.4)	9	9	(100.0)
Norway		11	7	(63.6)	22	17	(77.3)	19	13	(68.4)	19	14	(73.7)
Poland		730	511	(70.0)	724	487	(67.3)	724	511	(70.6)	0	0	.
Portugal		217	155	(71.4)	261	201	(77.0)	266	204	(76.7)	243	170	(70.0)
<i>Romania</i>		3903	1807	(46.3)	5431	2543	(46.8)	4740	2353	(49.6)	5350	2594	(48.5)
Slovakia		104	85	(81.7)	86	77	(89.5)	50	46	(92.0)	47	43	(91.5)
Slovenia		23	19	(82.6)	30	23	(76.7)	26	20	(76.9)	25	17	(68.0)
Spain		-	-	-	-	-	-	-	-	-	-	-	-
Sweden		14	6	(42.9)	22	15	(68.2)	19	16	(84.2)	15	0	(0.0)
United Kingdom		185	115	(62.2)	209	124	(59.3)	193	132	(68.4)	197	126	(64.0)
<b>Subtotal EU/EEA</b>		<b>6984</b>	<b>3573</b>	<b>(51.2)</b>	<b>8349</b>	<b>4255</b>	<b>(51.0)</b>	<b>7637</b>	<b>4068</b>	<b>(53.3)</b>	<b>7189</b>	<b>3535</b>	<b>(49.2)</b>

'European Region' comprises the 53 countries of the WHO European Region and Liechtenstein. WHO European Region 18 TB High Priority Countries presented in italics.

<sup>a</sup> Excluding Greenland data (see Chapter 1.1).



	2005			2006			2007			2008			2009			2010		
	Cases reported	Success		Cases reported	Success		Cases reported	Success		Cases reported	Success		Cases reported	Success		Cases reported	Success	
		N	(%)		N	(%)		N	(%)		N	(%)		N	(%)		N	(%)
	20	16	(80.0)	11	9	(81.8)	10	4	(40.0)	8	8	(100.0)	22	12	(54.5)	15	9	(60.0)
	34	18	(52.9)	50	29	(58.0)	49	32	(65.3)	42	26	(61.9)	51	37	(72.5)	51	32	(62.7)
	-	-	-	-	-	-	146	61	(41.8)	152	91	(59.9)	190	110	(57.9)	196	101	(51.5)
	0	0	.	0	0	.	1	0	(0.0)	3	3	(100.0)	4	1	(25.0)	0	0	.
	55	40	(72.7)	37	24	(64.9)	44	32	(72.7)	38	27	(71.1)	38	26	(68.4)	30	20	(66.7)
	14	14	(100.0)	23	12	(52.2)	18	9	(50.0)	23	20	(87.0)	28	22	(78.6)	26	16	(61.5)
	68	33	(48.5)	65	32	(49.2)	69	44	(63.8)	76	45	(59.2)	63	35	(55.6)	60	33	(55.0)
	-	-	-	-	-	-	7	7	(100.0)	9	6	(66.7)	6	5	(83.3)	7	6	(85.7)
	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	243	150	(61.7)	218	137	(62.8)	183	124	(67.8)	158	122	(77.2)	186	116	(62.4)	185	131	(70.8)
	20	0	(0.0)	18	7	(38.9)	-	-	-	-	-	-	-	-	-	-	-	-
	129	62	(48.1)	119	61	(51.3)	130	71	(54.6)	126	63	(50.0)	86	46	(53.5)	87	43	(49.4)
	0	0	.	0	0	.	1	0	(0.0)	0	0	.	1	1	(100.0)	0	0	.
	21	17	(81.0)	23	9	(39.1)	28	16	(57.1)	16	8	(50.0)	25	17	(68.0)	18	11	(61.1)
	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	200	141	(70.5)	179	117	(65.4)	167	121	(72.5)	147	112	(76.2)	141	83	(58.9)	106	65	(61.3)
	-	-	-	-	-	-	0	0	.	-	-	-	-	-	-	-	-	-
	435	150	(34.5)	436	182	(41.7)	423	130	(30.7)	354	155	(43.8)	401	163	(40.6)	360	113	(31.4)
	-	-	-	-	-	-	0	0	.	0	0	.	0	0	.	0	0	.
	0	0	.	0	0	.	1	0	(0.0)	3	2	(66.7)	0	0	.	2	1	(50.0)
	27	23	(85.2)	20	14	(70.0)	19	17	(89.5)	23	18	(78.3)	25	20	(80.0)	26	17	(65.4)
	14	11	(78.6)	16	11	(68.8)	18	16	(88.9)	16	14	(87.5)	17	15	(88.2)	22	14	(63.6)
	628	265	(42.2)	668	316	(47.3)	690	426	(61.7)	635	408	(64.3)	633	384	(60.7)	587	350	(59.6)
	226	0	(0.0)	223	173	(77.6)	182	140	(76.9)	174	135	(77.6)	176	119	(67.6)	127	0	(0.0)
	5833	3099	(53.1)	5156	2992	(58.0)	4942	2654	(53.7)	4656	2522	(54.2)	4506	2561	(56.8)	4228	2236	(52.9)
	61	55	(90.2)	60	42	(70.0)	42	36	(85.7)	58	47	(81.0)	35	27	(77.1)	29	24	(82.8)
	26	23	(88.5)	7	5	(71.4)	13	10	(76.9)	14	11	(78.6)	7	6	(85.7)	11	7	(63.6)
	-	-	-	0	0	.	-	-	-	-	-	-	-	-	-	224	128	(57.1)
	11	7	(63.6)	6	0	(0.0)	13	9	(69.2)	24	21	(87.5)	25	21	(84.0)	24	17	(70.8)
	204	131	(64.2)	184	124	(67.4)	196	155	(79.1)	207	156	(75.4)	263	195	(74.1)	187	121	(64.7)
	<b>8269</b>	<b>4255</b>	<b>(51.5)</b>	<b>7519</b>	<b>4296</b>	<b>(57.1)</b>	<b>7392</b>	<b>4114</b>	<b>(55.7)</b>	<b>6962</b>	<b>4020</b>	<b>(57.7)</b>	<b>6929</b>	<b>4022</b>	<b>(58.0)</b>	<b>6608</b>	<b>3495</b>	<b>(52.9)</b>

Country	Trend in percentage, 2001–2010	2001			2002			2003			2004		
		Cases reported	Success		Cases reported	Success		Cases reported	Success		Cases reported	Success	
			N	(%)		N	(%)		N	(%)		N	(%)
<b>Non-EU/EEA</b>													
Albania		24	18	(75.0)	10	7	(70.0)	7	7	(100.0)	37	32	(86.5)
Andorra		-	-	-	-	-	-	-	-	-	-	-	-
Armenia		46	31	(67.4)	62	19	(30.6)	356	169	(47.5)	143	69	(48.3)
Azerbaijan		268	100	(37.3)	67	43	(64.2)	802	410	(51.1)	2188	900	(41.1)
Belarus		-	-	-	-	-	-	-	-	-	-	-	-
Bosnia and Herzegovina		71	68	(95.8)	58	54	(93.1)	98	92	(93.9)	97	89	(91.8)
Croatia		-	-	-	-	-	-	-	-	-	132	38	(28.8)
Georgia		677	307	(45.3)	983	376	(38.3)	1172	486	(41.5)	2034	1006	(49.5)
Israel		7	5	(71.4)	14	13	(92.9)	15	13	(86.7)	13	11	(84.6)
Kazakhstan		2900	1916	(66.1)	3307	2109	(63.8)	7952	4034	(50.7)	4294	2097	(48.8)
Kyrgyzstan		296	225	(76.0)	850	365	(42.9)	849	630	(74.2)	885	651	(73.6)
Macedonia, the former Yugoslav Republic of		26	14	(53.8)	29	20	(69.0)	102	72	(70.6)	70	61	(87.1)
Moldova		49	28	(57.1)	453	167	(36.9)	1940	716	(36.9)	1486	566	(38.1)
Monaco		-	-	-	-	-	-	-	-	-	-	-	-
Montenegro		-	-	-	-	-	-	-	-	-	-	-	-
Russia		854	413	(48.4)	1924	888	(46.2)	1892	848	(44.8)	3011	1172	(38.9)
San Marino		-	-	-	-	-	-	2	2	(100.0)	-	-	-
Serbia		-	-	-	-	-	-	-	-	-	-	-	-
Serbia excluding UN Administered Province of Kosovo <sup>b</sup>		-	-	-	-	-	-	-	-	-	-	-	-
UN Administered Province of Kosovo <sup>b</sup>		-	-	-	-	-	-	-	-	-	-	-	-
Switzerland		-	-	-	-	-	-	-	-	-	-	-	-
Tajikistan		98	55	(56.1)	-	-	-	114	76	(66.7)	648	479	(73.9)
Turkey		-	-	-	-	-	-	101	66	(65.3)	-	-	-
Turkmenistan		554	387	(69.9)	529	333	(62.9)	558	347	(62.2)	-	-	-
Ukraine		-	-	-	-	-	-	-	-	-	-	-	-
Uzbekistan		-	-	-	519	318	(61.3)	1610	1100	(68.3)	6195	5012	(80.9)
<b>Subtotal non-EU/EEA</b>		<b>5870</b>	<b>3567</b>	<b>(60.8)</b>	<b>8805</b>	<b>4712</b>	<b>(53.5)</b>	<b>17570</b>	<b>9068</b>	<b>(51.6)</b>	<b>21233</b>	<b>12183</b>	<b>(57.4)</b>
<b>Total European Region</b>		<b>12854</b>	<b>7140</b>	<b>(55.5)</b>	<b>17154</b>	<b>8967</b>	<b>(52.3)</b>	<b>25207</b>	<b>13136</b>	<b>(52.1)</b>	<b>28422</b>	<b>15718</b>	<b>(55.3)</b>
<b>Subtotal 18 HPC</b>		<b>10738</b>	<b>5730</b>	<b>(53.4)</b>	<b>15063</b>	<b>7546</b>	<b>(50.1)</b>	<b>23043</b>	<b>11621</b>	<b>(50.4)</b>	<b>27002</b>	<b>14820</b>	<b>(54.9)</b>

<sup>b</sup> In accordance with the UN Security Council Resolution No. 1244 (1999).

	2005			2006			2007			2008			2009			2010		
	Cases reported	Success		Cases reported	Success		Cases reported	Success		Cases reported	Success		Cases reported	Success		Cases reported	Success	
		N	(%)		N	(%)		N	(%)		N	(%)		N	(%)		N	(%)
	30	22	(73.3)	29	25	(86.2)	25	21	(84.0)	28	21	(75.0)	21	16	(76.2)	30	27	(90.0)
	-	-	-	3	2	(66.7)	1	1	(100.0)	-	-	-	2	2	(100.0)	-	-	-
	327	133	(40.7)	502	218	(43.4)	590	274	(46.4)	534	272	(50.9)	542	344	(63.5)	451	302	(67.0)
	1314	489	(37.2)	1272	590	(46.4)	1081	479	(44.3)	3084	1557	(50.5)	1687	897	(53.2)	4194	2626	(62.6)
	-	-	-	898	574	(63.9)	862	537	(62.3)	815	477	(58.5)	616	258	(41.9)	792	379	(47.9)
	106	98	(92.5)	93	88	(94.6)	156	144	(92.3)	77	58	(75.3)	116	97	(83.6)	101	96	(95.0)
	92	30	(32.6)	82	51	(62.2)	-	-	-	-	-	-	22	11	(50.0)	37	28	(75.7)
	2037	1111	(54.5)	1873	1057	(56.4)	1847	1031	(55.8)	1542	765	(49.6)	1521	908	(59.7)	1421	879	(61.9)
	7	6	(85.7)	5	4	(80.0)	8	8	(100.0)	4	3	(75.0)	9	6	(66.7)	5	4	(80.0)
	4085	1911	(46.8)	21242	7816	(36.8)	18722	9922	(53.0)	8662	3616	(41.7)	9392	4549	(48.4)	8734	4119	(47.2)
	845	600	(71.0)	933	662	(71.0)	1035	696	(67.2)	897	631	(70.3)	924	655	(70.9)	-	-	-
	97	55	(56.7)	72	43	(59.7)	71	46	(64.8)	56	40	(71.4)	56	44	(78.6)	52	34	(65.4)
	1713	710	(41.4)	1715	734	(42.8)	2167	781	(36.0)	1865	643	(34.5)	1663	569	(34.2)	1702	545	(32.0)
	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	10	2	(20.0)	19	6	(31.6)	23	13	(56.5)	10	8	(80.0)	11	8	(72.7)	14	12	(85.7)
	10855	4003	(36.9)	28419	13417	(47.2)	18527	6619	(35.7)	18070	6562	(36.3)	16726	5663	(33.9)	14609	4984	(34.1)
	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	284	207	(72.9)	322	238	(73.9)	355	260	(73.2)	309	234	(75.7)	244	180	(73.8)	172	129	(75.0)
	284	207	(72.9)	322	238	(73.9)	355	260	(73.2)	309	234	(75.7)	244	180	(73.8)	172	129	(75.0)
	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	1762	1343	(76.2)	1715	1248	(72.8)	1995	1495	(74.9)	1881	1422	(75.6)	1618	1165	(72.0)	1732	1243	(71.8)
	1593	1118	(70.2)	1951	1474	(75.6)	1885	1435	(76.1)	1692	1262	(74.6)	1459	1069	(73.3)	1368	940	(68.7)
	142	97	(68.3)	240	176	(73.3)	116	48	(41.4)	737	596	(80.9)	-	-	-	-	-	-
	-	-	-	9380	4055	(43.2)	5240	2866	(54.7)	7152	2960	(41.4)	10424	4909	(47.1)	9812	4540	(46.3)
	3999	2758	(69.0)	5248	4066	(77.5)	4617	3468	(75.1)	5046	3608	(71.5)	2451	1689	(68.9)	4527	3284	(72.5)
	<b>29298</b>	<b>14693</b>	<b>(50.2)</b>	<b>76013</b>	<b>36544</b>	<b>(48.1)</b>	<b>59323</b>	<b>30144</b>	<b>(50.8)</b>	<b>52461</b>	<b>24735</b>	<b>(47.1)</b>	<b>49504</b>	<b>23039</b>	<b>(46.5)</b>	<b>49753</b>	<b>24171</b>	<b>(48.6)</b>
	<b>37567</b>	<b>18948</b>	<b>(50.4)</b>	<b>83532</b>	<b>40840</b>	<b>(48.9)</b>	<b>66715</b>	<b>34258</b>	<b>(51.3)</b>	<b>59423</b>	<b>28755</b>	<b>(48.4)</b>	<b>56433</b>	<b>27061</b>	<b>(48.0)</b>	<b>56234</b>	<b>27666</b>	<b>(49.2)</b>
	<b>35208</b>	<b>17696</b>	<b>(50.3)</b>	<b>81224</b>	<b>39410</b>	<b>(48.5)</b>	<b>64431</b>	<b>32661</b>	<b>(50.7)</b>	<b>57362</b>	<b>27296</b>	<b>(47.6)</b>	<b>54324</b>	<b>25627</b>	<b>(47.2)</b>	<b>54292</b>	<b>26389</b>	<b>(48.6)</b>

Table XI: Treatment success of all MDR-TB cases, European Region, 2005–2009

Country	Trend in percentage, 2005–2009	2005			2006			2007			2008			2009		
		MDR-TB cases (N)	Success		MDR-TB cases (N)	Success		MDR-TB cases (N)	Success		MDR-TB cases (N)	Success		MDR-TB cases (N)	Success	
			N	(%)		N	(%)		N	(%)		N	(%)		N	(%)
<b>EU/EEA</b>																
Austria		13	7 (53.8)	10	4 (40.0)	9	0 (0.0)	15	6 (40.0)	23	10 (43.5)					
Belgium		11	7 (63.6)	18	12 (66.7)	14	10 (71.4)	21	16 (76.2)	10	4 (40.0)					
Bulgaria		-	-	-	-	76	22 (28.9)	31	15 (48.4)	43	8 (18.6)					
Cyprus		-	-	-	-	-	-	1	1 (100.0)	4	0 (0.0)					
Czech Republic		13	5 (38.5)	12	5 (41.7)	8	3 (37.5)	11	7 (63.6)	8	0 (0.0)					
Denmark <sup>a</sup>		5	5 (100.0)	3	3 (100.0)	-	-	-	-	2	1 (50.0)					
Estonia		78	38 (48.7)	55	25 (45.5)	82	44 (53.7)	73	39 (53.4)	85	35 (41.2)					
Finland		-	-	-	-	-	-	-	-	-	-					
France		-	-	-	-	-	-	-	-	-	-					
Germany		103	48 (46.6)	82	42 (51.2)	66	46 (69.7)	49	28 (57.1)	62	38 (61.3)					
Greece		-	-	-	-	-	-	-	-	-	-					
Hungary		17	10 (58.8)	14	8 (57.1)	12	6 (50.0)	13	4 (30.8)	18	3 (16.7)					
Iceland		-	-	-	-	-	-	-	-	-	-					
Ireland		3	3 (100.0)	4	1 (25.0)	7	1 (14.3)	2	0 (0.0)	-	-					
Italy		-	-	-	-	-	-	-	-	-	-					
Latvia		161	112 (69.6)	142	87 (61.3)	99	63 (63.6)	128	84 (65.6)	131	77 (58.8)					
Liechtenstein		-	-	-	-	-	-	-	-	-	-					
Lithuania		-	-	-	-	-	-	276	81 (29.3)	322	97 (30.1)					
Luxembourg		-	-	-	-	-	-	-	-	-	-					
Malta		-	-	2	2 (100.0)	1	1 (100.0)	-	-	-	-					
Netherlands		8	5 (62.5)	6	5 (83.3)	6	6 (100.0)	15	14 (93.3)	20	12 (60.0)					
Norway		-	-	-	-	3	3 (100.0)	4	3 (75.0)	8	5 (62.5)					
Poland		-	-	-	-	22	14 (63.6)	19	9 (47.4)	21	12 (57.1)					
Portugal		-	-	-	-	-	-	-	-	-	-					
Romania		-	-	673	212 (31.5)	673	147 (21.8)	792	155 (19.6)	624	102 (16.3)					
Slovakia		8	2 (25.0)	7	4 (57.1)	7	2 (28.6)	4	1 (25.0)	1	0 (0.0)					
Slovenia		-	-	-	-	-	-	2	1 (50.0)	1	0 (0.0)					
Spain		-	-	-	-	-	-	-	-	-	-					
Sweden		-	-	-	-	15	14 (93.3)	11	10 (90.9)	13	11 (84.6)					
United Kingdom		-	-	-	-	56	29 (51.8)	53	34 (64.2)	60	45 (75.0)					
<b>Subtotal EU/EEA</b>		<b>417</b>	<b>239 (57.3)</b>	<b>1024</b>	<b>409 (39.9)</b>	<b>1149</b>	<b>410 (35.7)</b>	<b>1518</b>	<b>508 (33.5)</b>	<b>1456</b>	<b>460 (31.6)</b>					

<sup>a</sup> 'European Region' comprises the 53 countries of the WHO European Region and Liechtenstein. WHO European Region 18 TB High Priority Countries presented in italics.

<sup>b</sup> Excluding Greenland data (see Chapter 1.1).

Country	Trend in percentage, 2005–2009	2005			2006			2007			2008			2009		
		MDR-TB cases (N)	Success		MDR-TB cases (N)	Success		MDR-TB cases (N)	Success		MDR-TB cases (N)	Success		MDR-TB cases (N)	Success	
			N	(%)		N	(%)		N	(%)		N	(%)		N	(%)
<b>Non-EU/EEA</b>																
Albania		-	-	-	1	0	(0.0)	-	-	-	-	-	-	-	-	-
Andorra		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Armenia		-	-	-	27	11	(40.7)	57	30	(52.6)	77	42	(54.5)	134	69	(51.5)
Azerbaijan		-	-	-	-	-	-	-	-	-	23	13	(56.5)	100	74	(74.0)
Belarus		-	-	-	-	-	-	-	-	-	-	-	-	1422	572	(40.2)
Bosnia and Herzegovina		-	-	-	-	-	-	-	-	-	-	-	-	1	1	(100.0)
Croatia		-	-	-	-	-	-	-	-	-	-	-	-	2	1	(50.0)
Georgia		-	-	-	-	-	-	61	23	(37.7)	417	235	(56.4)	503	270	(53.7)
Israel		16	14	(87.5)	20	18	(90.0)	14	12	(85.7)	11	10	(90.9)	6	5	(83.3)
Kazakhstan		-	-	-	930	752	(80.9)	1609	1237	(76.9)	2268	1680	(74.1)	3897	2851	(73.2)
Kyrgyzstan		-	-	-	66	32	(48.5)	132	66	(50.0)	262	130	(49.6)	545	193	(35.4)
Macedonia, the former Yugoslav Republic of		-	-	-	6	2	(33.3)	9	2	(22.2)	2	0	(0.0)	1	0	(0.0)
Moldova		-	-	-	-	-	-	254	133	(52.4)	522	253	(48.5)	-	-	-
Monaco		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Montenegro		-	-	-	3	2	(66.7)	3	0	(0.0)	-	-	-	1	1	(100.0)
Russia		-	-	-	-	-	-	-	-	-	1537	783	(50.9)	-	-	-
San Marino		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Serbia		-	-	-	-	-	-	-	-	-	-	-	-	10	6	(60.0)
Serbia excluding UN Administered Province of Kosovo <sup>b</sup>		-	-	-	-	-	-	-	-	-	-	-	-	10	6	(60.0)
UN Administered Province of Kosovo <sup>b</sup>		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Switzerland		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Tajikistan		-	-	-	-	-	-	-	-	-	-	-	-	52	37	(71.2)
Turkey		-	-	-	249	177	(71.1)	240	155	(64.6)	263	180	(68.4)	222	147	(66.2)
Turkmenistan		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Ukraine		-	-	-	-	-	-	-	-	-	-	-	-	3299	906	(27.5)
Uzbekistan		-	-	-	-	-	-	330	180	(54.5)	294	193	(65.6)	464	285	(61.4)
<b>Subtotal non-EU/EEA</b>		<b>16</b>	<b>14</b>	<b>(87.5)</b>	<b>1302</b>	<b>994</b>	<b>(76.3)</b>	<b>2709</b>	<b>1838</b>	<b>(67.8)</b>	<b>5676</b>	<b>3519</b>	<b>(62.0)</b>	<b>10659</b>	<b>5418</b>	<b>(50.8)</b>
<b>Total European Region</b>		<b>433</b>	<b>253</b>	<b>(58.4)</b>	<b>2326</b>	<b>1403</b>	<b>(60.3)</b>	<b>3858</b>	<b>2248</b>	<b>(58.3)</b>	<b>7194</b>	<b>4027</b>	<b>(56.0)</b>	<b>12115</b>	<b>5878</b>	<b>(48.5)</b>
<b>Subtotal 18 HPC</b>		<b>239</b>	<b>150</b>	<b>(62.8)</b>	<b>2142</b>	<b>1296</b>	<b>(60.5)</b>	<b>3613</b>	<b>2100</b>	<b>(58.1)</b>	<b>6963</b>	<b>3883</b>	<b>(55.8)</b>	<b>11843</b>	<b>5723</b>	<b>(48.3)</b>


<sup>b</sup> In accordance with the UN Security Council Resolution No. 1244 (1999).



## 5. Maps & figures

A decorative graphic consisting of a thin blue horizontal bar at the top, followed by a thin white horizontal bar, and a large solid green rectangular area at the bottom of the page.


**Map 1a:** Estimated TB mortality per 100 000 population, European Region, 2011<sup>a</sup>



<sup>a</sup> Data from UN Administrated Province of Kosovo (in accordance with Security Council Resolution 1244 (1999)) is not included in the figures reported for Serbia




**Map 1b: Estimated TB prevalence per 100 000 population, European Region, 2011<sup>a</sup>**




<sup>a</sup> Data from UN Administrated Province of Kosovo (in accordance with Security Council Resolution 1244 (1999)) is not included in the figures reported for Serbia

**Map 1c: Estimated TB incidence per 100 000 population, European Region, 2011<sup>a</sup>**




<sup>a</sup> Data from UN Administrated Province of Kosovo (in accordance with Security Council Resolution 1244 (1999)) is not included in the figures reported for Serbia

**Map 2: TB notification rates per 100 000 population, European Region, 2011<sup>a</sup>**




<sup>a</sup> Data from UN Administrated Province of Kosovo (in accordance with Security Council Resolution 1244 (1999)) is not included in the figures reported for Serbia

**Map 3: TB notification rates, new and relapse cases per 100 000 population, European Region, 2011<sup>a</sup>**




<sup>a</sup> Data from UN Administrated Province of Kosovo (in accordance with Security Council Resolution 1244 (1999)) is not included in the figures reported for Serbia

**Map 4:** Percentages of notified TB cases of foreign origin among all TB cases, European Region, 2011<sup>a</sup>




<sup>a</sup> Data from UN Administrated Province of Kosovo (in accordance with Security Council Resolution 1244 (1999)) is not included in the figures reported for Serbia

**Map 5:** Percentages of notified extrapulmonary TB cases among all TB cases, European Region, 2011<sup>a</sup>




<sup>a</sup> Data from UN Administrated Province of Kosovo (in accordance with Security Council Resolution 1244 (1999)) is not included in the figures reported for Serbia

**Map 6:** Percentages of smear positive pulmonary TB cases among new pulmonary TB, European Region, 2011<sup>a</sup>




<sup>a</sup> Data from UN Administrated Province of Kosovo (in accordance with Security Council Resolution 1244 (1999)) is not included in the figures reported for Serbia

**Map 7:** Percentage of TB cases confirmed by culture and smear among new pulmonary TB cases, European Region, 2011<sup>a</sup>




<sup>a</sup> Data from UN Administrated Province of Kosovo (in accordance with Security Council Resolution 1244 (1999)) is not included in the figures reported for Serbia

**Map 8: Percentage of notified TB cases with multidrug resistance among new laboratory-confirmed pulmonary TB cases, European Region, 2011<sup>a</sup>**




<sup>a</sup> Data from UN Administrated Province of Kosovo (in accordance with Security Council Resolution 1244 (1999)) is not included in the figures reported for Serbia

**Map 9: Percentage of notified TB cases with multidrug resistance among previously treated laboratory-confirmed pulmonary TB cases, European Region, 2011<sup>a</sup>**




<sup>a</sup> Data from UN Administrated Province of Kosovo (in accordance with Security Council Resolution 1244 (1999)) is not included in the figures reported for Serbia

**Map 10: Percentage of notified TB cases with multidrug resistance among all TB cases with DST results, European Region, 2011<sup>a</sup>**




<sup>a</sup> Data from UN Administrated Province of Kosovo (in accordance with Security Council Resolution 1244 (1999)) is not included in the figures reported for Serbia

**Map 11: Percentage of notified TB cases with extensive drug resistance among MDR-TB cases with second-line DST results, European Region, 2011<sup>a</sup>**




<sup>a</sup> Data from UN Administrated Province of Kosovo (in accordance with Security Council Resolution 1244 (1999)) is not included in the figures reported for Serbia

**Map 12: Percentage of HIV positive TB cases among all TB cases with known HIV status, European Region, 2011<sup>a</sup>**




<sup>a</sup> Data from UN Administrated Province of Kosovo (in accordance with Security Council Resolution 1244 (1999)) is not included in the figures reported for Serbia

**Map 13: Success rate of new laboratory-confirmed pulmonary TB cases, European Region, 2010<sup>a</sup>**




<sup>a</sup> Data from UN Administrated Province of Kosovo (in accordance with Security Council Resolution 1244 (1999)) is not included in the figures reported for Serbia

**Map 14:** Success rate of previously treated laboratory-confirmed pulmonary TB cases, European Region, 2010<sup>a</sup>



<sup>a</sup> Data from UN Administrated Province of Kosovo (in accordance with Security Council Resolution 1244 (1999)) is not included in the figures reported for Serbia


**Map 15:** Success rate of all MDR-TB cases after 24 months, European Region, 2009<sup>a</sup>




<sup>a</sup> Data from UN Administrated Province of Kosovo (in accordance with Security Council Resolution 1244 (1999)) is not included in the figures reported for Serbia



**Figure 1: TB estimated incidence and notification per 100 000 population, European Region, 2002–2011**



**Figure 2: Estimated TB prevalence per 100 000 population, European Region, 2002–2011**



**Figure 3:** Estimated TB mortality per 100 000 population, European Region, 2002–2011







Figure 4: Total TB notifications by previous treatment history and total TB case rates, Europe, 2002–2011



\* Excluded: 2002–2011: Liechtenstein




\* Excluded: 2002: Belarus, Liechtenstein, Montenegro, Russian Federation, Tajikistan, Turkey, Ukraine; 2003: Belarus, Liechtenstein, Monaco, Montenegro, Tajikistan, Ukraine; 2004: Kyrgyzstan, Liechtenstein, Monaco, Montenegro, Turkey, Ukraine; 2005: Liechtenstein, Monaco, San Marino, Ukraine; 2006: Liechtenstein, Monaco, San Marino; 2007: Monaco, San Marino; 2008: Austria, Liechtenstein, Monaco, San Marino; 2009: Liechtenstein, Monaco, San Marino; 2010: Liechtenstein, San Marino; 2011: Liechtenstein, Monaco, San Marino, Turkmenistan




\* Excluded: 2002: Belarus, Russian Federation, Tajikistan, Turkey, Ukraine; 2003: Belarus, Tajikistan, Ukraine; 2004: Kyrgyzstan, Turkey, Ukraine; 2005: Ukraine; 2011: Turkmenistan

Data sources: TESSy, CISID, EuroTB historical database: Sitebac.


**Figure 5: Percentages of MDR among laboratory-confirmed TB cases, European Region, 2002–2011**




**Figure 6: Percentage of TB cases with HIV infection among TB cases with known HIV status, Europe, 2008–2011**



\* Excluded: 2008: Austria, Finland, France, Germany, Greece, Hungary, Italy, Lithuania, Luxembourg, Norway, Poland, Romania, Sweden, United Kingdom; 2009: Austria, Cyprus, Finland, France, Germany, Greece, Hungary, Italy, Lithuania, Luxembourg, Norway, Poland, Sweden, United Kingdom; 2010: Austria, Finland, France, Germany, Greece, Hungary, Italy, Lithuania, Norway, Poland, Romania, Sweden, United Kingdom; 2011: Austria, Cyprus, Denmark, Finland, Germany, Greece, Hungary, Italy, Liechtenstein, Norway, Poland, Portugal, Sweden, United Kingdom




\* Excluded: 2008: Andorra, Austria, Bosnia and Herzegovina, Croatia, Finland, France, Germany, Greece, Hungary, Italy, Lithuania, Luxembourg, Monaco, Norway, Poland, San Marino, Serbia, Sweden, Switzerland, Turkey, Turkmenistan, United Kingdom; 2009: Andorra, Austria, Azerbaijan, Bosnia and Herzegovina, Croatia, Cyprus, Finland, France, Germany, Greece, Hungary, Italy, Lithuania, Luxembourg, Monaco, Norway, Poland, San Marino, Serbia, Sweden, Switzerland, Turkey, Turkmenistan, United Kingdom; 2010: Andorra, Austria, Azerbaijan, Bosnia and Herzegovina, Croatia, Cyprus, Denmark, Finland, France, Germany, Greece, Hungary, Italy, Lithuania, Monaco, Norway, Poland, San Marino, Serbia, Sweden, Switzerland, United Kingdom; 2011: Andorra, Austria, Bosnia and Herzegovina, Croatia, Cyprus, Denmark, Finland, Germany, Greece, Hungary, Italy, Liechtenstein, Monaco, Norway, Poland, Portugal, San Marino, Sweden, United Kingdom, Turkmenistan




\* Excluded: 2008: Lithuania, Turkey, Turkmenistan; 2009: Azerbaijan, Lithuania, Turkey, Turkmenistan; 2010: Azerbaijan, Lithuania; 2011: Turkmenistan


**Figure 7: Treatment outcome, new laboratory-confirmed pulmonary TB cases, Europe, 2001–2010**



\* Excluded: France, Greece, Italy, Liechtenstein, Luxembourg




\* Excluded: 2010: Andorra, France, Greece, Italy, Monaco, Portugal, San Marino, Switzerland, Turkmenistan




\* Excluded: 2010: Turkmenistan


**Figure 8: Treatment outcome, previously treated laboratory-confirmed pulmonary TB cases, Europe, 2001–2010**



\* Excluded: France, Greece, Italy




\* Excluded: Andorra, France, Greece, Italy, Monaco, Portugal, San Marino, Switzerland, Turkmenistan





\* Excluded: Turkmenistan



**Figure 9: Treatment outcome after 24 months of MDR-TB cases, Europe, 2007–2009**



\* Excluded: Finland, France, Greece, Liechtenstein, Luxembourg, Portugal, Spain




\* Excluded: 2010: Turkmenistan



## 6. Country profiles







AD	Andorra	GE	Georgia	PL	Poland
AL	Albania	HR	Croatia	PT	Portugal
AM	Armenia	HU	Hungary	RO	Romania
AT	Austria	IE	Ireland	RS	Serbia
AZ	Azerbaijan	IL	Israel	RU	Russia
BA	Bosnia and Herzegovina	IS	Iceland	SE	Sweden
BE	Belgium	IT	Italy	SI	Slovenia
BG	Bulgaria	KG	Kyrgyzstan	SK	Slovakia
BY	Belarus	KZ	Kazakhstan	TJ	Tajikistan
CH	Switzerland	LT	Lithuania	TM	Turkmenistan
CY	Cyprus	LU	Luxembourg	TR	Turkey
CZ	Czech Republic	LV	Latvia	UA	Ukraine
DE	Germany	MD	Moldova	UK	United Kingdom
DK	Denmark	ME	Montenegro	UZ	Uzbekistan
EE	Estonia	MK	The former Yugoslav Republic of Macedonia		
EL	Greece	MT	Malta		
ES	Spain	NL	Netherlands		
FI	Finland	NO	Norway		
FR	France				



# Albania

Population estimate 2011 by UN Statistical Database: 3 215 988

## Tuberculosis case notifications, 2011

Total number of cases	431
Notification rate per 100 000	13.4
New & relapses (lab+) number	422
New & relapses (lab+) notification rate per 100 000	13.1
Pulmonary	294 (68.2%)
of which smear-positive	189 (64.3%)
Laboratory-confirmed pulmonary TB cases	218 (74.1%)
Mean age of new TB cases, nationals	45 years
Mean age of new TB cases, non-nationals	-
Foreign origin of all TB cases	0 (0.0%)
New (not previously treated)	413 (95.8%)

## Drug resistance surveillance & TB-HIV co-infection, 2011

Completeness of DRS data*	No
Completeness of HIV data**	No
Case-linked data reporting	Yes
Cases with DST results	205 (100.0%)
Cases resistant to isoniazid	27 (13.2%)
Cases resistant to rifampicin	11 (5.4%)
Estimated MDR N, (best-low-high)	8-2-14
MDR cases	5 (2.4%)
of which XDR cases	-
Cases resistant to ethambutol	-
Cases resistant to streptomycin	-
TB cases tested for HIV	170 (39.4%)
HIV-positive TB cases	2 (1.2%)


\* National coverage 100% or culturing 90%, C+/All TB cases 50%, DST done for C+ 75%, EQA 95%

\*\* More than 50% of TB cases tested for HIV.


## Treatment outcome monitoring, 2010

Geographical coverage	National
Outcome cohort	New pulmonary culture positive
Case-linked data reporting	Yes
Notified in 2010	145
Success	132 (91.0%)
Died	4 (2.8%)
Failed	0 (0.0%)
Defaulted	6 (3.5%)
Still on treatment	-
Lost to follow up	5 (3.4%)


## Tuberculosis notification rates by treatment history, 2002–2011




## New TB cases - notification rates by age group, 2002–2011




## Tuberculosis cases by geographical origin, 2002–2011




## TB-HIV co-infection, 2006–2011



## MDR-TB cases by previous treatment history, 2002–2011



## Treatment outcome, new pulmonary smear-positive cases, 2002–2010



# Andorra

Population estimate 2011 by UN Statistical Database: 86 165

## Tuberculosis case notifications, 2011

Total number of cases	4
Notification rate per 100 000	4.6
New & relapses (lab+) number	3
New & relapses (lab+) notification rate per 100 000	3.5
Pulmonary	3 (75.0%)
of which smear-positive	1 (33.3%)
Laboratory-confirmed pulmonary TB cases	1 (33.3%)
Mean age of new TB cases, nationals	40 years
Mean age of new TB cases, non-nationals	-
Foreign origin of all TB cases	0 (0.0%)
New (not previously treated)	3 (75.0%)

## Drug resistance surveillance & TB-HIV co-infection, 2011

Completeness of DRS data*	No
Completeness of HIV data**	Yes
Case-linked data reporting	Yes
Cases with DST results	2 (66.7%)
Cases resistant to isoniazid	1 (50.0%)
Cases resistant to rifampicin	0 (0.0%)
Estimated MDR N, (best-low-high)	0-0-0
MDR cases	0 (0.0%)
of which XDR cases	- -
Cases resistant to ethambutol	- -
Cases resistant to streptomycin	- -
TB cases tested for HIV	- -
HIV-positive TB cases	- -


\* National coverage 100% or culturing 90%, C+/All TB cases 50%, DST done for C+ 75%, EQA 95%

\*\* More than 50% of TB cases tested for HIV.


## Treatment outcome monitoring, 2010

No case reported


## Tuberculosis notification rates by treatment history, 2002–2011



## New TB cases - notification rates by age group, 2002–2011



## Tuberculosis cases by geographical origin, 2002–2011




## TB-HIV co-infection, 2006–2011

No case reported

## MDR-TB cases by previous treatment history, 2002–2011

No MDR cases reported

## Treatment outcome, new pulmonary culture-positive cases, 2002–2010





# Armenia

Population estimate 2011 by UN Statistical Database: 3100236

## Tuberculosis case notifications, 2011

Total number of cases	1582
Notification rate per 100 000	51.0
New & relapses (lab+) number	1261
New & relapses (lab+) notification rate per 100 000	40.7
Pulmonary	1056 (66.8%)
of which smear-positive	404 (38.3%)
Laboratory-confirmed pulmonary TB cases	521 (49.3%)
Mean age of new TB cases, nationals	41.1 years
Mean age of new TB cases, non-nationals	-
Foreign origin of all TB cases	0 (0.0%)
New (not previously treated)	1200 (75.9%)

## Drug resistance surveillance & TB-HIV co-infection, 2011


Completeness of DRS data*	No
Completeness of HIV data**	Yes
Case-linked data reporting	No
Cases with DST results	529 (100.0%)
Cases resistant to isoniazid	164 (31.0%)
Cases resistant to rifampicin	94 (17.8%)
Estimated MDR N, (best-low-high)	250-220-280
MDR cases	79 (14.9%)
of which XDR cases	0 (0.0%)
Cases resistant to ethambutol	-
Cases resistant to streptomycin	-
TB cases tested for HIV	1499 (94.8%)
HIV-positive TB cases	49 (3.3%)

\* National coverage 100% or culturing 90%, C+/All TB cases 50%, DST done for C+ 75%, EQA 95%  
 \*\* More than 50% of TB cases tested for HIV.


## Treatment outcome monitoring, 2010

Geographical coverage	National
Outcome cohort	New pulmonary culture positive
Case-linked data reporting	Yes
Notified in 2010	339
Success	243 (71.7%)
Died	15 (4.4%)
Failed	51 (15.0%)
Defaulted	27 (8.0%)
Still on treatment	-
Lost to follow up	3 (0.9%)


## Tuberculosis notification rates by treatment history, 2002–2011




## New TB cases - notification rates by age group, 2002–2011




## Tuberculosis cases by geographical origin, 2002–2011



## TB-HIV co-infection, 2006–2011



## MDR-TB cases by previous treatment history, 2002–2011



## Treatment outcome, new pulmonary smear-positive cases, 2002–2010



# Austria

Total population at 1 January 2011 by EUROSTAT: 8 404 252

## Tuberculosis case notifications, 2011

Total number of cases	687
Notification rate per 100 000	8.2
New & relapses (laboratory-confirmed) number	401
New & relapses (laboratory-confirmed) notification rate per 100 000	4.8
Pulmonary of which smear-positive	540 (78.6%) 133 (24.6%)
Laboratory-confirmed pulmonary TB cases	388 (71.9%)
Mean age of new TB cases, nationals	55 years
Mean age of new TB cases, non-nationals	33.9 years
Foreign origin of all TB cases	326 (47.5%)
New (not previously treated)	396 (57.6%)

## Drug resistance surveillance & TB-HIV co-infection, 2011

Completeness of DRS data*	Yes
Completeness of HIV data**	-
Case-linked data reporting	Yes
Cases with DST results	450 (96.6%)
Cases resistant to isoniazid	49 (10.9%)
Cases resistant to rifampicin	21 (4.7%)
Estimated MDR N, (best-low-high)	12-4-19
MDR cases of which XDR cases	19 (4.2%) 6 (31.6%)
Cases resistant to ethambutol	15 (3.3%)
Cases resistant to streptomycin	38 (8.4%)
TB cases tested for HIV	-
HIV-positive TB cases	-


\* National coverage 100% or culturing 90%, C+/All TB cases 50%, DST done for C+ 75%, EQA 95%

\*\* More than 50% of TB cases tested for HIV.


## Treatment outcome monitoring, 2010

Geographical coverage	National
Outcome cohort	New laboratory-confirmed pulmonary TB cases
Case-linked data reporting	Yes
Notified in 2010	206
Success	133 (64.6%)
Died	13 (6.3%)
Failed	0 (0.0%)
Defaulted	13 (6.3%)
Still on treatment	31 (15.0%)
Lost to follow up	16 (7.8%)


## Tuberculosis notification rates by treatment history, 2002–2011



## New TB cases - notification rates by age group, 2002–2011




## Tuberculosis cases by geographical origin, 2002–2011




## TB-HIV co-infection, 2006–2011

Data not available

## MDR-TB cases by previous treatment history, 2002–2011



## Treatment outcome, new pulmonary culture-positive cases, 2002–2010



# Azerbaijan

Population estimate 2011 by UN Statistical Database: 9 306 023

## Tuberculosis case notifications, 2011

Total number of cases	9 805
Notification rate per 100 000	105.4
New & relapses (lab+) number	6 515
New & relapses (lab+) notification rate per 100 000	70.0
Pulmonary	6 290 (64.2%)
of which smear-positive	2 652 (29.7%)
Laboratory-confirmed pulmonary TB cases	3 541 (39.6%)
Mean age of new TB cases, nationals	28.8 years
Mean age of new TB cases, non-nationals	-
Foreign origin of all TB cases	0 (0.0%)
New (not previously treated)	5 296 (54.0%)

## Drug resistance surveillance & TB-HIV co-infection, 2011

Completeness of DRS data*	No
Completeness of HIV data**	Yes
Case-linked data reporting	No
Cases with DST results	720 (33.1%)
Cases resistant to isoniazid	178 (24.7%)
Cases resistant to rifampicin	100 (13.9%)
Estimated MDR N, (best-low-high)	3400-3200-3700
MDR cases	90 (12.5%)
of which XDR cases	3 (3.3%)
Cases resistant to ethambutol	-
Cases resistant to streptomycin	-
TB cases tested for HIV	6 179 (63.0%)
HIV-positive TB cases	76 (1.2%)


\* National coverage 100% or culturing 90%, C+/All TB cases 50%, DST done for C+ 75%, EQA 95%

\*\* More than 50% of TB cases tested for HIV.


## Treatment outcome monitoring, 2010

Geographical coverage	National
Outcome cohort	New pulmonary culture positive
Case-linked data reporting	No
Notified in 2010	1 919
Success	1 470 (76.6%)
Died	64 (3.3%)
Failed	86 (4.5%)
Defaulted	188 (9.8%)
Still on treatment	-
Lost to follow up	111 (5.8%)


## Tuberculosis notification rates by treatment history, 2002–2011




## New TB cases - notification rates by age group, 2002–2011




## Tuberculosis cases by geographical origin, 2002–2011




## TB-HIV co-infection, 2006–2011



## MDR-TB cases by previous treatment history, 2002–2011



## Treatment outcome, new pulmonary smear-positive cases, 2002–2010



# Belarus

Population estimate 2011 by UN Statistical Database: 9559441

## Tuberculosis case notifications, 2011

Total number of cases	5118
Notification rate per 100 000	53.5
New & relapses (lab+) number	4697
New & relapses (lab+) notification rate per 100 000	49.1
Pulmonary	4634 (90.5%)
of which smear-positive	1739 (37.5%)
Laboratory-confirmed pulmonary TB cases	3087 (66.6%)
Mean age of new TB cases, nationals	43.8 years
Mean age of new TB cases, non-nationals	-
Foreign origin of all TB cases	0 (0.0%)
New (not previously treated)	4043 (79.0%)

## Drug resistance surveillance & TB-HIV co-infection, 2011

Completeness of DRS data*	No
Completeness of HIV data**	Yes
Case-linked data reporting	No
Cases with DST results	3032 (96.7%)
Cases resistant to isoniazid	1713 (56.5%)
Cases resistant to rifampicin	1637 (54.0%)
Estimated MDR N, (best-low-high)	2000-1900-2100
MDR cases	1594 (52.6%)
of which XDR cases	0 (0.0%)
Cases resistant to ethambutol	-
Cases resistant to streptomycin	-
TB cases tested for HIV	4747 (92.8%)
HIV-positive TB cases	217 (4.6%)


\* National coverage 100% or culturing 90%, C+/All TB cases 50%, DST done for C+ 75%, EQA 95%

\*\* More than 50% of TB cases tested for HIV.


## Treatment outcome monitoring, 2010

Geographical coverage	National
Outcome cohort	New pulmonary culture positive
Case-linked data reporting	No
Notified in 2010	2184
Success	1447 (66.3%)
Died	183 (8.4%)
Failed	491 (22.5%)
Defaulted	12 (0.5%)
Still on treatment	-
Lost to follow up	51 (2.3%)


## Tuberculosis notification rates by treatment history, 2002–2011




## New TB cases - notification rates by age group, 2002–2011




## Tuberculosis cases by geographical origin, 2002–2011




## TB-HIV co-infection, 2006–2011



## MDR-TB cases by previous treatment history, 2002–2011



## Treatment outcome, new pulmonary definite cases, 2002–2010



# Belgium

Total population at 1 January 2011 by EUROSTAT: 10951266

## Tuberculosis case notifications, 2011

Total number of cases	1044
Notification rate per 100 000	9.5
New & relapses (laboratory-confirmed) number	705
New & relapses (laboratory-confirmed) notification rate per 100 000	6.4
Pulmonary	747 (71.6%)
of which smear-positive	338 (45.2%)
Laboratory-confirmed pulmonary TB cases	592 (79.3%)
Mean age of new TB cases, nationals	43.3 years
Mean age of new TB cases, non-nationals	35.7 years
Foreign origin of all TB cases	544 (52.1%)
New (not previously treated)	705 (67.5%)

## Drug resistance surveillance & TB-HIV co-infection, 2011

Completeness of DRS data*	Yes
Completeness of HIV data**	Yes
Case-linked data reporting	Yes
Cases with DST results	754 (94.6%)
Cases resistant to isoniazid	50 (6.6%)
Cases resistant to rifampicin	17 (2.3%)
Estimated MDR N, (best-low-high)	18-10-26
MDR cases	15 (2.0%)
of which XDR cases	3 (20.0%)
Cases resistant to ethambutol	17 (2.3%)
Cases resistant to streptomycin	0 (0.0%)
TB cases tested for HIV	845 (80.9%)
HIV-positive TB cases	44 (5.2%)


\* National coverage 100% or culturing 90%, C+/All TB cases 50%, DST done for C+ 75%, EQA 95%

\*\* More than 50% of TB cases tested for HIV.


## Treatment outcome monitoring, 2010

Geographical coverage	National
Outcome cohort	New laboratory-confirmed pulmonary TB cases
Case-linked data reporting	Yes
Notified in 2010	474
Success	357 (75.3%)
Died	33 (7.0%)
Failed	0 (0.0%)
Defaulted	53 (11.2%)
Still on treatment	16 (3.4%)
Lost to follow up	15 (3.2%)


## Tuberculosis notification rates by treatment history, 2002–2011




## New TB cases - notification rates by age group, 2002–2011




## Tuberculosis cases by geographical origin, 2002–2011




## TB-HIV co-infection, 2006–2011



## MDR-TB cases by previous treatment history, 2002–2011



## Treatment outcome, new pulmonary culture-positive cases, 2002–2010



# Bosnia and Herzegovina

Population estimate 2011 by UN Statistical Database: 3752228

## Tuberculosis case notifications, 2011

Total number of cases	1385
Notification rate per 100 000	36.9
New & relapses (lab+) number	1360
New & relapses (lab+) notification rate per 100 000	36.2
Pulmonary of which smear-positive	1259 (90.9%) 587 (46.6%)
Laboratory-confirmed pulmonary TB cases	748 (59.4%)
Mean age of new TB cases, nationals	52.6 years
Mean age of new TB cases, non-nationals	-
Foreign origin of all TB cases	0 (0.0%)
New (not previously treated)	1320 (95.3%)

## Drug resistance surveillance & TB-HIV co-infection, 2011

Completeness of DRS data*	Yes
Completeness of HIV data**	Yes
Case-linked data reporting	Yes
Cases with DST results	745 (100.0%)
Cases resistant to isoniazid	7 (0.9%)
Cases resistant to rifampicin	5 (0.7%)
Estimated MDR N, (best-low-high)	3-0-8
MDR cases of which XDR cases	5 (0.7%) 0 (0.0%)
Cases resistant to ethambutol	-
Cases resistant to streptomycin	-
TB cases tested for HIV	-
HIV-positive TB cases	-


\* National coverage 100% or culturing 90%, C+/All TB cases 50%, DST done for C+ 75%, EQA 95%

\*\* More than 50% of TB cases tested for HIV.


## Treatment outcome monitoring, 2010

Geographical coverage	National
Outcome cohort	New pulmonary culture positive
Case-linked data reporting	No
Notified in 2010	441
Success	434 (98.4%)
Died	5 (1.1%)
Failed	1 (0.2%)
Defaulted	1 (0.2%)
Still on treatment	-
Lost to follow up	0 (0.0%)


## Tuberculosis notification rates by treatment history, 2002–2011



## New TB cases - notification rates by age group, 2002–2011




## Tuberculosis cases by geographical origin, 2002–2011




## TB-HIV co-infection, 2006–2011

HIV status not reported

## MDR-TB cases by previous treatment history, 2002–2011



## Treatment outcome, new pulmonary smear/culture-positive cases, 2002–2010



# Bulgaria

Total population at 1 January 2011 by EUROSTAT: 7504 868

## Tuberculosis case notifications, 2011

Total number of cases	2407
Notification rate per 100 000	32.1
New & relapses (laboratory-confirmed) number	2173
New & relapses (laboratory-confirmed) notification rate per 100 000	29.0
Pulmonary of which smear-positive	1724 (71.6%) 897 (52.0%)
Laboratory-confirmed pulmonary TB cases	1043 (60.5%)
Mean age of new TB cases, nationals	44.8 years
Mean age of new TB cases, non-nationals	58.4 years
Foreign origin of all TB cases	9 (0.4%)
New (not previously treated)	2052 (85.3%)

## Drug resistance surveillance & TB-HIV co-infection, 2011


Completeness of DRS data*	No
Completeness of HIV data**	Yes
Case-linked data reporting	Yes
Cases with DST results	733 (68.4%)
Cases resistant to isoniazid	98 (13.4%)
Cases resistant to rifampicin	65 (8.9%)
Estimated MDR N, (best-low-high)	120-90-150
MDR cases of which XDR cases	55 (7.5%) 0 (0.0%)
Cases resistant to ethambutol	47 (6.4%)
Cases resistant to streptomycin	45 (6.1%)
TB cases tested for HIV	1698 (70.5%)
HIV-positive TB cases	5 (0.3%)

\* National coverage 100% or culturing 90%, C+/All TB cases 50%, DST done for C+ 75%, EQA 95%  
\*\* More than 50% of TB cases tested for HIV.


## Treatment outcome monitoring, 2010

Geographical coverage	National
Outcome cohort	New laboratory-confirmed pulmonary TB cases
Case-linked data reporting	Yes
Notified in 2010	946
Success	816 (86.3%)
Died	75 (7.9%)
Failed	15 (1.6%)
Defaulted	29 (3.1%)
Still on treatment	10 (1.1%)
Lost to follow up	1 (0.1%)


## Tuberculosis notification rates by treatment history, 2002–2011




## New TB cases - notification rates by age group, 2002–2011




## Tuberculosis cases by geographical origin, 2002–2011




## TB-HIV co-infection, 2006–2011



## MDR-TB cases by previous treatment history, 2002–2011



## Treatment outcome, new pulmonary definite cases, 2002–2010



# Croatia

Population estimate 2011 by UN Statistical Database: 4 395 560

## Tuberculosis case notifications, 2011

Total number of cases	619
Notification rate per 100 000	14.1
New & relapses (lab+) number	619
New & relapses (lab+) notification rate per 100 000	14.1
Pulmonary of which smear-positive	602 (97.3%) 230 (38.2%)
Laboratory-confirmed pulmonary TB cases	388 (64.5%)
Mean age of new TB cases, nationals	55.1 years
Mean age of new TB cases, non-nationals	-
Foreign origin of all TB cases	75 (12.1%)
New (not previously treated)	619 (100.0%)

## Drug resistance surveillance & TB-HIV co-infection, 2011


Completeness of DRS data*	Yes
Completeness of HIV data**	Yes
Case-linked data reporting	Yes
Cases with DST results	393 (100.0%)
Cases resistant to isoniazid	14 (3.6%)
Cases resistant to rifampicin	4 (1.0%)
Estimated MDR N, (best-low-high)	1-0-5
MDR cases of which XDR cases	2 (0.5%) 0 (0.0%)
Cases resistant to ethambutol	- -
Cases resistant to streptomycin	- -
TB cases tested for HIV	- -
HIV-positive TB cases	- -

\* National coverage 100% or culturing 90%, C+/All TB cases 50%, DST done for C+ 75%, EQA 95%  
\*\* More than 50% of TB cases tested for HIV.


## Treatment outcome monitoring, 2010

Geographical coverage	National
Outcome cohort	New pulmonary culture positive
Case-linked data reporting	Yes
Notified in 2010	181
Success	136 (75.1%)
Died	25 (13.8%)
Failed	0 (0.0%)
Defaulted	7 (3.9%)
Still on treatment	- -
Lost to follow up	13 (7.2%)


## Tuberculosis notification rates by treatment history, 2002–2011



## New TB cases - notification rates by age group, 2002–2011




## Tuberculosis cases by geographical origin, 2002–2011




## TB-HIV co-infection, 2006–2011

Not reported

## MDR-TB cases by previous treatment history, 2002–2011



## Treatment outcome, new pulmonary culture-positive cases, 2002–2010





# Cyprus

Total population at 1 January 2011 by EUROSTAT: 839 751

## Tuberculosis case notifications, 2011

Total number of cases	54
Notification rate per 100 000	6.4
New & relapses (laboratory-confirmed) number	31
New & relapses (laboratory-confirmed) notification rate per 100 000	3.7
Pulmonary of which smear-positive	44 (81.5%) 19 (43.2%)
Laboratory-confirmed pulmonary TB cases	38 (86.4%)
Mean age of new TB cases, nationals	54.0 years
Mean age of new TB cases, non-nationals	37.4 years
Foreign origin of all TB cases	45 (83.3%)
New (not previously treated)	31 (57.4%)

## Drug resistance surveillance & TB-HIV co-infection, 2011


Completeness of DRS data*	Yes
Completeness of HIV data**	No
Case-linked data reporting	Yes
Cases with DST results	40 (90.9%)
Cases resistant to isoniazid	3 (7.5%)
Cases resistant to rifampicin	1 (2.5%)
Estimated MDR N, (best-low-high)	0-0-0
MDR cases of which XDR cases	1 (2.5%) 0 -
Cases resistant to ethambutol	1 (2.5%)
Cases resistant to streptomycin	1 (2.5%)
TB cases tested for HIV	1 (1.9%)
HIV-positive TB cases	1 -

\* National coverage 100% or culturing 90%, C+/All TB cases 50%, DST done for C+ 75%, EQA 95%  
\*\* More than 50% of TB cases tested for HIV.


## Treatment outcome monitoring, 2010

Geographical coverage	National
Outcome cohort	New laboratory-confirmed pulmonary TB cases
Case-linked data reporting	Yes
Notified in 2010	20
Success	5 (25.0%)
Died	0 (0.0%)
Failed	0 (0.0%)
Defaulted	0 (0.0%)
Still on treatment	0 (0.0%)
Lost to follow up	15 (75.0%)


## Tuberculosis notification rates by treatment history, 2002–2011




## New TB cases - notification rates by age group, 2002–2011




## Tuberculosis cases by geographical origin, 2002–2011




## TB-HIV co-infection, 2006–2011



## MDR-TB cases by previous treatment history, 2002–2011



## Treatment outcome, new pulmonary smear-positive cases, 2002–2010



# Czech Republic

Total population at 1 January 2011 by EUROSTAT: 10532700

## Tuberculosis case notifications, 2011

Total number of cases	600
Notification rate per 100 000	5.7
New & relapses (laboratory-confirmed) number	569
New & relapses (laboratory-confirmed) notification rate per 100 000	5.4
Pulmonary of which smear-positive	522 (87.0%) 198 (37.9%)
Laboratory-confirmed pulmonary TB cases	395 (75.7%)
Mean age of new TB cases, nationals	57.8 years
Mean age of new TB cases, non-nationals	35.4 years
Foreign origin of all TB cases	112 (18.7%)
New (not previously treated)	569 (94.8%)

## Drug resistance surveillance & TB-HIV co-infection, 2011

Completeness of DRS data*	Yes
Completeness of HIV data**	No
Case-linked data reporting	Yes
Cases with DST results	408 (95.8%)
Cases resistant to isoniazid	12 (2.9%)
Cases resistant to rifampicin	13 (3.2%)
Estimated MDR N, (best-low-high)	12-4-20
MDR cases	7 (1.7%)
of which XDR cases	2 (28.6%)
Cases resistant to ethambutol	8 (2.0%)
Cases resistant to streptomycin	16 (3.9%)
TB cases tested for HIV	153 (25.5%)
HIV-positive TB cases	4 (2.6%)


\* National coverage 100% or culturing 90%, C+/All TB cases 50%, DST done for C+ 75%, EQA 95%

\*\* More than 50% of TB cases tested for HIV.


## Treatment outcome monitoring, 2010

Geographical coverage	National
Outcome cohort	New laboratory-confirmed pulmonary TB cases
Case-linked data reporting	Yes
Notified in 2010	361
Success	249 (69.0%)
Died	61 (16.9%)
Failed	0 (0.0%)
Defaulted	24 (6.6%)
Still on treatment	14 (3.9%)
Lost to follow up	13 (3.6%)


## Tuberculosis notification rates by treatment history, 2002–2011




## New TB cases - notification rates by age group, 2002–2011




## Tuberculosis cases by geographical origin, 2002–2011




## TB-HIV co-infection, 2006–2011



## MDR-TB cases by previous treatment history, 2002–2011



## Treatment outcome, new pulmonary culture-positive cases, 2002–2010



# Denmark

Total population at 1 January 2011 by EUROSTAT: 5560 628

## Tuberculosis case notifications, 2011

Total number of cases	381
Notification rate per 100 000	6.9
New & relapses (laboratory-confirmed) number	359
New & relapses (laboratory-confirmed) notification rate per 100 000	6.5
Pulmonary of which smear-positive	240 (63.0%) 135 (56.3%)
Laboratory-confirmed pulmonary TB cases	231 (96.3%)
Mean age of new TB cases, nationals	48.4 years
Mean age of new TB cases, non-nationals	41.1 years
Foreign origin of all TB cases	235 (61.7%)
New (not previously treated)	359 (94.2%)

## Drug resistance surveillance & TB-HIV co-infection, 2011


Completeness of DRS data*	Yes
Completeness of HIV data**	No
Case-linked data reporting	Yes
Cases with DST results	271 (99.6%)
Cases resistant to isoniazid	13 (4.8%)
Cases resistant to rifampicin	3 (1.1%)
Estimated MDR N, (best-low-high)	2-0-4
MDR cases of which XDR cases	3 (1.1%) 0 (0.0%)
Cases resistant to ethambutol	3 (1.1%)
Cases resistant to streptomycin	1 (0.4%)
TB cases tested for HIV	9 (2.4%)
HIV-positive TB cases	9 -

\* National coverage 100% or culturing 90%, C+/All TB cases 50%, DST done for C+ 75%, EQA 95%  
\*\* More than 50% of TB cases tested for HIV.


## Treatment outcome monitoring, 2010

Geographical coverage	National
Outcome cohort	New laboratory-confirmed pulmonary TB cases
Case-linked data reporting	Yes
Notified in 2010	218
Success	141 (64.7%)
Died	23 (10.6%)
Failed	5 (2.3%)
Defaulted	1 (0.5%)
Still on treatment	7 (3.2%)
Lost to follow up	41 (18.8%)


## Tuberculosis notification rates by treatment history, 2002–2011




## New TB cases - notification rates by age group, 2002–2011



## Tuberculosis cases by geographical origin, 2002–2011




## TB-HIV co-infection, 2006–2011



## MDR-TB cases by previous treatment history, 2002–2011

Insufficient data for graphic presentation

## Treatment outcome, new pulmonary culture-positive cases, 2002–2010



# Estonia

Total population at 1 January 2008 by EUROSTAT: 1340 194

## Tuberculosis case notifications, 2011

Total number of cases	341
Notification rate per 100 000	25.4
New & relapses (laboratory-confirmed) number	297
New & relapses (laboratory-confirmed) notification rate per 100 000	22.2
Pulmonary	321 (94.1%)
of which smear-positive	158 (49.2%)
Laboratory-confirmed pulmonary TB cases	255 (79.4%)
Mean age of new TB cases, nationals	44.0 years
Mean age of new TB cases, non-nationals	56.7 years
Foreign origin of all TB cases	48 (14.1%)
New (not previously treated)	265 (77.7%)

## Drug resistance surveillance & TB-HIV co-infection, 2011

Completeness of DRS data*	Yes
Completeness of HIV data**	Yes
Case-linked data reporting	Yes
Cases with DST results	262 (99.2%)
Cases resistant to isoniazid	97 (37.0%)
Cases resistant to rifampicin	79 (30.2%)
Estimated MDR N, (best-low-high)	100-83-120
MDR cases	78 (29.8%)
of which XDR cases	14 (17.9%)
Cases resistant to ethambutol	79 (30.2%)
Cases resistant to streptomycin	104 (39.7%)
TB cases tested for HIV	313 (91.8%)
HIV-positive TB cases	47 (15.0%)


\* National coverage 100% or culturing 90%, C+/All TB cases 50%, DST done for C+ 75%, EQA 95%

\*\* More than 50% of TB cases tested for HIV.


## Treatment outcome monitoring, 2010

Geographical coverage	National
Outcome cohort	New laboratory-confirmed pulmonary TB cases
Case-linked data reporting	Yes
Notified in 2010	192
Success	129 (67.2%)
Died	20 (10.4%)
Failed	3 (1.6%)
Defaulted	7 (3.6%)
Still on treatment	33 (17.2%)
Lost to follow up	0 (0.0%)


## Tuberculosis notification rates by treatment history, 2002–2011




## New TB cases - notification rates by age group, 2002–2011




## Tuberculosis cases by geographical origin, 2002–2011




## TB-HIV co-infection, 2006–2011



## MDR-TB cases by previous treatment history, 2002–2011



## Treatment outcome, new pulmonary culture-positive cases, 2002–2010



# Finland

Total population at 1 January 2011 by EUROSTAT: 5375276

## Tuberculosis case notifications, 2011

Total number of cases	325
Notification rate per 100 000	6.0
New & relapses (laboratory-confirmed) number	312
New & relapses (laboratory-confirmed) notification rate per 100 000	5.8
Pulmonary of which smear-positive	236 (72.6%) 87 (36.9%)
Laboratory-confirmed pulmonary TB cases	189 (80.1%)
Mean age of new TB cases, nationals	67.0 years
Mean age of new TB cases, non-nationals	32.3 years
Foreign origin of all TB cases	79 (24.3%)
New (not previously treated)	312 (96.0%)

## Drug resistance surveillance & TB-HIV co-infection, 2011


Completeness of DRS data*	Yes
Completeness of HIV data**	-
Case-linked data reporting	Yes
Cases with DST results	245 (97.2%)
Cases resistant to isoniazid	16 (6.5%)
Cases resistant to rifampicin	5 (2.0%)
Estimated MDR N, (best-low-high)	7-1-13
MDR cases of which XDR cases	5 (2.0%) 0 (0.0%)
Cases resistant to ethambutol	4 (1.6%)
Cases resistant to streptomycin	10 (4.1%)
TB cases tested for HIV	3 0.9
HIV-positive TB cases	3 -

\* National coverage 100% or culturing 90%, C+/All TB cases 50%, DST done for C+ 75%, EQA 95%  
\*\* More than 50% of TB cases tested for HIV.


## Treatment outcome monitoring, 2010

Geographical coverage	National
Outcome cohort	New laboratory-confirmed pulmonary TB cases
Case-linked data reporting	Yes
Notified in 2010	185
Success	138 (74.6%)
Died	16 (8.6%)
Failed	0 (0.0%)
Defaulted	4 (2.2%)
Still on treatment	10 (5.4%)
Lost to follow up	17 (9.2%)


## Tuberculosis notification rates by treatment history, 2002–2011



## New TB cases - notification rates by age group, 2002–2011




## Tuberculosis cases by geographical origin, 2002–2011




## TB-HIV co-infection, 2006–2011

Data not available

## MDR-TB cases by previous treatment history, 2002–2011



## Treatment outcome, new pulmonary culture-positive cases, 2002–2010



# France

Total population at 1 January 2011 by EUROSTAT: 65 048 412

## Tuberculosis case notifications, 2011

Total number of cases	4942
Notification rate per 100 000	7.6
New & relapses (laboratory-confirmed) number	2639
New & relapses (laboratory-confirmed) notification rate per 100 000	4.1
Pulmonary	3600 (72.8%)
of which smear-positive	1704 (47.3%)
Laboratory-confirmed pulmonary TB cases	1794 (49.8%)
Mean age of new TB cases, nationals	49.0 years
Mean age of new TB cases, non-nationals	40.2 years
Foreign origin of all TB cases	2456 (49.7%)
New (not previously treated)	2639 (53.4%)

## Drug resistance surveillance & TB-HIV co-infection, 2011


Completeness of DRS data*	No
Completeness of HIV data**	No
Case-linked data reporting	Yes
Cases with DST results	1568 (67.9%)
Cases resistant to isoniazid	114 (7.3%)
Cases resistant to rifampicin	43 (2.7%)
Estimated MDR N, (best-low-high)	43-26-61
MDR cases	40 (2.6%)
of which XDR cases	-
Cases resistant to ethambutol	-
Cases resistant to streptomycin	-
TB cases tested for HIV	1354 (27.4%)
HIV-positive TB cases	95 (7.0%)

\* National coverage 100% or culturing 90%, C+/All TB cases 50%, DST done for C+ 75%, EQA 95%  
 \*\* More than 50% of TB cases tested for HIV.


## Treatment outcome monitoring, 2010

Data not reported


## Tuberculosis notification rates by treatment history, 2002–2011




## New TB cases - notification rates by age group, 2002–2011




## Tuberculosis cases by geographical origin, 2002–2011



## TB-HIV co-infection, 2006–2011



## MDR-TB cases by previous treatment history, 2002–2011



## Treatment outcome, new pulmonary culture-positive cases, 2002–2010

Not available

# Georgia

Population estimate 2011 by UN Statistical Database: 4 329 026

## Tuberculosis case notifications, 2011

Total number of cases	5533
Notification rate per 100 000	127.8
New & relapses (lab+) number	4 547
New & relapses (lab+) notification rate per 100 000	105.0
Pulmonary of which smear-positive	3 676 (66.4%) 2 499 (68.0%)
Laboratory-confirmed pulmonary TB cases	2 985 (81.2%)
Mean age of new TB cases, nationals	36.8 years
Mean age of new TB cases, non-nationals	-
Foreign origin of all TB cases	0 (0.0%)
New (not previously treated)	4 223 (76.3%)

## Drug resistance surveillance & TB-HIV co-infection, 2011


Completeness of DRS data*	No
Completeness of HIV data**	No
Case-linked data reporting	Yes
Cases with DST results	2 872 (97.2%)
Cases resistant to isoniazid	810 (28.2%)
Cases resistant to rifampicin	485 (16.9%)
Estimated MDR N, (best-low-high)	760-700-820
MDR cases	453 (15.8%)
of which XDR cases	28 (6.2%)
Cases resistant to ethambutol	-
Cases resistant to streptomycin	-
TB cases tested for HIV	2 550 (46.1%)
HIV-positive TB cases	50 (2.0%)

\* National coverage 100% or culturing 90%, C+/All TB cases 50%, DST done for C+ 75%, EQA 95%  
\*\* More than 50% of TB cases tested for HIV.


## Treatment outcome monitoring, 2010

Geographical coverage	National
Outcome cohort	New pulmonary culture positive
Case-linked data reporting	Yes
Notified in 2010	2 500
Success	1 908 (76.3%)
Died	70 (2.8%)
Failed	289 (11.6%)
Defaulted	173 (6.9%)
Still on treatment	-
Lost to follow up	60 (2.4%)


## Tuberculosis notification rates by treatment history, 2002–2011




## New TB cases - notification rates by age group, 2002–2011




## Tuberculosis cases by geographical origin, 2002–2011




## TB-HIV co-infection, 2006–2011



## MDR-TB cases by previous treatment history, 2002–2011



## Treatment outcome, new pulmonary smear-positive cases, 2002–2010



# Germany

Total population at 1 January 2011 by EUROSTAT: 81751602

## Tuberculosis case notifications, 2011

Total number of cases	4 316
Notification rate per 100 000	5.3
New & relapses (laboratory-confirmed) number	3 577
New & relapses (laboratory-confirmed) notification rate per 100 000	4.4
Pulmonary	3 346 (77.5%)
of which smear-positive	1 133 (33.9%)
Laboratory-confirmed pulmonary TB cases	2 485 (74.3%)
Mean age of new TB cases, nationals	54.7 years
Mean age of new TB cases, non-nationals	43.0 years
Foreign origin of all TB cases	2 025 (46.9%)
New (not previously treated)	3 490 (80.9%)

## Drug resistance surveillance & TB-HIV co-infection, 2011

Completeness of DRS data*	Yes
Completeness of HIV data**	-
Case-linked data reporting	Yes
Cases with DST results	2 821 (91.9%)
Cases resistant to isoniazid	203 (7.2%)
Cases resistant to rifampicin	63 (2.2%)
Estimated MDR N, (best-low-high)	110-61-150
MDR cases	56 (2.0%)
of which XDR cases	0 (0.0%)
Cases resistant to ethambutol	45 (1.6%)
Cases resistant to streptomycin	203 (7.2%)
TB cases tested for HIV	-
HIV-positive TB cases	-


\* National coverage 100% or culturing 90%, C+/All TB cases 50%, DST done for C+ 75%, EQA 95%

\*\* More than 50% of TB cases tested for HIV.


## Treatment outcome monitoring, 2010

Geographical coverage	National
Outcome cohort	New laboratory-confirmed pulmonary TB cases
Case-linked data reporting	Yes
Notified in 2010	2 090
Success	1 600 (76.6%)
Died	256 (12.2%)
Failed	3 (0.1%)
Defaulted	33 (1.6%)
Still on treatment	54 (2.6%)
Lost to follow up	144 (6.9%)


## Tuberculosis notification rates by treatment history, 2002–2011



## New TB cases - notification rates by age group, 2002–2011




## Tuberculosis cases by geographical origin, 2002–2011




## TB-HIV co-infection, 2006–2011

Not available

## MDR-TB cases by previous treatment history, 2002–2011



## Treatment outcome, new pulmonary culture-positive cases, 2002–2010





# Greece

Total population at 1 January 2011 by EUROSTAT: 11309885

## Tuberculosis case notifications, 2011

Total number of cases	489
Notification rate per 100 000	4.3
New & relapses (lab+) number	452
New & relapses (lab+) notification rate per 100 000	4.0
Pulmonary	426 (87.1%)
of which smear-positive	254 (59.6%)
Laboratory-confirmed pulmonary TB cases	254 (59.6%)
Mean age of new TB cases, nationals	55.8 years
Mean age of new TB cases, non-nationals	30.9 years
Foreign origin of all TB cases	216 (44.2%)
New (not previously treated)	452 (92.4%)

## Drug resistance surveillance & TB-HIV co-infection, 2011

Completeness of DRS data*	No
Completeness of HIV data**	-
Case-linked data reporting	Yes
Cases with DST results	159 (57.2%)
Cases resistant to isoniazid	20 (12.6%)
Cases resistant to rifampicin	6 (3.8%)
Estimated MDR N, (best-low-high)	6-0-14
MDR cases	5 (3.1%)
of which XDR cases	2 -
Cases resistant to ethambutol	6 (3.8%)
Cases resistant to streptomycin	22 (13.8%)
TB cases tested for HIV	- -
HIV-positive TB cases	- -


\* National coverage 100% or culturing 90%, C+/All TB cases 50%, DST done for C+ 75%, EQA 95%

\*\* More than 50% of TB cases tested for HIV.


## Treatment outcome monitoring, 2010

Data not reported


## Tuberculosis notification rates by treatment history, 2002–2011



## New TB cases - notification rates by age group, 2002–2011




## Tuberculosis cases by geographical origin, 2002–2011



## TB-HIV co-infection, 2006–2011

Data not available

## MDR-TB cases by previous treatment history, 2002–2011



## Treatment outcome, new pulmonary culture-positive cases, 2002–2010

Not available

# Hungary

Total population at 1 January 2011 by EUROSTAT: 9985722

## Tuberculosis case notifications, 2011

Total number of cases	1445
Notification rate per 100 000	14.5
New & relapses (laboratory-confirmed) number	1278
New & relapses (laboratory-confirmed) notification rate per 100 000	12.8
Pulmonary	1389 (96.1%)
of which smear-positive	301 (21.7%)
Laboratory-confirmed pulmonary TB cases	590 (42.5%)
Mean age of new TB cases, nationals	53.7 years
Mean age of new TB cases, non-nationals	34.1 years
Foreign origin of all TB cases	27 (1.9%)
New (not previously treated)	1223 (84.6%)

## Drug resistance surveillance & TB-HIV co-infection, 2011

Completeness of DRS data*	No
Completeness of HIV data**	-
Case-linked data reporting	Yes
Cases with DST results	479 (80.2%)
Cases resistant to isoniazid	30 (6.3%)
Cases resistant to rifampicin	8 (1.7%)
Estimated MDR N, (best-low-high)	44-24-64
MDR cases	7 (1.5%)
of which XDR cases	0 (0.0%)
Cases resistant to ethambutol	3 (0.6%)
Cases resistant to streptomycin	20 (4.2%)
TB cases tested for HIV	1 0.1
HIV-positive TB cases	1 -


\* National coverage 100% or culturing 90%, C+/All TB cases 50%, DST done for C+ 75%, EQA 95%

\*\* More than 50% of TB cases tested for HIV.


## Treatment outcome monitoring, 2010

Geographical coverage	National
Outcome cohort	New laboratory-confirmed pulmonary TB cases
Case-linked data reporting	Yes
Notified in 2010	515
Success	355 (68.9%)
Died	64 (12.4%)
Failed	0 (0.0%)
Defaulted	51 (9.9%)
Still on treatment	27 (5.2%)
Lost to follow up	18 (3.5%)


## Tuberculosis notification rates by treatment history, 2002–2011



## New TB cases - notification rates by age group, 2002–2011




## Tuberculosis cases by geographical origin, 2002–2011




## TB-HIV co-infection, 2006–2011

Data not available

## MDR-TB cases by previous treatment history, 2002–2011



## Treatment outcome, new pulmonary culture-positive cases, 2002–2010



# Iceland

Total population at 1 January 2011 by EUROSTAT: 318452

## Tuberculosis case notifications, 2011

Total number of cases	9
Notification rate per 100 000	2.8
New & relapses (lab+) number	8
New & relapses (lab+) notification rate per 100 000	2.5
Pulmonary	3 (33.3%)
of which smear-positive	1 (33.3%)
Laboratory-confirmed pulmonary TB cases	0 (0.0%)
Mean age of new TB cases, nationals	43.0 years
Mean age of new TB cases, non-nationals	32.5 years
Foreign origin of all TB cases	7 (77.8%)
New (not previously treated)	8 (88.9%)

## Drug resistance surveillance & TB-HIV co-infection, 2011

Completeness of DRS data*	No
Completeness of HIV data**	Yes
Case-linked data reporting	Yes
Cases with DST results	4 (100.0%)
Cases resistant to isoniazid	0 (0.0%)
Cases resistant to rifampicin	0 (0.0%)
Estimated MDR N, (best-low-high)	0-0-0
MDR cases	0 (0.0%)
of which XDR cases	0 -
Cases resistant to ethambutol	0 (0.0%)
Cases resistant to streptomycin	0 (0.0%)
TB cases tested for HIV	8 (88.9%)
HIV-positive TB cases	0 (0.0%)


\* National coverage 100% or culturing 90%, C+/All TB cases 50%, DST done for C+ 75%, EQA 95%

\*\* More than 50% of TB cases tested for HIV.


## Treatment outcome monitoring, 2010

Geographical coverage	National
Outcome cohort	New pulmonary culture positive
Case-linked data reporting	Yes
Notified in 2010	16
Success	14 (87.5%)
Died	1 (6.3%)
Failed	0 (0.0%)
Defaulted	0 (0.0%)
Still on treatment	0 (0.0%)
Lost to follow up	1 (6.3%)


## Tuberculosis notification rates by treatment history, 2002–2011




## New TB cases - notification rates by age group, 2002–2011



## Tuberculosis cases by geographical origin, 2002–2011




## TB-HIV co-infection, 2006–2011



## MDR-TB cases by previous treatment history, 2002–2011

Insufficient data for graphic presentation

## Treatment outcome, new pulmonary culture-positive cases, 2002–2010



# Ireland

Total population at 1 January 2011 by EUROSTAT: 4 480 858

## Tuberculosis case notifications, 2011

Total number of cases	425
Notification rate per 100 000	9.5
New & relapses (lab+) number	280
New & relapses (lab+) notification rate per 100 000	6.2
Pulmonary of which smear-positive	293 (68.9%) 120 (41.0%)
Laboratory-confirmed pulmonary TB cases	221 (75.4%)
Mean age of new TB cases, nationals	45.4 years
Mean age of new TB cases, non-nationals	34.1 years
Foreign origin of all TB cases	179 (42.1%)
New (not previously treated)	280 (65.9%)

## Drug resistance surveillance & TB-HIV co-infection, 2011


Completeness of DRS data*	Yes
Completeness of HIV data**	No
Case-linked data reporting	Yes
Cases with DST results	239 (83.0%)
Cases resistant to isoniazid	15 (6.3%)
Cases resistant to rifampicin	3 (1.3%)
Estimated MDR N, (best-low-high)	3-0-7
MDR cases of which XDR cases	3 (1.3%) 0 (0.0%)
Cases resistant to ethambutol	4 (1.7%)
Cases resistant to streptomycin	12 (5.0%)
TB cases tested for HIV	94 (22.1%)
HIV-positive TB cases	19 (20.2%)

\* National coverage 100% or culturing 90%, C+/All TB cases 50%, DST done for C+ 75%, EQA 95%  
\*\* More than 50% of TB cases tested for HIV.


## Treatment outcome monitoring, 2010

Geographical coverage	National
Outcome cohort	New pulmonary culture positive
Case-linked data reporting	Yes
Notified in 2010	164
Success	119 (72.6%)
Died	12 (7.3%)
Failed	0 (0.0%)
Defaulted	2 (1.2%)
Still on treatment	2 (1.2%)
Lost to follow up	29 (17.7%)


## Tuberculosis notification rates by treatment history, 2002–2011




## New TB cases - notification rates by age group, 2002–2011




## Tuberculosis cases by geographical origin, 2002–2011




## TB-HIV co-infection, 2006–2011



## MDR-TB cases by previous treatment history, 2002–2011



## Treatment outcome, new pulmonary culture-positive cases, 2002–2010



# Israel

Population estimate 2011 by UN Statistical Database: 7562194

## Tuberculosis case notifications, 2011

Total number of cases	418
Notification rate per 100 000	5.5
New & relapses (lab+) number	412
New & relapses (lab+) notification rate per 100 000	5.4
Pulmonary of which smear-positive	351 (84.0%) 139 (39.6%)
Laboratory-confirmed pulmonary TB cases	249 (70.9%)
Mean age of new TB cases, nationals	31.6 years
Mean age of new TB cases, non-nationals	37.3 years
Foreign origin of all TB cases	374 (89.5%)
New (not previously treated)	408 (97.6%)

## Drug resistance surveillance & TB-HIV co-infection, 2011


Completeness of DRS data*	Yes
Completeness of HIV data**	Yes
Case-linked data reporting	Yes
Cases with DST results	284 (100.0%)
Cases resistant to isoniazid	27 (9.5%)
Cases resistant to rifampicin	12 (4.2%)
Estimated MDR N, (best-low-high)	14-6-22
MDR cases of which XDR cases	11 (3.9%) 0 (0.0%)
Cases resistant to ethambutol	-
Cases resistant to streptomycin	-
TB cases tested for HIV	384 (91.9%)
HIV-positive TB cases	24 (6.3%)

\* National coverage 100% or culturing 90%, C+/All TB cases 50%, DST done for C+ 75%, EQA 95%  
\*\* More than 50% of TB cases tested for HIV.


## Treatment outcome monitoring, 2010

Geographical coverage	National
Outcome cohort	New pulmonary culture positive
Case-linked data reporting	Yes
Notified in 2010	99
Success	75 (75.8%)
Died	11 (11.1%)
Failed	0 (0.0%)
Defaulted	0 (0.0%)
Still on treatment	-
Lost to follow up	13 (13.1%)


## Tuberculosis notification rates by treatment history, 2002–2011




## New TB cases - notification rates by age group, 2002–2011




## Tuberculosis cases by geographical origin, 2002–2011



## TB-HIV co-infection, 2006–2011



## MDR-TB cases by previous treatment history, 2002–2011



## Treatment outcome, new pulmonary culture-positive cases, 2002–2010



# Italy

Total population at 1 January 2011 by EUROSTAT: 60 626 442

## Tuberculosis case notifications, 2011

Total number of cases	3521
Notification rate per 100 000	5.8
New & relapses (lab+) number	2018
New & relapses (lab+) notification rate per 100 000	3.3
Pulmonary of which smear-positive	2582 (73.3%) 1040 (40.3%)
Laboratory-confirmed pulmonary TB cases	969 (37.5%)
Mean age of new TB cases, nationals	54.8 years
Mean age of new TB cases, non-nationals	34.7 years
Foreign origin of all TB cases	1677 (47.6%)
New (not previously treated)	2018 (57.3%)

## Drug resistance surveillance & TB-HIV co-infection, 2011

Completeness of DRS data*	No
Completeness of HIV data**	-
Case-linked data reporting	No
Cases with DST results	2542 (98.7%)
Cases resistant to isoniazid	244 (9.6%)
Cases resistant to rifampicin	99 (3.9%)
Estimated MDR N, (best-low-high)	57-42-72
MDR cases of which XDR cases	81 (3.2%) 6 (7.4%)
Cases resistant to ethambutol	72 (2.8%)
Cases resistant to streptomycin	238 (9.4%)
TB cases tested for HIV	-
HIV-positive TB cases	-


\* National coverage 100% or culturing 90%, C+/All TB cases 50%, DST done for C+ 75%, EQA 95%

\*\* More than 50% of TB cases tested for HIV.


## Treatment outcome monitoring, 2010

Data not reported


## Tuberculosis notification rates by treatment history, 2002–2011



## New TB cases - notification rates by age group, 2002–2011




## Tuberculosis cases by geographical origin, 2002–2011



## TB-HIV co-infection, 2006–2011

Not available

## MDR-TB cases by previous treatment history, 2002–2011



## Treatment outcome, new pulmonary culture-positive cases, 2002–2010

Not available

# Kazakhstan

Population estimate 2011 by UN Statistical Database: 16 206 750

## Tuberculosis case notifications, 2011

Total number of cases	23 076
Notification rate per 100 000	142.4
New & relapses (lab+) number	18 254
New & relapses (lab+) notification rate per 100 000	112.6
Pulmonary	20 806 (90.2%)
of which smear-positive	10 398 (50.0%)
Laboratory-confirmed pulmonary TB cases	13 905 (66.8%)
Mean age of new TB cases, nationals	33.8 years
Mean age of new TB cases, non-nationals	-
Foreign origin of all TB cases	0 (0.0%)
New (not previously treated)	14 396 (62.4%)

## Drug resistance surveillance & TB-HIV co-infection, 2011

Completeness of DRS data*	No
Completeness of HIV data**	Yes
Case-linked data reporting	Yes
Cases with DST results	11 555 (100.0%)
Cases resistant to isoniazid	4 827 (41.8%)
Cases resistant to rifampicin	4 634 (40.1%)
Estimated MDR N, (best-low-high)	8 200-8 000-8 400
MDR cases	4 575 (39.6%)
of which XDR cases	187 (4.1%)
Cases resistant to ethambutol	-
Cases resistant to streptomycin	-
TB cases tested for HIV	22 480 (97.4%)
HIV-positive TB cases	352 (1.6%)


\* National coverage 100% or culturing 90%, C+/All TB cases 50%, DST done for C+ 75%, EQA 95%

\*\* More than 50% of TB cases tested for HIV.


## Treatment outcome monitoring, 2010

Geographical coverage	National
Outcome cohort	New pulmonary culture positive
Case-linked data reporting	Yes
Notified in 2010	4 919
Success	2 995 (60.9%)
Died	158 (3.2%)
Failed	329 (6.7%)
Defaulted	116 (2.4%)
Still on treatment	-
Lost to follow up	1 321 (26.9%)


## Tuberculosis notification rates by treatment history, 2002–2011




## New TB cases - notification rates by age group, 2002–2011




## Tuberculosis cases by geographical origin, 2002–2011




## TB-HIV co-infection, 2006–2011



## MDR-TB cases by previous treatment history, 2002–2011



## Treatment outcome, new pulmonary smear-positive cases, 2002–2010



# Kyrgyzstan

Population estimate 2011 by UN Statistical Database: 5392580

## Tuberculosis case notifications, 2011

Total number of cases	6 254
Notification rate per 100 000	116.0
New & relapses (lab+) number	5 529
New & relapses (lab+) notification rate per 100 000	102.5
Pulmonary of which smear-positive	4 835 (77.3%) 1 997 (41.3%)
Laboratory-confirmed pulmonary TB cases	1 997 (41.3%)
Mean age of new TB cases, nationals	36.6 years
Mean age of new TB cases, non-nationals	-
Foreign origin of all TB cases	0 (0.0%)
New (not previously treated)	5 180 (82.8%)

## Drug resistance surveillance & TB-HIV co-infection, 2011

Completeness of DRS data*	No
Completeness of HIV data**	No
Case-linked data reporting	No
Cases with DST results	- -
Cases resistant to isoniazid	919 -
Cases resistant to rifampicin	849 -
Estimated MDR N, (best-low-high)	1500-1400-1700
MDR cases of which XDR cases	806 - 0 (0.0%)
Cases resistant to ethambutol	- -
Cases resistant to streptomycin	- -
TB cases tested for HIV	153 (2.4%)
HIV-positive TB cases	- -


\* National coverage 100% or culturing 90%, C+/All TB cases 50%, DST done for C+ 75%, EQA 95%

\*\* More than 50% of TB cases tested for HIV.


## Treatment outcome monitoring, 2010

Data not reported


## Tuberculosis notification rates by treatment history, 2002–2011



## New TB cases - notification rates by age group, 2002–2011




## Tuberculosis cases by geographical origin, 2002–2011




## TB-HIV co-infection, 2006–2011

Data not reported

## MDR-TB cases by previous treatment history, 2002–2011



## Treatment outcome, new pulmonary culture-positive cases, 2002–2010





# Latvia

Total population at 1 January 2011 by EUROSTAT: 2229641

## Tuberculosis case notifications, 2011

Total number of cases	885
Notification rate per 100 000	39.7
New & relapses (lab+) number	866
New & relapses (lab+) notification rate per 100 000	38.8
Pulmonary of which smear-positive	796 (89.9%) 345 (43.3%)
Laboratory-confirmed pulmonary TB cases	649 (81.5%)
Mean age of new TB cases, nationals	39.3 years
Mean age of new TB cases, non-nationals	51.8 years
Foreign origin of all TB cases	59 (6.7%)
New (not previously treated)	788 (89.0%)

## Drug resistance surveillance & TB-HIV co-infection, 2011


Completeness of DRS data*	Yes
Completeness of HIV data**	Yes
Case-linked data reporting	Yes
Cases with DST results	644 (96.0%)
Cases resistant to isoniazid	203 (31.5%)
Cases resistant to rifampicin	96 (14.9%)
Estimated MDR N, (best-low-high)	120-96-140
MDR cases of which XDR cases	95 (14.8%) 12 (12.6%)
Cases resistant to ethambutol	78 (12.1%)
Cases resistant to streptomycin	191 (29.7%)
TB cases tested for HIV	752 (85.0%)
HIV-positive TB cases	71 (9.4%)

\* National coverage 100% or culturing 90%, C+/All TB cases 50%, DST done for C+ 75%, EQA 95%  
\*\* More than 50% of TB cases tested for HIV.


## Treatment outcome monitoring, 2010

Geographical coverage	National
Outcome cohort	New pulmonary culture positive
Case-linked data reporting	Yes
Notified in 2010	596
Success	451 (75.7%)
Died	47 (7.9%)
Failed	3 (0.5%)
Defaulted	37 (6.2%)
Still on treatment	58 (9.7%)
Lost to follow up	0 (0.0%)


## Tuberculosis notification rates by treatment history, 2002–2011




## New TB cases - notification rates by age group, 2002–2011




## Tuberculosis cases by geographical origin, 2002–2011




## TB-HIV co-infection, 2006–2011



## MDR-TB cases by previous treatment history, 2002–2011



## Treatment outcome, new pulmonary culture-positive cases, 2002–2010



# Lithuania

Total population at 1 January 2011 by EUROSTAT: 3244 601

## Tuberculosis case notifications, 2011

Total number of cases	1904
Notification rate per 100 000	58.7
New & relapses (lab+) number	1748
New & relapses (lab+) notification rate per 100 000	53.9
Pulmonary	1714 (90.0%)
of which smear-positive	971 (56.7%)
Laboratory-confirmed pulmonary TB cases	1369 (79.9%)
Mean age of new TB cases, nationals	45.3 years
Mean age of new TB cases, non-nationals	52.1 years
Foreign origin of all TB cases	44 (2.3%)
New (not previously treated)	1532 (80.5%)

## Drug resistance surveillance & TB-HIV co-infection, 2011

Completeness of DRS data*	Yes
Completeness of HIV data**	No
Case-linked data reporting	Yes
Cases with DST results	1403 (100.0%)
Cases resistant to isoniazid	446 (31.8%)
Cases resistant to rifampicin	306 (21.8%)
Estimated MDR N, (best-low-high)	360-320-390
MDR cases	296 (21.1%)
of which XDR cases	53 (17.9%)
Cases resistant to ethambutol	224 (16.0%)
Cases resistant to streptomycin	438 (31.2%)
TB cases tested for HIV	1352 (71.0%)
HIV-positive TB cases	22 (1.6%)


\* National coverage 100% or culturing 90%, C+/All TB cases 50%, DST done for C+ 75%, EQA 95%

\*\* More than 50% of TB cases tested for HIV.


## Treatment outcome monitoring, 2010

Geographical coverage	National
Outcome cohort	New pulmonary culture positive
Case-linked data reporting	Yes
Notified in 2010	959
Success	656 (68.4%)
Died	107 (11.2%)
Failed	13 (1.4%)
Defaulted	104 (10.8%)
Still on treatment	75 (7.8%)
Lost to follow up	4 (0.4%)


## Tuberculosis notification rates by treatment history, 2002–2011




## New TB cases - notification rates by age group, 2002–2011




## Tuberculosis cases by geographical origin, 2002–2011




## TB-HIV co-infection, 2006–2011



## MDR-TB cases by previous treatment history, 2002–2011



## Treatment outcome, new pulmonary culture-positive cases, 2002–2010



# Luxembourg

Total population at 1 January 2011 by EUROSTAT: 511840

## Tuberculosis case notifications, 2011

Total number of cases	26
Notification rate per 100 000	5.1
New & relapses (lab+) number	11
New & relapses (lab+) notification rate per 100 000	2.1
Pulmonary	22 (84.6%)
of which smear-positive	9 (40.9%)
Laboratory-confirmed pulmonary TB cases	17 (77.3%)
Mean age of new TB cases, nationals	41.7 years
Mean age of new TB cases, non-nationals	34.8 years
Foreign origin of all TB cases	21 (80.8%)
New (not previously treated)	11 (42.3%)

## Drug resistance surveillance & TB-HIV co-infection, 2011

Completeness of DRS data*	Yes
Completeness of HIV data**	No
Case-linked data reporting	Yes
Cases with DST results	19 (100.0%)
Cases resistant to isoniazid	3 (15.8%)
Cases resistant to rifampicin	2 (10.5%)
Estimated MDR N, (best-low-high)	0-0-0
MDR cases	2 (10.5%)
of which XDR cases	0 (0.0%)
Cases resistant to ethambutol	1 (5.3%)
Cases resistant to streptomycin	4 (21.1%)
TB cases tested for HIV	5 (19.2%)
HIV-positive TB cases	2 (40.0%)


\* National coverage 100% or culturing 90%, C+/All TB cases 50%, DST done for C+ 75%, EQA 95%

\*\* More than 50% of TB cases tested for HIV.


## Treatment outcome monitoring, 2010

Geographical coverage	National
Outcome cohort	New pulmonary culture positive
Case-linked data reporting	Yes
Notified in 2010	14
Success	0 (0.0%)
Died	1 (7.1%)
Failed	0 (0.0%)
Defaulted	0 (0.0%)
Still on treatment	0 (0.0%)
Lost to follow up	13 (92.9%)

## Tuberculosis notification rates by treatment history, 2002–2011




## New TB cases - notification rates by age group, 2002–2011\*




\* No previous treatment history reported for 2007–2009

## Tuberculosis cases by geographical origin, 2002–2011



## TB-HIV co-infection, 2006–2011\*



\* No data available for 2006–2009

## MDR-TB cases by previous treatment history, 2002–2011

Insufficient data for graphic presentation

## Treatment outcome, new pulmonary culture-positive cases, 2002–2010

Not available

# The former Yugoslav Republic of Macedonia

Population estimate 2011 by UN Statistical Database: 2063893

## Tuberculosis case notifications, 2011

Total number of cases	362
Notification rate per 100 000	17.5
New & relapses (lab+) number	335
New & relapses (lab+) notification rate per 100 000	16.2
Pulmonary of which smear-positive	271 (74.9%) 160 (59.0%)
Laboratory-confirmed pulmonary TB cases	209 (77.1%)
Mean age of new TB cases, nationals	41.0 years
Mean age of new TB cases, non-nationals	-
Foreign origin of all TB cases	15 (4.1%)
New (not previously treated)	307 (84.8%)

## Drug resistance surveillance & TB-HIV co-infection, 2011

Completeness of DRS data*	No
Completeness of HIV data**	No
Case-linked data reporting	Yes
Cases with DST results	155 (100.0%)
Cases resistant to isoniazid	7 (4.5%)
Cases resistant to rifampicin	7 (4.5%)
Estimated MDR N, (best-low-high)	2-0-6
MDR cases	1 (0.6%)
of which XDR cases	0 (0.0%)
Cases resistant to ethambutol	-
Cases resistant to streptomycin	-
TB cases tested for HIV	45 (12.4%)
HIV-positive TB cases	0 (0.0%)


\* National coverage 100% or culturing 90%, C+/All TB cases 50%, DST done for C+ 75%, EQA 95%

\*\* More than 50% of TB cases tested for HIV.


## Treatment outcome monitoring, 2010

Geographical coverage	National
Outcome cohort	New pulmonary culture positive
Case-linked data reporting	Yes
Notified in 2010	143
Success	128 (89.5%)
Died	6 (4.2%)
Failed	4 (2.8%)
Defaulted	3 (2.1%)
Still on treatment	0 (0.0%)
Lost to follow up	2 (1.4%)


## Tuberculosis notification rates by treatment history, 2002–2011




## New TB cases - notification rates by age group, 2002–2011




## Tuberculosis cases by geographical origin, 2002–2011




## TB-HIV co-infection, 2006–2011



## MDR-TB cases by previous treatment history, 2002–2011



## Treatment outcome, new pulmonary smear-positive cases, 2002–2010



# Malta

Total population at 1 January 2011 by EUROSTAT: 417 617

## Tuberculosis case notifications, 2011

Total number of cases	33
Notification rate per 100 000	7.9
New & relapses (lab+) number	22
New & relapses (lab+) notification rate per 100 000	5.3
Pulmonary	22 (66.7%)
of which smear-positive	9 (40.9%)
Laboratory-confirmed pulmonary TB cases	15 (68.2%)
Mean age of new TB cases, nationals	77.3 years
Mean age of new TB cases, non-nationals	31.5 years
Foreign origin of all TB cases	28 (84.8%)
New (not previously treated)	22 (66.7%)

## Drug resistance surveillance & TB-HIV co-infection, 2011


Completeness of DRS data*	Yes
Completeness of HIV data**	Yes
Case-linked data reporting	Yes
Cases with DST results	22 (91.7%)
Cases resistant to isoniazid	1 (4.5%)
Cases resistant to rifampicin	0 (0.0%)
Estimated MDR N, (best-low-high)	-
MDR cases	0 (0.0%)
of which XDR cases	-
Cases resistant to ethambutol	0 (0.0%)
Cases resistant to streptomycin	3 (13.6%)
TB cases tested for HIV	30 (90.9%)
HIV-positive TB cases	5 (16.7%)

\* National coverage 100% or culturing 90%, C+/All TB cases 50%, DST done for C+ 75%, EQA 95%  
 \*\* More than 50% of TB cases tested for HIV.


## Treatment outcome monitoring, 2010

Geographical coverage	National
Outcome cohort	New pulmonary culture positive
Case-linked data reporting	Yes
Notified in 2010	5
Success	4 (80.0%)
Died	0 (0.0%)
Failed	0 (0.0%)
Defaulted	0 (0.0%)
Still on treatment	0 (0.0%)
Lost to follow up	1 (20.0%)


## Tuberculosis notification rates by treatment history, 2002–2011



## New TB cases - notification rates by age group, 2002–2011




## Tuberculosis cases by geographical origin, 2002–2011



\* By nationality for 2000–2006


## TB-HIV co-infection, 2006–2011



## MDR-TB cases by previous treatment history, 2002–2011

Insufficient data for graphic presentation

## Treatment outcome, new pulmonary culture-positive cases, 2002–2010



# Moldova

Population estimate 2011 by UN Statistical Database: 3544 864

## Tuberculosis case notifications, 2011

Total number of cases	5341
Notification rate per 100 000	150.7
New & relapses (lab+) number	4 208
New & relapses (lab+) notification rate per 100 000	118.7
Pulmonary of which smear-positive	4 851 (90.8%) 2 086 (43.0%)
Laboratory-confirmed pulmonary TB cases	2 844 (58.6%)
Mean age of new TB cases, nationals	39.1 years
Mean age of new TB cases, non-nationals	-
Foreign origin of all TB cases	0 (0.0%)
New (not previously treated)	3 836 (71.8%)

## Drug resistance surveillance & TB-HIV co-infection, 2011

Completeness of DRS data*	No
Completeness of HIV data**	Yes
Case-linked data reporting	Yes
Cases with DST results	2385 (93.1%)
Cases resistant to isoniazid	1214 (50.9%)
Cases resistant to rifampicin	1026 (43.0%)
Estimated MDR N, (best-low-high)	1600-1500-1700
MDR cases of which XDR cases	1001 (42.0%) 0 (0.0%)
Cases resistant to ethambutol	-
Cases resistant to streptomycin	-
TB cases tested for HIV	5017 (93.9%)
HIV-positive TB cases	285 (5.7%)


\* National coverage 100% or culturing 90%, C+/All TB cases 50%, DST done for C+ 75%, EQA 95%

\*\* More than 50% of TB cases tested for HIV.


## Treatment outcome monitoring, 2010

Geographical coverage	National
Outcome cohort	New pulmonary culture positive
Case-linked data reporting	Yes
Notified in 2010	1267
Success	724 (57.1%)
Died	145 (11.4%)
Failed	67 (5.3%)
Defaulted	166 (13.1%)
Still on treatment	-
Lost to follow up	165 (13.0%)


## Tuberculosis notification rates by treatment history, 2002–2011




## New TB cases - notification rates by age group, 2002–2011




## Tuberculosis cases by geographical origin, 2002–2011




## TB-HIV co-infection, 2006–2011



## MDR-TB cases by previous treatment history, 2002–2011



## Treatment outcome, new pulmonary smear-positive cases, 2002–2010



# Montenegro

Population estimate 2011 by UN Statistical Database: 632 261

## Tuberculosis case notifications, 2011

Total number of cases	112
Notification rate per 100 000	17.7
New & relapses (lab+) number	110
New & relapses (lab+) notification rate per 100 000	17.4
Pulmonary	107 (95.5%)
of which smear-positive	60 (56.1%)
Laboratory-confirmed pulmonary TB cases	69 (64.5%)
Mean age of new TB cases, nationals	43.9 years
Mean age of new TB cases, non-nationals	-
Foreign origin of all TB cases	0 (0.0%)
New (not previously treated)	100 (89.3%)

## Drug resistance surveillance & TB-HIV co-infection, 2011

Completeness of DRS data*	Yes
Completeness of HIV data**	Yes
Case-linked data reporting	Yes
Cases with DST results	72 (100.0%)
Cases resistant to isoniazid	2 (2.8%)
Cases resistant to rifampicin	2 (2.8%)
Estimated MDR N, (best-low-high)	2-0-5
MDR cases	1 (1.4%)
of which XDR cases	-
Cases resistant to ethambutol	-
Cases resistant to streptomycin	-
TB cases tested for HIV	92 (82.1%)
HIV-positive TB cases	0 (0.0%)


\* National coverage 100% or culturing 90%, C+/All TB cases 50%, DST done for C+ 75%, EQA 95%

\*\* More than 50% of TB cases tested for HIV.

## Treatment outcome monitoring, 2010


Geographical coverage	National
Outcome cohort	New pulmonary culture positive
Case-linked data reporting	Yes
Notified in 2010	39
Success	34 (87.2%)
Died	2 (5.1%)
Failed	0 (0.0%)
Defaulted	1 (2.6%)
Still on treatment	-
Lost to follow up	2 (5.1%)

## Tuberculosis notification rates by treatment history, 2002–2011\*




\* Established in 2006 following the split of Serbia and Montenegro; data starting from 2005.

## New TB cases - notification rates by age group, 2002–2011\*




\* Established in 2006 following the split of Serbia and Montenegro; data starting from 2005.

## Tuberculosis cases by geographical origin, 2002–2011\*




\* Established in 2006 following the split of Serbia and Montenegro; data starting from 2005.

## TB-HIV co-infection, 2006–2011\*




\* Established in 2006 following the split of Serbia and Montenegro; data starting from 2005.

## MDR-TB cases by previous treatment history, 2002–2011



## Treatment outcome, new pulmonary smear and/or culture-positive cases, 2002–2010\*



\* Established in 2006 following the split of Serbia and Montenegro; data starting from 2005.

# Netherlands

Total population at 1 January 2011 by EUROSTAT: 16 655 799

## Tuberculosis case notifications, 2011

Total number of cases	1007
Notification rate per 100 000	6.0
New & relapses (lab+) number	974
New & relapses (lab+) notification rate per 100 000	5.8
Pulmonary of which smear-positive	563 (55.9%) 190 (33.7%)
Laboratory-confirmed pulmonary TB cases	464 (82.4%)
Mean age of new TB cases, nationals	45.1 years
Mean age of new TB cases, non-nationals	38.3 years
Foreign origin of all TB cases	710 (70.5%)
New (not previously treated)	958 (95.1%)

## Drug resistance surveillance & TB-HIV co-infection, 2011


Completeness of DRS data*	Yes
Completeness of HIV data**	No
Case-linked data reporting	Yes
Cases with DST results	726 (99.2%)
Cases resistant to isoniazid	62 (8.5%)
Cases resistant to rifampicin	16 (2.2%)
Estimated MDR N, (best-low-high)	11-5-17
MDR cases of which XDR cases	15 (2.1%) 0 (0.0%)
Cases resistant to ethambutol	8 (1.1%)
Cases resistant to streptomycin	47 (6.5%)
TB cases tested for HIV	460 (45.7%)
HIV-positive TB cases	31 (6.7%)

\* National coverage 100% or culturing 90%, C+/All TB cases 50%, DST done for C+ 75%, EQA 95%  
\*\* More than 50% of TB cases tested for HIV.


## Treatment outcome monitoring, 2010

Geographical coverage	National
Outcome cohort	New pulmonary culture positive
Case-linked data reporting	Yes
Notified in 2010	470
Success	365 (77.7%)
Died	31 (6.6%)
Failed	0 (0.0%)
Defaulted	19 (4.0%)
Still on treatment	18 (3.8%)
Lost to follow up	37 (7.9%)


## Tuberculosis notification rates by treatment history, 2002–2011




## New TB cases - notification rates by age group, 2002–2011




## Tuberculosis cases by geographical origin, 2002–2011




## TB-HIV co-infection, 2006–2011



## MDR-TB cases by previous treatment history, 2002–2011



## Treatment outcome, new pulmonary culture-positive cases, 2002–2010





# Norway

Total population at 1 January 2011 by EUROSTAT: 4 920 305

## Tuberculosis case notifications, 2011

Total number of cases	361
Notification rate per 100 000	7.3
New & relapses (lab+) number	314
New & relapses (lab+) notification rate per 100 000	6.4
Pulmonary of which smear-positive	200 (55.4%) 47 (23.5%)
Laboratory-confirmed pulmonary TB cases	158 (79.0%)
Mean age of new TB cases, nationals	48.7 years
Mean age of new TB cases, non-nationals	31.1 years
Foreign origin of all TB cases	317 (87.8%)
New (not previously treated)	314 (87.0%)

## Drug resistance surveillance & TB-HIV co-infection, 2011

Completeness of DRS data*	Yes
Completeness of HIV data**	-
Case-linked data reporting	Yes
Cases with DST results	257 (98.1%)
Cases resistant to isoniazid	20 (7.8%)
Cases resistant to rifampicin	4 (1.6%)
Estimated MDR N, (best-low-high) 9-2-15	
MDR cases of which XDR cases	4 (1.6%) 0 (0.0%)
Cases resistant to ethambutol	3 (1.2%)
Cases resistant to streptomycin	17 (6.6%)
TB cases tested for HIV	-
HIV-positive TB cases	-


\* National coverage 100% or culturing 90%, C+/All TB cases 50%, DST done for C+ 75%, EQA 95%

\*\* More than 50% of TB cases tested for HIV.


## Treatment outcome monitoring, 2010

Geographical coverage	National
Outcome cohort	New pulmonary culture positive
Case-linked data reporting	Yes
Notified in 2010	139
Success	127 (91.4%)
Died	4 (2.9%)
Failed	1 (0.7%)
Defaulted	0 (0.0%)
Still on treatment	5 (3.6%)
Lost to follow up	2 (1.4%)


## Tuberculosis notification rates by treatment history, 2002–2011



## New TB cases - notification rates by age group, 2002–2011




## Tuberculosis cases by geographical origin, 2002–2011




## TB-HIV co-infection, 2006–2011

Data not available

## MDR-TB cases by previous treatment history, 2002–2011



## Treatment outcome, new pulmonary culture-positive cases, 2002–2010



# Poland

Total population at 1 January 2011 by EUROSTAT: 38 200 037

## Tuberculosis case notifications, 2011

Total number of cases	8 478
Notification rate per 100 000	22.2
New & relapses (lab+) number	7 950
New & relapses (lab+) notification rate per 100 000	20.8
Pulmonary of which smear-positive	7 879 (92.9%) 2 989 (37.9%)
Laboratory-confirmed pulmonary TB cases	5 327 (67.6%)
Mean age of new TB cases, nationals	53.3 years
Mean age of new TB cases, non-nationals	35.9 years
Foreign origin of all TB cases	38 (0.4%)
New (not previously treated)	7 515 (88.6%)

## Drug resistance surveillance & TB-HIV co-infection, 2011

Completeness of DRS data*	Yes
Completeness of HIV data**	-
Case-linked data reporting	Yes
Cases with DST results	4 993 (89.5%)
Cases resistant to isoniazid	185 (3.7%)
Cases resistant to rifampicin	49 (1.0%)
Estimated MDR N, (best-low-high)	68-46-89
MDR cases of which XDR cases	41 (0.8%) 1 (2.4%)
Cases resistant to ethambutol	19 (0.4%)
Cases resistant to streptomycin	156 (3.1%)
TB cases tested for HIV	26 (0.3%)
HIV-positive TB cases	26 -


\* National coverage 100% or culturing 90%, C+/All TB cases 50%, DST done for C+ 75%, EQA 95%

\*\* More than 50% of TB cases tested for HIV.


## Treatment outcome monitoring, 2010

Geographical coverage	National
Outcome cohort	New pulmonary culture positive
Case-linked data reporting	Yes
Notified in 2010	3 998
Success	2 631 (65.8%)
Died	242 (6.1%)
Failed	10 (0.3%)
Defaulted	354 (8.9%)
Still on treatment	15 (0.4%)
Lost to follow up	746 (18.7%)


## Tuberculosis notification rates by treatment history, 2002–2011



## New TB cases - notification rates by age group, 2002–2011




## Tuberculosis cases by geographical origin, 2002–2011



## TB-HIV co-infection, 2006–2011

Data not available

## MDR-TB cases by previous treatment history, 2002–2011



## Treatment outcome, new pulmonary culture-positive cases, 2002–2010



# Portugal

Total population at 1 January 2011 by EUROSTAT: 10 636 979

## Tuberculosis case notifications, 2011

Total number of cases	2540
Notification rate per 100 000	23.9
New & relapses (lab+) number	2413
New & relapses (lab+) notification rate per 100 000	22.7
Pulmonary of which smear-positive	1857 (73.1%) 966 (52.0%)
Laboratory-confirmed pulmonary TB cases	1385 (74.6%)
Mean age of new TB cases, nationals	48.3 years
Mean age of new TB cases, non-nationals	38.5 years
Foreign origin of all TB cases	385 (15.2%)
New (not previously treated)	2325 (91.5%)

## Drug resistance surveillance & TB-HIV co-infection, 2011

Completeness of DRS data*	Yes
Completeness of HIV data**	-
Case-linked data reporting	Yes
Cases with DST results	1252 (78.8%)
Cases resistant to isoniazid	98 (7.8%)
Cases resistant to rifampicin	24 (1.9%)
Estimated MDR N, (best-low-high)	32-17-47
MDR cases of which XDR cases	22 (1.8%) 0 (0.0%)
Cases resistant to ethambutol	20 (1.6%)
Cases resistant to streptomycin	146 (11.7%)
TB cases tested for HIV	-
HIV-positive TB cases	-


\* National coverage 100% or culturing 90%, C+/All TB cases 50%, DST done for C+ 75%, EQA 95%

\*\* More than 50% of TB cases tested for HIV.


## Treatment outcome monitoring, 2010

Data not reported


## Tuberculosis notification rates by treatment history, 2002–2011




## New TB cases - notification rates by age group, 2002–2011




## Tuberculosis cases by geographical origin, 2002–2011




## TB-HIV co-infection, 2006–2011



## MDR-TB cases by previous treatment history, 2002–2011



## Treatment outcome, new pulmonary culture-positive cases, 2002–2010



# Romania

Total population at 1 January 2011 by EUROSTAT: 21 413 815

## Tuberculosis case notifications, 2011

Total number of cases	19 212
Notification rate per 100 000	89.7
New & relapses (lab+) number	16 992
New & relapses (lab+) notification rate per 100 000	79.4
Pulmonary of which smear-positive	16 431 (85.5%) 10 852 (66.0%)
Laboratory-confirmed pulmonary TB cases	12 446 (75.7%)
Mean age of new TB cases, nationals	42.0 years
Mean age of new TB cases, non-nationals	37.4 years
Foreign origin of all TB cases	50 (0.3%)
New (not previously treated)	14 543 (75.7%)

## Drug resistance surveillance & TB-HIV co-infection, 2011


Completeness of DRS data*	No
Completeness of HIV data**	No
Case-linked data reporting	Yes
Cases with DST results	6 026 (48.4%)
Cases resistant to isoniazid	867 (14.4%)
Cases resistant to rifampicin	597 (9.9%)
Estimated MDR N, (best-low-high)	850-650-1000
MDR cases of which XDR cases	530 (8.8%) 30 (5.7%)
Cases resistant to ethambutol	218 (3.6%)
Cases resistant to streptomycin	300 (5.0%)
TB cases tested for HIV	9 383 (48.8%)
HIV-positive TB cases	243 (2.6%)

\* National coverage 100% or culturing 90%, C+/All TB cases 50%, DST done for C+ 75%, EQA 95%  
\*\* More than 50% of TB cases tested for HIV.


## Treatment outcome monitoring, 2010

Geographical coverage	National
Outcome cohort	New pulmonary culture positive
Case-linked data reporting	Yes
Notified in 2010	9 445
Success	7 916 (83.8%)
Died	441 (4.7%)
Failed	379 (4.0%)
Defaulted	538 (5.7%)
Still on treatment	171 (1.8%)
Lost to follow up	0 (0.0%)


## Tuberculosis notification rates by treatment history, 2002–2011




## New TB cases - notification rates by age group, 2002–2011




## Tuberculosis cases by geographical origin, 2002–2011




## TB-HIV co-infection, 2006–2011



## MDR-TB cases by previous treatment history, 2002–2011



## Treatment outcome, new pulmonary culture-positive cases, 2002–2010



# Russia

Population estimate 2011 by UN Statistical Database: 142 835 555

## Tuberculosis case notifications, 2011

Total number of cases	159 479
Notification rate per 100 000	111.7
New & relapses (lab+) number	112 910
New & relapses (lab+) notification rate per 100 000	79.0
Pulmonary of which smear-positive	136 775 (85.8%) 47 144 (34.5%)
Laboratory-confirmed pulmonary TB cases	64 975 (47.5%)
Mean age of new TB cases, nationals	38.7 years
Mean age of new TB cases, non-nationals	-
Foreign origin of all TB cases	2 821 (1.8%)
New (not previously treated)	104 320 (65.4%)

## Drug resistance surveillance & TB-HIV co-infection, 2011


Completeness of DRS data*	No
Completeness of HIV data**	No
Case-linked data reporting	No
Cases with DST results	47 627 (91.7%)
Cases resistant to isoniazid	13 785 (28.9%)
Cases resistant to rifampicin	13 785 (28.9%)
Estimated MDR N, (best-low-high)	44000-40000-48000
MDR cases of which XDR cases	13 785 (28.9%) - -
Cases resistant to ethambutol	- -
Cases resistant to streptomycin	- -
TB cases tested for HIV	79 494 (49.8%)
HIV-positive TB cases	4 104 (5.2%)

\* National coverage 100% or culturing 90%, C+/All TB cases 50%, DST done for C+ 75%, EQA 95%  
\*\* More than 50% of TB cases tested for HIV.


## Treatment outcome monitoring, 2010

Geographical coverage	National
Outcome cohort	New pulmonary culture positive
Case-linked data reporting	No
Notified in 2010	30 123
Success	15 984 (53.1%)
Died	3 531 (11.7%)
Failed	6 970 (23.1%)
Defaulted	2 131 (7.1%)
Still on treatment	-
Lost to follow up	1 507 (5.0%)


## Tuberculosis notification rates by treatment history, 2002–2011




## New TB cases - notification rates by age group, 2002–2011




## Tuberculosis cases by geographical origin, 2002–2011




## TB-HIV co-infection, 2006–2011



## MDR-TB cases by previous treatment history, 2002–2011



## Treatment outcome, new pulmonary smear-positive cases, 2002–2010



# Serbia

Population estimate 2011 by UN Statistical Database: 9853969

## Tuberculosis case notifications, 2011

Total number of cases	1341
Notification rate per 100 000	13.6
New & relapses (lab+) number	1296
New & relapses (lab+) notification rate per 100 000	13.2
Pulmonary	1175 (87.6%)
of which smear-positive	739 (62.9%)
Laboratory-confirmed pulmonary TB cases	1025 (87.2%)
Mean age of new TB cases, nationals	51.8 years
Mean age of new TB cases, non-nationals	-
Foreign origin of all TB cases	6 (0.4%)
New (not previously treated)	1205 (89.9%)

## Drug resistance surveillance & TB-HIV co-infection, 2011

Completeness of DRS data*	Yes
Completeness of HIV data**	No
Case-linked data reporting	Yes
Cases with DST results	966 (94.2%)
Cases resistant to isoniazid	25 (2.6%)
Cases resistant to rifampicin	9 (0.9%)
Estimated MDR N, (best-low-high)	20-9-31
MDR cases	9 (0.9%)
of which XDR cases	2 (22.2%)
Cases resistant to ethambutol	-
Cases resistant to streptomycin	-
TB cases tested for HIV	67 (5.0%)
HIV-positive TB cases	6 (9.0%)


\* National coverage 100% or culturing 90%, C+/All TB cases 50%, DST done for C+ 75%, EQA 95%

\*\* More than 50% of TB cases tested for HIV.


## Treatment outcome monitoring, 2010

Geographical coverage	National
Outcome cohort	New pulmonary culture positive
Case-linked data reporting	Yes
Notified in 2010	702
Success	602 (85.8%)
Died	48 (6.8%)
Failed	7 (1.0%)
Defaulted	31 (4.4%)
Still on treatment	-
Lost to follow up	14 (2.0%)


## Tuberculosis notification rates by treatment history, 2002–2011



## New TB cases - notification rates by age group, 2002–2011




## Tuberculosis cases by geographical origin, 2002–2011




## TB-HIV co-infection, 2006–2011

Data not available

## MDR-TB cases by previous treatment history, 2002–2011



## Treatment outcome, new pulmonary definite cases, 2002–2010



# Slovakia

Total population at 1 January 2011 by EUROSTAT: 5435273

## Tuberculosis case notifications, 2011

Total number of cases	399
Notification rate per 100 000	7.3
New & relapses (lab+) number	352
New & relapses (lab+) notification rate per 100 000	6.5
Pulmonary of which smear-positive	337 (84.5%) 123 (36.5%)
Laboratory-confirmed pulmonary TB cases	178 (52.8%)
Mean age of new TB cases, nationals	50.6 years
Mean age of new TB cases, non-nationals	35.5 years
Foreign origin of all TB cases	3 (0.8%)
New (not previously treated)	323 (81.0%)

## Drug resistance surveillance & TB-HIV co-infection, 2011


Completeness of DRS data*	No
Completeness of HIV data**	Yes
Case-linked data reporting	Yes
Cases with DST results	185 (98.4%)
Cases resistant to isoniazid	9 (4.9%)
Cases resistant to rifampicin	4 (2.2%)
Estimated MDR N, (best-low-high)	5-0-11
MDR cases of which XDR cases	3 (1.6%) 0 (0.0%)
Cases resistant to ethambutol	1 (0.5%)
Cases resistant to streptomycin	6 (3.2%)
TB cases tested for HIV	395 (99.0%)
HIV-positive TB cases	0 (0.0%)

\* National coverage 100% or culturing 90%, C+/All TB cases 50%, DST done for C+ 75%, EQA 95%  
\*\* More than 50% of TB cases tested for HIV.


## Treatment outcome monitoring, 2010

Geographical coverage	National
Outcome cohort	New pulmonary culture positive
Case-linked data reporting	Yes
Notified in 2010	177
Success	149 (84.2%)
Died	22 (12.4%)
Failed	0 (0.0%)
Defaulted	5 (2.8%)
Still on treatment	0 (0.0%)
Lost to follow up	1 (0.6%)


## Tuberculosis notification rates by treatment history, 2002–2011




## New TB cases - notification rates by age group, 2002–2011




## Tuberculosis cases by geographical origin, 2002–2011




## TB-HIV co-infection, 2006–2011



## MDR-TB cases by previous treatment history, 2002–2011



## Treatment outcome, new pulmonary culture-positive cases, 2002–2010



# Slovenia

Total population at 1 January 2011 by EUROSTAT: 2050189

## Tuberculosis case notifications, 2011

Total number of cases	192
Notification rate per 100 000	9.4
New & relapses (lab+) number	190
New & relapses (lab+) notification rate per 100 000	9.3
Pulmonary	165 (85.9%)
of which smear-positive	88 (53.3%)
Laboratory-confirmed pulmonary TB cases	161 (97.6%)
Mean age of new TB cases, nationals	55.8 years
Mean age of new TB cases, non-nationals	45.5 years
Foreign origin of all TB cases	57 (29.7%)
New (not previously treated)	181 (94.3%)

## Drug resistance surveillance & TB-HIV co-infection, 2011

Completeness of DRS data*	Yes
Completeness of HIV data**	Yes
Case-linked data reporting	Yes
Cases with DST results	182 (100.0%)
Cases resistant to isoniazid	3 (1.6%)
Cases resistant to rifampicin	0 (0.0%)
Estimated MDR N, (best-low-high)	0-0-0
MDR cases	0 (0.0%)
of which XDR cases	- -
Cases resistant to ethambutol	0 (0.0%)
Cases resistant to streptomycin	4 (2.2%)
TB cases tested for HIV	147 (76.6%)
HIV-positive TB cases	0 (0.0%)


\* National coverage 100% or culturing 90%, C+/All TB cases 50%, DST done for C+ 75%, EQA 95%

\*\* More than 50% of TB cases tested for HIV.


## Treatment outcome monitoring, 2010

Geographical coverage	National
Outcome cohort	New pulmonary culture positive
Case-linked data reporting	Yes
Notified in 2010	121
Success	104 (86.0%)
Died	12 (9.9%)
Failed	0 (0.0%)
Defaulted	1 (0.8%)
Still on treatment	2 (1.7%)
Lost to follow up	2 (1.7%)


## Tuberculosis notification rates by treatment history, 2002–2011




## New TB cases - notification rates by age group, 2002–2011



## Tuberculosis cases by geographical origin, 2002–2011




## TB-HIV co-infection, 2006–2011



## MDR-TB cases by previous treatment history, 2002–2011

Insufficient data for graphic presentation

## Treatment outcome, new pulmonary culture-positive cases, 2002–2010





# Spain

Total population at 1 January 2011 by EUROSTAT: 46 152 926

## Tuberculosis case notifications, 2011

Total number of cases	6 762
Notification rate per 100 000	14.7
New & relapses (lab+) number	6 044
New & relapses (lab+) notification rate per 100 000	13.1
Pulmonary	4 979 (73.6%)
of which smear-positive	2 471 (49.6%)
Laboratory-confirmed pulmonary TB cases	3 584 (72.0%)
Mean age of new TB cases, nationals	46.9 years
Mean age of new TB cases, non-nationals	32.9 years
Foreign origin of all TB cases	2 138 (31.6%)
New (not previously treated)	6 044 (89.4%)

## Drug resistance surveillance & TB-HIV co-infection, 2011

Completeness of DRS data*	No
Completeness of HIV data**	Yes
Case-linked data reporting	No
Cases with DST results	1 273 (29.0%)
Cases resistant to isoniazid	108 (8.5%)
Cases resistant to rifampicin	45 (3.5%)
Estimated MDR N, (best-low-high)	36-15-58
MDR cases	41 (3.2%)
of which XDR cases	1 (2.4%)
Cases resistant to ethambutol	-
Cases resistant to streptomycin	-
TB cases tested for HIV	4 541 (67.2%)
HIV-positive TB cases	415 (9.1%)


\* National coverage 100% or culturing 90%, C+/All TB cases 50%, DST done for C+ 75%, EQA 95%

\*\* More than 50% of TB cases tested for HIV.


## Treatment outcome monitoring, 2010

Geographical coverage	National
Outcome cohort	New pulmonary culture positive
Case-linked data reporting	Yes
Notified in 2010	3 574
Success	2 516 (70.4%)
Died	211 (5.9%)
Failed	5 (0.1%)
Defaulted	27 (0.8%)
Still on treatment	31 (0.9%)
Lost to follow up	784 (21.9%)


## Tuberculosis notification rates by treatment history, 2002–2011




## New TB cases - notification rates by age group, 2002–2011




## Tuberculosis cases by geographical origin, 2002–2011




## TB-HIV co-infection, 2006–2011



## MDR-TB cases by previous treatment history, 2002–2011



## Treatment outcome, new pulmonary culture-positive cases, 2002–2010



# Sweden

Total population at 1 January 2011 by EUROSTAT: 9415570

## Tuberculosis case notifications, 2011

Total number of cases	586
Notification rate per 100 000	6.2
New & relapses (lab+) number	457
New & relapses (lab+) notification rate per 100 000	4.9
Pulmonary of which smear-positive	358 (61.1%) 123 (34.4%)
Laboratory-confirmed pulmonary TB cases	306 (85.5%)
Mean age of new TB cases, nationals	46.4 years
Mean age of new TB cases, non-nationals	33.5 years
Foreign origin of all TB cases	524 (89.4%)
New (not previously treated)	454 (77.5%)

## Drug resistance surveillance & TB-HIV co-infection, 2011

Completeness of DRS data*	Yes
Completeness of HIV data**	-
Case-linked data reporting	Yes
Cases with DST results	475 (99.8%)
Cases resistant to isoniazid	59 (12.4%)
Cases resistant to rifampicin	19 (4.0%)
Estimated MDR N, (best-low-high)	18-9-27
MDR cases of which XDR cases	17 (3.6%) 0 (0.0%)
Cases resistant to ethambutol	10 (2.1%)
Cases resistant to streptomycin	23 (4.8%)
TB cases tested for HIV	-
HIV-positive TB cases	-


\* National coverage 100% or culturing 90%, C+/All TB cases 50%, DST done for C+ 75%, EQA 95%

\*\* More than 50% of TB cases tested for HIV.


## Treatment outcome monitoring, 2010

Geographical coverage	National
Outcome cohort	New pulmonary culture positive
Case-linked data reporting	Yes
Notified in 2010	289
Success	246 (85.1%)
Died	14 (4.8%)
Failed	1 (0.3%)
Defaulted	2 (0.7%)
Still on treatment	17 (5.9%)
Lost to follow up	9 (3.1%)


## Tuberculosis notification rates by treatment history, 2002–2011



## New TB cases - notification rates by age group, 2002–2011




## Tuberculosis cases by geographical origin, 2002–2011




## TB-HIV co-infection, 2006–2011

Not available

## MDR-TB cases by previous treatment history, 2002–2011



## Treatment outcome, new pulmonary culture-positive cases, 2002–2010



# Switzerland

Population estimate 2011 by UN Statistical Database: 7701690

## Tuberculosis case notifications, 2011

Total number of cases	578
Notification rate per 100 000	7.5
New & relapses (lab+) number	379
New & relapses (lab+) notification rate per 100 000	4.9
Pulmonary	359 (62.1%)
of which smear-positive	119 (33.1%)
Laboratory-confirmed pulmonary TB cases	303 (84.4%)
Mean age of new TB cases, nationals	56.1 years
Mean age of new TB cases, non-nationals	36.5 years
Foreign origin of all TB cases	428 (74.0%)
New (not previously treated)	379 (65.6%)

## Drug resistance surveillance & TB-HIV co-infection, 2011

Completeness of DRS data*	Yes
Completeness of HIV data**	Yes
Case-linked data reporting	Yes
Cases with DST results	454 (93.2%)
Cases resistant to isoniazid	33 (7.3%)
Cases resistant to rifampicin	11 (2.4%)
Estimated MDR N, (best-low-high)	6-12
MDR cases	8 (1.8%)
of which XDR cases	0 (0.0%)
Cases resistant to ethambutol	-
Cases resistant to streptomycin	-
TB cases tested for HIV	-
HIV-positive TB cases	-


\* National coverage 100% or culturing 90%, C+/All TB cases 50%, DST done for C+ 75%, EQA 95%

\*\* More than 50% of TB cases tested for HIV.


## Treatment outcome monitoring, 2010

Data not reported


## Tuberculosis notification rates by treatment history, 2002–2011



## New TB cases - notification rates by age group, 2002–2011




## Tuberculosis cases by geographical origin, 2002–2011



## TB-HIV co-infection, 2006–2011

Data not available

## MDR-TB cases by previous treatment history, 2002–2011



## Treatment outcome, new pulmonary smear-positive cases, 2002–2010

Not available

# Tajikistan

Population estimate 2011 by UN Statistical Database: 6976958

## Tuberculosis case notifications, 2011

Total number of cases	7 609
Notification rate per 100 000	109.1
New & relapses (lab+) number	6 290
New & relapses (lab+) notification rate per 100 000	90.2
Pulmonary of which smear-positive	5 996 (78.8%) 3 103 (51.8%)
Laboratory-confirmed pulmonary TB cases	3 103 (51.8%)
Mean age of new TB cases, nationals	32.8 years
Mean age of new TB cases, non-nationals	-
Foreign origin of all TB cases	0 (0.0%)
New (not previously treated)	5 935 (78.0%)

## Drug resistance surveillance & TB-HIV co-infection, 2011

Completeness of DRS data*	No
Completeness of HIV data**	Yes
Case-linked data reporting	No
Cases with DST results	576 (35.5%)
Cases resistant to isoniazid	405 (70.3%)
Cases resistant to rifampicin	395 (68.6%)
Estimated MDR N, (best-low-high)	1000-910-1200
MDR cases of which XDR cases	380 (66.0%) 12 (3.2%)
Cases resistant to ethambutol	-
Cases resistant to streptomycin	-
TB cases tested for HIV	6 241 (82.0%)
HIV-positive TB cases	115 (1.8%)


\* National coverage 100% or culturing 90%, C+/All TB cases 50%, DST done for C+ 75%, EQA 95%

\*\* More than 50% of TB cases tested for HIV.


## Treatment outcome monitoring, 2010

Geographical coverage	National
Outcome cohort	New pulmonary culture positive
Case-linked data reporting	No
Notified in 2010	2 290
Success	1 834 (80.1%)
Died	111 (4.8%)
Failed	246 (10.7%)
Defaulted	72 (3.1%)
Still on treatment	-
Lost to follow up	27 (1.2%)


## Tuberculosis notification rates by treatment history, 2002–2011




## New TB cases - notification rates by age group, 2002–2011




## Tuberculosis cases by geographical origin, 2002–2011




## TB-HIV co-infection, 2006–2011



## MDR-TB cases by previous treatment history, 2002–2011



## Treatment outcome, new pulmonary culture-positive cases, 2002–2010



# Turkey

Population estimate 2011 by UN Statistical Database: 73639596

## Tuberculosis case notifications, 2011

Total number of cases	15 679
Notification rate per 100 000	21.3
New & relapses (lab+) number	15 054
New & relapses (lab+) notification rate per 100 000	20.4
Pulmonary of which smear-positive	9 909 (63.2%) 5 643 (56.9%)
Laboratory-confirmed pulmonary TB cases	7 245 (73.1%)
Mean age of new TB cases, nationals	40.7 years
Mean age of new TB cases, non-nationals	-
Foreign origin of all TB cases	202 (1.3%)
New (not previously treated)	14 417 (92.0%)

## Drug resistance surveillance & TB-HIV co-infection, 2011


Completeness of DRS data*	No
Completeness of HIV data**	No
Case-linked data reporting	No
Cases with DST results	4 823 (30.8%)
Cases resistant to isoniazid	660 (13.7%)
Cases resistant to rifampicin	325 (6.7%)
Estimated MDR N, (best-low-high)	560-240-880
MDR cases of which XDR cases	262 (5.4%) 1 (0.4%)
Cases resistant to ethambutol	-
Cases resistant to streptomycin	-
TB cases tested for HIV	7 241 (46.2%)
HIV-positive TB cases	29 (0.4%)

\* National coverage 100% or culturing 90%, C+/All TB cases 50%, DST done for C+ 75%, EQA 95%  
\*\* More than 50% of TB cases tested for HIV.


## Treatment outcome monitoring, 2010

Geographical coverage	National
Outcome cohort	New pulmonary culture positive
Case-linked data reporting	No
Notified in 2010	5 375
Success	4 905 (91.3%)
Died	165 (3.1%)
Failed	40 (0.7%)
Defaulted	136 (2.5%)
Still on treatment	-
Lost to follow up	129 (2.4%)


## Tuberculosis notification rates by treatment history, 2002–2011




## New TB cases - notification rates by age group, 2002–2011




## Tuberculosis cases by geographical origin, 2002–2011




## TB-HIV co-infection, 2006–2011



## MDR-TB cases by previous treatment history, 2002–2011



## Treatment outcome, new pulmonary smear-positive cases, 2002–2010



# Turkmenistan

Population estimate 2011 by UN Statistical Database: 5105301

## Tuberculosis case notifications, 2011

Data not reported


## Drug resistance surveillance & TB-HIV co-infection, 2011

Data not reported


## Treatment outcome monitoring, 2010

Data not reported


### Tuberculosis notification rates by treatment history, 2002–2011




### New TB cases - notification rates by age group, 2002–2011




### Tuberculosis cases by geographical origin, 2002–2011



### TB-HIV co-infection, 2006–2011



### MDR-TB cases by previous treatment history, 2002–2011



### Treatment outcome, new pulmonary smear-positive cases, 2002–2010



# Ukraine

Population estimate 2011 by UN Statistical Database: 45 190 180

## Tuberculosis case notifications, 2011

Total number of cases	42 676
Notification rate per 100 000	94.4
New & relapses (lab+) number	34 237
New & relapses (lab+) notification rate per 100 000	75.8
Pulmonary	33 165 (77.7%)
of which smear-positive	16 764 (50.5%)
Laboratory-confirmed pulmonary TB cases	16 764 (50.5%)
Mean age of new TB cases, nationals	42.0 years
Mean age of new TB cases, non-nationals	-
Foreign origin of all TB cases	0 (0.0%)
New (not previously treated)	31 188 (73.1%)

## Drug resistance surveillance & TB-HIV co-infection, 2011

Completeness of DRS data*	No
Completeness of HIV data**	Yes
Case-linked data reporting	No
Cases with DST results	14 765 (73.4%)
Cases resistant to isoniazid	4 719 (32.0%)
Cases resistant to rifampicin	4 530 (30.7%)
Estimated MDR N, (best-low-high)	9 500-8 700-10 000
MDR cases	4 305 (29.2%)
of which XDR cases	-
Cases resistant to ethambutol	-
Cases resistant to streptomycin	-
TB cases tested for HIV	31 776 (74.5%)
HIV-positive TB cases	5 893 (18.5%)


\* National coverage 100% or culturing 90%, C+/All TB cases 50%, DST done for C+ 75%, EQA 95%

\*\* More than 50% of TB cases tested for HIV.


## Treatment outcome monitoring, 2010

Geographical coverage	National
Outcome cohort	New pulmonary culture positive
Case-linked data reporting	No
Notified in 2010	13 279
Success	7 935 (59.8%)
Died	1 665 (12.5%)
Failed	2 212 (16.7%)
Defaulted	1 009 (7.6%)
Still on treatment	-
Lost to follow up	458 (3.4%)


## Tuberculosis notification rates by treatment history, 2002–2011




## New TB cases - notification rates by age group, 2002–2011




## Tuberculosis cases by geographical origin, 2002–2011




## TB-HIV co-infection, 2006–2011



## MDR-TB cases by previous treatment history, 2002–2011



## Treatment outcome, new pulmonary smear or culture-positive cases, 2002–2010



# United Kingdom

Total population at 1 January 2011 by EUROSTAT: 62 498 612

## Tuberculosis case notifications, 2011

Total number of cases	8 963
Notification rate per 100 000	14.3
New & relapses (lab+) number	7 850
New & relapses (lab+) notification rate per 100 000	12.6
Pulmonary of which smear-positive	4 603 (51.4%) 1 384 (30.1%)
Laboratory-confirmed pulmonary TB cases	3 213 (69.8%)
Mean age of new TB cases, nationals	41.6 years
Mean age of new TB cases, non-nationals	38.4 years
Foreign origin of all TB cases	6 287 (70.1%)
New (not previously treated)	7 850 (87.6%)

## Drug resistance surveillance & TB-HIV co-infection, 2011

Completeness of DRS data*	Yes
Completeness of HIV data**	-
Case-linked data reporting	Yes
Cases with DST results	5 127 (97.0%)
Cases resistant to isoniazid	388 (7.6%)
Cases resistant to rifampicin	89 (1.7%)
Estimated MDR N, (best-low-high)	71-55-87
MDR cases of which XDR cases	81 (1.6%) 6 (7.4%)
Cases resistant to ethambutol	58 (1.1%)
Cases resistant to streptomycin	265 (5.2%)
TB cases tested for HIV	-
HIV-positive TB cases	-


\* National coverage 100% or culturing 90%, C+/All TB cases 50%, DST done for C+ 75%, EQA 95%

\*\* More than 50% of TB cases tested for HIV.


## Treatment outcome monitoring, 2010

Geographical coverage	National
Outcome cohort	New pulmonary culture positive
Case-linked data reporting	Yes
Notified in 2010	2 603
Success	2 106 (80.9%)
Died	135 (5.2%)
Failed	0 (0.0%)
Defaulted	154 (5.9%)
Still on treatment	118 (4.5%)
Lost to follow up	90 (3.5%)


## Tuberculosis notification rates by treatment history, 2002–2011



## New TB cases - notification rates by age group, 2002–2011




## Tuberculosis cases by geographical origin, 2002–2011




## TB-HIV co-infection, 2006–2011

Not available

## MDR-TB cases by previous treatment history, 2002–2011



## Treatment outcome, new pulmonary culture-positive cases, 2002–2010





# Uzbekistan

Population estimate 2011 by UN Statistical Database: 27 760 267

## Tuberculosis case notifications, 2011

Total number of cases	15 913
Notification rate per 100 000	57.3
New & relapses (lab+) number	14 501
New & relapses (lab+) notification rate per 100 000	52.2
Pulmonary of which smear-positive	11 824 (74.3%) 5 076 (42.9%)
Laboratory-confirmed pulmonary TB cases	5 997 (50.7%)
Mean age of new TB cases, nationals	38.1 years
Mean age of new TB cases, non-nationals	-
Foreign origin of all TB cases	24 (0.2%)
New (not previously treated)	13 995 (87.9%)

## Drug resistance surveillance & TB-HIV co-infection, 2011

Completeness of DRS data*	No
Completeness of HIV data**	Yes
Case-linked data reporting	Yes
Cases with DST results	2 217 (50.0%)
Cases resistant to isoniazid	1 652 (74.5%)
Cases resistant to rifampicin	1 408 (63.5%)
Estimated MDR N, (best-low-high)	3 000-2 700-3 400
MDR cases of which XDR cases	1 385 (62.5%) 12 (0.9%)
Cases resistant to ethambutol	-
Cases resistant to streptomycin	-
TB cases tested for HIV	15 913 (100.0%)
HIV-positive TB cases	546 (3.4%)


\* National coverage 100% or culturing 90%, C+/All TB cases 50%, DST done for C+ 75%, EQA 95%

\*\* More than 50% of TB cases tested for HIV.


## Treatment outcome monitoring, 2010

Geographical coverage	National
Outcome cohort	New pulmonary culture positive
Case-linked data reporting	Yes
Notified in 2010	4 711
Success	3 819 (81.1%)
Died	272 (5.8%)
Failed	276 (5.9%)
Defaulted	215 (4.6%)
Still on treatment	-
Lost to follow up	129 (2.7%)


## Tuberculosis notification rates by treatment history, 2002–2011




## New TB cases - notification rates by age group, 2002–2011




## Tuberculosis cases by geographical origin, 2002–2011




## TB-HIV co-infection, 2006–2011



## MDR-TB cases by previous treatment history, 2002–2011



## Treatment outcome, new pulmonary smear-positive cases, 2002–2010





## 7. Annexes





## Annex 1: Tuberculosis surveillance system overview, 2012

Country	Data source	Legal character <sup>a</sup>	Comprehensiveness <sup>b</sup>	Type <sup>c</sup>	Coverage <sup>d</sup>	Data used:		
						EuroTB aggregated data	EuroTB case-based data <sup>e</sup>	TESSy case-based data <sup>f</sup>
Austria	AT-TUBERKULOSEGESETZ	Cp	Co	C	Y	-	-	1985–2011
Belgium	BE-TUBERCULOSIS	Cp	Co	C	Y	-	1995–2004	2005–2011
Bulgaria	BG-MOH	Cp	Co	C	-	1995–2006	-	2007–2011
Cyprus	CY-NOTIFIED_DISEASES	Cp	Co	C	Y	1995–2001	2002–2004	2005–2011
Czech Republic	CZ-TUBERCULOSIS	Cp	Co	C	Y	-	1995–2004	2005–2011
Denmark	DK-EuroTB_Historical	Cp	Co	C	Y	-	1995–2004	2005–2011
Estonia	EE-TBC	Cp	Co	C	Y	-	1995–2004	2005–2011
Finland	FI-NIDR	Cp	Co	C	Y	-	-	1980–2011
France	FR-MANDATORY_INFECTIOUS_DISEASES	Cp	Co	C	Y	-	1995–1999	2000–2011
Germany	DE-SURVNET@RKI-7.1/4	Cp	Co	C	Y	1995–2000	2001–2004	2005–2011
Greece	GR-NOTIFIABLE_DISEASES	Cp	Co	C	Y	1995–2001	2002–2004	2006–2011
Hungary	HU-TUBERCULOSIS	Cp	Co	C	Y	1995–1998	1999–2004	2005–2011
Iceland	IS-TUBERCULOSIS	Cp	Co	C	Y	-	1995–2004	2005–2011
Ireland	IE-TB	Cp	Co	C	Y	1995–1997	1998–2004	2005–2011
Italy	IT-NRS	Cp	O	C	Y	-	1995–2004	2005–2011
Latvia	LV-TB	Cp	Co	C	Y	1995–2000	2001–2004	2005–2011
Liechtenstein	-	-	-	-	-	-	-	-
Lithuania	LT-TB_REGISTER	Cp	Co	C	-	1995–2002	2003, 2004	2005–2011
Luxembourg	LU-SYSTEMo	Cp	Co	C	Y	-	1995–2006	2007–2011
Malta	MT-DISEASE_SURVEILLANCE	Cp	Co	C	Y	-	1995–2004	2005–2011
Netherlands	NL-NTR	Cp	Co	C	Y	-	1995–2004	2005–2011
Norway	NO-MSIS_A	Cp	Co	C	Y	-	1995–2005	2006–2011
Poland	PL_CR	Cp	Co	C	Y	1995–1999	2000–2005	2006–2011
Portugal	PT-TUBERCULOSIS	Cp	Co	C	Y	1995–1999	2000–2005	2006–2011
Romania	RO-EuroTB_Historical	Cp	Co	C	Y	-	1995–2004	2005–2011
Slovakia	SK-NRT	Cp	Co	C	Y	1995	1996–2004	2005–2011
Slovenia	SI-TUBERCULOSIS	Cp	Co	C	Y	-	1995–2004	2005–2011
Spain	ES-STATUTORY_DISEASES	Cp	Co	C	Y	1995–2006	-	2007–2011
Sweden	SE-SweTBReg	Cp	Co	C	Y	-	1995–2006	2007–2011
United Kingdom	UK-TUBERCULOSIS	Cp	Co	C	Y	1995–1997	1998	1999–2011

<sup>a</sup> Legal: compulsory reporting - Cp

<sup>b</sup> Comprehensiveness: comprehensive - Co, Sentinel - Se, Other - O

<sup>c</sup> Type: case based - C, unknown - U

<sup>d</sup> Coverage: national - Y, Not specified in TESSy “-”

<sup>e</sup> Data uploaded to TESSy in 2010, not updated later.

<sup>f</sup> TME data for DST analysis of France, Spain and Italy and aggregated HIV data for France, Latvia, the Netherlands and Poland

Annex 2: List of TESSy variables for 2012 TB data collection<sup>a</sup>

List	Description
<b>Common set of variables</b>	
1 RecordId	Unique identifier for each record generated by the national surveillance system
2 RecordType	Structure and format of the data
3 RecordTypeVersion	Indicates which version the sender uses when generating the data for upload
4 Subject	Disease to report
5 Status	Status of reporting NEW/UPDATE or DELETE (inactivate)
6 DataSource	The data source (surveillance system) that the record originates from.
7 ReportingCountry	The country reporting the record.
8 PlaceOfNotification <sup>b</sup>	Place of the first notification of the case to a regional authority.
9 PlaceOfResidence <sup>b</sup>	Place of residence of patient at the time of disease onset.
10 Age	Age of patient in years as reported in the national system.
11 Gender	Gender of the reported case.
12 Outcome <sup>c</sup>	Information on whether the case is alive or deceased. (Not applicable for TB. Use DiagnosedAnteMortem instead).
13 DateOfOnset <sup>b</sup>	Date of onset of disease. (Optional for TB. Not reflected on reports.)
14 DateOfDiagnosis	First date of clinical or lab diagnosis.
15 DateOfNotification	Date when the case is first reported to public health authorities.
16 DateUsedForStatistics	The reference date used for standard reports. Usually date of notification or date of diagnosis.
17 Classification	Case classification according to EU case definition.
18 LaboratoryResult	Laboratory criteria used to classify a case as confirmed or probable.
19 EpiLinked (OP)	The criteria for an epidemiological link in the case definition is met. Not analysed for TB.
<b>Disease-specific variables</b>	
20 BornReportingCountry	The patient was born in the country of report.
21 CountryOfBirth	Country of birth of patient.
22 CountryOfNationality	Country of nationality of patient.
23 NationalityReportingCountry	Origin of the patient (based on citizenship).
24 MajorSiteOfTB	Major site of the disease.
25 MinorSiteOfTB	Minor site of the disease.
26 PrevDiagnosis	Previous diagnosis of tuberculosis in the past.
27 PrevDiagnosisYear	Year of previous diagnosis.
28 PrevTreatment	Previous anti-TB drug treatment (at least one month of drug combination).
29 PrevTreatmentCompletion	Completion of the previous anti-tuberculosis drug treatment.
30 DiagnosedAnteMortem	Vital status of the patient at the time of diagnosis. Was TB diagnosed ante-mortem?
31 Outcome12Months	Patient first outcome at 12 months from the start of the treatment.
32 Outcome24Months	The first outcome observed 13 to 24 months from the start of treatment.
33 Outcome36Months	The first outcome observed 25 to 36 months from the start of treatment.
34 ResultCulture	The result of the culture test for <i>M. tuberculosis</i> complex.
35 ResultMicroscopy	The result of the microscopy test performed.
36 ResultOtherTest	Additional lab test results.
37 Pathogen	Species and gene ( <i>M. tuberculosis</i> complex) of the pathogen which is the cause of the reported disease.
38 HIVStatus	Result of the last HIV test.
39 SIR_AMK	Susceptibility to Amikacin (without Intermediate)
40 SIR_CAP	Susceptibility to Capreomycin (without Intermediate)
41 SIR_CIP	Susceptibility to Ciprofloxacin (without Intermediate)
42 SIR_ETH	Susceptibility to Ethambutol.
43 SIR_INH	Susceptibility to Isoniazid.
44 SIR_KAN	Susceptibility to Kanamycin.
45 SIR_OFX	Susceptibility to Ofloxacin.
46 SIR_RIF	Susceptibility to Rifampicin.
47 SIR_STR	Susceptibility to Streptomycin.
48 IsolateID	Unique identifier for each isolate within the data source / lab system related to the case.
49 ECDCIsolateID	Identifier for each isolate record that is guaranteed to be unique across countries/labs/pathogens and not contain additional encoded information.
50 SpoligoCode	Spoligo pattern code.
51 RflpCode	National cluster code based on IS6110 RFLP.
52 MiruCode	MIRU pattern code.
51 RflpCode	National cluster code based on IS6110 RFLP.
53 BeijingGenotype	Beijing genotype identification.

<sup>a</sup> Notification of TB cases for 2011, treatment outcome data updated for cohort 2010 and MDR-TB treatment outcome data updated for cohort 2009

<sup>b</sup> Optional for TB reporting

<sup>c</sup> Not applicable for TB, use variable DiagnosedAnteMortem instead

## Annex 3: Reporting completeness by TESSy variable

Variable (for description, see Annex 2)	2010				2011			
	Number of reporting countries	Completeness (%)	Minimum (%)	Maximum (%)	Number of reporting countries	Completeness (%)	Minimum (%)	Maximum (%)
DateUsedForStatistics	29	(100.0)	(100.0)	(100.0)	29	(100.0)	(100.0)	(100.0)
Classification	29	(100.0)	(99.4)	(100.0)	29	(100.0)	(55.6)	(100.0)
Age	29	(99.9)	(95.1)	(100.0)	29	(99.9)	(99.1)	(100.0)
Gender	29	(99.9)	(99.5)	(100.0)	29	(99.9)	(99.2)	(100.0)
NationalityReportingCountry	5	(100.0)	(100.0)	(100.0)	5	(99.9)	(99.0)	(100.0)
MajorSiteOfTB	29	(99.7)	(80.9)	(100.0)	29	(99.6)	(75.4)	(100.0)
MinorSiteOfTB	25	-	-	-	26	-	-	-
BornReportingCountry	24	(97.8)	(92.5)	(100.0)	24	(97.5)	(86.6)	(100.0)
CountryOfNationality	5	(99.4)	(96.1)	(100.0)	5	(96.3)	(99.6)	(100.0)
CountryOfBirth	24	(84.3)	(25.0)	(100.0)	24	(95.6)	(83.5)	(100.0)
LaboratoryResult	29	(93.8)	(53.1)	(100.0)	29	(94.3)	(72.7)	(100.0)
PrevDiagnosis	29	(88.8)	(6.2)	(100.0)	29	(92.6)	(7.2)	(100.0)
PrevTreatment	29	(91.2)	(11.9)	(100.0)	29	(91.0)	(5.2)	(100.0)
DateOfNotification	28	(90.4)	(0.0)	(100.0)	28	(90.5)	(0.0)	(100.0)
DiagnosedAnteMortem	24	(73.1)	(0.0)	(100.0)	24	(83.4)	(0.8)	(100.0)
PrevTreatmentCompletion	15	(81.5)	(0.0)	(100.0)	19	(81.5)	(0.0)	(100.0)
ResultCulture	29	(83.2)	(41.3)	(100.0)	29	(77.8)	(41.5)	(100.0)
ResultMicroscopy	28	(73.5)	(27.0)	(100.0)	29	(72.5)	(26.3)	(100.0)
DateOfDiagnosis	20	(63.9)	(1.1)	(100.0)	19	(66.2)	(46.3)	(100.0)
SIR_KAN	13	(60.2)	(0.0)	(100.0)	13	(66.0)	(0.0)	(100.0)
SIR_OFX	16	(56.0)	(0.0)	(100.0)	18	(59.8)	(0.0)	(100.0)
PrevDiagnosisYear	20	(60.0)	(33.3)	(100.0)	21	(57.6)	(37.0)	(100.0)
Pathogen	28	(52.2)	(0.2)	(89.5)	28	(42.3)	(0.6)	(94.8)
SIR_INH	26	(36.1)	(32.8)	(90.1)	26	(39.1)	(31.4)	(94.8)
SIR_RIF	26	(36.1)	(32.9)	(90.1)	26	(39.1)	(30.5)	(94.8)
SIR_AMK	15	(32.3)	(0.0)	(100.0)	17	(37.9)	(0.0)	(100.0)
SIR_CAP	16	(32.5)	(0.0)	(100.0)	19	(36.0)	(0.0)	(100.0)
SIR_ETH	26	(28.5)	(3.5)	(90.1)	26	(31.1)	(4.0)	(94.8)
SIR_STR	26	(24.0)	(1.4)	(90.1)	26	(27.0)	(1.0)	(94.8)
HIVStatus	14	(23.3)	(2.5)	(100.0)	16	(26.3)	(0.9)	(99.9)
ResultOtherTest	20	(20.3)	(3.5)	(100.0)	18	21.7	(3.9)	(100.0)
SIR_CIP	4	(9.9)	(0.0)	(44.4)	6	(12.9)	(0.0)	(100.0)
IsolateID	3	(0.1)	(0.0)	(91.7)	4	(1.1)	(0.0)	(86.3)
ECDCIsolateID	0	-	-	-	-	-	-	-
RflpCode	4	(1.2)	(0.0)	(100.0)	4	(1.0)	(0.0)	(100.0)
MiruCode	5	(8.8)	(0.0)	(100.0)	6	(0.5)	(0.0)	(91.7)
SpoligoCode	2	(0.1)	(2.2)	(2.5)	1	(0.03)	(1.80)	(1.80)
BeijingGenotype	4	(0.1)	(0.0)	(4.6)	5	(0.0)	(81.4)	(81.4)
Outcome12Months <sup>a</sup>	24	(74.9)	(43.0)	(100.0)	25	(77.7)	(3.4)	(100.0)
Outcome24Months <sup>b</sup>	17	(41.4)	(0.0)	(100.0)	19	(39.4)	(0.0)	(100.0)
Outcome36Months <sup>c</sup>	5	(50.0)	(0.0)	(100.0)	0	-	-	-

<sup>a</sup> Data for 2009/2010 cohort<sup>b</sup> Data for 2008/2009 cohort<sup>c</sup> Data for 2007/2008 cohort









## **HOW TO OBTAIN EU PUBLICATIONS**

### **Free publications:**

- via EU Bookshop (<http://bookshop.europa.eu>);
- at the European Commission's representations or delegations. You can obtain their contact details on the Internet (<http://ec.europa.eu>) or by sending a fax to +352 2929-42758.

### **Priced publications:**

- via EU Bookshop (<http://bookshop.europa.eu>).

### **Priced subscriptions (e.g. annual series of the Official Journal of the European Union and reports of cases before the Court of Justice of the European Union):**

- via one of the sales agents of the Publications Office of the European Union ([http://publications.europa.eu/others/agents/index\\_en.htm](http://publications.europa.eu/others/agents/index_en.htm)).

**European Centre for Disease  
Prevention and Control (ECDC)**

Postal address:  
ECDC, 171 83 Stockholm, Sweden

Visiting address:  
Tomtebodavägen 11A, Solna, Sweden

Phone +46 (0)8 58 60 1000  
Fax +46 (0)8 58 60 1001  
[www.ecdc.europa.eu](http://www.ecdc.europa.eu)

An agency of the European Union  
[www.europa.eu](http://www.europa.eu)



■ Publications Office

ISBN 978-92-9193-447-8



9 789291 934478